COVID-19 Impact on Global Sports Stokes Fears Across Industries

Interested in staying up-to-date on COVID-19’s impact across sectors? Visit our Coronavirus Impact Tracker for daily updates pulled from earnings calls, press releases, 8ks, and more.

 

As Coronavirus fears mount, local and state governments are beginning to implement stricter guidelines on large group gatherings and social distancing measures. In response, sporting events around the world are seeing suspensions, postponements, modifications and cancellations.

Continue reading “COVID-19 Impact on Global Sports Stokes Fears Across Industries”

Coronavirus Cheatsheet | Week of March 9th, 2020

Interested in staying up-to-date on COVID-19’s impact across sectors? Visit our Coronavirus Impact Tracker for daily updates pulled from earnings calls, press releases, 8ks, and more.

 

Takeaways:

  • The travel environment has deteriorated with multiple travel companies withdrawing guidance just weeks after initially providing it
  • With a decrease in tourist sales, US retail is watching the situation closely as domestic case volume increases
  • Stresses in credit are becoming evident with companies pulling on revolvers and US Bancorp commenting on the potential for credit quality pressure
  • Companies beginning to talk about cost cutting measures

Don’t miss critical insights: Sign up for a free trial or login here.

 

Week of 3/9: Live Updates

3/12 Commentary: We’re hearing more widespread effects of Coronavirus across multiple industries and regions. US Bancorp spoke to the potential of credit quality pressure in Energy, Transports, and Travel. We’ve seen companies such as Hilton draw down Revolving Credit Facilities. Even companies like Visa are taking cost reduction measures.

TransUnion (3/12 – Bank of America Securities Information Services Conference)

So, certainly, we’re doing our part there now in terms of the impact that we’ve seen because of the coronavirus and our business, you know, I can say that overall the company continues to perform well. We feel like – we feel comfortable with the guidance that we provided for the first quarter.

And you know when we look to our Asia business while we get experience some – I mean more or less we’re – we’re performing as expected there when we look at our Hong Kong operations. Now, Hong Kong while part of China is certainly not the heart of virus concerns on the three-point kind of severity scale, it’s a level one environment. And you know the good news is that business has performed fine. However, it may not be the perfect benchmark for the rest of our portfolio. There’s more higher subscription component in that business, but at this point I think – I think we’re holding up quite well. And if anything, we’ve really benefited from the lower interest rates because a good portion or a decent portion of our portfolio has some mortgage exposure. It’s about 8% and we’ve seen quite a bit of growth in that due to the low interest rates and the refinance boom that it’s driven. So I’ll pause there. That’s what we have experienced kind of to-date in the first quarter.

 

CVS Health Corp (3/12 – Barclays Virtual Global Healthcare Conference)

So, just to give you some color, each of our business leaders are working to ensure business continuity plans are in order to meet the needs of our customers. In terms of that, as we think about pharmacy supply, we’ve experienced no disruption at this point. We’re in close contact with all of our suppliers. And, what they’ve shared with us is, they tend to carry on average, three to six months of inventory. And, I would say, given our size and scale and the power of Red Oak and the diversity of our suppliers, we think we’re in very good shape at this point. We also are able to have, I’ll say, additional information around API sourcing and what have you to enable us to be proactive on that front.

As you look at what we’ve done to ensure consistency of care, everyone probably saw our announcement of offering zero co-pay telemedicine for visits for any medical reason, not just specific to COVID-19. With the goal of eliminating potential exposure in the physician offices or with others, we have waived our out-of-pocket costs for all diagnostic testing related to COVID-19 for all of our Aetna plan members.

And finally, as you look at the front store of our business, clearly, we’ve seen an increase in utilization in certain categories, particularly around cleaning supplies, masks, sanitizers, those types of categories. And, overall, from a supply perspective, our front store supply remained strong. We have had challenges. I’d say, we’re essentially out of stock on masks. And, you could see, on sanitizers, sporadically, we’re out of stock. But, we’re continuing to receive supply…

 So, let me take a step back from the quarterly guidance and just talk about the full year from a – for a second. Overall, with everything we know today, we’re confident with our full-year adjusted EPS guidance range that we have provided of $7.04 to $7.17. Obviously, as I said a few minutes ago, right, coronavirus is fluid. There are some positives there. There are some challenges. But, with everything we know today, we’re confident with that range.

 

Dollar General Corporation (3/12 – Form 8-K)

Based on information currently known by management, the Company does not anticipate that supply chain disruptions experienced to date as a result of the coronavirus outbreak are likely to have a material impact on its fiscal 2020 financial results. However, the Company continues to monitor this evolving situation, and there is no guarantee that this outbreak will not have a more significant impact on its business.

 

Caterpillar Inc (3/11 – CONEXPO Conference)

So, in our top 25 suppliers, for example, at the moment, only 3 of those are Chinese vendors, so that is a signal. But obviously we don’t know, the other 22, where their supply chains go.

And so obviously if you’re thinking about a coronavirus type impact, particularly on the supply chain at this stage, we haven’t really seen anything. But obviously we are planning on the assumption that at some stage, some of those smaller Chinese manufacturers will have some impact somewhere along the line and building our contingency plans ready. And then obviously where we are sole sourced, that is the greatest area of risk and that’s obviously going to get the greatest degree of attention in the short-term.

Those places where we have alternative supply choices, we will continue to monitor those as well and obviously flex those through over the next few months. But obviously what we don’t want to do is end up in a situation where we either can’t produce or we are constraining ourselves on production. We have lived with that a little bit over the last couple of years. That has been a big challenge for us. So that’s a really big opportunity for us to unleash the supply chain a little bit better than we had done recently.

 

Hilton Worldwide Holdings Inc (3/11 – 8K)

Hilton increased its borrowings under the Revolving Credit Facility as a precautionary measure in order to increase its cash position and preserve financial flexibility in light of current uncertainty in the global markets resulting from the COVID-19 outbreak. 

 

Moody’s Corp (3/11 – Investor Day)

We remain confident in our performance in the near-term, while acknowledging some uncertainty over the medium-term. We expect the lost revenue due to delayed issuances will reduce MIS’ top line growth in 2020 along where we guided to in February. As a result, we have revised our full-year 2020 MIS revenue guidance from mid-single-digit growth to the low-single-digit percent range. With the exception of MIS revenue, we have also announced today that we are reaffirming all other full-year 2020 guidance metrics. However, we are now expecting to be at the lower end of our adjusted diluted EPS range of $9.10 to $9.30.

We recently revised down our economic forecast to reflect the global spread of the virus and slower economic activity particularly in the first half of this year. Our new base case growth forecast for the G-20 economies was lowered 30 basis points to 2.1% in 2020.

The full extent of the economic costs (00:08:20) will be unclear for quite some time. The spread of the virus has already resulted in significant economic fallout with channels to credit affecting a range of sectors. The fear of contagion has dampened travel and tourism and will dampen consumer and business activity and disrupt the supply chain. It also takes a toll on healthcare systems with higher demand for healthcare services and products.

The fall in oil prices and other commodities now exacerbated by decisions by OPEC, Russia and other producers create new uncertainties for oil and gas companies and related sectors. Several sectors including airlines, shipping, bricks-and-mortar retail, hotels and cruise lines are already facing direct effects to their revenue, cost and finances. In addition, the impact of lower growth has hit oil and commodity prices, while supply chain disruptions are hurting manufacturing companies, including those in the auto sector.

There are some positive impacts, for example, remote communication, online retail, vaccine developers and others. With this slower economic growth outlook, we also raised our default forecast. Our global speculative-grade default rate projection will rise from 3.1% to 3.7% a year from now amid risks to growth, commodity prices and financial markets. Some issuers will face tighter financing conditions, particularly if the coronavirus duration and severity is greater than we currently expect.

In a more pessimistic scenario with wider spread, the speculative-grade default rate rises to 9.7%, comparable to the peak in 2002. A key input to our default forecast is the rating distribution. Many companies have taken advantage of easy market access and a stable credit environment in recent years, pushing up corporate leverage and brining many smaller and medium size companies into the capital markets. About 40% of 2019 first time corporate issuers in North America had B3 ratings. That’s twice the percentage during the last recession.

Private equity-owned companies dominate low speculative-grade issuance and ratings on highly leveraged companies are deliberately positioned at single B, reflecting the tighter default risk. These companies are the most vulnerable to (00:10:52) – are the most vulnerable companies to (00:10:54) this market volatility and economic slowdown, and our ratings reflect that. So, we’re actively monitoring sector and issuer-specific shocks, and we’ll update our sector views ratings and overall default forecast as this situation evolves…

 So, with this backdrop, we do expect a modest impact to MIS revenues due to some issuers that will postpone their activity in the wake of recent spread widening and market volatility. So, (00:11:34) it is prudent to lower our guidance to the low-single-digit percentage range, even recognizing that the postponed issuance could revive quickly. And while there’s still a lot of uncertainty in exactly how this current scenario will play out, we do believe that this is a story of near-term turbulence versus long-term opportunity.

 

DuPont De Nemours (3/11 – J.P. Morgan Aviation, Transportation & Industrials Conference)

 We took $100 million out from our prior guidance and that’s all related to the coronavirus. So we’re losing $100 million in sales due to the virus, again, the impact on EPS of that is $0.04.

Now, we are highly confident that we’re leaving the EPS range at $0.70 to $0.74, which is what we’ve said on the fourth quarter call. And we’re making up that $0.04 with additional cost actions mix enrichment that we’re having in a couple of our businesses, and one I would highlight right now is, obviously, our protective garment business, which is made of Tyvek, which is a nice margin business for us that is obviously shipping more than we would have before because of the virus.

Let me give you just a little color on each of the segments. And I’m going to give you the impact of the coronavirus so you can kind of get it by business for those that want to tweak some models around. And let me start with the N&B business. We’re losing about $40 million of revenue, $15 million of EBITDA, and that’s, again, just because of the virus, and that several of our customers’ factories were down in China, so we weren’t shipping to them. And I don’t expect that we’ll recover that in the quarter in N&B, the business is kind of lost.

In T&I, it’s about $40 million revenue impact, $15 million to EBITDA, mainly into the auto business in China. You all know that the numbers are significantly down over there and the February numbers were really bad. And – but we will, in T&I, make it up through mix enrichment and cost actions that we took.

And then in E&I, it’s only about $20 million of revenue, $10 million of EBITDA. We probably lose that for the time being. We might get that demand back later, but we won’t make that up in the quarter. And S&C, Safety & Construction, that ends up being neutral to revenue, positive to EBITDA, again, because the garment sales are so much higher. We do have some weakness in China in the Water business. It’s big in residential over there in Industrial and that is down, but it’s been more than made up on the garment side. So when you wrap the whole thing together, a $0.04 EPS impact from corona, but we make it all up mostly mix, cost actions being taken across the platform.

If I go to the full year, we’ve reduced revenue by $200 million from prior, so it’s somewhat of a minor tweak to the total number, but that’s the $100 million we lose on the sales in the first quarter from Corona and we took about another $100 million out for auto that probably hits in the second quarter mostly just because of things haven’t picked up yet.

From a EPS standpoint, we don’t know how to gauge, obviously, the impact moving forward on corona. If things resolve quickly, we’d be in, obviously, very good shape, but it is a dynamic situation. Obviously, we’re monitoring it daily with our supply chain. So we’re leaving our full year guidance in place. And obviously, we’ll readdress that if we have to when we do our first quarter earnings, depending how things play out over the next days and few weeks…

 

Emerson Electric Co (3/11 – J.P. Morgan Aviation, Transportation & Industrials Conference)

Okay, good. So relative to coronavirus, relative to China, we’ll start with China first. We are basically at a 100%. We’re 95%, 96% up and running, all of the facilities running. We are getting materials. We are shipping. Shipping is taking a little longer, but definitely we’re shipping out both within the country and outside the country. At this point in time, we are working through the backlog that we built up prior to the Chinese New Year’s and then also through the delay. From the perspective of all employees, none of our employees ever did get sick. And we’ve had probably three or four special inspections from the local officials making sure that we are honoring the commitments from the facilities for a health standpoint.

The big issue right now for us and hence the $100 million to $150 million we put out a couple of weeks ago now, it hasn’t changed, it’s still the same number we see. The big issue for me right now is the demand within China, it’s still below the pace of prior year, and our forecast which – that’s what we’re trying to compensate with this $100 million to $150 million, and we’ll – every day, it gets better. At this point in time, it’s hard to say when that demand will get back up to the full level. From the state of business for us, the big issue for our customers is around financing money. The government is trying to work with the banks to get the money out, but the big multinationals have no problem with money, it’s typically our small and medium-sized customers that have that problem.

Around the world of coronavirus, all facilities are up and running, including northern Italy, we have a lot of northern Italy facilities. We have close to 1,800 people in northern Italy in 20, 30 manufacturing facilities or sites not manufacturing. I think we have 3 or 4 manufacturing facilities. They’re all running, we’re shipping. Italy for us is around $300 plus million in sales and we do ship a lot out of Italy into the Middle East and Africa region. So far, we’ve not had any disruptions, but clear that is the one area that is still moving relative to controls in coronavirus.

 

Huntington Bancshares Inc (3/11 – RBC Capital Markets Financial Institutions Conference)

While most of our customers are yet to feel material effects, all have seen the unprecedented low levels of interest rates and the rapid sell-off in equity markets, both of which raised the specter of a near-term recession… 

The visibility we have into just how long the situation will last and how deep the economic impacts will be felt is low. On one hand, there are clearly reasons to be concerned. On the other, we also know the possibility of the virus will be contained and that we will see a recovery to a more normalized environment over the course of 2020. In addition, there is the potential for positive effects on the broader macroeconomy from lower interest rates and gas prices, as well as government support actions. We are taking steps in our business, including efforts to manage our revenues through deposit, interest rate reductions and loan production mix; actions to reduce our expenses while preserving our critical long-term investments; continuing our credit underwriting posture consistent with our aggregate moderate-to-low risk appetite; and ensuring the safety and soundness of the institution is maintained.

Given the uncertain environment, I will not be providing updated full-year 2020 guidance today. However, I will walk through some of the trends we’re seeing and expand on the actions we’re taking. In times like this, the temptation is to focus solely on the volatility, the distractions around us. However, we have a company to run and strategies to execute and we are doing so.

 

Mettler-Toledo International (3/11 – Barclays Virtual Global Healthcare Conference)

As you can imagine, the overall situation continues to evolve and change very quickly. And the spread of the virus has also, obviously, created a lot more uncertainty since our earnings release last month.

So, in terms of supply chain in China, overall, we feel pretty good about the situation in terms of our production capacity and in terms of our end-to-end supply chain processes. Our production workers are back to work and we’re currently around full capacity. As I mentioned, things can change quickly and it’s a very fluid situation. When we see situations like South Korea just in the last few weeks develop, it just shows you how intricate and interconnected the global supply chain can be. Fortunately, for us, we don’t have any significant exposure to electronic components but, of course, created a couple of topics for us to address. But, to me, I just more so highlighted as just an example of how things can change very quickly from day to day on the global supply chain despite the fact that today, we feel actually pretty good about the overall situation.

I think another thing when we reflect on the supply chain, it is one of the things that we can control better than customer demand and we tend to feel better about the things we can control. And I do think we also benefit from our very strong leadership team, as well as our organization in China. We’ve often talked about the strength of this team in the past. And if you even just look at the tenure of our Chinese leadership team, I think the average tenure with Mettler-Toledo is over 15 years. Many of these leaders managed our business through the SARS situation. And so, ever since the first conversations on day one, I think they were certainly familiar with how to handle such a situation and immediately launch into business continuity planning.

The second part of the situation is China demand. This one is, obviously, a little bit more difficult to assess at this time. When we provided guidance a month ago, we had a handful of different considerations. Overall, we assumed that we would lose some working days related to the different government restrictions whether it’s regarding travel or the ability to not work in the office or in the production facility. And we also had assumed that there would be lower productivity from a customer perspective given the lack of customer-facing activities after February 10. We didn’t have any specific algorithm in terms of, like, exactly what the productivity would be by day. But, overall, we did feel like the month of March would be a very important month and that we would start to make up for some of those lost workdays and lack of productivity in the month of March. So, accordingly, for us, March is going to be a very important month. And as I said before, the situation continues to be very fluid and difficult to estimate.

When we do look at China though, we do want to also highlight we also benefit here from our e-portals, we benefit also from our tele channel. We have over 100 people in inside sales, telesales and telemarketing and we have been working with this group throughout the Chinese New Year and kind of preparing them to launch various marketing campaigns right after February 10. And I think we also benefit in China as we do globally from the diversity of our business whether it be the diversity of our customers, our products or even the applications in which we serve.

And maybe a final comment on China, we did expect when we provided guidance last month that the government will stimulate the economy and we would anticipate some benefit during the second half of this year. At this time, it’s still unknown in terms of the timing and the magnitude of such a stimulus. But we would certainly expect there to be stimulus. I think they’ve been vocal about that. And when they do, we would expect to see some form of benefit in both our Laboratory, as well as our Industrial businesses.

In terms of demand outside of China, this is clearly a very fluid situation as well. We did not anticipate the spread of the virus outside of China in our previous guidance. We’re, obviously, very alert to the situation. We’re closely monitoring it and we’re also initiating various different business continuity plans in different countries around the world, very similar to how we approached the Chinese situation early on. I would say that there is certainly different potential outcomes with the spread of the virus, but overall, I would say it’s too early to judge for us at the moment and March will also be, I think, a very important month to see how things develop and expect we’ll have a little bit of a better handle on the situation as we kind of finalize the quarter.

 

The Western Union Company (3/11- Wolfe Research FinTech Forum)

Yeah. I mean, we’re not going to restate guidance at this stage because that was given in February, and we’ll give you our first quarter results in early May and we’ll give you the latest that we’re seeing. But with respect to the coronavirus, we have not seen a material impact as I mentioned, and then we’ll see how the oil price situation works out. But again, we have some natural offsets in our business as those things play out.

 

M&T Bank Corporation (3/11 – RBC Capital Markets Conference)

So it’s a little too early to see the actual impact on our balance sheet, but we’ve been out in a very diligent way. All of our RMs are talking to customers very actively, and that covers lots of portfolios. But we’ve got a special emphasis on healthcare, where we have maybe about $6 billion of loans in assisted living facilities, basically senior housing and those types of things. And then, we’re staying focused on hospitality. So think there of about $4 billion of real estate around hotels and so forth.

 

Sherwin Williams Co (3/11 – J.P. Morgan Aviation, Transportation & Industrials Conference)

We do not have any changes to that guidance at this time as the impact of the virus is not currently material to our consolidated results. For The Americas Group, we expect it to be at or above the high-end of the first quarter sales guidance. We’re on track for that through February, and March which is the largest month in the quarter has started off as expected.

The Consumer Brands Group first quarter and full year 2020 sales were expected to be flat to up slightly, excluding the impact of the Ace business we exited in 2019. We’re seeing a short-term impact of sales due to the virus in China. But again, all of Asia-Pacific sales for Consumer represents approximately 7%. Our Performance Coatings Group’s sales in our first quarter and full year were expected to be up low single-digits with industrial demand to remain variable by geography and end market. We are obviously seeing that in our first quarter. The virus will have an unfavourable impact on the first quarter sales for this segment. But we do not believe it is material enough to update our guidance.

 

Johnson & Johnson (3/11 – Barclays Virtual Global Healthcare Conference)

I would say, first of all, Johnson & Johnson being the global healthcare leader it is, is closely monitoring the coronavirus situation and we’re trying to take steps to prevent, first of all, help the spread of the virus as well as exploring the potential for a vaccine. I think you know that we have a division in our pharm organization that is very much involved with vaccines in regards to Ebola, but also now with the COVID virus.

As you can imagine, we’re closely monitoring the coronavirus situation of – an area of impact and interest certainly for you all is manufacturing. Our manufacturing centers are producing Medical and Pharmaceutical products, as we speak. Also, in China, to a large extent, we’re back online and producing products. Of course, we’re in close alignment with the Chinese government to ensure that we can continue to provide and supply critical products to our customers.

The impact that we are seeing is more on elective procedures. As you can imagine, in China, Japan and South Korea, the impact has been meaningful. Those procedures are starting to come back online, but I would say, they’re not back to historic levels. We’re starting to see a similar trend in certain parts of Europe. And in the US, I would say, we’re in the early innings of this whole event evolving. It’s a fluid situation I would say. We’re closely monitoring it.

 

US Bancorp (3/11 – RBC Capital Markets Conference)

The areas that we’re watching are the ones that are most directly impacted by the coronavirus, so you have airlines and transportation, you have the hospitality industries, energy maybe not quite so related to the coronavirus but certainly has been in the news recently.

And then anything that really is kind of dependent upon the supply chain relative to China and those areas. With respect to, for example, airlines it’s a relatively small exposure for us. It represents about 0.5 percentage point just in terms of airlines, transportation overall is a little over 1%. So when you end up looking at each one of those exposures, very manageable from our perspective, but there’s going to be credit quality pressure I think in those particular spaces at least in the short-term. And I think a big part of that is just how long this pan epidemic continues.

 

Visa Inc (3/11 – Wolfe Research FinTech Forum)

As it relates to our business and the spending trends, as you said, we released an 8-K last week on March 2nd. As you know and everybody’s been tracking, since then, the virus has continued to spread to countries outside of Asia. As we expected, spending has continued to deteriorate especially in travel. We factored this continuing deterioration during the month of March into the updated Q2 revenue projection that you referenced a moment ago and we included in our 8-K. And just given the recency of the spread and the impact that we’re seeing on spending, it’s honestly too early to tell what the overall impact is going to be. As I think you would expect and you would hope in terms of expenses, we’re doing a number of things inside our company. We’re taking a series of actions to reduce expenses where we think it’s smart and it’s not going to impact the health of our business certainly in the medium to the long term. We continue to believe and I look forward to talking about a tremendous set of growth opportunities that we have for the company and we outlined on Investor Day.

So they’re in, listen, the situation is very fluid. There’s no question we continue to monitor it very closely. Given the uncertainty surrounding the magnitude, duration, the geographic reach of the impact, we’re going to give an update of our views for future quarters and the full year for 2020 on our earnings call in April.

 

Rockwell Automation Inc (3/11 – J.P. Morgan Aviation, Transportation and Industrials Conference)

In China, we have plants in Harbin which is way up in the Northeast, and as well as in Shanghai. People are back to work and our production in our plants is keeping pace with current demand. From a supply chain standpoint, we mentioned before that some of the supply chain actions that we took to mitigate tariff impact are actually benefiting us now based on the current environment.

It’s still a very fluid situation, and we’re working with suppliers in all regions to mitigate any potential disruption or lead time increases. And we’re selectively increasing our inventory levels of some components and products to protect the supply for our distributors and our customers. And I should mention that all our distributors in China are back to work.

In terms of China order intake; for reference, China is about 6% of our total sales. There’s a clear impact, as you would suspect, of coronavirus in China particularly in February. But in the end of February and into early March, we did see some weekly sequential improvement in order intake. We expect China to be down versus expectations year-over-year in quarter two, but it’s too early to determine the fiscal 2020 impact as we assess what sales were lost versus delayed.

From a rest of world standpoint, North American product sales through last week were encouraging, but obviously, March will be key with respect to our worldwide Q2 performance. So, that’s a little bit of a rundown with some additional information, Steve.

 

Citigroup Inc (3/11 – RBC Capital Markets Conference)

And so as I sit here and think about it, I think the prospect of slower growth and an impact on growth more broadly is certain. When you can see it, when you look at – if you just look at Asia and you look at the manufacturing production numbers that are coming out of Asia, we can look at the purchase sale volumes coming out of Asia. We can look at corporates adjusting their expectations. Gerard, the simple fact that we’re doing this conference call via virtual, we’re doing this conference via virtually is again evidence that there’s going to be an impact from many of these macro factors that are out there.

And then there’s the other piece, which is how this plays out across the businesses. We obviously have operations in Asia. With Asia, it represents about 20% of our revenues. About half of that is institutional, about half of that is our consumer revenues. If you think about the countries most impacted, China, Hong Kong, Japan, Korea, they represent about 8% of our revenues. And we’ve seen kind of mixed activity there. Activity, obviously, that involves direct consumer engagement has come to a halt. That said, activity that is geared around the investments we’ve made into digital capabilities, we’ve seen continued good activity there in terms of clients or consumer, customers trading, and what have you, things they can do online versus requiring direct engagement.

On the corporate side, we have a large corporate client base broadly in and outside of Asia, and the impact there will vary depending on the sector. So, certain sectors like hospitality and travel, we’ve seen the impact of that already. On the flip side, we’ve also seen a flight to quality as it relates to deposits. And you’d expect to see that, I think, in uncertain times and we’ve certainly experienced that thus far. We’ve also seen market volatility. So, think about the significant decline in equity valuations, the 10-year being meaningfully down. Those types of things are creating volatility, causing our clients to engage, to take positions. And it, obviously, creates opportunities for us to serve those clients, and that flows through as a benefit in our Markets revenues. And so, there’s a mix of things that are playing through, some puts and takes, as you would imagine.

 

CSX Corp (3/11 – J.P. Morgan Aviation, Transportation & Industrials Conference)

I mean, we know that there was an extended outage in China. We know there were a large number and abnormal number of vessel sailings canceled. We expect that as a result of that volumes would be down, takes a while for that both cycles to get over to the west coast. And sure enough, it’s – what I did – last week whatever it was down 10% and as it down 20%. It’s kind of what everyone anticipated, the steamship companies at least some of them seem to have an optimistic view of a quicker – quick return to normalcy at least out of China. And so you know we’re prepared if the – you know we’re – if anything based upon all of the changes we’ve made in the way we run the railroad today, we’ve proven the fact that we can pivot a lot faster, are a lot more nimble and can adapt to changes as they are thrown at us. So if more traffic comes to us through our interline partners, with our channel partners, our interline partners and our channel partners from the west, we’re clearly able to like I said pivot and handle that business as well. So we’ve got a great running railroad and capacity to handle traffic changes, whether it comes east or west. I think that’s just kind of the one thing from a railroad perspective, you know one day we’re – one day we’re operating in a polar vortex, the next day we’re operating with mudslides and the next day we’re operating with hurricanes. We’re used to this kind of environment. We’re used to being able to need to change and have been thinking about how to make sure that we’re ready to handle our customer’s products, however, they decide to ship it.

 

Fifth Third Bancorp (3/11 – RBC Capital Markets Conference)

So, obviously, a lot of our customer – or some of our customer base that has a direct exposure to China pipelines and so forth is concerned. We’re starting to see that pick up a little bit better. But net-net, as this rolls into United States, which is a large portion of our customer base obviously is US-based, is the concern about making sure to take care of the employees, identifying where the risks are, and making sure that they’re protecting their capital and liquidity also as they manage through a very difficult environment….

We haven’t seen evidence yet. We’ve certainly seen – we’ve had a number of conversations with our customers, and if you look at public data about airlines – the expectations about air travel and what’s going to happen from a tourism perspective, we can certainly speculate. But in terms of actual activity in financial results, we haven’t seen that from our customers yet. We’re in active dialogue with them to make sure we understand both what’s happening on the ground from an activity perspective, their liquidity positions working with our customers to make sure that we understand the downside that they are facing and then we stressed that as well.

 

Cigna Corporation (3/11 – Barclays Virtual Global Healthcare Conference)

Now, in terms of financial impact which is where you went, at this point, we’re not expecting a material financial impact to Cigna overall. As you know, we recently reaffirmed our 2020 earnings guidance and continue to be very excited about our growth across all four of our growth platforms.

In terms of your specific question, as you know, we have businesses both inside the US and outside the US. With our international business, we have both a global health benefits business and a local supplemental benefits business. With the latter, we offer a wide range of supplemental individual products. And as you know, we have quite a material business operations in Asia, in China, and Korea specifically. As it relates to China, what we’ve seen there is we’ve seen lower levels of elective discretionary utilization as people are really avoiding hospitals overall and healthcare facilities. But we’re also seeing some dampening on the revenue side from new sales. But all in all, outside the US, we would not expect a material financial impact to the total enterprise based upon the dynamics.

I think your question and where you referred to some of the other companies was more what was happening within the US. Within our Integrated Medical, we would – very similarly to others, we would really expect to see the coronavirus unfold much like the flu. And as you know, over time, Cigna has never really pointed to the flu as a key driver to our earnings even in years where they’re more severe than other years.

As you size it and we think about it, we think about the full-range impact. In terms of our MCR, medical cost ratio, or medical trend, for us, it’s usually relatively muted. It’s usually in the single- to low-double-digit-basis-point range. So, not a significant event. We continue to see the coronavirus in that context.

Now back to the second part of your question which is, obviously, if this would persist over time, from our viewpoint, we could obviously adjust that in a commercial pricing more quickly and then certainly for our governmental business, on the annual basis. But I would highlight, for Cigna, we’ve historically been less exposed to this – based upon the mix of our business and the nature of how our book of business has been positioned. So once again, I would stress, the flu, for us, high-single-digit, low-double-digit basis point as it relates to our MCR and our medical cost trend.

 

Boston Scientific Corp (3/11 – Barclays Virtual Global Healthcare Conference)

But happy to talk about the company. The COVID-19, obviously, is getting daily, hourly attention. When we’ve provided guidance for full year, we talked about 6.5% to 8.5% growth on our call. And then, we obviously saw the COVID-19 impact pretty early. So, we tried to do our best to call out a potential negative impact from China back on February 5, which as you said was 10% to 40%.

And so, longer-term, we’re very comfortable with the three-year CAGR we’ve talked about on the 6% to 9% organic growth. I’m sure we’ll talk about a lot of the growth drivers and products. But the COVID-19 has been quite a big challenge for us as it’s – so it is true for almost (00:02:46) everybody. Starting in China, a lot of focus on our employees and our actions there, and you basically saw procedures slowed down significantly in first quarter based on the impact there, most of our reps working from home, leveraging digital tools and the hospitals managing the virus.

And it’s super early. There’s maybe some hopes that the China situation is getting a little bit better, but it’s been significant impact since that call, and obviously, it spread some of the impact to other regions in Asia, in Korea, as well as some challenges in Japan, and obviously in Italy. And as you’ve seen, all of – the (00:03:37) impact in the US with some hospitals preventing sales reps from entering in the hospitals and quarantine situations and so forth.

So, it’s certainly been an evolving situation. When we look at it, we’re doing everything we can to support our employees and our patients. We feel very good about the underlying growth, the core Boston Scientific business ex-COVID-19, but we continue to challenge our work to be (00:04:06) a challenging situation, we’re not going to reiterate our guidance. At this point, we’re not going to update our guidance from that February 5 call and we’ll do that on our April call.

 

Moody’s Corporation (3/11 – 8K)

“We are revising Moody’s Investors Service’s full year 2020 revenue guidance from mid-single-digit to low-single-digit percent growth reflecting ongoing uncertainty related to the coronavirus,” said Raymond McDaniel, President and Chief Executive Officer of Moody’s. “We will continue to monitor and proactively manage our response to the situation as we work to meet stakeholder expectations.”

 

Hilton Worldwide Holdings Inc (3/11 – 8K)

On its February 11, 2020 earnings call, Hilton Worldwide Holdings Inc. (“We” or the “Company”) provided an estimated potential impact of the COVID-19 outbreak. As the outbreak has now spread beyond China and the Asia Pacific region, we believe that the potential negative impact will be greater than our previous estimate and have issued a press release to announce that we are withdrawing our previously announced first quarter and full year 2020 outlook. We expect to provide further information during our first quarter earnings call based on information available to us at that time.

 

Dick’s Sporting Goods (8K – 3/10)

The Company’s outlook balances the enthusiasm it has for its business with the rapidly evolving coronavirus situation. Accordingly, the low-end of the Company’s outlook includes some caution related to supply chain disruption potentially impacting its results beginning in the second quarter.

 

At Home Group (8K – 3/10)

Mr. Bird continued, “We are also closely monitoring the impact of the Coronavirus outbreak on our supply chain and consumer demand while prioritizing the health of our team members and customers. Given the fluid nature of the situation, we look forward to sharing an update on current trends during our upcoming earnings call on March 24, 2020.”

 

Macy’s (Bank of America Merrill Lynch Consumer & Retail Technology Conference – 3/10)

Answer – Lorraine Corrine Maikis Hutchinson: Thanks so much, Paula. I wanted to kick things off with a broader macro question. How do you think your core consumer is today?

Answer – Paula A. Price: Well, what I would say, Lorraine, is very similar to what we’ve said before, with the obvious caveat being that our outlook was prior to the COVID-19 outbreak and the oil plunge. So here’s how we think about the consumer fundamentals.

U.S. job, wage and income growth remain solid, which should contribute to consumer spending. But while the consumer environment remains healthy, we do expect slower economic growth overall versus prior years. And so with that in mind, we would expect that we would maintain our relative market share as a starting point for how we think about 2020.

Answer – Lorraine Corrine Maikis Hutchinson: Excellent. The potential impact to supply chains and sales from the coronavirus is top of mind for investors right now. In terms of sales, are you seeing any impact from the softer tourism? And how exposed are you to this revenue stream?

Answer – Paula A. Price: Yes. So I would start by, again, just saying, as I said in my opening comments, that this continues to be very much an evolving process, and we’re getting updates from our teams on a daily basis. And again, first and foremost, our colleagues and customers are top of mind, and we’re taking every precaution there. And so as this continues to evolve and more cases are being identified throughout the U.S., it’s still too soon to quantify what the impact on sales could be. But what we can say is that we’re certainly seeing a slowdown in international tourist sales. And as for the impact from the domestic customer, we’ll continue to monitor that very closely.

 

Ryanair (6K – 3/10)

Ryanair does not expect these traffic reductions to have a material impact on FY20 (31 March 2020) PAT guidance. It is far too early to assess the impact of Covid-19 on FY21 traffic and earnings. The Ryanair Group will continue to focus on delivering cost savings and improved operational efficiency in FY21. Ryanair is one of the strongest airlines in the industry with €4bn in cash, industry leading unit costs, 90% of the fleet is owned with over 70% debt free.

 

Royal Caribbean (8K – 3/10)

The company had previously communicated that its 2020 guidance did not include the impact of the COVID-19 outbreak. Given the recent government actions and the heightened impact and uncertainty of changes in the magnitude, duration and geographic reach of COVID-19, the company is withdrawing its first quarter and full-year 2020 guidance.

Quest Diagnostics (Barclays Global Health Conference – 310) 

Question – Jack Meehan: Just wanted to start, Mark, with the here and now obviously, the topic de jure has been the coronavirus. I was curious if you could weigh-in just how you expect this to impact the business and demand for testing services and have you seen any increased testing rates so far related to the new test?

Answer – Mark J. Guinan: Right. Thanks for the question, Jack, and pleasure to be on the phone here. What we’ve shared publicly is that we started yesterday with specimens collected yesterday in California, at our Esoteric Lab in San Juan Capistrano, we’ll be ramping up capacity. There’s a validation process across multiple pieces of equipment and then across multiple sites. It’s going to take us several weeks to maximize our capacity through that validation process across the 2 Esoteric sites and then some — we do have some of that equipment, we’re using in some of our regional labs, and Steve shared yesterday in an interview that within several weeks, we expect to be able to do several tens of thousands of tests a week.

Now we’re all speculating. So I have no idea what demand will be. But based on the discussion that took place in D.C. last week with the Vice President — or with Secretary Azar, the sense is that the demand could far outweigh capacity even with us and our — the international lab and multiple regionals and hospitals all ramping up as quickly as possible that it is a race to increase capacity. So we’re not in any way, sizing this, and saying, we think we’re going to get x, and therefore, we’re only going to create so much capacity. We’re going to create as much capacity as we possibly can as quickly as we can. And then, obviously, monitor the incidence rate and see if we need to slow that down, but we’re not at all being cautious.

The next phase, Jack, would be likely, there are several IVD manufacturers who have suggested they have some kits that would be available as well. We’re probably a couple of weeks away from those. If that ends up being accepted and validated, then the next step of capacity would be acquiring some of those kits in addition to the laboratory-developed tests that we’ve already put up and got approval for it through emergency use.

So that’s kind of where we’re at. We’ve shared a couple of instances already where we can’t size this. We’re not going to predict how much testing we’re going to ultimately do. It’s unpredictable. And that we do think there is potential for an offset on utilization because society seems to be changing behavior around certain things. We’re not having this conference in personThat’s a prime example.

And so one could imagine that some people might choose to engage less with the health care in structure for concerns around catching something in the office and the waiting room from the doctor, et cetera. We don’t know. And we’ve already had a couple of investor 101s this morning. I’ve been asked certainly, we don’t share mid-quarter updates. However, if there was anything material that we’ve seen a change in our business, we’d feel obligated to share something. And again, we don’t know. So one thing you might think about is our average patient counter, which is our acquisition is the mid-$40 range. Certainly, the coronavirus reimbursement should at least cover that, if not be a little higher. And so you’d say a one-for-one swap would be about even, but we don’t know how many people is going to be one-for-one and office visits replaced for a corona visit. And then the other question is mix. If people who don’t engage are skewed toward healthy annual wellness check. Certainly, we do a lot of tests in those — the whole battery of chemistries and lipids and blood count and so on, how our seniors are going to react. Seniors consume more of our business. So are they going to be more or less likely to go the doctor, one camp can say, “Hey, for the smallest sniffle, they may rush in because, obviously, I want to get — seriously, I only want to get in-treatment quickly.” And the other thing is they’re the mostly at risk. So therefore, maybe they’re going to mills cautious. We don’t know. So all we can share is some of our thinking, but we can’t quantify any at this point. We just want to acknowledge that. Like other industries, we think that there could be some potential for negative impact to our business if people change their behaviors. However, unlike many other industries, we also will do some testing specifically related to corona.


Teleflex (Barclays Global Health Conference – 3/10)

Question – Kristen Marie Stewart: Obviously — yes. Obviously, the big topic all around here has been coronavirus, the reason why we are virtual today. You’ve said that basically, the amount that you included within your guidance thus far has been a $5 million to $10 million impact. I was wondering if you could kind of talk with us just about any updated forecast you may or may not have? Or just kind of thinking, as you’ve seen the virus spread through different geographies, just how you’re thinking about that today?

Answer – Liam J. Kelly: Yes, thank you. So you’re correct. Yes, we have $5 million to $10 million in revenue in Q1 and an impact of $0.05 to $0.10 associated with the coronavirus. That is based on what we saw when we gave our guidance for the year, and it’s included in our guidance. And it was really the impact that we saw in China. The lower end of that range would have been if China get back to normal in early March. The upper end of that range is contemplated that China gets back to normal in April. Now what we are seeing on the ground, we have 1 small manufacturing plant in China, that has been up and running now for about 10 days and running pretty well. Our office got back to a pretty normal working conditions over a week ago. So yesterday week, our people went back to work in the office. And 2 weeks ago, the individuals that had left Shanghai — so 2.5 weeks ago, in a population of 20 million people, there were only 10 million people living in Shanghai. Two weekends ago, all of those individuals returned. So now there’s 19 million people. Obviously, Hubei is still in lockdown. So the travel was restricted there. But our people tell us that things are slowly starting to get back to normal in Shanghai, which is probably a good indicator for at least the Eastern seaboard, where most of our products are sold and our expectation is that as we go through the month of March that Shanghai, Beijing and large cities like that will get back to some semblance of normality.

Kroger Co – (Bank of America Merrill Lynch Consumer & Retail Technology Conference – 3/10)

From a financial standpoint, it’s too early to tell what the effect will be on our business and it isn’t included in our guidance for 2020, in terms of business preparedness, we have established an internal task force that is activated our pandemic preparedness plan with a focus on our customers, associates and supply chain, we generally believe that we have a limited supply chain exposure in China as the majority of the product we source is domestic.

Laboratory Corp. of America Holdings (Barclays Virtual Global Healthcare Conference – 3/10)

In terms of impact, as I mentioned on the fourth quarter call, we believe the range that we’ve given for guidance will cover what we currently believe the impact to be from the coronavirus. So though there will be some pushes and pulls. We give annual guidance. We don’t give quarterly guidance. But I do believe that there will be some things within the quarter that may occur, particularly if we think about our central lab in China for example where we had quite a backlog as China took an extended holiday through the New Year’s, and therefore that laboratory had a backlog we’re trying to work through that backlog, people are back to work in the laboratory, but whether that happens in the first quarter or second quarter is yet to be determined. In addition to that, in some of Asia and but also in certain parts of Europe we’ve seen clinical trial enrollment slowed down for a period of time. And we see the impact of that as we continue to see the coronavirus in other countries in the world, but we do believe that there may be some impact there. If you look at the diagnostic testing that we do in the United States, we haven’t seen any significant impact of the number of tests, type of tests as we sit here today, but of course we’ll be watching it very closely and when you start to think about people going in for wellness exams for example or going to doctors for routine testing that might slow down a bit even as we coronavirus testing go up a bit in the diagnostic area in the United States. So net-net we still believe that we’re covered with the guidance that we provided in the first quarter but with some pushes and pause across the business, and there may be some quarterly shifting, but we still feel based on where we are today realizing it’s still a very fluid situation that in the guidance.

 

Reynolds Consumer Products Inc. (Earnings Call – 3/10)

Recently, we’ve seen some retailers increasing orders and higher-than-normal consumer takeaway. We believe that the inventory and pantry load to be temporary, possibly shifting some volume into the near term and then reversing before year-end. Therefore, we don’t expect a material impact from the coronavirus at this time. We will continue to monitor the developing situation and are developing plans to escalate in North America as the virus could have an impact on our operations and supply chain. As we continue to think about ways to adapt to changing consumer preferences, e-commerce is a primary focus for Reynolds. Our products are shelf stable and are cost effective to ship directly to consumers which makes us well-positioned for growth in the e-commerce channel. In our role as the leading CPG company, it is essential that we effect change to establish sustainable business practices. For years, we’ve been focused on sustainability and have created a broad line of eco-friendly products that are better for the earth. We have a team dedicated developing products made with recycled, renewable, and compostable materials including wax paper sandwich bags, compostable paper plates and food bags made from resin using sugar cane as a feedstock. 43% of the products we sell in the US are recyclable and are made from recyclable material. And while we’re proud that we’ve achieved this level, we continue to strive for improvement. Our goal is to reduce 80% of our solid waste in the US operations and design all packaging for recycling by 2025.

It’s really early days of what we’re seeing from commodity costs as a result of coronavirus. Our forward guidance is based on what we’ve seen to-date and are – we believe that if the current prices that we are seeing remain at this level or decrease, there’ll be some modest tailwind for our earnings going forward.

Cardinal Health Inc  (Barclays Virtual Global Healthcare Conference – 3/10)

As far as on P segment and the tie it to the coronavirus we do – we had anticipated this a while back so we first saw it in China, our team immediately began looking through our database to see where we either had finished those which very little coming from China but more importantly where there is any raw materials coming from and in particular the Wuhan province where was ground zero for this. There are some raw materials that have nearby province so knowing that we did stock up on some extra inventory on key products that had raw materials coming from that area very early on to make sure that we understood that we – you know what was going on that we could have some extra, we have done this as it’s moved around the world we constantly use our database to understand if we’re going to have any finished good or raw material problems with any of the pharmaceutical items so we looked in Italy when it began to hit Italy et cetera and we continue to adjust our inventory where we can get extra product to stock up to make sure that we’re staying ahead of it. The good news is through our conversations and I’ve had a few myself directly, most of the manufacturers are carrying a few months’ worth of inventory on hand. So feel like at least for the next few months we should be fine to be able to get the majority of items that we need. Now if this were to extend past the early summer then I think everyone’s going to be looking at some potential supply disruptions not only because of the API materials but one of the other piece that’s harder to track because there are so many of them is key starting materials or KSMs so the items that go into the manufacturing of the API. Some of those are have some potential disruptions and so some of the suppliers again are keeping their eyes on those. But tell us so far that they hold several months of APIs, finished dose stock and KSMs and we should – that we should be okay for a few months…

 I am — I would say so far we’ve not seen any material price increases that I would say are related to the coronavirus yet. There are manufacturers that are starting to see some price increases on API. And as you know we’ve talked about this in the past, our goal for Red Oak is to never take any price increases. So we’re always going to fight aggressively to make sure that we’re getting after the lowest cost. Now there are times when you sometimes do take them at the right thing for ourselves and the supplier; and when we do we are typically able to pass those price increases through to our customers. And the goal there being to maintain our cell margin per unit. So I think it’s while generally in the past I would say it’s been true that in a inflating market you tend to see your dollar margin per unit increase. I’m not sure if that’s it’s definitely not always the case. We’re going to have to see where this goes going forward and what we’re able to do based on the items that go up in supply and different things. But it’s — when your costs go up the key is can you pass through on your sell side of equal at least an equal dollar amount. Sometimes you can pass through a little bit higher dollar amount and you have lower margin rates with higher margin dollars and sometimes you can’t. So it’s really about understanding the market, understanding reimbursement, understanding the other pieces of the market to make those decisions. So right now, like I said we haven’t seen anything material. We’re keeping our eye on it. So it’s a little hard to predict at this point in time what we would expect. We don’t really have anything to build into our guidance at this time that was assuming price increases and increased margins necessarily related to the coronavirus.

Delta Airlines (JPMorgan Aviation, Transportation and Industrials Conference – 3/10)

As the situation has evolved, our first priority has been protecting the health and the safety of our customers and our employees. Our team has significantly increased resources to insuring our aircraft and facilities are clean and exceed our already high safety standards. While our year had gotten off to a strong start, in fact being ahead of plan for the first two months. Two weeks ago, our revenue trajectory changed dramatically as the virus spread meaningfully outside of Asia. Since then, we have seen a 25% to 30% decline in net bookings and are prepared for it to get worse. We expect demand erosion will continue in the near term and a built-up plan that prioritizes free cash flow generation and preserves liquidity.

Besides the safety of our employees and customers, our overarching goal during this time is cash preservation. We are targeting a minimum $5 billion in liquidity, being free cash flow positive and maintaining our investment grade balance sheet. And we’re taking a number of actions to address the financial impact.

First, the biggest lever that we have is capacity. We are actioning system capacity reductions of at least 15% down versus our plan. We are taking international down 20% to 25% and domestic down 10% to 15%. Importantly, we’re prepared to do more as the situation evolves. Second, we’re implementing cost reduction initiatives and are taking out $1.8 billion of expense versus our plan. This includes capacity related expenses as well as incremental cost initiatives that include a hiring freeze, offering voluntary leave options and lowering maintenance expense by temporarily grounding aircraft.

We have also had the benefit of approximately $2 billion of lower fuel expenses. Jet fuel prices have dropped significantly since the start of this year. Finally, we’ve also undertaken $3 billion of cash flow and liquidity-enhancing initiatives including CapEx deferrals, delaying voluntary pension contributions and suspending share repurchases. By taking these actions now, we can mitigate the impact going forward.

Unfortunately, there’s little we can do to impact the March quarter which we currently expect will see a mid to high-single digit decline in unit revenues for the quarter. We are also withdrawing our full-year guidance until we have more clarity on the duration and severity of the current situation…

Thanks, Ed. With customer demand impacted by virus-related fear of travel and corporates implementing a significant travel restriction, we’ve seen load factors under pressure. For the first seven days of March, domestic load factor was 77%. With bookings softness and increased cancellation rates, we expect our March full month domestic load factor will be closer to 65% to 70%. This would be down roughly 20 points over last year but people are still flying.

To better serve our customers during this uncertain time, we have extended our broad-based change fee waiver for existing bookings for travel through April 30 as well as all new bookings made in March and matter the travel period and are remaining flexible as the situation evolves.

But with these types of load factor declines, we must rationalize our capacity to adjust to the new level of demand. In the near term, we are reducing system capacity by at least 15 points versus what we previously scheduled. This reflects a 20% to 25% reduction in international flying with the 00:07:39 production in the Pacific. Our Pacific franchise is now down by 65% including full suspension of flying to China and significant reduction in both Japan and Korea.

The trans-Atlantic will be reduced by 15% to 20% The transatlantic will be reduced by 15% to 20% with the biggest production to Italy. Suspension of JFK Tel Aviv and cuts to leisure markets which are expected to see weakness throughout the summer. While Latin has been the least affected so far, we are monitoring closely and trimming weak demand flights.

Finally, domestic is where we have the most uncertainty as booking trends have worsened materially over the past week. We are currently targeting a 10% to 15% reduction in planned capacity. Domestic capacity reductions are primarily accomplished in high frequency markets and through the removal of utilization flying. Initially, when the outbreak was limited to Asia, we redeployed widebody aircraft to uneffected regions. But with recent deployments – with recent developments, we are parking both widebody and narrowbody aircraft and are evaluating early retirements of older, less efficient airplanes. Importantly, we continue to have significant flexibility on capacity allowing us to react quickly as trends change and they are changing quickly.

Honeywell International Inc (JPMorgan Aviation, Transportation, and Industrials Conference – 3/10)

We did also talk about the planning assumptions that underpin the guidance, including among other things our expectation that there’d be minimal economic impact from China and the global economy from the coronavirus as well as, the assumption that the macroeconomic environment as we exited the fourth quarter, would remain pretty you know consistent throughout 2020. Those last two things, obviously are being challenged, real time and the corona situation and its implications are changing day-by-day as frankly evidenced even by, what’s happening real time even now in places like Italy. Despite all that and based on our best possible forecast despite all that and based on our best possible forecasts as we see things today, we are reaffirming our original guidance for the first quarter. You know keep in mind our quarters tend to be back-end loaded in general with about 50% of our sales happening in the third month of every quarter. And with some of the challenges that have been going on this year that’s probably even a bit more true than usual. That does make things a bit more difficult to call, which means among our guided metrics, organic sales growth will likely experience the most pressure when all is said and done, but we do know how to execute in environments like this, and we’re going to continue to operate the company for the long-term for value creation, we do think this is a transitory impact at this stage…

At this stage, we’re expecting the coronavirus to be short-term disruption as I mentioned, but that really does continue to evolve daily, in fact I just got out of our morning call probably 30 minutes ago with our team to understand what the effects of that are real-time.

United Airlines (8K – 3/10)

United Airlines, Inc. (“United”), a wholly-owned subsidiary of United Airlines Holdings, Inc. (“UAL”, and together with United, the “Company”) has continued to experience a material decline in demand for both international and domestic travel, as well as an increase in trip cancellations, resulting from the spread of coronavirus (“COVID-19”). As such, the Company has taken proactive steps to mitigate the financial and operational impact to the business.

As a result of the decline in demand resulting from COVID-19, in addition to the capacity reductions on the Company’s trans-Pacific routes announced last month, the Company has also announced that it has pulled down 10% of its domestic schedules and 20% of its international schedules in April. The Company also anticipates making reductions in May of at least 20% and plans to proactively evaluate and cancel flights on a rolling 90-day basis until it sees signs of a recovery in demand. The Company’s capacity reductions have been focused on, but not limited to, reducing frequencies in markets with the ability to re-accommodate passengers on other frequencies or through other hubs, destinations in level 3 or level 4 travel advisory regions and surrounding areas and routes performing significantly below the system average.

As such, the Company is responding to this changing environment by adjusting its capital expenditures, operating expenditures and liquidity position. With respect to capital expenditures, the Company has postponed projects deemed non-critical to the operation. Therefore, the Company currently expects adjusted capital expenditures1 for full year 2020 to be approximately $4.5 billion. The Company’s capital expenditures were front loaded in 2020, and as such, the Company has spent approximately $2 billion year-to-date. The Company also suspended share buybacks under its existing share repurchase program on Monday, February 24, 2020 after the virus outbreak expanded to Italy.

American Airlines  (8K – 3/10)

In particular, the consequences of the coronavirus outbreak to economic conditions and the travel industry in general and the financial position and operating results of our company in particular have been material, are changing rapidly, and cannot be predicted.

Centene Corp (Barclays Virtual Healthcare Conference – 3/10)

We’re reaching out to the various constituencies. I think as we said last week we feel like we’re well-positioned for a situation like this given the local approach that our Centene has always had to managing it’s populations in the markets we participate in. So, I would say again prefacing it by saying it’s still early. We haven’t seen a change from the comments we made last week on the March 4 call where we did the 2020 guidance.

And we – I just throw a couple of the other data points out there that we highlighted last week on this topic are greater than 8% of the cases that have been out there so far on Coronavirus are mild and as far as populations go the, the older one seem to be the more vulnerable at Centene which includes WellCare. We’ve got 94% of our combined population patient membership population 94% younger than 70 years of age and 45% is less than 20 given our big participation number one market share and Medicaid especially the TANF and the CHIP populations.

 

Delta Airlines (8K – 3/10)

“In the weeks since COVID-19 emerged, Delta people have risen to the challenge, taking every possible action to take care of and protect our customers during a stressful time,” said Delta CEO Ed Bastian. “As the virus has spread, we have seen a decline in demand across all entities, and we are taking decisive action to also protect Delta’s financial position. As a result, we have made the difficult, but necessary decision to immediately reduce capacity and are implementing cost reductions and cash flow initiatives across the organization.” 

To align capacity with expected demand, Delta is reducing system capacity by 15 points versus its plan, with international capacity reduced by 20-25 percent, and domestic capacity reduced by 10-15 percent. The company will continue to make adjustments to planned capacity as demand trends change.

Freeport-McMoran Inc  (8K – 3/10)

“Despite market volatility and potential economic impacts of the Coronavirus and turmoil in the global oil market, our team remains focused on execution of our plans to enhance performance at low copper prices and provide opportunities for superior performance as market conditions improve. Copper is an essential element of the global economy and its fundamental long-term outlook remains favorable.”

FCX also announced that there have been no significant disruptions to its supply chain or product shipments since the outbreak of the Coronavirus.

 

Qantas Airlines (IR Circulars – 3/9)

Announcing the changes, Qantas Group CEO Alan Joyce, said: “In the past fortnight we’ve seen a sharp drop in bookings on our international network as the global coronavirus spread continues.

“We expect lower demand to continue for the next several months, so rather than taking a piecemeal approach we’re cutting capacity out to mid-September. This improves our ability to reduce costs as well as giving more certainty to the market, customers and our people.

 

Akamai Technologies (3/9 – Deutsche Bank Media, Internet & Telecom Conference)

But I’m pleased to say, within the last 1.5 years, we’ve kicked in some initiatives that would allow us to find some new logos around the globe, and that continues to add in some booking strength in terms of growth. So I would say, in the near term, you’re going to continue to see the security solutions that we offer is kind of the main driver of growth. You have some new products, like page integrity that come out later this year, that should be, hopefully, very, very successful and probably pretty easy to roll into the quota-bearing reps sort of bag.

And then you have some longer-term sort of opportunities around identity cloud or customer identity as well as what the coronavirus is, working from home, our enterprise solutions would be a very logical selection for companies as they continue to reach a remote audience with cloud-based applications. And so we have like a much more dynamic, improved, secure gateway product that rolls out later this year. And so I’m pretty excited about some of the opportunities in the enterprise security space, which my belief is that the addressable markets in that sort of dwarf the security space that we’re in today.

Bookings.com (8K – 3/9)

Glenn D. Fogel, President and Chief Executive Officer of Booking Holdings, said, “As we explained when we provided first quarter 2020 guidance during our fourth quarter earnings announcement on February 26, 2020, the circumstances of the COVID-19 outbreak are changing rapidly and our guidance was based on the information we had at the time. As the situation has worsened and the negative impact on travel demand has increased since we provided guidance, in particular more broadly across Europe and in North America, we have decided to withdraw that guidance. Given the rapidly evolving situation, we are unable at this time to reliably quantify the impact of the COVID-19 outbreak on our future financial results. We plan to provide more information during our first quarter earnings call based on the information we have available at that time.”

Mr. Fogel continued, “While the full impact and duration of the COVID-19 outbreak is unknown at this time, we have been through travel disruptions in the past and expect that this disruption will ultimately be temporary. We believe the company has a strong operating model and solid balance sheet, which will enable us to weather this disruption. We remain confident in our long-term prospects and strategy, and we will continue to manage the company in a measured way to build value for the long term. In the meantime, we will continue to monitor the situation and support our customers, partners and employees during this difficult time. Our thoughts remain with the people impacted by this outbreak.”

 

Host Hotels (8K – 3/9)

Host Hotels & Resorts, Inc. (NYSE: HST), the nation’s largest lodging real estate investment trust (the “Company”), today announced it is withdrawing its full-year 2020 guidance due to the ongoing financial impact of reduced travel demand as a result of the global coronavirus (COVID-19) outbreak.

 

Vail Resorts (8K – 3/9)

Regarding the Company’s outlook, Katz said, “Given the uncertainty surrounding the impact of the coronavirus on the broader U.S. travel market and any specific impact to the performance of our Company, we are not issuing guidance at this time for fiscal 2020 and are withdrawing our previous guidance issued on January 17, 2020. In the week ended March 8, 2020, we saw a marked negative change in performance from the prior week, with destination skier visits modestly below expectations. We expect this trend to continue and potentially worsen in upcoming weeks.”

 

Interpublic (Deutsche Bank Media, Internet & Telecom Conference – 3/9)

Now, you’re correct that when we put together that number, the coronavirus was sort of in its early stages, we didn’t have a handle on what impact that’s going to be, but we were conservative in the number that we put out there for a number of reasons. One, if you look at us historically, we have a tendency to beat the numbers that we put out as guidance as we did on organic, our guidance was 2% to 3% in 2019 and we came in at 3.3%. And the year before, we beat even more with respect to the guidance.

So, we’re fairly conservative in the numbers we put out there because we understand that our analysts, such as yourself, use this for modeling purposes and we do build in some conservatism in these numbers, both with respect to the organic growth as well as the margin numbers that we put out there.

That said, the issue of the coronavirus has obviously changed dramatically since we did that. But I did want to put out there that we do have some conservatism in the forecast that we did and it’s based on a bottoms-up numbers. It doesn’t go top down. Some companies take last year’s performance and just provide a factor of increase over that. That’s not the way we do it. We start with zero and we have our agencies build up what their numbers will look like.

 

Varian Medical Systems Inc – Conference Call – March 9th

 Today, we announced that the COVID-19 outbreak will negatively impact our operating results.

Across the company’s Asia Pacific geographies, health care resources are being prioritized for the treatment and management of the outbreak. Consequently, we are experiencing delays in hardware and software installations and acceptance as well as in delivery of interventional oncology procedures. While no orders have been canceled, we expect revenues to be negatively impacted. And as of today, estimate second quarter of fiscal 2020 revenues to be in the range of $800 million to $825 million. While uncertainty remains around the duration, severity and geographic scope of the COVID-19 outbreak, we preliminarily estimate 7% to 9% revenue growth for fiscal year 2020.

Yes, Matt, specifically, there were 7 provinces in China that were hit quite hard with coronavirus. And as part of that, as Dow noted, with cancer treatments being inpatient in the country, the hospital beds were allocated to coronavirus patients and that really drove the focus away from radiation oncology, and so we had some delays in installs, acceptances, et cetera. We see those continuing forward as things get back to normal. We’ve seen progression in 6 of the 7 provinces in that direction. And just to echo what Dow noted about the market as a whole, our NPS in China has been 84%…

Answer – Dow R. Wilson: Net — that’s Net Promoter Score.

Answer – Christopher A. Toth: Net Promoter Score has been 84%. And during this time, our system uptime has continued to be very high as well as we’ve been able to continue to provide service. So the net result from our customer base has been continued positive feedback. So feeling really good about market perception, and we’re seeing progression to come back to some level of normalcy over the next 45, 60 days…

So in China, it’s really just been the access issue and the focus within the hospitals on providing care. As Dow shared earlier, in China, cancer care is inpatient. So the focus has been on coronavirus. As we are getting back to some level of normalcy, that will just installs and acceptance will follow. We have not been seeing, in other areas, a deprioritization with respect to wanting to proceed forward, just some efforts and timing related to some of the intake of new patients and hospitals getting their policies together for handling the virus.

________

Don’t miss critical insights. AlphaSense gives you access to full Earnings call transcripts and allows you to keep track of themes unfolding within your coverage universe through intelligent AI-powered search.

Sign up for a free trial to learn how AlphaSense enhances the workflow of 70% of the world’s hedge funds and over 50% of the S&P 500. Already have an account? Login here.

 

Coronavirus Hits Auto Industry With Supply Chain Disruptions

Interested in staying up-to-date on COVID-19’s impact across sectors? Visit our Coronavirus Impact Tracker for daily updates pulled from earnings calls, press releases, 8ks, and more.

 

The automotive industry has been heavily impacted by Coronavirus in Q1. This is on top of already tough trends squeezing global volumes, such as robust emissions standards.

Due to COVID-19, Wall Street lowered global automotive volume sales by 2.5% in 2020, a revision of the previous projection of .09%. These disruptions are especially evident in China, as the virus response prompted workforce shortages and supply chain disruptions. Chinese 2020 automotive sales forecasts were reduced by 2.9% in 2020 due to Coronavirus, a major swing from the previous projection of 1% growth. These trends are likely to continue into Q2 and beyond, but analysts do expect volumes to improve in 2021.

 

Takeaways:

  • Global decline in automotive sales will continue through 2020 and will impact almost every level of the automotive supply chain and global economy.
  • In the US, these pains will be felt by further disruptions and supply chain problems at the southern border, delays in manufacturing and shipments from China, and increased hostility towards global trade. All these factors will raise automotive prices and hurt revenue forecasts

Don’t miss critical insights: Sign up for a free trial or login here.

Here are the highlights. [Note: We are updating this post  to reflect the most recent commentary. Last updated 4/13.]

Ford (8K – 4/13)

The economic slowdown attributable to COVID-19 has led to a global decrease in vehicle sales in markets around the world. Moreover, as a result of the restrictions described above and consumers’ reaction to COVID-19 in general, showroom traffic at our dealers has dropped significantly and many dealers have temporarily ceased operations, thereby reducing the demand for our products and leading dealers to purchase fewer vehicles from us, as well as a reduction in parts and accessories sales

The full impact of the COVID-19 pandemic on our financial condition and results of operations will depend on future developments, such as the ultimate duration and scope of the outbreak, its impact on our customers and suppliers, how quickly normal economic conditions, operations, and the demand for our products can resume, and whether the pandemic leads to recessionary conditions in any of our key markets.

Nevertheless, despite the uncertainty of the COVID-19 situation, we expect our full year 2020 results of operations to be adversely affected.
 
The COVID-19 pandemic may also exacerbate other risks disclosed in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2019, including, but not limited to, our competitiveness, demand or market acceptance for our products, shifting consumer preferences, and vehicle residual values.

General Motors (Press Release – 4/8)

General Motors Corporation is closing most of its North American production facilities, delaying updates and withdrawing production of many of the vehicles with Chevrolet, Cadillac, and GMC badges.

The plant closures are due to coronavirus outbreaks around the world. The automaker stated that the stoppages will delay cycle updates and production volume.

 

Tesla (Press Release – 4/8)

Waiting times for new electric vehicles are set to be the same as for petrol and diesel models as the new car market recovers from the coronavirus crisis, according to exclusive research by Britain’s leading new car buying platform and consumer champion, What Car?.

The findings come after the Society of Motor Manufacturers and Traders (SMMT) revealed new car registrations fell by 44.4% in March due to the effects of the coronavirus shutdown. Despite this, electric vehicle registrations rose 197.4% year-on-year in March*, reflecting booming interest.

 

General Motors (8K – 4/2)

The company reported sales at 618,335 vehicles in the first quarter of 2020, down 7 percent compared to the year-ago period.

The company says that the decrease in sales is because of the COVID-19 outbreak.

 

Ford (Press Release – 4/1)

The automaker is also offering price protection for BS6 vehicle orders until April 30, 2020.

The company has announced service and warranty extensions due to the Coronavirus pandemic. According to the automaker, all vehicle warranty, extended warranty and free service and paid service will be extended until June 30.

 

Ford (Press Release- 3/25)

Ford Motor Company (NYSE: F), a United States-based automaker, is not reopening its plants in North America on March 30 as originally planned.

The automaker is taking this step because of various stay-at-home orders due to the coronavirus. It stated that it is to offer additional updates once more details are confirmed.

 

General Motors (Press Release – 3/24)

General Motors (NYSE: GM) announced today that it intends to drawdown approximately $16.0 billion from its revolving credit facilities. This is a proactive measure to increase GM’s cash position and preserve financial flexibility in light of current uncertainty in global markets resulting from the COVID-19 pandemic. The funds will supplement the company’s strong cash position of approximately $15 billion to $16 billion expected at the end of March.

 

General Motors (8K – 3/24)

GM is suspending its 2020 guidance due to uncertainty around the business impact of the COVID-19 pandemic.

 

Ford (Press Release- 3/20)

Ford is working closely with all our partners as we navigate through the current Coronavirus effects across the globe and our business operations. Due to the dramatic impact this ongoing crisis is having on the European market and the supplier industry, we have decided to bring forward part of the summer shutdown period for our UK operations to the Easter period.

 

Volkswagen (Press Release- 3/23)

Volkswagen AG (Xetra: VW), a Germany-based automaker, is joining other manufacturers round the world to explore using 3D printing to make hospital ventilators to combat the COVID-19 virus.

Governments are enlisting automakers including FordGeneral Motors, Ferrari and Nissan to increase production of ventilators and other equipment they are short of to treat the fast-spreading disease.

 

Ford (Press Release – 3/23)

Ford Motor Company is temporarily suspending vehicle and engine production at its International Markets Group (IMG) manufacturing sites in response to the growing impact of the coronavirus.

The IMG production suspensions began Saturday, March 21, and will continue for several weeks depending on the pandemic situation, national restrictions, supplier constraints and dealer stock requirements.

 

Cummins (8k – 3/20)

Columbus, Indiana – Cummins Inc. (NYSE: CMI) provided a business update in light of recent changes in customer demand and a weaker outlook for the global economy. Today, the Company suspended production at its Midrange Engine Plant in Walesboro, IN, for two weeks in response to the decision by its customer Fiat Chrysler Automobiles to shutdown pickup truck assembly until at least the end of March, as a consequence of the coronavirus pandemic. This news follows recent communication of lower commercial truck production rates by some of its customers in North America and other plant shutdowns by various OEMs in Europe over the past few days. While the Company is not announcing any other production suspensions or plant shutdowns at this time, the Company cannot predict if and when further suspensions or shutdowns may arise. 

Possible causes for further shutdowns include changes in customer demand, shortfalls in supplier deliveries and the impact of government regulations or mandates.

Cummins’ financial results for the first quarter will be impacted by these changes in customer production plans, but a more significant concern is the growing uncertainty about demand for the remainder of 2020. As a result, the Company has withdrawn its guidance for full year 2020 results, which did not factor in the effects of the coronavirus pandemic. The Company will comment on its 2020 outlook during its First Quarter 2020 earnings call scheduled for April 28, 2020.

“Cummins is in a strong financial position, we have experienced leaders who have managed through several challenging situations in the past and we will successfully navigate through this difficult period,” said Chairman and CEO Tom Linebarger. As of December 31, 2019, the company held cash, cash equivalents and marketable securities of $1.5 billion and committed borrowing capacity of $2.8 billion under existing revolving credit facilities.

 

Fiat Chrysler (6K – 3/19)

Working with the UAW and listening to the concerns of our people, we have agreed to cease production at our plants across North America, starting progressively from today through the end of March. While production is paused, the Company will put actions into place to facilitate the steps agreed through the joint task-force set up between the UAW and the automakers. Through this period, which we will reevaluate at the end of this month, FCA will work to enhance its manufacturing operations to facilitate the changes agreed with the UAW including shift timings, structures and enhanced cleaning protocols.

Commenting on this action, FCA CEO, Mike Manley said: “ Working with the UAW, and having visited many of our plants yesterday, we need to ensure employees feel safe at work and that we are taking every step possible to protect them. We will continue to do what is right for our people through this period of uncertainty .”

With our priority towards the health and safety of our workforce we are also evaluating the impact of all steps being taken inside the company and on macro-economic conditions related to the Coronavirus emergency on our current financial guidance. We will provide an update on our financial guidance when that evaluation is complete and we have sufficient visibility on market conditions.

 

Ford (8K – 3/19)

Ford this week announced plans to temporarily at its plants in North America and Europe starting today. The actions were taken to protect the health and safety of employees and respond to issues with supply chain and other constraints. The company will work with labor representatives to safely and effectively restart production in the weeks to come.

 

Tesla (Gizmodo – 3/18)

According to the Los Angeles Times, Tesla CEO Elon Musk—who is not a doctor or public health expert, but has fought claims of unsafe conditions at Tesla facilities for years—downplayed concerns about the virus in a Monday email to staff. Musk wrote “My frank opinion is that the harm from the coronavirus panic far exceeds that of the virus itself” and stated his belief that covid-19 cases “will not exceed 0.1% of the population.”

“I will personally be at work, but that’s just me,” Musk wrote. “I’d rather you were at home and not stressed, than at work and worried.”

Sgt. Ray Kelly, a spokesman for the Alamedia sheriff, told CNBC that “Our directive was clear” and trying to prevent a slump in production does not constitute an essential service. Many other automakers including General Motors, Ford, and Fiat Chrysler have temporarily suspended U.S. car production on a rotating basis.

According to Bloomberg, an Alameda County spokesperson said that Tesla is preparing to reduce staffing at the facility by 75 percent, though the company didn’t reply to their request for comment.

 

GM (PR – 3/18)

GM and the UAW have always put the health and safety of the people entering GM plants first, and we have agreed to a systematic, orderly suspension of production to aid in fighting COVID-19/coronavirus,” said GM Chairman and CEO Mary Barra. “We have been taking extraordinary precautions around the world to keep our plant environments safe and recent developments in North America make it clear this is the right thing to do now. I appreciate the teamwork of UAW President Rory Gamble, UAW Vice President Terry Dittes and local leadership as we take this unprecedented step.”

“UAW members, their families and our communities will benefit from today’s announcement with the certainty that we are doing all that we can to protect our health and safety during this pandemic,” said UAW President Rory Gamble. “This will give us time to review best practices and to prevent the spread of this disease. We appreciate General Motors’ actions today and will continue to work with them on health and safety plans to be implemented when we resume production.”

To ensure that production stops in a safe and orderly fashion, plants will suspend operations in a cadence, with each facility receiving specific instructions from manufacturing leadership.

 

Peugeot (PR – 3/16)

Due to the acceleration observed in recent days of serious COVID-19 cases close to certain production sites, supply disruptions from major suppliers, as well as the sudden decline in the automobile markets, the Chairman of the Executive Board with the members of the crisis unit, decided the principle of the closure of the vehicle production sites, according to the following schedule and until March 27.

Fiat Chrysler (PR – 3/16)

FCA Responds to COVID-19 Emergency in Europe

Fiat Chrysler Automobiles N.V. (NYSE: FCAU / MTA: FCA) (“FCA”) announced today that its subsidiaries FCA Italy and Maserati will temporarily suspend production across the majority of their European manufacturing plants.

 

Toyota – Prospectus 3/11

It is possible that the continued spread of COVID-19 could cause an economic slowdown or recession (which could adversely affect the demand for vehicles and the demand for our financing and insurance products and increase our delinquencies, credit losses and dealer defaults), cause disruption in the supply chains of the vehicles we finance, or cause other unpredictable events, each of which could adversely affect our business, results of operations or financial condition. 

 

Fiat Chrysler (PR – 3/11)

Fiat Chrysler Automobiles is implementing new measures across its facilities in Italy to support the nationwide campaign addressing the COVID-19 crisis. As a result of taking these actions the company will, where necessary, make temporary closures of its plants across Italy.

 

Localiza Rent a Car SA (Earnings Call – 3/11)

About the car prices for 2020. If we consider ex coronavirus or COVID-19, we had a positive evolution of car prices that 2019 didn’t follow inflation, and that it would at least follow inflation, go up new car prices, then Seminovos, your used cars and then depreciation would lower. With the impact of COVID-19 to the sales of the used cars, there’s some uncertainty. People might say that there’s a lower demand, but there’s also a scenario that could be less supply, as a result of lack of parts at the automakers and less working hours in automakers, and there’s the exchange rate, so Seminovos or used cars would be — cars, so the price would go up, and then we would reduce depreciation faster.

So to summarize, if you ex COVID-19, we don’t see depreciation going up. But even with COVID-19, we don’t see this hypotheses in all the scenarios that we simulate. The depreciation would still drop.

 

Cadillac (PR – 3/11)

Cadillac, a subsidiary of General Motors Corporation (NYSE: GM), has withdrawn plans to launch its Lyriq on April 2, 2020 due to the continued threat at large gatherings from the spread of the Covid-19 virus.

The vehicle is to be based on General Motors’ newly unveiled EV platform

 

Workhorse Group (8K – 3/10)

“We also made meaningful progress in our transition from a development-stage company to a production-focused enterprise. We have now begun production and have obtained the needed certifications that will allow us to deliver a limited number of vehicles to our customers starting in April. While our intent had been to deliver initial vehicles in the first quarter of 2020, we were impeded by material supply disruptions related to the global outbreak of the novel coronavirus. Despite these near-term headwinds, we are setting a 2020 production target of 300-400 vehicles and are looking forward to delivering our state-of-the-art truck to our customers.”

 

Schaeffler AG (Earnings Call – 3/10)

Answer – Klaus Rosenfeld: Sure. No, happy to share some thoughts on this. Don’t get the auto business is clearly more impacted directly by the corona environment because it’s a customer business. And while there is no immediate sort of connection between sales and products, so that if sales go down, production goes also equally down at the same moment in time, it’s obvious that if the car market sales dropped dramatically, then somehow production has to follow. So I think that is one part of the equation. On the contrary, the Industrial business is more balanced. It’s more short cyclical, and it has this large element of wind into that because the wind business is continuing. And also, the rail business is continuing and so it’s a different profile. And clearly, also it’s a different operating leverage that stands behind that. While Automotive is maybe the third element has a a transformation that you all know in terms of powertrain, but also in terms of Chassis that is undergoing in Industrial that is different. So maybe that explains why we have a little bit of a different view on the 2 businesses, and why I think that this guidance is logical and plausible.

 

US Auto Parts Network (10K – 3/10)

Our financial condition and results of operations for fiscal year 2020 may be adversely affected by the recent COVID-19 (also known as coronavirus) outbreak. The ongoing coronavirus outbreak emanating from China at the beginning of 2020 has resulted in increased travel restrictions and extended shutdowns of certain businesses in the region. We acquire a majority of our products from manufacturers and distributors located in Taiwan and China, and we maintain international business operations in the Philippines.  Consequently, we are susceptible to factors adversely affecting this region. The effects could include restrictions on our ability to travel to support our suppliers located in Asia, disruptions in our ability to distribute our products in the Asia region, and/or temporary closures of the facilities of our manufacturers and distributors. Disruption to the operations of our manufacturers and distributors would likely impact our sales and operating results.  The extent to which the coronavirus impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others.

 

Continental AG – (Earnings Call – 3/5)

In replacement tire sales for passenger vehicles, we expect slightly negative volumes in Europe, stable demand in North America and negative growth in China due to COVID-19. For commercial vehicles, we anticipate significant production declines in all regions. Truck tire replacement volumes are expected to decline marginally.

Also not shown on the slide, we also expect that weaker macroeconomic conditions in Europe, North America and China will result in a year-on-year decline in demand from industrial and aftermarket customers. The headwind will restrain that 50% of Continental sales that are tied to these markets.

The expectations for PLT replacement tires, commercial vehicles and — commercial vehicle tires as well as industrial and aftermarket do not account for currently, obviously, unforeseeable impact from COVID-19, as mentioned before.

 

Ballard Power Systems (Earnings Call 3/5)

Question Craig Edward Irwin: Okay, excellent. Thank you for clarifying that. The second thing is COVID-19 is a difficult subject, right? Our hearts and prayers go out to the people of China as they deal with this. And now we’re all dealing with it globally. Can you maybe walk us through the logic of not including an impact from COVID-19 in the guidance? Those of us that follow the Chinese market know that February auto sales were down 80% year-over-year. Is there anything that allows you the visibility where you’re not going to see that kind of weight impact you over the next couple of months and also in February as the Chinese are working through the challenges of this epidemic?

Answer – R. Randall MacEwen: Craig, it’s Randy. Thanks for the question. So I think there’s a couple of points to keep in mind is, one is that where our joint venture is in its development, right? So we’re not actually in production. So production of the joint venture isn’t being disrupted. Where we have had a couple of week delay or actually 2-month delay really is in completing the construction. And so — but Weichai is in Shandong province, the joint venture is in Shandong province. It’s not had the same impact from an operational perspective, we’ll get to supply chain in a minute, as have had some other provinces like Hubei province, obviously.

So what we’ve seen is that Weichai and the joint venture are actually at very high staffing levels and have been for a couple of weeks now. So from a joint venture perspective and a staffing perspective, I think activity levels have resumed. There’s been temporary disruption as a result of COVID-19 activities in China.

 

Methode Electronics (Earnings Call – 3/5)

Question – Ryan Ronald Sigdahl: Congrats on the really strong quarter and being able to maintain the guidance in this challenging environment. Maybe to start just on the guidance. I mean, it seems like global auto production forecasts have been weakening almost by the day, plus you have coronavirus impacts. So I guess, it seems like several material negatives versus the last quarter when you gave guidance. So what are the — can you please explain the positive surprise, I guess, over the last couple of months and what the offset to those negatives are?

Answer – Donald W. Duda: Well, as I was talking about with Chris, we’ve had very good success. We’re taking cost out the Grakon factory, which I would say, exceeded our expectations maybe in 6 months ago. Class 8 decline, not as great as they think as some forecasted. And yes, volumes are down in auto, but our new launches which we pointed to, I think all year, the majority of those would start to ramp in the third and fourth quarters, and we’ve seen that. Ron is it (inaudible)

Answer – Ronald L.G. Tsoumas: Yes. I have a couple of things to the margin expansion as well. Compared to last year, consolidated margins are up year-to-date, almost 1%. Auto margins are — have maintained well in spite of the challenges in auto. Our industrial group margins have gone up quite a bit. So all of those things together, and then a couple of the other things is, obviously, with our EPS and all that, we — our tax rate is a little lower than we thought it might have been when we came out last June. We’ve done a nice job mitigating tariffs and you start adding all of those things together, increased sensor sales, that product has increased year-over-year pretty significantly at higher margin, a lot of know-how a lot of IP. So you add all those things together and they make a cumulative impact that has been very favorable to the company, operating in a difficult environment.

 

Martinrea (Earnings Call – 3/5)

For Q1, our adjusted EPS is projected to be between $0.60 and $0.65, reflective of some volume softness in certain areas of Europe and including the impact the coronavirus is having on China vehicle production. Actually, given some of the headwinds, a good projection from an earnings perspective to kick off 2020. Q1 guidance also includes one month of results from our just closed acquisition of Metalsa Structural Components business, which I will discuss in more detail momentarily.

 

Autozone Inc (UBS Global Consumer and Retail Conference – 3/5) 

Yes, we’re seeing some slowness coming from Asia, but the product — there is product flowing. Obviously, it isn’t flowing at the level that it needs to be. And it’s our understanding the factories are coming online and are progressing online, and the government is going through a certification process with each of the factories. And they’re ramping up, specifically the factories that are supplying us are ramping up. So we think that it will be, as we said on the call or Bill said on the call, it’s — the next few weeks will be critical as we kind of watch them continue to ramp up. To your point, you’re right. Our inventory turns relatively slow. We have X amount of weeks of supply in the system. We also have the ability to buy from ourselves, if we are able to rebalance out some of that inventory. So for now, we seem to be okay. And for what we can see in front of us, we don’t see a significant disruption. If things change, then we’ll have to address that when it happens. But at the moment, it feels as though we have inventory available. There’s inventory coming and will be coming based on our understanding. And so we don’t see this as being, at the moment, disruption of any great magnitude. I’m sure that there will be a little bit of a flow for the — our distribution folks as it will be for any company, who is getting very low volume right now and will get ramped up pretty significantly.

 

Umicore (IR Presentation – 3/5)

As communicated in April 2019, Umicore expects to grow revenues and earnings in 2020 despite a deterioration in the global macro-economic environment since then, particularly in the automotive sector. This growth outlook assumes that the recent coronavirus outbreak will not result in a protracted or material effect on the economy in 2020.

While there are no signs of an imminent recovery in the automotive market, the business group Catalysis is expected to continue to benefit from its strong market position in gasoline catalyst applications and a further penetration of higher value gasoline particulate filters in Europe and China

 

Progressive (Earnings Call – 3/4)

Question – Michael David Zaremski: My first question is on any potential impact from the current situation with the coronavirus. The New York Times has come out and said that they’re seeing just recently ad spend fall fairly materially across the brand with (inaudible) to 25%. And I’m curious if you think Progressive should in the near term — or is part of that? And also, are you seeing any impact maybe from your [call medics] drivers on the work frequencies if people are maybe working from home?

Answer – Susan Patricia Griffith: Mike, that’s a great question. So I’ll start with the ad spend. Right now, we’re going to continue to spend. This is a prime time of the year when people are buying insurance, we’re getting into that season. We’ll continue to spend. That we have some flexibility in. But again, whether you drive a little bit or a lot, you still are required to have auto insurance. And so our intentions will be to spend as long as we feel sufficient. So again, we’ll have to be nimble because all of this, as you know, is ever-changing.

The great question on the UBI. So with the recent deaths in Washington, we asked the UBI team, just to take a look at UBI vehicle miles driven or traveled by week in January and February this year compared to the prior 2 years. And we are not quite seeing a difference. And again, that’s very little data, but that tells us we haven’t seen it yet. Again, now that we’ll look at it weekly, we can start to see that. We’ll look at it across the country where we can. So we’ll be able to understand pretty quickly. If you go back to something like the financial crisis, I was running claims at the time and we saw frequency drop really quickly. And so we’ll have some good insight. We get our frequency data on a daily basis. So we’ll understand very quickly where we’re at.

From a vendor perspective, we always think of the concerns around auto parts that are possibly made in China. So we had our property process team talk to all of our OE vendors, the percentage of OE that we use on our vehicles, the percentage they get from China, et cetera. For the most part, with the exception of one OE, we feel like there’s low risk at this time. And even with that partner, they have an inventory. Again, it’s always those like first and second order effects. So it could be that more cars are told, because you can’t get parts and then there’s used car parts. So it’s — we’re going to keep watching that.

So right now, we aren’t seeing any effect. But again, this is such a moving target that we have a lot of data points that we’re going to be looking at literally on a daily basis to understand how it will affect possibly our frequency.

 

Quaker Chemical (Earnings Call – 3/3)

Answer – Jonathan E. Tanwanteng: Okay. Got it. And just a quick one, what amount of global steel and auto production are you assuming this year in your EBITDA outlook?

Answer – Michael F. Barry: The — I would say the latest forecast that we’ve seen, certainly before the coronavirus, still was 1.5% to 2%, in that kind of range. And now what I’ve seen lately is global steel is maybe closer to 1% growth. And then from an automotive perspective, some of the forecast I saw before the coronavirus is negative 1%. And now it’s certainly going to be knocked down another 1% or 2% from that, but who knows exactly? But that is a negative, even was negative before coronavirus.

 

Jason Industries (Earnings Call – 3/3)

Automotive markets continued to decline and channel inventories remain at healthy levels. Our Osborn polishing business is faring better than this core market, however, due to diverse sources of revenue and intense commercial focus as part of our acquisition integration activity. Construction and heavy equipment manufacturers are forecasting declines in the range of 5% to 10%, directly impacting our Milsco business.

Additionally, residential riding mower production is down in the mid-teens as reported by the Outdoor Power Equipment Industry Association. Many of our customers are taking a wait-and-see approach to the spring season. Finally, while it is too early to predict the full impact of the coronavirus, Jason’s current perspective is balanced. Osborn’s China JV is feeling the effects of the China automotive slowdown but overall, our supply chain has only pockets of direct China exposure and where we do have links to the region, we maintain alternatives that can be substituted. Our primary concern relates to our customers as they may encounter issues that further curtail build schedules or other activity. I guess we can sum up our served markets with one word, challenge. Fortunately, our team consists of fighters that relish challenges, and there are many reasons we continue to be energetic.

 

Cummins (Evercore ISI Conference – 3/3)

So I think as you’re aware, when we gave our guidance back at the beginning of February, we didn’t include any impact of the coronavirus at the time. Things were still moving pretty rapidly, a pretty fluid situation.

What we’ve seen right now, we have about 10 facilities in the Hubei province in China, many more dotted throughout the rest of the country. In general, our facilities open 1 to 4 weeks after the Lunar New Year. So a delay on opening there. And our total China exposure on consolidated sales is about $40 million to $50 million a week. In addition to that, our JV income is about $200 million a year in China. So definitely had some negative impacts on domestic China consumption given the delays in start-up of our facilities. Almost all of the facilities now are up and running to some degree. Some of them 100%, some less than that. And I’d say the ones that are running a little less than that, it’s really driven at this point by OEM partners whose facilities aren’t up and running 100%.

So we’ll know a little bit more about what the full year impact is, the demand, I think, by the time we get to Q1 earnings. Just need to see to what extent potentially the government does some stimulus and whether the demand that we did lose in the first quarter comes back in the second half of the year.

So from a finished Cummins product perspective, we do not export a significant amount of material outside of China. We generally produce and sell in country. The area that we’re paying very close attention to is more some of our Tier 2 and Tier 3 suppliers that have some of their facilities out in China that export some of those to our global facilities.

So at this point, we’ve had no disruption, 20 of our facilities related to that. But certainly a very concerted effort by our supply chain organization tracking individual part numbers and understanding where the risks could be in the supply chain related to some of the delays of those Tier 2 or 3 suppliers that have been ramping up production.

 

Autozone Inc – (Earnings Call – 3/3)

At this point, I’d like to talk about any disruption we may be seeing from the ongoing coronavirus epidemic. While we have not incurred disruption thus far, we must and are being diligent. We have created a contingency plan for each merchandise category sourced from China. Our teams have done a wonderful job planning for potential scenarios. At this point, we have nothing substantial to report. But the longer this outbreak lasts, the more it will impact ourselves in both our and the overall retail industry. It is currently a very fluid situation as many of the factories have just begun to reopen after an extended Chinese Lunar New Year holiday. Some are coming back online quickly while others quite slowly, and certain of them haven’t come back online yet. The next few weeks will be critical.

As you would expect, over the last month or so, we have been very focused on the supply chain aspects of coronavirus and, in the last week or 2, more and more focused on what’s happening here in the United States and, ultimately, Mexico and Brazil. We see no indications at this point in time of any demand destruction as a result to coronavirus. But just like we said with the supply chain, it’s an incredibly, incredibly fluid situation. I think the next couple of weeks to a month, are going to be critical to see what actually happens. We don’t have good insights into that.

 

Tata Motors (6K – 3/2)

According to Mr. Mayank Pareek, President, Passenger Vehicles Business Unit, Tata Motors Ltd.,,”Our new Altroz received an overwhelming response. Our NEW FOREVER product portfolio has built a strong order book since its launch end of January. However, the outbreak of COVID-19 in China and a recent fire incident at one of our strategic vendors affected the vehicle production and wholesale volume. Multiple actions are being taken to reduce the impact, staying close to our customers by providing transparency of the delivery situation. On a positive note our BSIV vehicle stock is well below the targeted level, we are well placed for the BSIV-BSVI transition and with the strong customer interest in the NEW FOREVER portfolio and a step up in market activation, we are confident of improving our market competitiveness and volume growth in the coming months”

 

CIE Automotive (Earnings Call – 2/28)

And we’d like to conclude by talking about China. In spite of the very chaotic situation, it has had the best performance in Q4 with a growth of plus 1%. But that’s not been, by far sufficient to recover the drop over the year. A slight improvement in the fourth quarter vis-à-vis the previous quarters due to other factors and — because the transition standard has been overcome, and the rest will come in July. But 2020 has brought us coronavirus and with it, all the measures by the — implemented by the government to contain the spread, which has meant closing factories and very significant logistical restrictions, like to hold 14-day quarantines to workers that travel to work or to quarantine situations for lorry drivers after delivery.

So this has meant the extension of the production shutdowns beyond the Chinese year, and the factories are resuming certain activities — certain degree of activity, except for Hubei where they’re still close. And although these shutdowns will have an impact in production for 2020, we also expect the recovery over the rest of the quarters of a part of the lost volumes since the existing idle capacity in the country and demand peaks that have existed in previous health crisis.

The last focus for the Chinese market in 2020 considers a loss of approximately 1 million vehicles produced by the coronavirus impact, and it’s a drop of minus 4%, reaching 23.6 million vehicles.

 

Shawcor Limited (Earnings Call – 2/28)

Answer – Keith MacKey: And just on the Automotive and Industrial segment, the last few questions maybe just to play off of that, is just what do you kind of see as the breakdown of revenue between automotive things that may be more affected by this potential long-term negative scenario of coronavirus versus the industrial, which may not be as exposed?

Answer – Stephen M. Orr: First of all, I’ll point you to the name change. So the company has moved. Historically Petrochemical was a good way to capture this segment because it participated a lot in the — a lot around Western Canada on the heavy oil extraction and processing, our value-add component. The segment is now called Automotive and Industrial and it’s the Canusa DSG, Canusa (inaudible) heat shrink and cold shrink is heavily weighted to automotive. And so ShawFlex, which is a cable business, I think will be quite positive this year because of not only does it participate in the high-run cable business, it is nicely positioned for the rebuild of nuclears, which are our nuclear work, which is right in its niche of high specialized cable.

So I think a good way to look at the business is just have a look at 2008, our Petrochemical and Industrial, and see the magnitude of what a global slowdown can do to a GDP-focused business. But to answer your question, a large percentage of Automotive and Industrial is based on direct supplying wire harnessing and wire components and protection of wiring components into automotive, a high percentage. Greater than 50%.

 

Superior Industries (Earnings Call – 2/28)

Answer – Richard Phelan: I had 3 questions. First is, wasn’t clear to me the status of the Fayetteville restructuring. If you could just update us in terms of — are all the workers gone? What’s the plan with the real estate there as we head into 2020? Second question was around the working capital. If you could just update us with the accounts receivable factoring outstanding at year-end? And lastly, I’d love to get any comments you have. You mentioned in the guidance that there’s no adverse impact from coronavirus. But perversely, your business is one of the few in the auto space, which is a potential beneficiary, if I can say that because so much of your competition has manufacturing in China. And so I’m wondering if — any color you can provide in terms of problems that your competitors may be facing either starting up plants or otherwise.

Answer – Matti M. Masanovich: I’ll take the first part, and then Majdi can add to the question. So first part of the question was on Fayetteville. We have no production in Fayetteville after Q4. So December, we — the workforce was rationalized. The production workforce rationalized. So what we’re doing now is cleaning up the facility, moving some equipment to various facilities around the globe where we had equipment that we wanted to utilize, which should help offset some of the CapEx needs of the company on a go-forward basis. So we’re — we have a — I don’t want to give you the exact number, but there’s a very small workforce left. We do have an engineering center, which we will maintain in Fayetteville. And we have no chance — no plans to change or modify the engineering center that’s there where we have R&D and technical capabilities and test capabilities. So we’ll continue with our engineering center in Fayetteville.

As far as the building goes, we haven’t made any announcements. We have a lot of work to do to clean it up and clean up the equipment. So — but I would say that there’s not a significant amount of proceeds coming that would change the cash flow if that what’s you’re getting at.

As far as AR factoring goes, we ended the year $10 million lower than the prior year for AR factoring. So we’ve got about, Troy, $45 million in AR — total AR factoring?

Answer – Troy Ford: That’s right.

Answer – Matti M. Masanovich: About $45 million of total AR factoring at the end of the year. So we were able to lower the water level from a factoring perspective.

And then specifically on your China question, we have received calls over the course of the last 2 weeks from various OEMs inquiring on our capacity and where we have open pockets of capacity. So we believe that potentially, it could be a tailwind. If nothing else, it could be neutral to us, but there could be a tailwind coming. So from a supply chain standpoint, I don’t want to comment on where the competitors are at and if they’re having difficulty, but we have had inquiries over the last 2 weeks.

 

Garrett Motion (Earnings Call – 2/27)

In addition to the impacts we just discussed, the coronavirus has altered our industry outlook as well for 2020 as follows: we currently expect global light vehicles auto production to be down between 5% and 7% for the year or minus 2% versus — minus 2% before the coronavirus impact. Global commercial vehicle production is expected to decrease between 7% and 10% compared to minus 4% pre-coronavirus. As of today, we expect 2020 net sales to be down between minus 4% to minus 1% at constant currency. The estimated impacts from the coronavirus on our annual net sales is approximately minus 6% to minus 7%. Nevertheless, we expect to outperform global light vehicle auto production by 300 to 400 basis points in 2020.

 

Aston Martin (Earnings Call – 2/27)

Question – Sanjay Jha: Americas. I’m just trying to understand how many of these orders are canceled, given what’s happening in Asia Pac. The — what I’m saying is can they just be canceled.

Answer – Mark Gerrard Wilson: Well, yes. I mean they have a contract with the dealer, and the dealer places the order with us in the same way they do for any cars. If you’re getting to coronavirus impact, then clearly, the thing we’d say about coronavirus impact is no — everybody is taking it very, very seriously. We’ve said in the presentation earlier that we are, helpfully, not affected at this point in time. And those areas that we are affected by, we’re managing adequately.

I’d also say this, just another point, in terms of DBX when it delivers, of course, it delivers in Half 2, there’s a greater distance between delivering a DBX to China than there is taking it out of gate and bring it to London. And of course, they will naturally be a later market anyway. So there is a level of protection in there for this year in that respect. And if you look at what people like the Agios said yesterday on how they expect the coronavirus to develop, clearly, by that part of the year, our expectation is that things may well be returned to normal.

Answer – Andrew C. Palmer: I think there’s some — let me reiterate the last region to launch DBX is China, not because of the coronavirus at all, because of plan, because the homologation cycle to launch a car in China is longer than any other market. So it’s later this year, and one hopes and prays that the coronavirus is passed by then. To the earlier question, we have announced the Roadster price. It’s GBP 126,950. So GBP 127,000.

 

Georg Fischer AG (Earnings Call – 2/26)

We do not expect that March is fully recovering since we are also going to see a slowdown in the businesses. And since we don’t know whether this impact of the coronavirus is ending at that point of time, we’re also going to assume that Q2 will be required to fully recover and to get back to normal operations.

But also, as you correctly said, we do not have a crystal ball, and therefore we can only be pretty vague on whatever has to be expected. We trust know that in case that full demand comes back, our companies are now ready to deliver at the level as it was expected. First, it is important that our people have, especially in that regions where we have the high outbreaks of the coronavirus, that our people stay safe.

It is — which kind of scenarios? It is a good question. Otherwise, if we would have the answer to that, we would have given an answer in our outlook.

Which of our divisions are impacted? For us, China is a very important market, approximately 1/5 of our business is being realized in China. And all 3 divisions are present there. And for all 3 divisions, it is one of the largest markets as a single country. So therefore, all 3 businesses have been affected in the month of February.

Question – Martin Flueckiger: Okay. Coronavirus and car market is sort of interconnected these days with the China situation. But just leaving corona aside for a while, it’s not just the China car market, which was in the doldrums, at least as far as I’ve been reading. But also the European market has been quite difficult. My understanding is German car production was also quite challenging to say the least.

 

Visteon (Earnings Call – 2/20)

I would like to discuss our outlook for vehicle volume production from 2020 through 2023, which is updated from the prior outlook communicated in January of 2019. Due to the rising uncertainty in the global automotive market, we feel it is prudent at this time to not extend the outlook beyond the previously communicated years. It should also be noted that the outlook does not reflect the impact of the coronavirus as the situation is still very dynamic and uncertain.

From a regional perspective, we expect 2020 vehicle production in North America to remain flat over last year due to relatively stable macroeconomic environment. We expect Europe to be down again in 2020 due to the impact of emissions regulations, Brexit and the general slowdown in the Eurozone economies. Prior to the coronavirus, China was expected to have lower production in 2020 due to weak consumer demand, which will only get further stress now with the outbreak of the virus. And the rest of Asia is expected to be down as well, with lower production, mainly in Japan and India.

 

Tenneco (Earnings Call – 2/20)

We continue to monitor the effects of the coronavirus on the automotive industry. The uncertainty of its full impact results in a wider outlook range for revenue and EBITDA than is customary. Included in our outlook is our current estimate that the equivalent of 4 full weeks of production will be lost in China in the first quarter, which would have an estimated negative impact of approximately $150 million on revenue and $50 million on EBITDA.

 

Cognex (8K – 2/13)

Revenue for Q1-20 is expected to be between $155 million and $170 million. This range represents a decline from both Q4-19 and Q1-19 primarily due to continued weakness in automotive and the estimated impact of the coronavirus outbreak. The decrease is expected to be partially offset by growth in logistics.

 

——

Don’t miss critical insights. AlphaSense gives you access to full Earnings call transcripts and allows you to keep track of themes unfolding within your coverage universe through intelligent AI-powered search.

Sign up for a free trial to learn how AlphaSense enhances the workflow of 70% of the world’s hedge funds and over 50% of the S&P 500. Already have an account? Login here.

 

Global Supply Chains Impacted as Virus Spreads Through U.S. & Europe

Interested in staying up-to-date on COVID-19’s impact across sectors? Visit our Coronavirus Impact Tracker for daily updates pulled from earnings calls, press releases, 8ks, and more.

 

Supply chains across multiple industries have seen impacts in production due to the coronavirus outbreak in China. With workers at home and factories temporarily closed, the disruption is causing a broad range of companies to report uncertainty in their financial performance.

As global COVID-19 cases continue to increase, particularly in the United States and in Europe, how are companies communicating supply chain impacts? We’ll be updating the post with commentary from management teams regarding supply chain impact from the Coronavirus.

 

Takeaways:

  • Companies across sectors are still unsure about the direct impact of supply chain delays on their bottom line.
  • Many companies refer to global supply chain issues while maintaining that their specific supply chain interruptions will not be enough to have a material impact on their 2020 financial results.
  • Volkswagen suspended production until April 9th, due to decrease in demand for automobiles and the challenges in the supply chain due to COVID-19.
  • FedEx says they “remain well positioned to adjust to market conditions to assist our customers as they work to manage their supply chains and inventories. Due to the crucial role we play in moving supply chains and delivering critical relief, FedEx is considered an essential business and is continuing to operate under state-of-emergency and shelter-in-place orders recently issued in the U.S. and globally.”
  • Companies, such as Ross Stores Inc. temporarily closed stores.
  • Companies like Adobe, Nvidia, and Best Buy have all recognized that supply chain disruptions could significantly impact their businesses and distribution systems.

Don’t miss critical insights: Sign up for a free trial or login here.

[Note: We are updating this post and our compilation post to reflect the most recent commentary. Last updated 4/5.]

 

FedEx (4/3 – 8K)

We remain well positioned to adjust to market conditions to assist our customers as they work to manage their supply chains and inventories. Due to the crucial role we play in moving supply chains and delivering critical relief, FedEx is considered an essential business and is continuing to operate under state-of-emergency and shelter-in-place orders recently issued in the U.S. and globally. We are flexing our network and making adjustments as needed to align with volumes and operating conditions. We are taking additional measures and incurring additional expense to protect the health and safety of our employees, contractors, and the public and are working with customers to accommodate special requests around modified store hours, closings, and delivery alternatives to comply with applicable government restrictions and safety guidance.

We expect the significance of the COVID-19 pandemic, including the extent of its effect on our financial condition and results of operations, to be dictated by, among other things, its duration, the success of efforts to contain it and the impact of actions taken in response. While we are not able at this time to estimate the impact of the COVID-19 pandemic, an extended period of global supply chain and economic disruption could materially and adversely affect our business, results of operations, access to sources of liquidity and financial condition. In addition, an extended global recession caused by the COVID-19 pandemic would have a further adverse impact on our financial condition and operations.

Ross Stores (3/31 – 10K)

A disruption within our logistics or supply chain network could adversely affect our ability to timely and efficiently transport merchandise to our stores or our distribution centers, which could impair our ability to meet customer demand for products and result in lost sales or increased supply chain costs. 

Due to the current economic uncertainty stemming from the COVID-19 pandemic, we have temporarily suspended our stock repurchase program as of March 2020, and plan to continue to monitor the situation based on business conditions and regard for our financial liquidity needs.

Due to the COVID-19 pandemic and related economic disruptions, and with the temporary closure of all store locations effective March 20, 2020 through April 3, 2020, (and with extended or further closures possibly necessary), we anticipate that we will be required to rely far more heavily on our cash reserves and lines of credit, and we expect to carefully monitor and manage our cash position in light of ongoing conditions and levels of operations.

Volkswagen (3/27 – Press Release)

Volkswagen AG (Xetra: VW), a Germany-based automaker, has suspends its production at its passenger cars brand, commercial vehicles and Volkswagen group components until April 9.

The automaker has taken this step due to decrease in demand for automobiles and the challenges in the supply chain due to the coronavirus outbreak.

The company stated that the application for an extension of short-time working for a total of 80,000 of the automaker’s employees has been submitted and it plans to end short-time working with the night shift of April 9 to 10.

 

Te Connectivity Ltd (3/26 – 8K)

We could suffer significant business interruptions, including as a result of COVID-19.

Our operations and those of our suppliers and customers, and the supply chains that support their operations, may be vulnerable to interruption by natural disasters such as earthquakes, tsunamis, typhoons, or floods; or other disasters such as fires, explosions, acts of terrorism or war, disease or other adverse health developments, including as a result of the Coronavirus Disease 2019 (“COVID-19”), or failures of management information or other systems due to internal or external causes. 

COVID-19 is currently impacting countries, communities, workforces, supply chains and markets around the world and as a result we have experienced disruptions and restrictions on our employees’ ability to travel, as well as temporary closures of our facilities and the facilities of our customers, suppliers, and other vendors in our supply chain. COVID-19 may have a material impact on our liquidity, financial condition, and results of operations. The extent to which COVID-19 will impact our business and our financial results will depend on future developments, which are highly uncertain and cannot be predicted. Such developments may include the geographic spread of the virus, the severity of the virus, the duration of the outbreak, the actions that may be taken by various governmental authorities in response to the outbreak, and the possible impact on the global economy and local economies in which we operate.

 

Micron Technologies (3/26 – 10Q)

The effects of a public health crisis caused by the COVID-19 outbreak and the measures being taken to limit COVID-19’s spread are uncertain and difficult to predict, but may include:
 A decrease in short-term and/or long-term demand and/or pricing for our products, and a global economic recession that could further reduce demand and/or pricing for our products, resulting from actions taken by governments, businesses, and/or the general public in an effort to limit exposure to and spreading of such infectious diseases, such as travel restrictions, quarantines, and business shutdowns or slowdowns;
 Negative impacts to our operations, including reductions in production levels, R&D activities, and qualification activities with our customers, and increased costs resulting from our efforts to mitigate the impact of COVID-19 through social-distancing measures we have enacted at certain of our locations around the world in an effort to protect our employees’ health and well-being (including working from home, limiting the number of employees attending meetings, reducing the number of people in our sites at any one time and suspending employee travel);
 Deterioration of worldwide credit and financial markets that could limit our ability to obtain external financing to fund our operations and capital expenditures, result in losses on our holdings of cash and investments due to failures of financial institutions and other parties, and result in a higher rate of losses on our accounts receivables due to credit defaults; and
 Disruptions to our supply chain in connection with the sourcing of materials, equipment and engineering support, and services from geographic areas that have been impacted by COVID-19 and by efforts to contain the spread of COVID-19.
 
The resumption of normal business operations after such interruptions may be delayed or constrained by lingering effects of COVID-19 on our suppliers, third-party service providers, and/or customers.

CSX Corp (3/19 – 8K)

As COVID-19 continues to spread and significantly impact the United States, CSX is taking a variety of measures to ensure the availability of its transportation services, promote the safety and security of its employees and support the communities in which it operates. However, public and private sector policies and initiatives to reduce the transmission of COVID-19, such as the imposition of travel restrictions, the promotion of social distancing and the adoption of work-from-home and online learning by companies and institutions, could adversely affect demand for the commodities and products that the Company transports, including import and export volume. In addition, COVID-19 and the related initiatives may result in supply chain disruption, which could have an adverse impact on volumes and make it more difficult for the Company to serve its customers.

 

NVIDIA (3/26 – 424B5)

The global pandemic of COVID-19 continues to rapidly evolve, and we will continue to monitor the COVID-19 situation closely. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. The extent of the impact of the COVID-19 pandemic on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected time frame, will depend on future developments, including, but not limited to, the duration and spread of the pandemic, its severity, the actions to contain the disease or treat its impact, related restrictions on travel, and the duration, timing and severity of the impact on customer spending, including any recession resulting from the pandemic, all of which are uncertain and cannot be predicted. An extended period of global supply chain and economic disruption as a result of the COVID-19 pandemic could have a material negative impact on our business, results of operations, access to sources of liquidity and financial condition, though the full extent and duration is uncertain.

 

Adobe Inc (3/25 – 10Q)

In addition, the ongoing COVID-19 pandemic could potentially disrupt the supply chain of hardware needed to maintain these third-party systems and services or to run our business.

Should financial market conditions worsen in the future, including from impacts of the COVID-19 pandemic, investments in some financial instruments may pose risks arising from market liquidity and credit concerns. In addition, any deterioration of the capital markets could cause our other income and expense to vary from expectations. As of February 28, 2020 , we had no material impairment charges associated with our short-term investment portfolio, and although we believe our current investment portfolio has little risk of material impairment, we cannot predict future market conditions, market liquidity or credit availability, and can provide no assurance that our investment portfolio will remain materially unimpaired.

 

Thermo Fisher Scientific Inc (3/24 – 424B5)

COVID-19 is having, and will continue to have, an adverse impact on our operations, supply chains and distribution systems, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. Due to these impacts and measures, we have experienced, and will continue to experience, significant and unpredictable reductions or increases in demand for certain of our products. 

 

IHS Markit LTD (3/24 – 10Q)

There may also be lower activity levels in the end markets we service or declining financial performance of our customers, which could result in lower demand, cancellations, reductions, or delays for our products and services, or in lower revenues. The extent to which our results are affected by COVID-19 will largely depend on future developments which cannot be accurately predicted and are uncertain, but the COVID-19 pandemic or the perception of its effects could have a material adverse effect on our business, financial condition, results of operations, or cash flows.

Best Buy Co (3/23 – 10K)

Concerns have rapidly grown regarding the outbreak of COVID-19. As the pandemic continues to grow, consumer fear about becoming ill with the virus and recommendations and/or mandates from federal, state and local authorities to avoid large gatherings of people or self-quarantine have increased, which will adversely affect traffic to our stores.In particular, we recently announced a shift to enhanced curbside service only for all of our stores on an interim basis. Further, all in-home installation and repair has been temporarily suspended and all in-home consultations are being conducted virtually.

The significant reduction in customer visits to, and spending at, our stores caused by COVID-19 will likely result in a loss of sales and profits and other material adverse effects. We may further restrict the operations of our stores and distribution facilities if we deem this necessary or if recommended or mandated by authorities and these measures could have a further material impact on our sales and profits. Also, if we do not respond appropriately to the pandemic, or if customers do not perceive our response to be adequate for a particular region or our company as a whole, we could suffer damage to our reputation and our brand, which could adversely affect our business in the future.

COVID-19 also impacted our supply chain for products we sell, particularly as a result of mandatory shutdowns in locations where our products are manufactured. We could also see significant disruptions to our supply chain in the U.S. as well as significant deterioration in macroeconomic factors that typically affect us, such as consumer spending.

 

Dollar General Corp (3/19 – 10K)

As of the date of this filing, we do not anticipate that supply chain disruptions either known or experienced to date as a result of the COVID-19 outbreak are likely to have a material impact on our financial results in 2020. However, the extent to which the COVID-19 outbreak may impact our distribution network, results of operations (including sales) or business in the future is uncertain as the situation continues to evolve, and such impact could be more significant.

 

Clorox Co (3/18 – PR)

Free and Charitable Clinics are on the front lines providing access to health care and battling Covid-19 for over 2 million patients in communities throughout the U.S.,” said Nicole Lamoureux, President and CEO of the National Association of Free and Charitable Clinics. “In the face of this pandemic, our member organizations are challenged with dwindling resources and limited access to personal protective equipment for their staff and volunteers. This donation will allow clinics to continue the important work of providing health care to the uninsured and combating Covid-19, while ensuring their staff, volunteers and patients are safe in this uncertain time.”

As global supply chains have contracted as a result of the pandemic, Direct Relief has expanded its operations in the U.S. and globally.

 

Ford Motor Co (3/18 – PR)

While it is hoped this action will only be required for a short period, the exact duration depends on a number of factors. These include the spread of the coronavirus; national government and European Union restrictions on movement, including across borders; the supplier industry’s ability to supply components; and the return of customers to dealerships, many of which are now closed as part of the measures taken at a national level.

 

Fedex Corp (3/17 – 10Q)

We anticipate that weak global economic conditions will be exacerbated in the fourth quarter of 2020 by the impacts of the COVID-19 pandemic, including the disruption of manufacturing operations and supply chains around the world. While the global economy may recover quickly from repercussions linked to the COVID-19 pandemic, we cannot currently predict if or when the economic recovery will occur.

 

Baxter International Inc (3/17 – 10Q)

Our global operations expose us to risks associated with public health crises and epidemics/pandemics, such as the novel strain of coronavirus that recently originated in China (COVID-19). COVID-19 may have an adverse impact on our operations, supply chains and distribution systems and increase our expenses, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. Due to these impacts and measures, we may experience significant and unpredictable reductions or increases in demand for certain of our products as health care customers re-prioritize the treatment of patients

 

Motorola Solutions (3/17 – Recommended cash acquisition of IndigoVision)

Although IndigoVision has made progress in recent years in limiting its exposure to China as it sought to diversify its supplier base, China remains a key part of IndigoVision’s supply chain. This exposure presents risks associated in the short-term with the COVID-19 pandemic currently affecting the region and, in the longer-term, with international trade and tariffs, particularly in the USA, a key region for IndigoVision as it expands, in light of the recently introduced National Defence Authorization Act (“NDAA”).

 

VF Corp (3/16 – 8K)

VF’s supply chain operations have experienced limited disruption to date as a result of the COVID-19 situation. Ongoing diversification efforts, such as re-directing manufacturing and materials sourcing, are underway in an attempt to mitigate potential future disruption. While it is not possible to gauge the full impact to VF’s supply chain at this time, VF continues to believe its global supply chain represents a key competitive advantage during periods of uncertainty and market volatility.

 

Burlington Stores Inc (3/13 – 10K)

Finally, if the COVID-19 pandemic continues to grow, our import supply chain could experience severe delays due to closed factories and/or reduction in processing capacity as a result of workers not being able to return back to work or other labor shortages, which could cause disruptions in our business, a loss of sales and profits, and other adverse effects.

 

Oracle Corp (3/12 – Q3 2020 Earnings Call)

So, there was a little bit of an impact actually in Q3, as certain components were in short supply. And so, in fact, once again, Q3 would have been even higher but for some shortages in components to our suppliers and to our suppliers’ suppliers as a result of the coronavirus in China. I think that we’re trying to work through all of that, and we’ll see what the availability is in Q4. We think some impacts may continue, but my guidance on this does include our ability to deliver some, but not all, of what we could possibly sell in Q4.

 

Broadcom Inc (3/12 – Q1 2020 Earnings Call)

But what we’ve seen so far is what happened in China, Asia, obviously. And that hit badly big but – so it could come from two parts, demand and supply chain. What we saw in the supply chain was not much impact partly because a lot of supply chain contract manufacturing and all that was not in China, part of it was but there was also inventory in the pipeline pre-COVID-19. So that kept supply chain going. So our supply chain has not been impacted to any meaningful level.

 

Dollar General (3/12 – 8K)

Based on information currently known by management, the Company does not anticipate that supply chain disruptions experienced to date as a result of the coronavirus outbreak are likely to have a material impact on its fiscal 2020 financial results. However, the Company continues to monitor this evolving situation, and there is no guarantee that this outbreak will not have a more significant impact on its business.

 

Caterpillar Inc (3/11 – CONEXPO Conference)

We’ve talked about, if you look around the supply chain – I mean the issue for us around the supply chain, where there potentially is risk in the current environment, probably is not necessarily our Tier 1 suppliers. It would tend to be your Tier 2, Tier 3 because these are smaller enterprises, are feeding into the larger manufacturers. So, in our top 25 suppliers, for example, at the moment, only 3 of those are Chinese vendors, so that is a signal. But obviously we don’t know, the other 22, where their supply chains go.

And so obviously if you’re thinking about a coronavirus type impact, particularly on the supply chain at this stage, we haven’t really seen anything. But obviously we are planning on the assumption that at some stage, some of those smaller Chinese manufacturers will have some impact somewhere along the line and building our contingency plans ready. And then obviously where we are sole sourced, that is the greatest area of risk and that’s obviously going to get the greatest degree of attention in the short-term.

Those places where we have alternative supply choices, we will continue to monitor those as well and obviously flex those through over the next few months. But obviously what we don’t want to do is end up in a situation where we either can’t produce or we are constraining ourselves on production. We have lived with that a little bit over the last couple of years. That has been a big challenge for us. So that’s a really big opportunity for us to unleash the supply chain a little bit better than we had done recently.

 

CSX (3/11 – JP Morgan Aviation, Transportation, and Industrials Conference)

Question – Brian P. Ossenbeck: All right. Thank you, Jim. So, you start-off with some of the impact of expectations from the coronavirus. Do you have any specific visibility that you can call out from within your supply chain? And if it does come back, there’s a concern that it might move a bit faster or need to move faster on the air, or on truck and that might kind of skip over the rail service supply chain. So, any thoughts on that, knowing it’s still early days?

Answer – James M. Foote: Yeah. We don’t have any unique visibility that everybody else can see. I mean, we know that there was an extended outage in China. We know there were a large number, an abnormal number of vessel sailings canceled. We expected as a result of that, volumes would be down. It takes a while for both cycles to get over to the West Coast. And sure enough, last week whatever it was down 10%, this week down 20%, it’s kind of what everyone anticipated.

The steamship companies, at least some of them, seem to have an optimistic view of a quick return to normalcy at least out of China. And so, we’re prepared if the – we’re – if anything based upon all of the changes we’ve made in the way we run the railroad today, we’ve proven the fact that we can pivot a lot faster, are a lot more nimble and can adapt to changes as they are thrown at us

 

AT&T Inc (3/10 – Deutsche Bank Media, Internet & Telecom Conference)

From a supply chain perspective, and I don’t want to suggest we’ve seen anything significant at this time, we continue to talk to our suppliers. Of course, when you think about the situation, we’re about handsets, and tablets, and watches, and those kinds of things, and other computer equipment, routers, and so forth. But so far, we’ve been in very good shape with that. We’ll see how long or if there’s an impact going forward, and we’ll leave it to our suppliers to kind of give their guidance in those kinds of things. But so far, we’ve been working closely with them and working through the entire corona situation.

 

Freeport – McMoran Inc (3/10 – 8K)

FCX also announced that there have been no significant disruptions to its supply chain or product shipments since the outbreak of the Coronavirus. The Company continues to monitor the situation closely and will carefully manage all costs, capital expenditures and production plans during this period of uncertainty.

 

AbbVie (3/9 – Press Release – Revised Guidance)

While helping respond to the COVID-19 crisis is a high priority, the company is committed to protecting the supply of Kaletra/Aluvia for HIV patients. AbbVie is actively assessing the increased demand for Kaletra/Aluvia and has taken steps to increase supply for COVID-19 patients without impacting treatment supply for HIV patients.

AbbVie continues to closely monitor manufacturing and supply chain resources around the world and does not anticipate any disruption to its medicine supply as a result of COVID-19.

 

ON Semiconductor (3/9 – Q1 Press Release – Revised Guidance)

ON Semiconductor Corporation (Nasdaq: ON), a supplier of semiconductor-based solutions, on Friday provided an update to its Q1 revenues outlook, which incorporates the potential impact of change in business conditions due to the novel coronavirus known as COVID-19.

According to the company, based on preliminary assessment of the current business environment, it anticipates that its revenues for Q1 2020 will be in range of USD1,275m to USD1,325m, as compared with the prior guidance of USD1,355m to USD1,405m, issued on 3 February 2020.

Reportedly, the company saw soft order trends in China in the weeks following Lunar New Year holidays, but orders have since picked up and it has not seen any significant cancellations of orders. Also, its factories in China have returned to normal levels of operations after mandatory shutdown following the end of Lunar New Year holidays.

However, public health outlook due to COVID-19 is uncertain and continues to evolve, and business impact of these conditions is difficult to forecast. This revised guidance is based on the information available to date, the company added.

 

Motorola Solutions (3/9 – Motorola Solutions Statement on Coronavirus Preparedness)

Motorola Solutions continues to closely monitor the widespread impact of the coronavirus, and the safety and well-being of our employees, customers, partners and suppliers remains our top priority.

 

CooperCompanies (3/9 – 10Q)

“… new regulations, global trade barriers including additional tariffs, the trend of consolidations within the health care industry and uncertainty regarding the scope and impact of the recent outbreak of the coronavirus referred to as COVID-19 on our sales and operations and on the operations of our significant suppliers and customers could impact our current performance and continue to represent a risk to our future performance.

 

Walmart Inc  (3/5 – UBS Global Consumer Retail Conference)

From a supply chain standpoint, we haven’t seen major impacts. So not much different than I would have said a couple of weeks ago. I do think in ways, the work that our merchants did around tariffs over the last 12 to 18 months helped us think about some things differently that are probably paying off some now and how you think about supply chain differently. It does feel like — I’m reading the same things you are, but it does feel like China is starting to kind of come back to work, which will help from a factory standpoint. And we’ll just have to keep monitoring it day-to-day, week-to-week.

 

Lowe’s Companies Inc (3/5 – UBS Global Consumer and Retail Conference)

Well, as recently as last night, I’m looking at factory production around the world and what their capacity is relative to where they’re accustomed to being. And so that’s the level of visibility we’re placing on this, tracking every PO, by manufacturer, by geographic location. And all I can say is we see no short-term negative benefits to our business. Our supply chain, relative to what we need for our spring business is either in the store, in the DC or on the water. And so we’re in a really good position there.

We’re going into this season, with our best in-stock position in over 5 years. So we’re really ready for spring. But beyond that, it’s hard to have clarity because we just don’t know what’s going to happen, but we’re staying close to it, and we’re going to be as flexible and as agile as we can.

 

Akamai Technologies Inc (3/5 – Morgan Stanley Technology, Media & Telecom Conference)

So in terms of the supply chain, there could be some timing issues. If there — we do have some component parts that come out of China. Most of our manufacturing is not done there in terms of our servers. We do a really good job of planning out in advance. So to the extent that this is a temporary shift, you may see some CapEx lower Q1, maybe it picks up a bit Q2, Q3. But we’re not anticipating anything that would have a major impact on the business at this point. But obviously, if this goes on for many, many months, it could have a little bit of an impact.

 

Autozone Inc (3/5 – UBS Global Consumer and Retail Conference)

Yes, we’re seeing some slowness coming from Asia, but the product — there is product flowing. Obviously, it isn’t flowing at the level that it needs to be. And it’s our understanding the factories are coming online and are progressing online, and the government is going through a certification process with each of the factories. And they’re ramping up, specifically the factories that are supplying us are ramping up. So we think that it will be, as we said on the call or Bill said on the call, it’s — the next few weeks will be critical as we kind of watch them continue to ramp up. To your point, you’re right. Our inventory turns relatively slow. We have X amount of weeks of supply in the system. We also have the ability to buy from ourselves, if we are able to rebalance out some of that inventory. So for now, we seem to be okay. And for what we can see in front of us, we don’t see a significant disruption. If things change, then we’ll have to address that when it happens. But at the moment, it feels as though we have inventory available. There’s inventory coming and will be coming based on our understanding. And so we don’t see this as being, at the moment, disruption of any great magnitude. I’m sure that there will be a little bit of a flow for the — our distribution folks as it will be for any company, who is getting very low volume right now and will get ramped up pretty significantly.

 

Zebra Technologies Corp (3/5 – Morgan Stanley Technology, Media & Telecom Conference)

 Obviously, the coronavirus makes a very fluid situation. Lots of news coming out every day and lots of reactions… For us, it has been predominantly a supply chain impact. In our call 3 weeks back, we did highlight some softness in China from tariffs and from the coronavirus, demand issues. But since our supply chain is largely China based, that was the bigger issue. We have dedicated teams that are working very closely with all our Tier 1, Tier 2, Tier 3 suppliers to make sure that we are in contact several times a day to make sure we have up-to-date information that we can help if there’s issues and stuff. The supply chain is definitely coming back to life in China. They’re definitely ramping up. Depending on the supply — the contract manufacturer or the region they’re in, they’re slightly different ramps. If they source more people from Wuhan, they might be a little slower to getting back into gear, but todays its definitely either people are almost at capacity or getting at towards capacity. So from what we’ve seen so far, it seems to be kind of developing in a reasonable fashion.

 

Hewlett Packard Enterprise Co (3/5 – Morgan Stanley Technology, Media & Telecom Conference)

On the supply chain side, obviously, we see an impact. And that’s where I said in the call, “Because of the uncertainty and because of the time the supply chain will time — will take to recover, we felt prudent, a, to not guide for Q2 because whatever number I give The Street, it will be wrong; and b, is to adjust the free cash flow for the timing of the recovery.” Because as you can imagine, the revenue will take a little bit of time to recover. And then you have the need to augment the inventory as you rebuild some of the buffers, because ultimately, you’ve got to get that motion in place.

And I will say I spend a lot of time with my suppliers. In fact, I have spoken to 50 of the top suppliers; and yesterday, to the top 2 suppliers. And I will characterize this as a recovery in progress. Most of the, what I call, the PCAs, PCBs, which are manufactured in China, we expect on the capacity side, recover between the next 2 to 4 weeks. Some of them will be online, but they are — all of them are online, but there will be a full labor capacity in the next 2 weeks to 4 weeks.

The question is the entire supply chain behind them, it takes a little bit of time because you think about the components that these people need to build these motherboards and circuit boards and other components, will take a little bit of time. But from a capacity perspective, between 2, 4 weeks, we expect them to be at full capacity.

And then there is all the other stuff we have to worry about, logistics. I was telling Katy before we came here, that — remember that 50% of the logistics is done through commercial airline and 50% through freight airlines. And when you have no commercial airlines going to China, and therefore, the bellies of these planes are not full or that people are not traveling, it is a challenge that we have been working through.

So I think I will say demand side, not a significant impact. We don’t see it yet. Supply chain, definitely, and will take 4 to 8 weeks to recover. And ultimately, we expect that to improve as we go along. And then also on the commodity side, we expect that to improve as well over time.

 

Costco Wholesale Corp (3/5 – Earnings Call)

In terms of supply chain, closures of many manufacturing facilities extended well beyond the typical 1 week Chinese New Year holiday, which was the last week in January. In many cases, factories over there were closed for 1 to 2 additional weeks. That’s now improving each week. Initially, 2 to 3 weeks of factory — so initially, there are 2 to 3 weeks of factory closures, not 1. Then about 3 weeks ago, and just pulling some of the buyers that — a deal with the factories, they felt there was a rough number of 20% to 25% production levels, moving up to 40% and now as high as 60% to 80%. But again, it’s improving, and this still has a little ways to go.

In terms of transportation issues, whether it’s Chinese New Year and then a couple of additional closure weeks. There were not only product issues but also trucking and port issues. These are also abating with port capacity in China improving each day as well. And I say port capacity, it’s also the shipping lines that come to the various ports.

Domestically, truck capacity is plentiful. However, exporting items, including KS items as well as other U.S.-manufactured items to our locations in Asia and Australia. It’s been a little bit of a challenge because of some container shortages here. But overall okay, just taking a little more work.

We’re finding other ways to handle any potential out of stocks by shifting SKUs to alternative items and categories, particularly in the areas of domestic goods, food and sundries and fresh.

 

Advanced Micro Devices Inc (3/5 – Financial Analyst Day)

From a business standpoint, it is a very dynamic situation. So let me give you some color to kind of give you, a view of what’s going on.

From an overall supply chain standpoint, our supply chain is primarily focused in China, Malaysia as well as Taiwan. And I would say, it’s a very robust supply chain. So we have taken a number of actions to ensure that we have continuity in that supply chain. And based on what we see today, we’re actually back to near-normal supply capacity in our supply chain.

So that is something that we continue to be very focused on. We’re also monitoring our customers, since a lot of our customers have supply chains that are very dependent on China and some of those operations. And we did see some disruptions, certainly through Chinese New Year and in month of February. There’s a lot of progress being made. I would say, all of us in the ecosystem are trying to return those operations to as normal as possible. And we expect that to continue over the next couple of weeks, I’m sorry, over the next coming weeks.

 

Western Digital Corp (3/5 – Morgan Stanley Technology, Media & Telecom Conference)

So we have a factory in Shanghai and a factory in Shenzhen that we were able to operate through that whole period of time. So that’s gone extremely well. We’ve done a lot of work in terms of the downstream supply chain, and it’s also done very well. We had a couple of suppliers that were in the Wuhan area. One of them is back up and running. One, we’re expecting to be back up and running on March 10. And from this quarter’s standpoint, we’re obviously burning into some of our buffer inventory, but we think we’ll be fine in terms of the shipments for this quarter. And that we expect to have our buffer inventories back to normal levels by the end of April.

 

Kroger Co (3/5 – Earnings Call)

We generally believe that we have limited supply chain exposure in China as the majority of the products we source is domestic. 

 

Dell Technologies Inc  (3/4 – Morgan Stanley Technology, Media & Telecom Conference)

And then the question becomes — it’s a question we think about a lot, which is — and then — let me go to the other part, and I’ll come back to that, which is around supply chain. So our supply chain, we’re in pretty good shape right now in the supply chain. We’ve — we had, had the — I think more — maybe more luck than not. We had our notebook factories running over Chinese New Year. We were paying overtime to our workers to work because of the building supply and inventory. And so we’re in pretty good shape on notebooks. Our server and storage capabilities are generally unaffected by this. We’ve had to adjust a few lead times in certain of our clients, those new products.

And so with what we know today — and there’s still certain factories that need to reopen in China. But we feel generally okay about our supply chain as long as they reopen in the time frame that the government says they’re going to be allowed to reopen. If that changes, then we’ll have to ship — we are spending a few extra dollars on logistics costs as you move parts and product around the supply chain, but that’s just — and some of the logistics dynamics are a bit more complicated these days.

 

Roku Inc (3/4 – Morgan Stanley Technology, Media & Telecom Conference)

Yes, in terms of coronavirus, what we mentioned is, today, we’ve only seen minor impacts, largely around supply chain in manufacturing. We had moved our Player manufacturing into Vietnam in the fall as a result of the potential tariff situation. But like the rest of the industry, a lot of the component supply chain runs in part through China. And so to the extent there’s continued disruption or significant disruption of the supply chain, so that can impact our ability to replenish our inventory.

 

Dollar Tree (3/4 – Earnings Call)

Our global sourcing group and merchants along with our logistics team are meeting daily and updating our progress on visibility to individual purchase orders. Generally, we are seeing production pickup, and factory attendance is increasing each week. Our global sourcing team in China and third parties that provide quality assurance inspections are nearly at normal levels. All ports and third-party freight consolidators are open and operating at near-normal levels, and we are getting all needed space on vessels for our freight. At this point, all of our Easter merchandise and lawn and garden seasonal product is in our domestic supply chain, either in distribution centers or flowing to stores. At this point, we see a very small percentage of product canceled and some products moving on to later delivery, usually by a few weeks. And our teams are working to mitigate with sources elsewhere, including domestic sources, to mitigate any effect there. More to come.

 

Xilinx (3/4 – Morgan Stanley Tech Conference)

With respect to impacts to the company on the supply side, we don’t have — most of our supply chain is not in China. So we don’t see any impact of availability of products. With respect to the demand side, we haven’t seen capacity normalizing post-Lunar New Year, to the extent we would have expected by now. And so while the impact currently has been modest, I think the expectations are if this obviously is protracted, global consequences, there could be more meaningful impacts to the business in subsequent quarters.

 

Home Depot (3/4 – Raymond James Conference)

So on our global supply chain, I would say, for Q1, we’re in pretty good shape. So product for Q1 is largely in our stores. So Q1 and 2, for us, is a big strength. Spring and outdoor project business, we’re largely set. So all our merchandising space has largely transitioned to spring product. We’ll be finished with that in our northernmost markets in the next week or 2. But — so all that product that comes in, think grills and patio sets and the outdoor power equipment I was talking about previously, for Q1, that product is largely in-store, in our supply chains or on the water.

Q2, I would say, it’s a very fluid situation. So as you say, we have very strong relationships with our supplier partners. For our direct imports, where we’re working directly with factories in Asia, we are in constant contact with them and monitoring their capacity and how they’re getting back up to speed and what their shipping horizons, timing is going into Q2. It’s fluid. We’re literally looking at this PO to PO. The good news is the ports are open and functioning. We haven’t had delays in ports. It’s really a matter of workers getting back to factories from the Chinese New Year. Most of those workers or many of those workers are in residence at the factories. And for those 2 weeks of Chinese New Year’s, they travel home to wherever their provinces may be out of the major cities. So it’s been a transportation issue in restrictions of travel intra-country to get those workers back to the factories.

So again, we’re in contact, varying degrees, as you can imagine, of building back to capacity. The next set of suppliers are suppliers that, while we don’t procure directly from China, we know the country of origin is China and Asia. And we’re in constant contact with them, starting to build orders into Q2. Again, it’s PO to PO. You’re obviously not going to order too deep into Q2. You just — the supply chain won’t handle that sort of cube. So we just have to keep working it. Nothing alarming at this point. 

 

Sirius XM (3/3 – Morgan Stanley Conference)

We’ve checked supply chains with the OEMs. And honestly, things look — looks pretty good. The supply chain for automotive is fairly long as I think most people know. And so if it goes on for a couple of months, I think there’s probably not a whole heck of a lot of impact on us. If it goes on for much longer than that where people can’t get in. We can’t get printed circuit board supply, right? That could be an issue. But it’s got to run for a few months before we think we start to see anything. So other than that, it’s just keep cracking away the business everyday.

 

Hewlett Packard Enterprise (3/3 – Earnings Call)

Additionally, the outbreak of the coronavirus at the end of January impacted component manufacturing, resulting in higher quarter end backlog.

Also, we do feel it is prudent to revise our fiscal year ’20 free cash flow outlook from $1.9 billion to $2.1 billion to $1.6 billion to $1.8 billion, given that we expect some impact on cash conversion cycles driven by the ongoing recovery from supply constraints and impact of the coronavirus.

Unfortunately, this is also causing supply and demand disruptions and affecting our revenue profile. The outbreak at the end of January started to impact component manufacturing and resulted in constrained supply and higher quarter-end backlog worldwide, and we have been in constant contact with our suppliers and are establishing specific mitigation and recovery plans. So this is affecting our revenue profile for the full year. This is why we’re not guiding in the short term. And relative to what we said at SAM, where we were experiencing — we’re thinking we would be returning to growth in fiscal year ’20, I don’t think that it is likely at this stage that we’ll grow in fiscal year ’20, as a whole for the fiscal year. But we do anticipate recovery of those supply chain constraints over time and face easier comps during the course of the year.

Obviously, this is very fluid at this point in time. There is uncertainty. We have a daily process with each of our suppliers that we managed very, very tightly. And some of those suppliers are dependent on other suppliers because, as you can imagine, the supply chain is a little bit longer with Tier 2, Tier 3 suppliers that provide what I call low-level components to build what I call the printed circuit boards or the PCIs or the PCBAs, and that’s a challenge we see today. And we see recovery, but obviously, it’s going to take time. And that’s why Tarek said we cannot provide right now a definite guidance. I think it will be not appropriate. And that’s why we felt prudent not to provide Q2, but because the recovery is going to happen through the year that we felt comfortable reaffirming the 2020 guidance.

 

Ross Stores (3/3 – Earnings Call)

As noted in our press release, our guidance does not reflect the potential unknown impact from the evolving coronavirus outbreak. While we’re closely monitoring the situation, there remains a high level of uncertainty over supply chain disruptions in China. In addition, it is unclear how a further possible spread of the coronavirus could negatively impact U.S. consumer demand.

 

Digital Realty Trust (3/3 – Citi Conference)

From a supply chain standpoint, we are — obviously have the potential risk of impact given numerous components within our 4 walls. Could be manufactured or imported for some of the countries impacted. From our advanced discussions that well predate today where we are on this coronavirus. We feel that we look — appear to be insulated, whether it pertains to batteries, UPS, switchgear, for at least 12 months’ worth of time. So, so far so good. But again, as I mentioned in the opening statements, we don’t know where this is going.

 

AT&T (3/3 – Morgan Stanley Conference)

I do expect that there are going to be some impacts that flow through handsets, especially for those vendors that are more oriented towards China. And we’re already starting to see that happen. I don’t expect that those shortages are going to be anything that probably impact first quarter dynamics in any significant way for voice postpaid kind of constructs around things. We’re seeing some things in prepaid entities, like if — I shouldn’t say prepaid, but watches, tablets, maybe some shortages popping up there that are particular SKUs that may have some nominal impacts, but it’s not significant.

Look, I think the vendors right now are fairly optimistic that this is contained and it’s going to be isolated to several weeks of delay for particular SKU items, not that there’s going to be complete stockouts. I think this morning, Foxconn indicated that they felt like they were starting to get some of their production in China turned back up and that they would get themselves back to somewhat normal constructs around the end of March. Obviously, once they get back to normal at the end of March, it takes a period of time for that to work its way through the entire supply chain and replenish. But if that in fact happens, then we expect it’s going to be relatively contained and manageable, and all the tactics we’ve used to stockpile and allocate those types of things should be able to get us through with some reasonable confidence.

 

Alnylam Pharmaceuticals (3/3 – Cowen Conference)

I mean, we’ve done — obviously, as all companies are doing right now, done a systematic review of our supply chain in light of the COVID-19 epidemic, and we are in a very good position. We don’t see any implication for our commercial or clinical products. Most of our — we do no drug substance manufacturing or drug product manufacturing in China. And we do that in either the U.S. or in Europe as a company. And we have no — we have sufficient inventory of all of our commercial products as well as clinical development programs as well. So there’s no supply chain implications. Now turning to specific markets and where there might be issues, thus we can talk about Japan. Japan is a big market for us. It probably will exit 2020 as our second largest market. So far, we haven’t seen any implication of the COVID-19 epidemic in Japan.

 

Verizon (3/3 – Morgan Stanley Conference)

As you see on the handset side, I think there is a risk on the equipment revenue side that we’ll see an impact there. Not so much in the first quarter. Obviously, there was handsets in the pipeline as the impact started to come through. But if we see continued disruption, you’ve heard some of the handset companies talk publicly about. If that carries on for a significant time period, I think we’ll see a more material impact on our equipment revenue line. That doesn’t really impact the earnings profile as significantly for us, given that it’s not where most of the earnings come from. The earnings come from the service revenue. But certainly, there may be some — in the future months some impact on the equipment. So we’ll have to wait and see.

And then you mentioned on the network side and not seeing anything material impacting our supply chain at this point. But I think, obviously, the major thing is, this is obviously a fluid situation, and we’ll have to wait and see how it continues to evolve. And as it evolves, if it’s going to impact either the income statement as we think about revenue or consumer behavior or the way that our supply chain on our network side will operate, we’ll update everyone as appropriate. But as of right now, not a material impact, but we’ll wait and see how it plays out.

And obviously, we’ll have to see how if the supply chain around that gets disrupted with the coronavirus. But we still have line of sight to 20-plus 5G devices coming into our ecosystem during the course of 2020. You’ve seen some of those announced already. You’ve got the Samsung models launching later this week. So absolutely still feel good about seeding the ecosystem with a lot more 5G devices this year than what we saw last year.

 

Autozone (3/3 – Earnings Call)

As you would expect, over the last month or so, we have been very focused on the supply chain aspects of coronavirus and, in the last week or 2, more and more focused on what’s happening here in the United States and, ultimately, Mexico and Brazil. We see no indications at this point in time of any demand destruction as a result to coronavirus. But just like we said with the supply chain, it’s an incredibly, incredibly fluid situation. I think the next couple of weeks to a month, are going to be critical to see what actually happens. We don’t have good insights into that.

 

Chevron (3/3 – Analyst Meeting)

First, let me address the short-term impacts of the coronavirus. No doubt, demand for our products is down. Our focus is on protecting our people and maintaining safe operations. This time, our operations and supply chains are functioning normally. We’re taking all appropriate precautions to keep it this way, but it’s a fast-changing situation.

 

United Rentals (3/3 – Evercore ISI Conference)

Supply chain seems to be what’s been disrupted in most industries right now. We have not had this disruption. And I wasn’t here for all of Terex’s commentary, but our suppliers have not pushed out any lead times for us, the things that would be meaningful for our business. We haven’t had any of those impacts. That’s one of the areas where we think coronavirus is showing up early.

 

Qorvo (3/3 – Raymond James Conference)

As far as the commercial effects of the virus, we’re seeing both supply and demand effects. On the supply side, some parts of the supply chain are experiencing reduced labor, which is limiting throughput. There have also been some isolated component shortages. At present, neither of these factors appears to be getting worse and from recent customer comments and our interactions across the supply chain, it may be getting better.

 

Trimble (3/2 – Morgan Stanley Conference)

What we — what I’d anchor you is on December — February 12 on our earnings call, we talked about the impact within a Q1 context and within a Q1 context, we quantified about 3 weeks of delay minus a couple weeks of buffer equal to about 1-week impact on the supply chain plus a degradation in the sales within the China market that was baked into our Q1 — I think, our Q1 guide.

 

Stanley, Black and Decker (3/2 – Raymond James Conference)

But probably the bigger question you have in your mind is our supply chain. Our supply chain in China serves 40% of our capacity across the company.

As it relates to the virus and where we are on China as far as our manufacturing capabilities as of today. We shut down these 10 plants for the 2 weeks of the holiday season around Chinese New Year. The week after that, these plants began to open up and the production capabilities and utilization have got to about 50%, 60% on average across those plants sometime last week. We’re continuing to make progress on that. And those numbers continue to improve as we sit here today. And we’re continuing to focus on getting more employees back to work, that’s one of the challenges we have right now, where all the employees have not returned to the plants. We have a process that we need to go through with every employee before they get into the plant around checking for fever and other symptoms that are visible and then, obviously, wearing masks within the plant to try to protect our employees as much as possible in that environment. We do believe it will take another 2 or 3 weeks probably to get to 100% utilization in these plants. And that obviously is assuming that the virus doesn’t worsen in China, that it stabilizes and begins to — to begin to go — retract or go backwards.

If that happens to get worse, then obviously, those numbers could change. But right now, that’s what our plans are, and we believe that’s achievable based on where we are today. This will cause some pressure for us in March and April from a revenue perspective. So we see that revenue in the last 2 weeks of March will probably be pressured based on these capacity challenges we’re having and also in the month of April. We do believe it’s more of a timing-related matter at this stage. But obviously, that’s very dependent on where the virus goes and how significant it is. If things stabilize, and we don’t see a dramatic worsening, we think that’s probably where we are. We have a timing issue we have to work through for the first half of the year and the full year as well.

 

Dentsply Sirona (3/2 – Earnings Call)

At the current time, we have not experienced a significant disruption to our global supply chain due to coronavirus. However, in many parts of China, dental clinics and hospitals remain closed for business. And in other parts of the world, we are beginning to see an impact.

 

Carlyle Group – Feb 28th – CS Conference

There’s definitely going to be a short-term financial hit. You can’t have half of the world’s second largest economy be dormant and not have an impact to global economy. You can’t have 55% of global manufacturing output go through China in some shape or form without there being a short-term hit. And I think people underestimate the disruption to the supply chain. We’ve got estimates of close to 60,000 containers that are in the wrong places, wrong ports, wrong railway stations because everything is disrupted. To get that all moving and going in sequence in the right way, it’s going to take a long time.

Don’t miss critical insights. AlphaSense gives you access to full Earnings call transcripts and allows you to keep track of themes unfolding within your coverage universe through intelligent AI-powered search.

Sign up for a free trial to learn how AlphaSense enhances the workflow of 70% of the world’s hedge funds and over 50% of the S&P 500. Already have an account? Login here.

COVID-19’s Impact On Travel Creates Widespread Uncertainty

Interested in staying up-to-date on COVID-19’s impact across sectors? Visit our Coronavirus Impact Tracker for daily updates pulled from earnings calls, press releases, 8ks, and more.

Early on in the coronavirus pandemic, the TSA reported a 96% drop in air travel, nearly 80% of hotel rooms laying empty and the CDC renewing the No Sail Order for cruise ships, Coronavirus had all but stopped the travel industry in its tracks. The World Travel & Tourism councils estimated up to 75 million jobs are at immediate risk and in 2020 alone, the global economy could stand to lose $2.1 trillion.

Who is talking about how travel is impacting their businesses? Learn which companies are communicating on COVID-19’s travel impacts and how they expect the virus to affect financial results.

 

Takeaways:

  • United Airlines reported a net loss of USD (1.7m) in the first quarter 2020, and an adjusted net loss of USD (639) million.
  • Delta Airlines’ Executive VP & CFO noted that “5 years from now, I expect things to be relatively returned to normal.”
  • The majority of major airlines, online bookings sites, hotel groups, and cruise lines have pulled financial guidance for 2020
  • Cost reduction measures such as lay-offs, furloughs and wage cuts have become commonplace and many businesses are drawing down credit facilities
  • Industrial parts manufacturers that support these businesses have been forced to cut production significantly

Don’t miss critical insights: Sign up for a free trial or login here.

Here are the highlights:

[Note: We are updating this post and our compilation post to reflect the most recent commentary. Last updated 5/22]

Deutsche Post AG (Conference Transcript – 5/20)

So overall, we plan right now quarter-by-quarter. So what quarter 3 will bring is it already a bit too early to tell. But one thing we do sense is that the capacity on the air freight side will remain stressed because the passenger airplanes will not come back as we were used before corona — before the corona situation. And if we see these ghost flights where airlines bring empty passenger planes into certain trade lanes and markets, they are a bit of a relief, but they are not a real relief.

 

Delta Airlines (Earnings Call Transcript – 5/19)

Question – Hunter Kent Keay: Okay. What is the — over a business cycle up until pre-coronavirus, what was the return on invested capital on a wide-body aircraft versus a narrowbody aircraft?

And the second part of the question is, what are the odds that Delta doesn’t fly any wide-body aircrafts 5 years from now?

Answer – Paul A. Jacobson: I would say that the return on invested capital is a little bit lower for the wide-bodies, and that trends consistently with the domestic being the most profitable and then the international regions sort of sequencing down from there.

5 years from now, I expect things to be relatively returned to normal. Of course, we can’t see that far into the future. We don’t know what a COVID resurgence looks like. But I do have a lot of faith in economic systems where there are a lot of really, really smart people with a lot of capital working to solve this crisis for everybody. And usually, when that happens, when there’s an abundance of both things, problems get solved.

Ryanair (Press Release – 5/18)

Covid-19 flight restrictions and aircraft groundings in the 2nd half of March reduced traffic by over 5m in Q4.

The widespread grounding of aircraft as a result of EU governments reactions to the spread of Covid-19 means that the Group will operate a significantly reduced flying schedule in FY21 compared to what was originally expected.  Therefore, the Group is recording an exceptional hedge ineffectiveness charge of €392M.

This was primarily due to increased pilot pay and higher crewing ratios, increased ownership costs due to the Boeing MAX delivery delays and a 15% reduction in Q4 traffic due to the response of EU Governments to stop the spread of the Covid-19 virus. Since mid-March responses included wide spread flight bans and travel restrictions which have closed Europe’s skies to all but a tiny number of rescue and medical flights.

Singapore Airlines (Trading Update – 5/8)

The COVID-19 pandemic continues to have a severe impact on air travel, as border controls and travel restrictions remain in place around the world. This has affected the entire global aviation industry, and the SIA Group has not been spared either, with the impact on the SIA Group exacerbated by the lack of a domestic market for it to fall back upon. To address this collapse in demand, SIA and SilkAir have extended their combined capacity cuts of approximately 96% until the end of June 2020, while Scoot is expecting
capacity cuts of approximately 98%. The collapse of fuel prices in March 2020 has led to fuel hedging losses on contracts maturing in the final quarter of FY2019/2020. The unprecedented scale of the capacity cuts by the SIA Group as a result of COVID-19 has also resulted in the SIA Group being in an over-hedged position with respect to the expected fuel consumption for FY2020/2021.
 

American Airlines (Press Release – 5/4)

American Airlines Group has announced it plans to officially retire five types of older, less fuel-efficient aircraft from its fleet, the company said.

The exiting aircraft are being retired amid a period of record low demand for air travel due to the coronavirus pandemic.

In March, American Airlines said it was planning to accelerate the retirement of some older aircraft from its fleet sooner than originally planned. The company will retire a total of about 100 older aircraft.

 

Boeing (Press Release – 5/4)

United Airlines (UAL) has reported a net loss of USD (1.7m) in the first quarter 2020, and an adjusted net loss of USD (639) million, the company said.

The company’s total liquidity as of the close of business on Wednesday, April 29, 2020 was approximately USD 9.6 billion, including USD 2 billion under its undrawn revolving credit facility. The company currently expects daily cash burn to average between USD 40 million and USD 45 million during the second quarter of 2020.

The company took early and aggressive action intended to mitigate the impact of COVID-19 to position the company to bounce back quickly and make United stronger when demand returns.

 

Ryanair (Press Release – 5/1)

We are in active negotiations with both Boeing, and Laudamotion’s A320 lessors to cut the number of planned aircraft deliveries over the next 24 months, which could reduce our capex commitments, to more accurately reflect a slower and more distorted EU air travel market in a post Covid-19 world.

Boeing Co (Press Release – 4/30)

Boeing‘s results showed dire figures, especially for its Commercial Airplanes business. Boeing President and CEO David Calhoun pointed to the COVID-19 pandemic as the root of the company’s troubles. The fall in revenues for Commercial Aircrafts, declining from US$11,822bn to US$6,205bn year-on-year and featuring US$2bn in operating losses, could be foreseen from the recent succession of cancellations that stroke Boeing‘s backlog, especially the B737.

Boeing‘s troubles started last year with the grounding of the B737 MAX after two successive crashes. Boeing‘s commercial aircrafts’ order backlog is 80% composed of single-aisles in unit terms, according to GlobalDataHowever, this figure tends to diminish in relative terms with cancellations such as Avolon’s (75 MAXs) or GE Capital Aviation’s (69 MAXs) in April this year. The crisis of air travel generated by the pandemic is another nail in the single-aisle fuel-efficient coffin. The jetliner market was confronted to a slowdown of the Asian market already before the COVID-19 outbreak and narrow-body also have to live with the growing irrelevance of fuel efficiency since the collapse of oil price.

Costar Group (10Q – 4/29)

COVID-19 has surfaced in nearly all regions around the world and resulted in travel restrictions and business slowdowns or shutdowns in affected areas. The full impact of the COVID-19 pandemic is unknown and rapidly evolving. The COVID-19 pandemic did not materially affect the Company’s condensed consolidated financial statements for the three months ended March 31, 2020 As the extent and duration of the impacts from COVID-19 remain unclear…

…In response to the COVID-19 pandemic, we have also taken steps to manage our costs including minimizing hiring to essential positions, restricting business travel and canceling in-person marketing events. As the situation evolves, we may implement additional cost reductions.

Southwest Airlines (Earnings Call Transcript – 4/28)

On our last call, I gave a quick update on our GDS initiative, which you might recall is focused on growing our share of the corporate travel market. When we announced last week that we’ll be going live on May 4 with travel ports Apollo and Worldspan GDS platforms, which means that all of our everyday low-fare content will now be available with industry standard ticketing and settlement capabilities. And the response from the travel management companies and corporate travel managers across the country has been absolutely phenomenal, and we’re excited about what this means for us and for our customers.

So from a corporate travel perspective, in spite of COVID, it is full speed ahead, and we will be in a strong position as business travel begins to come back. It’s going to take some time, but it will come back, and we’ll take more than our share.

UPS (Earnings Call Transcript – 4/28)

Question – Scott Andrew Schneeberger: Could you please discuss volumes, and particularly pricing, you’ve encountered on international export parcels? And what is the fluctuating level of commercial airlines flying cargo in the belly space over the past few months due to the coronavirus impact?

Answer – Nando Cesarone: Yes. Just — I’ll start off. It’s Nando. Thanks. Just talk about belly capacity for a second. We know it’s limited right now, and for a period of time into the future, the industry is down around 80% at this point in time and approximately 70,000 daily tons. So quite a bit of capacity that’s been taken out of the market. Not sure how long the condition will last, but certainly, a recovery will most likely happen when businesses — business travel and tourist travel begin again into the future. And that’s really the big question mark. For now, we have added aircraft, we have added flights where we see, and if it’s appropriate in terms of profitability, we will purchase transportation. But we are dealing with that capacity that’s not available as it was in the past and allowing us to make sure we run our network as efficiently as possible.

Caterpillar Inc (Earnings Call Transcript – 4/28)

From a cost control perspective, we reduced discretionary expenses, including consulting, travel and entertainment.

Given the COVID-19 environment, we suspended 2020 base salary increases and short-term incentive compensation plans for many employees and all our senior executives. We’ll continue to look for ways to make our cost structure more flexible and competitive.

Turning to our suppliers. We keep a close eye on their financial health as well. In the event that a supplier faces financial distress, we identify solutions to support them whilst also ensuring supply for Caterpillar’s products. In particular, our suppliers have access to working capital support through a partnership with one of our third-party banks. This can provide quick access to cash flow to help them cover their payment commitments, all of no risk to Caterpillar.

Southwest Airlines (Preliminary Prospectus Supplement – 4/28)

Our financial results have been significantly affected by the COVID-19 pandemic, as demand for both business and leisure air travel has declined considerably. The extent of the impact of the COVID-19 pandemic on our financial performance will depend on future developments, including the duration, spread, severity, and any recurrence, of the COVID-19 pandemic; the duration and scope of related government orders and restrictions; and the extent of the impact of COVID-19 on overall demand for air travel, all of which are highly uncertain and cannot be predicted.

Air travel is also significantly affected by general economic conditions, the amount of disposable income available to consumers, unemployment levels, corporate travel budgets, fears or actual outbreaks of infectious disease, extreme or severe weather and natural disasters, fears of terrorism or war, and other factors beyond our control. These and other factors, such as the price of jet fuel in some periods, the nature of our fuel hedging program, and the periodic volatility of commodities used by us for hedging jet fuel, have created, and may continue to create, significant volatility in our financial results.

Southwest Airlines (10Q – 5/28)

The speed with which the effects of the COVID-19 pandemic have changed the U.S. economic landscape, outlook, and in particular the travel industry, has been swift and unexpected. The Company began to see a negative impact on bookings for future travel in late February 2020, which quickly accelerated into and throughout March. January and February operating revenues were generally in line with the Company’s expectations, but March results were significantly below expectations due to the sharp decline in Passenger demand and bookings, combined with an unprecedented level of close-in trip cancellations (Customers canceling close to scheduled flight times). On March 22, the Company began proactively canceling a significant portion of its scheduled flights, and increased those cancellations further beginning on March 27, 2020. In addition, the cancellation of flights, both in March 2020 and for future periods, has resulted in a significant amount of cash refunds and issuance of travel credits to Customers. Further, due to the fears and restrictions involved with travel in the near term, sales of tickets for future travel have been well below the Company’s expectations. These events have created a liquidity risk, and the Company reacted quickly by taking the following steps to better enable it to meet all financial obligations as they become due.

In response to flight schedule adjustments due to the effects of the COVID-19 pandemic, a number of aircraft were taken out of the Company’s schedule beginning in late March. As of March 31, a portion of the Company’s fleet had been placed in temporary storage and the Company was actively canceling a significant portion of its previously scheduled flying. Given the current expectation that these aircraft have been grounded temporarily, the Company has continued to record depreciation expense associated with them.

Lockheed Martin (10Q – 4/22)

For example, we had a brief pause in operations at the F-35 Final Assembly and Check Out (FACO) facilities in Japan and Italy in March in observance of such countries’ COVID-19 policies and additional closures could occur, and we are seeing impacts from base closures and travel restrictions both within and outside the U.S. In many cases facilities are not operating under full staffing as a result of COVID-19, which could have a longer-term impact. Flight test operations and training are being impacted by travel restrictions as a result of COVID-19, which could delay our deliveries to customers. We also have some limited operations that are not designated as critical infrastructure and therefore have been mandated to close or operate at only minimum basic operations. However, these closures to date have not been material.

 

AIRBUS SE (PR – 4/8)

Airbus provides update on March commercial aircraft orders & deliveries and adapts production rates in COVID-19 environment

– Business impacted by COVID-19 pandemic

– 21 net orders and 36 deliveries in March 2020

– 290 net orders and 122 deliveries in Q1 2020

– Production rates revised downwards adapting to new market environment

After a solid commercial and industrial performance at the beginning of the year, Airbus (stock exchange symbol: AIR) is now revising its production rates downwards to adapt to the new Coronavirus market environment.

In Q1 2020, Airbus booked 290 net commercial aircraft orders and delivered 122 aircraft.

A further 60 aircraft were produced during the quarter, highlighting the solid industrial performance, however they remain undelivered due to the evolving COVID-19 pandemic.

36 aircraft were delivered in March across the different aircraft families, down from 55 in February 2020. This reflects customer requests to defer deliveries, as well as other factors related to the ongoing COVID-19 pandemic.

The new average production rates going forward have been set as follows:

– A320 to rate 40 per month

– A330 to rate 2 per month

– A350 to rate 6 per month

This represents a reduction of the pre-coronavirus average rates of roughly one third. With these new rates, Airbus preserves its ability to meet customer demand while protecting its ability to further adapt as the global market evolves.

 

BOOKING HOLDINGS (Prospectus – 4/8)

Although the COVID-19 pandemic is unprecedented in scope and effect, we believe that travel will rebound at some point as it did following other events such as SARS, 9/11 and the global financial crisis of 2008-2009. We believe that we will be well positioned to emerge from the COVID-19 crisis and extend our leadership with the size of our demand platform becoming increasingly more valuable to our supply partners, our ability to take advantage of customer acquisition opportunities when travel demand returns and our strong cash and liquidity position, which may provide opportunistic uses of capital following the crisis.

 

CARNIVAL PLC (Interim Report – 4/3)

Due to the spread of COVID-19 and the effects of growing port restrictions around the world, we previously announced a voluntary pause of our global fleet cruise operations. Significant events affecting travel, including COVID-19, typically have an impact on booking patterns, with the full extent of the impact generally determined by the length of time the event influences travel decisions. We believe the ongoing effects of COVID-19 on our operations and global bookings have had, and will continue to have a material negative impact on our financial results and liquidity, and such negative impact may continue well beyond the containment of such outbreak.

We cannot assure you that our assumptions used to estimate our liquidity requirements will be correct because we have never previously experienced a complete cessation of our cruising operations, and as a consequence, our ability to be predictive is uncertain. In addition, the magnitude, duration and speed of the global pandemic is uncertain. As a consequence, we cannot estimate the impact on our business, financial condition or near- or longer-term financial or operational results with reasonable certainty, but we expect a net loss on both a U.S. GAAP and adjusted basis for the fiscal year ending November 30, 2020. On March 13, 2020, we fully drew down our $3.0 billion multi-currency revolving credit facility (the “Existing Multicurrency

Facility”). We are taking further actions to improve our liquidity, including capital expenditure and operating expense reductions, suspending dividend payments on, and the repurchase of, the common stock of Carnival Corporation and the ordinary shares of Carnival plc and pursuing additional financing. Based on these actions and assumptions regarding the impact of COVID-19, we have concluded that we will be able to generate sufficient liquidity to satisfy our obligations and remain in compliance with our existing debt covenants for the next twelve months prior to giving effect to any additional financing that may occur.

 

RYANAIR HOLDINGS (6k – 4/3)

Ryanair is currently operating less than 20 daily flights, which is 99% less than its pre-Covid 19 daily schedule of over 2,500 flights. The airline expects its fleet to remain largely grounded for at least April and May. We therefore expect to record ineffectiveness on our FY21 fuel hedges as an exceptional item in our FY20 results. We currently estimate that this will amount to an exceptional charge of approximately €300m. Ryanair Group Airlines continue to work with EU Governments to maintain minimum flight links for emergency reasons, and to operate rescue and medical flights when requested to do so. Ryanair continues to operate occasional currency flights to ensure that its pilots and aircraft are ready for a return to service when this Covid-19 crisis passes, as it inevitably will.

Ryanair has one of the strongest balance sheets in the industry, with year-end cash equivalents of €3.8bn and 327 (77%) of the Group’s owned fleet unencumbered and debt free.  The Ryanair Group has already implemented a series of measures to cut operating costs, improve liquidity and cash flows. These include aircraft groundings, deferring capex, suspending share buybacks, freezing recruitment and discretionary spending, cutting all pay (including senior management) by 50% with immediate effect for April and May, and we are engaging with our people and our unions across all EU countries to agree payroll support mechanisms as they are put in place by EU Governments.

We are grateful to many EU Governments for their foresight and speed of response in recognising that the EU airlines are one of the most exposed industries to the Covid-19 pandemic and that our flights have been grounded by necessary Government restrictions to combat the spread of Covid-19.  However, we equally support the EU Commission’s position that any such Government supports must comply with all EU State Aid and Competition rules.

Given the continued uncertainty on the impact and duration of the Covid-19 pandemic, it is not possible to give FY21 guidance at this time. The Ryanair Group of Airlines will continue to focus on delivering cost savings, protecting jobs, working with EU Governments to support rescue and medical flights, and preparing for the return to normal service when the Covid-19 crisis has passed, which we hope will be sooner rather than later.

 

VAIL RESORTS (8k – 4/1)

Rob Katz, Chief Executive Officer, said, “The circumstances surrounding COVID-19 are unprecedented and the financial impact to our Company and the broader travel industry has been significant. Following the difficult decision to close our North American mountain resorts, retail stores and lodging properties for the remainder of the 2019/2020 North American ski season, we have quickly transitioned to evaluating the longer-term impacts for our Company and our resort operations. While we will continue to assess our ability to reopen select resorts for late-season skiing, we are keenly aware that the current travel restrictions may stay in place beyond that timeframe and could ultimately impact the timing of our ability to open our North American resorts for their summer season and our Australian resorts for their winter season. And once we are able to reopen, we assume weaker travel demand may continue, impacting our fourth fiscal quarter of 2020 and our first fiscal quarter of 2021.

“The Company went into this challenging time period with a strong financial position and based on recent events, we are currently incorporating more challenging scenarios into our planning for our fourth fiscal quarter of 2020 and the first fiscal quarter of 2021. As mentioned in our March 18, 2020 press release, we are taking additional proactive steps to align our capital spending and return of capital approach to ensure that we remain positioned for long-term success. We are also taking steps to address our operating costs and the inability of many of our employees to perform their roles in the current environment.

“We are reducing our capital plan for calendar 2020 by approximately $80-$85 million, with the vast majority of these savings coming from the deferral of many of our discretionary capital projects. We are planning to defer all new chair lifts, terrain expansions and other mountain and base area improvements, while continuing with the vast majority of our maintenance capital spending.

 

CARNIVAL CORPORATION (8k – 3/31)

Significant events affecting travel, including COVID-19, typically have an impact on booking patterns, with the full extent of the impact generally determined by the length of time the event influences travel decisions. We believe the ongoing effects of COVID-19 on our operations and global bookings have had, and will continue to have, a material negative impact on our financial results and liquidity, and such negative impact may continue well beyond the containment of such outbreak. In particular:

  • For the seven week period beginning January 26, 2020 and ending March 15, 2020, booking volumes for the remainder of 2020 were significantly behind the prior year on a comparable basis as a result of the effects of COVID-19. As of March 15, 2020, cumulative advanced bookings for the remainder of 2020 were meaningfully lower than the prior year and at prices that are considerably lower than the prior year on a comparable basis. As noted above, all of our global fleet operations are subject to voluntary pauses that we expect to be extended. Due to the unknown length of the pauses, booking volume data for 2020 may not be informative. In addition, because of our updated cancellation policies, booking volumes may not be representative of actual cruise revenues.
  • For the first half of 2021, booking volumes since mid-December 2019 through March 1, 2020, were running slightly higher than the prior year. In contrast, for the first half of 2021 and during the two weeks ended March 15, 2020, we booked 546,000 Occupied Lower Berth Days, which was considerably behind the prior year pace. As of March 15, 2020, cumulative advanced bookings for the first half of 2021 were slightly lower than the prior year.

As of February 29, 2020, we had a total of 16 cruise ships scheduled to be delivered through 2025, including four during the remainder of fiscal 2020. We believe the effects of COVID-19 on the shipyards where our ships are under construction will result in delays in ship deliveries, which we cannot predict and may be prolonged.

In March 2020, Moody’s and S&P Global downgraded our long-term issuer and senior unsecured debt ratings. In addition, our long-term ratings were placed on review for further downgrade by both rating agencies. Our short-term commercial paper credit ratings were also placed on review for downgrade.

On March 13, 2020, we fully drew down our $3.0 billion multi-currency unsecured revolving credit agreement (“Existing Multicurrency Facility”).  On March 24, 2020, we settled derivatives in a net gain position of approximately $200 million. Consequently, as of the date hereof, our principal source of immediate liquidity includes our available cash and cash equivalents.  Given the impact of COVID-19 on bookings, which are meaningfully reduced from the prior year comparative pace, and the pause of our global fleet cruise operations, which we expect to be extended, we are conducting the offering of the Notes and the Equity Offering to raise an additional $6.0 billion in aggregate gross proceeds (a portion of which will be subject to escrow arrangements).

 

HUAZHU GROUP LTD (Earnings Call – 3/27)

Answer – Justin Kwok: I got 3 questions, 2 related to the sector and perhaps the last one related to Europe. For the first 2 questions on the sector: can I get a sense on how management is seeing the potential behavioral change for the travel industry, regarding both the business travel and the leisure travel, after the entire COVID-19 is being settled? How would you expect the way business and the way leisure travelers will behave differently going forward? The second question on the sector is about the competition landscape. With 2019, actually the focus on the investor was on some of the new entrants into the China market and some of the mid- to smaller chain players seen — turning a lot more aggressive in going into expansion. How do you see this landscape in 2020 and ’21? The last one is actually on Deutsche Hospitality. How would management guide in terms of the EBITDA contribution for this segment, for this newly acquired company in 2020? Given the operating leverage, how should investors think about the contribution?

Answer – Yu Ida: Sorry. Justin, let me translate the questions to our management here. (foreign language)

Answer – Qi Ji: (foreign language)

Answer – Xinxin Liu: (foreign language)

Answer – Yu Ida: Okay. So sorry. Ms. Liu has several — sorry. She — let me just translate the first part of her answer.

[Interpreted] So before the COVID-19, I think the pattern of the business traveler and leisure traveler remained the same. During the pandemic, yes, we have to say the traffic of business travelers did slow down because the business activity has been stopped. However, the demand of local customers did rise. And at Huazhu, we have the full-scale sales capability. No matter it’s online and off-line, we combine them together. Just like what Jin Hui mentioned before, we equipped our local sales with IT equipments. We also promote all staff sales among the organization.

Answer – Xinxin Liu: (foreign language)

Answer – Yu Ida: [Interpreted] So we will further develop our corporate sales activities towards business travelers’ need. And we also anticipate the rise of leisure demand in upcoming April. And in short, we will utilize all kinds of tools to grasp — grab all the sales opportunities.

Answer – Hui Jin: (foreign language)

Answer – Yu Ida: [Interpreted] So first of all, as we mentioned before in the presentation, the scale effect and also the chain capability will really make the leading companies like us stand out during the pandemic.

Answer – Hui Jin: (foreign language)

Answer – Yu Ida: [Interpreted] Huazhu is advantaged in terms of our high efficiency and cost control, which will further stand out in the future competition compared to the high-cost operator.

Answer – Hui Jin: (foreign language)

Answer – Yu Ida: [Interpreted] And we are very positive about our growth potential in the next 3 years. Our target is open 10,000 hotels in 1,000 cities. I’m very pleased to report that we have already signed up 300-over hotels, no matter it’s a hard brand and soft brand, in our network in Q1.

Answer – Xinxin Liu: Jenny?

Answer – Qi Ji: (foreign language)

Answer – Min Zhang: (foreign language) Hello, can you hear me?

Answer – Yu Ida: Yes, Jenny. We can hear you.

Answer – Min Zhang: Okay, yes. DH, as we acquired it, we expect it to contribute significantly to our revenues. Based on its 2019 revenue, pro formally, it would increase. It will account for about 35% of the Huazhu pro forma group revenues. So it was expected to be a major revenue contributor. However, because most of their hotels are on the lease model, their margins is much lower than our China operations, so the profit contribution expectation was only around 5% to 10%. This year, with the COVID-19 situation, it’s a little bit unpredictable, but our German team, the European team, is also doing their best to fight for protecting our customers and our staff and also help the business to sail through the water and expect a rebound when the situation stabilizes. We appreciate the leadership team we have in Europe. And they have done a very good job so far.

 

MTU AERO ENGINES AG (PR – 3/26)

Munich, March 26, 2020: The executive board of MTU Aero Engines AG (the “Company”) resolved today to withdraw the guidance for the financial year 2020. The Company’s decision is based on the assessment of market scenarios presently deemed likely, and on a catalogue of expenditure reduction measures. The previous guidance was published on February 20, 2020, already with the reservation to review it during the year due to the Corona pandemic.

Especially due to significant reductions in passenger air traffic and the consequences for airlines, revenues and adjusted EBIT for the financial year 2020 are expected not to grow with a high single digit percentage as forecast. The cash conversion rate, expressing the ratio of free cashflow to net income adjusted, is also likely not to reach the forecast 70 percent in 2020. Due to the dynamic of worldwide developments in the context of COVID-19 a specification of expectations with regard to revenues, adjusted EBIT and especially the cash conversion rate, based on the developments of the coming weeks and the resulting consequences for the Company’s performance, can be made only at a later point in time.

MTU will publish its annual report for the financial year 2019 on March 27, 2020. The predications for the future business development in the financial year 2020 contained in the forecast are based especially on market assessments and estimations at the beginning of the year 2020 which were not regarded obsolete at the time of approval of the annual financial statements on March 17, 2020. In the light of the actual developments such predications cannot be maintained.

MTU closely observes the situation regarding COVID-19 and takes operative precautions to minimize consequences on its financial position, financial performance and cashflows.

 

BOOKING HOLDINGS (PR – 3/23)

I am also writing to give an update on new actions we are taking in response to COVID-19. As I discussed in my Town Hall video a few weeks ago, this is not the first major disruption to travel we have endured as a business, but the impact of COVID-19 is more than all the previous disruptions I mentioned combined.  We know that eventually COVID-19 will no longer dominate our lives and prevent people from traveling, but no one knows for sure when this will happen. This unpredictability requires us to act prudently and put control measures in place to position the company for the long haul. These actions will ensure that we can continue to support our employees, customers and partners through this crisis, and be better positioned for the recovery that we know will come. 

Some of the recent measures include:

  • Cutting non-essential business travel across our business
  • Cancelling internal company events and offsites
  • Dramatically reducing marketing spend worldwide
  • Implementing a general hiring freeze company-wide until further notice

In addition to the above measures, the brand CEOs (Steve Hafner, John Brown and Brett Keller) and I have made the decision to forego our salaries during this time of the crisis, effective immediately.  Our Board of Directors has also voluntarily declined to accept any cash retainer payments during the same time period.

 

HOST HOTELS & RESORT INC. (8k – 3/20)

Jim Risoleo, President and Chief Executive Officer, said, “Out of an abundance of caution, we have drawn $1.5 billion under the revolver portion of our Credit Facility providing Host with a total of approximately $2.8 billion of cash as of the date of this 8-K filing. We continue to maximize our financial flexibility as the duration and magnitude of the impact of COVID-19 on global travel demand remain uncertain. We are pleased to have executed a prudent and disciplined capital allocation strategy that prioritized creating significant balance sheet capacity and liquidity in recent years and expect our judicious capital allocation decisions to benefit all our stakeholders in the long-term.”

Mr. Risoleo continued, “Our world-class operators, including Marriott, Hyatt and Hilton, have coordinated with us to develop detailed cost-cutting contingency plans to eliminate unnecessary costs at each of our hotels. These plans are tailored to address the specific operational needs of each property and are expected to significantly reduce Host’s operating costs through this period of uncertainty.”

 

INTERCONTINENTAL HOTEL GROUP (8k – 3/20)                                                      

Keith Barr, Chief Executive Officer, IHG, said: “At this unprecedented time, our top priority remains the health and wellbeing of our guests, colleagues and partners, and ensuring that in light of such a significant impact on the global economy and, in particular, on the travel industry, we take the right steps to protect the long-term health of our business.

Demand for hotels is currently at the lowest levels we’ve ever seen. IHG has a robust business model and the measures we are announcing today to reduce costs and preserve cash give us the capacity to manage the business through this unique environment and to support our owners during this incredibly difficult time.

These were not easy choices and we are mindful of the impact these decisions will have on our colleagues and shareholders. However, we believe that these are essential to ensuring that we come out of this as strong as we possibly can and ready to capitalise on what remains an industry with excellent long-term growth potential.”

 

DELTA (8k – 3/20)

It has been an extraordinary few weeks, to say the least, for our business, our nation and our world. Just over a month ago we were celebrating a record Profit-Sharing Day; today we face the greatest economic challenge in our history as the world grapples with the growing COVID-19 (coronavirus) pandemic.

I want to thank the more than 13,000 people who have stepped up to take voluntary unpaid leaves – this is the most important thing anyone can do right now to support Delta. While I’m grateful to the thousands that have volunteered, we could use more, so please seriously consider whether this is the right short-term decision for you and your family.

Earlier this week I outlined the serious threat to our business and the difficult actions we’re taking over the next few months to protect our company. Our revenue outlook continues to deteriorate in the short term with the decline in travel demand. We’re now projecting our June quarter revenues will be down by $10 billion compared to a year ago – an 80 percent reduction. It’s also clear, given the underlying damage the virus has created to the overall economy, that demand recovery will take an extended period once the virus is contained.

In light of the unprecedented challenges facing us, we have entered into a $2.6 billion secured credit facility and are drawing down $3 billion under our existing revolving credit facilities. This will help fortify our cash position in the coming weeks and months. To put this in context, despite all the self-help measures we are taking, we are currently burning roughly $50 million in cash each day.

We also continue working with the President and Congress on disaster relief assistance, which is vital to protect our industry’s critical role in our nation’s economy. Amid those discussions, in recent days some critics have argued that the airlines have not been good stewards of our money during our profitable years. At Delta, nothing could be further from the truth. Our philosophy has always been a simple one: We put 50 percent of our operating cash flow back into our business by investing in our people and our customers, use 30 percent to pay down debt, and return 20 percent to our owners.

In fact, over the past five years Delta has invested over $20 billion in new aircraft, airport enhancements, technology and customer service improvements; and invested $19 billion in our people via profit-sharing and pension contributions and payments. In addition, we increased base pay by 30 percent during that period and regained the confidence of the financial markets by earning back our investment-grade credit rating. When the extent of the COVID-19 crisis became clear, we immediately suspended our share repurchases, and our Board of Directors has voted to suspend future dividend payments.

 

BOEING (8k – 3/19)

As we encounter the Covid-19 crisis, Boeing, along with many other companies, face another major set of challenges. I want to be part of helping the company as it pushes through it. However, the board and executive team are going in a direction I cannot support.

While I know cash is tight, that is equally true for numerous other industries and for millions of small businesses. I cannot support a move to lean on the federal government for a stimulus or bailout that prioritizes our company over others and relies on taxpayers to guarantee our financial position. I have long held strong convictions that this is not the role of government.

I strongly believe that when one is part of a team, and one cannot in good faith support the direction of the team, then the proper thing to do is to resign. As such, I hereby resign my position from the Boeing Board.

I hope you all know that I will continue to be a strong supporter of Boeing and its workforce. All of you have taught me so much over the past year. Serving with each and every one of you has been a privilege. I value the friendships I have made with all of you.

If I can ever be of help or service to the Boeing team in the future, please don’t hesitate to contact me.

My very best,

Nikki R. Haley

 

MARRIOTT (Business Update Call – 3/19)

The coronavirus or COVID-19 is fast becoming the most significant event to ever impact our business and that includes the 12-month period after 9/11 and the financial crisis of 2009. While the situation is changing by the day, we felt it important to update our key stakeholders on what we’ve seen to-date and detail the numerous steps we are taking to address and mitigate the negative impact on our business during this complex and unprecedented global crisis.

Let me start with what we’ve seen recently. While the first two months of the year saw a solid RevPAR growth in every region except for Asia-Pacific, the virus spread has clearly caused that picture to change dramatically over the last few weeks. In the Asia-Pacific region, which first saw the effects of COVID-19 in mid-January, RevPAR declined nearly 25% year-over-year through February with Greater China down 52% and RevPAR for the rest of the Asia-Pacific region down more than 8%.

So far in March as workers return to their jobs and regional travel resumes, albeit slowly, occupancy rates in China are beginning to rise. We’ve gone from over 90 hotels in Greater China closed at the height of the outbreak to under-30 closed today. It is encouraging to see the trend lines in China and the entire Asia-Pacific region starting to improve.

However as the virus has spread, there has been a sudden sharp decline in demand throughout the rest of the world and RevPAR at our hotels has dropped dramatically. Over the last few days occupancy rates in North America and Europe were under 25%, compared to around 70% a year ago. The crisis outside of the Asia-Pacific region is much more recent and the trends are still negative. Unfortunately, the situation will likely continue to get worse before it gets better. We do not expect to see a material improvement until there is a sense that the spread of the virus has moderated.

We continue to work with our customers to navigate this crisis. While there have been historically high levels of cancellations for stays through the first half of this year, there have not been a meaningful number of group cancellations for 2021 related to COVID-19, and many group customers are at least tentatively rebooking for dates in the second half of this year.

 

DELTA (Business Update Call – 3/18)

Following the national emergency that was declared by the U.S. President, demand for travel has dropped significantly. Revenue for the month of March is now expected to decline by almost $2 billion over last year, with our projection for April falling even more. Therefore, we will continue to make significant capacity reductions with a 70 percent systemwide pullback planned until demand starts to recover. Our international operation will take the largest reduction, with over 80 percent of flying reduced over the next two to three months.

We are having constructive discussions with the White House and Congress, and remain optimistic that our industry will receive support to help address this crisis. That said, we have to continue to take all necessary self-help measures. Cash preservation remains our top financial priority right now. Making swift decisions now to reduce the losses and preserve cash will provide us the resources to rebound from the other side of this crisis and protect Delta’s future.

 

AIRBUS (PR – 3/17)

Following the implementation of new measures in France and Spain to contain the COVID-19 pandemic, Airbus has decided to temporarily pause production and assembly activities at its French and Spanish sites across the Company for the next four days. This will allow sufficient time to implement stringent health and safety conditions in terms of hygiene, cleaning and self-distancing, while improving the efficiency of operations under the new working conditions. In those countries, the Company will also continue to maximise homeworking wherever possible.

These measures will be implemented locally in coordination with the social partners. Airbus is also working together with its customers and suppliers to minimise the impact of this decision on their operations.

Airbus continuously updates its workplace safety and travel recommendations to employees, customers and visitors, according to the latest developments.

 

UNITED AIRLINES (PR – 3/17)

United Airlines (NASDAQ: UAL) CEO, Oscar Munoz and president J. Scott Kirby have issued a message to United’s nearly 100,000 employees regarding the impact of the coronavirus on the company’s business and the steps the airline is taking to manage it, the company said.

The statement addressed the impact of the virus on United’s business has become worse with the new travel restrictions for the UK and Ireland. Munoz and Kirby said they feel an obligation to run the company in a way that protects the employees and to be open about the decisions facing the airlines.

The United leaders acknowledged March as its busiest month of the year, but is projecting that revenue in March 2020 will be USD 1.5 billion lower than last March.

United has taken steps to manage the crisis by reducing schedules, imposing a hiring freeze, introducing a voluntary leave program, reducing discretionary spending, cutting the CEO base by 100% and deferring a salary increase. Competitors have started to follow suit.

 

AVIS BUDGET GROUP (PR – 3/17)

NEW YORK (S&P Global Ratings) —S&P Global Ratings today took the rating actions listed above. The sharp decline in air travel due to the coronavirus pandemic will hurt demand for car rentals at airports, the largest part of Avis Budget’s business. Further, the pandemic and government actions to combat it will hurt economic activity, an effect likely to linger after cases of the virus decline. Car renters have some flexibility to respond to sharp demand shocks and have done so in the past. During the period following the Sept. 11, 2001, attacks, the U.S. car rental industry was able to downsize its fleet by around 20% in the following month by returning cars to the auto manufacturers under agreements that allowed such returns as long as certain conditions were met. However, most of Avis Budget’s vehicles today are not covered under these agreements, which could cause oversupply and thus pressure on used car prices.

 

SOUTHWEST AIRLINES (8K – 3/16)

The Company is withdrawing its previous 2020 financial guidance due to the rapidly changing environment as the COVID-19 pandemic evolves, and is providing the following updates.

The Company has experienced more dramatic declines in passenger bookings in March and second quarter 2020, as well as an unprecedented increase in close-in trip cancellations. The Company has recently experienced several days of net negative bookings, primarily in March and April 2020, where trip cancellations outpaced new passenger bookings. The Company’s month-to-date load factor through March 15, 2020, was approximately 67 percent, with recent days trending toward 50 percent. As the impact of the COVID-19 pandemic grows, and based on current booking and cancellation trends, we expect revenue trends for the remainder of March and second quarter 2020 to deteriorate further.

Given the continued uncertainty of revenue trends attributable to the COVID-19 pandemic, the Company has taken several actions to help manage the near-term financial impacts. The Company will soon reduce its published flight schedules, which will reduce available seat miles (ASMs, or capacity) by at least 20 percent for the time period April 14, 2020 through June 5, 2020. These flight schedule reductions are in addition to the Company’s existing capacity impact due to the Boeing 737 MAX groundings. The Company continues to evaluate further flight schedule reductions.

The Company is also instituting a hiring freeze; offering voluntary leave options for Employees; and aggressively evaluating all capital spending, discretionary spending, and all non-essential costs for near-term cost reductions or deferrals.

The Company’s investment-grade balance sheet and long-standing financial health has provided ready access to capital markets and bank financing. As announced recently, the Company issued $500 million of unsecured debt. As discussed in Item 2.03 above, on March 12, 2020, the Company entered into a $1.0 billion term loan credit facility agreement. In addition, as discussed in Item 2.03 above, the Company has drawn down the full $1.0 billion under its $1.0 billion revolving credit facility expiring in August 2022. Including these financing transactions, the Company’s current unrestricted cash balance is estimated to be approximately $6.2 billion. The Company currently has approximately 525 unencumbered aircraft valued at approximately $10 billion.

Upon completion of its current share repurchase program, the Company will have approximately $765 million remaining under its May 2019 $2.0 billion share repurchase authorization, and will suspend further share repurchases.

As it is difficult for the Company to estimate the duration and severity of the impact from the COVID-19 pandemic, the Company is actively pursuing additional opportunities to preserve cash, bolster liquidity, and improve its near-term working capital position to protect its business and restore long-term financial strength.

 

AIR CANADA (IR Circulars – 3/16)

MONTREAL, March 16, 2020 /CNW Telbec/ – Air Canada, along with the rest of the global airline industry, is facing a severe drop in traffic and a corresponding decline in revenue as a result of the coronavirus (COVID-19) outbreak and travel restrictions imposed in many countries around the world, including Canada and the United States. Although the company expects this disruption to be temporary, as the full impact and duration of the outbreak is unknown, Air Canada is withdrawing its previously announced first quarter and full year 2020 guidance as well as its full year 2021 guidance (including its free cash flow guidance for the 2019-2021 period) while it takes steps to mitigate the financial impact on its business.

“COVID-19 presents the global airline industry with unprecedented challenges, compounded by uncertainty as to the extent of its effects. However, we are confident that after a decade of transformation and record results, Air Canada today has the agility, the team and the route network to successfully navigate through this crisis. Most importantly for business continuity, it also has the necessary financial resources, including a solid balance sheet, record liquidity levels, higher debt ratings based on a low leverage ratio, and a significant pension plan surplus. These deep strengths enable us to fully focus our immediate attention on both the safety and well-being of our customers and our employees and on mitigating the financial impact of the virus,” said Calin Rovinescu, President and Chief Executive Officer of Air Canada

 

INTERNATIONAL CONSOLIDATED AIRLINES GROUP (PR – 3/16)

The rapid spread of COVID-19, and associated government travel restrictions and advisories are having a significant and increasingly negative impact on the demand for global air traffic on almost all routes operated by IAG’s airlines.

To date IAG has suspended flights to China, reduced capacity on Asian routes, cancelled all flights to, from and within Italy and made various changes to our network.

The US Presidential announcement to restrict entry of foreign nationals who have been in countries in the Schengen Area, the UK and Ireland has added to the uncertainty on North Atlantic routes. In addition, many other countries have banned or are restricting inward travel including Argentina, Chile, India and Peru. Spain has also been the subject of travel advisories, for example by the UK Foreign and Commonwealth Office (FCO).

IAG is implementing further initiatives in response to this challenging market environment. Capacity, in terms of available seat kilometres, in the first quarter of 2020 is now expected to be reduced by around 7.5 per cent compared to last year. For April and May, the Group plans to reduce capacity by at least 75 per cent compared to the same period in 2019.  

IAG is also taking actions to reduce operating expenses and improve cash flow. These include grounding surplus aircraft, reducing and deferring capital spending, cutting non-essential and non-cyber related IT spend, freezing recruitment and discretionary spending, implementing voluntary leave options, temporarily suspending employment contracts and reducing working hours. 

Given the continued uncertainty on the potential impact and duration of COVID-19, it is still not possible to give accurate profit guidance for the full year 2020.

 

SINGAPORE AIRLINES (IR Circulars – 3/16)

Since the start of February 2020, the SIA Group has progressively announced flight cuts
across the network as it adjusts capacity to match demand changes arising from the
spread of COVID-19 across the globe. Market conditions have continued to deteriorate in
March and, with WHO declaring COVID-19 a pandemic and multiple countries issuing travel
advisories and restrictions, travel demand is expected to weaken significantly in the near
term.

 

RYANAIR (6K – 3/16)

Over the past week, the spread of the Covid-19 virus and associated Government travel restrictions, many of which have been imposed without notice, have had a significant and negative impact on the schedules of all Ryanair Group Airlines.

Over the past 7 days, Italy, Malta, Hungary, Czech Republic, Slovakia, Austria, Greece, Morocco, Spain, Portugal, Denmark, Poland, Norway and Cyprus have imposed flight bans of varying degrees, from all flights to/from the country, or banned flights to/from countries with high risk of Covid infection. Over the weekend for example, Poland and Norway have banned all international flights, while in other countries (without travel bans) there has been severe reduction of ATC and essential airport services.

 

CARNIVAL CORPORATION (8K – 3/16)

Due to the spread and recent developments, including growing port restrictions around the world, related to the COVID-19 outbreak, the Corporation previously announced a voluntary and temporary pause of its fleet cruise operations by its continental Europe and North American brands. Subsequently, the Corporation implemented a temporary pause of its global fleet cruise operations across all brands. Each brand has separately announced the duration of its pause. Significant events affecting travel, including COVID-19, typically have an impact on booking patterns, with the full extent of the impact generally determined by the length of time the event influences travel decisions. The Corporation believes the ongoing effects of COVID-19 on its global bookings and operations will have a material negative impact on its financial results and liquidity. The Corporation is taking additional actions to improve its liquidity, including capital expenditure and operating expense reductions, and pursuing additional financing. Given the uncertainty of the situation, the Corporation is currently unable to provide an earnings forecast, however we expect results of operations for the fiscal year ending November 30, 2020 to result in a net loss.

 

EXPEDIA (8K – 3/13)

SEATTLE, WA – March 13, 2020 – Expedia Group, Inc. (NASDAQ: EXPE) announced today that it is withdrawing its full-year 2020 Adjusted EBITDA guidance due to the growing impact from the COVID-19 outbreak and the resulting uncertainty on travel trends. With the outbreak spreading significantly since Expedia’s fourth quarter earnings call on February 13, 2020, we now expect the negative impact in the first quarter related to COVID-19 to be in excess of the $30-$40 million range provided at that time. 

“As COVID-19 has rapidly spread from Asia to Europe and North America over the past few weeks, travel trends have continued to worsen. It remains difficult to predict how long this pandemic will persist, and given the lack of visibility on our trends we’ve decided to withdraw our 2020 guidance,” said Chairman Barry Diller and Vice Chairman Peter Kern.

HUDSON LTD (Earnings Call – 3/11)

Looking forward to 2020, we wanted to share with you what we have seen in traffic and sales trends year-to-date. In the first weeks of January, prior to the impact of the coronavirus, our sales increased slightly year-over-year despite the loss of New Orleans store closures in November last year. In the second half of January, as the coronavirus spread beyond China, we began to see lower traffic in our North American markets that extended into February, with sales down approximately 10%. We believe that based on the trends we’re currently seeing, the net sales in Q1 2020 will decline by low to mid-teens year-over-year.

Given the widening spread of the coronavirus and its related impact on travel, both business and personal, we expect continued pressure on traffic and sales in the near term. As we can’t currently estimate the duration of the future trajectory of travel disruption, we don’t believe it’s prudent to provide the full year outlook at this time. We do, however, remain optimistic about the stronger pipeline of RFPs this year and our improved competitive position. We expect to close our OHM acquisition early Q2 and to leverage the food and beverage business to drive sales momentum in 2020 and beyond, supported by the benefit of our Brookstone acquisition. We feel great about our ability to execute against the things that are in our control, including implementing efficiency initiatives to ensure disciplined cost management in response to the sales trends.

BOC AVIATION LTD (Earnings Call – 3/11)

In 2020, we are receiving requests from some of our customers for assistance as passenger demand and, therefore, airline revenue is affected by COVID-19. We’re a long-term partner to our airline customers, and we will evaluate any such request carefully in light of their cash flow forecasts and in light of the support provided by other stakeholders.

We’ll work with affected customers to find solutions, which we believe will likely involve partial deferrals of rent for 3 months or less with interest payable on overdue amounts or will involve more purchase and leaseback transactions with those customers. In this context, I’d like to remind everyone that we are the owner of our aircraft. We’re a senior creditor of our airline customers and our operating these contracts are well structured. We’re paid rent monthly or quarterly in advance. We collect security deposits, and for many of our customers, we collect security to provide protection against future major maintenance events. At the same time, we’re looking for opportunities to provide liquidity for our customers and to put good new business on our balance sheet. Since the beginning of 2020, we’ve added another 42 aircraft to our order book, comprising 20 A320NEO delivery positions, 10 of which we’ve already placed with an airline customer, and we’ve also executed our largest ever purchase and lease transaction for 22 Boeing 787, which is scheduled for delivery to American Airlines in 2020 and 2021. These transactions illustrate the strength of our global customer reach. It also highlights the way our team contributes to build good long-term business on the strength of our capital structure and our available liquidity.

Having over $5 billion in available liquidity as of today’s date and A- credit ratings positions us well to work with a global customer base and execute new investment opportunities. And with that, I’ll hand it over to Thim Fatt.

HILTON (8K – 3/11)

McLEAN, VA (March 10, 2020) – Hilton Worldwide Holdings Inc. (NYSE: HLT) today announced the withdrawal of its previously announced first quarter and full year 2020 outlook due to the evolving impact of the novel coronavirus (COVID-19) on the global economy.

Christopher J. Nassetta, President & Chief Executive Officer of Hilton, said, “Our first thoughts continue to be with our guests and team members affected by the coronavirus. It is times like these when the world needs our hospitality most, particularly in the communities that have been hit hardest by the outbreak.

“With the coronavirus now spreading beyond China and the Asia Pacific region, and the related increase in travel restrictions and cancellations around the world, we believe that the potential negative impact will be greater than our previous estimate and have decided to withdraw our previously announced guidance. We will provide an update during our first quarter earnings call, based on the information we have available at the time.

“As a 100-year company that takes the long view, we are confident in our resilient business model, the performance of our leading brand portfolio, and our ability to respond appropriately to market conditions.”

 

DELTA AIRLINES (JPMorgan Aviation, Transportation and Industrials Conference – 3/10)

As the situation has evolved, our first priority has been protecting the health and the safety of our customers and our employees. Our team has significantly increased resources to insuring our aircraft and facilities are clean and exceed our already high safety standards. While our year had gotten off to a strong start, in fact being ahead of plan for the first two months. Two weeks ago, our revenue trajectory changed dramatically as the virus spread meaningfully outside of Asia. Since then, we have seen a 25% to 30% decline in net bookings and are prepared for it to get worse. We expect demand erosion will continue in the near term and a built-up plan that prioritizes free cash flow generation and preserves liquidity

 

AMERICAN AIRLINES (8K – 3/10)

Due to the heightened uncertainty surrounding the outbreak of the COVID-19 virus, its duration and its impact on overall demand for air travel, American Airlines Group Inc. (the “Company”) is withdrawing its 2020 guidance issued on January 23, 2020.

 

DELTA AIRLINES (8K- 3/10)

In addition to the significant efforts underway to protect the health and safety of its customers and employees, Delta Air Lines (NYSE: DAL) is announcing additional steps to address the financial impact of the COVID-19 (coronavirus) outbreak.

“In the weeks since COVID-19 emerged, Delta people have risen to the challenge, taking every possible action to take care of and protect our customers during a stressful time,” said Delta CEO Ed Bastian. “As the virus has spread, we have seen a decline in demand across all entities, and we are taking decisive action to also protect Delta’s financial position. As a result, we have made the difficult, but necessary decision to immediately reduce capacity and are implementing cost reductions and cash flow initiatives across the organization.”

 

RYANAIR (6K – 3/10)

Ryanair does not expect these traffic reductions to have a material impact on FY20 (31 March 2020) PAT guidance. It is far too early to assess the impact of Covid-19 on FY21 traffic and earnings. The Ryanair Group will continue to focus on delivering cost savings and improved operational efficiency in FY21. Ryanair is one of the strongest airlines in the industry with €4bn in cash, industry leading unit costs, 90% of the fleet is owned with over 70% debt free.

 

ROYAL CARIBBEAN (8K – 3/10)

The company had previously communicated that its 2020 guidance did not include the impact of the COVID-19 outbreak. Given the recent government actions and the heightened impact and uncertainty of changes in the magnitude, duration and geographic reach of COVID-19, the company is withdrawing its first quarter and full-year 2020 guidance.

 

UNITED AIRLINES (8K – 3/10)

United Airlines, Inc. (“United”), a wholly-owned subsidiary of United Airlines Holdings, Inc. (“UAL”, and together with United, the “Company”) has continued to experience a material decline in demand for both international and domestic travel, as well as an increase in trip cancellations, resulting from the spread of coronavirus (“COVID-19”). As such, the Company has taken proactive steps to mitigate the financial and operational impact to the business.

As a result of the decline in demand resulting from COVID-19, in addition to the capacity reductions on the Company’s trans-Pacific routes announced last month, the Company has also announced that it has pulled down 10% of its domestic schedules and 20% of its international schedules in April. The Company also anticipates making reductions in May of at least 20% and plans to proactively evaluate and cancel flights on a rolling 90-day basis until it sees signs of a recovery in demand. The Company’s capacity reductions have been focused on, but not limited to, reducing frequencies in markets with the ability to re-accommodate passengers on other frequencies or through other hubs, destinations in level 3 or level 4 travel advisory regions and surrounding areas and routes performing significantly below the system average.

 

AIR NEW ZEALAND – (PR – 3/10)

Due to increased uncertainty surrounding the duration and scale of the Covid-19 outbreak, Air New Zealand has today announced that it will be withdrawing the full year 2020 earnings guidance it issued to the market on 24 February 2020 and reconfirmed at its interim results announcement on 27 February 2020.

Air New Zealand has taken numerous steps to mitigate the impact of reduced demand resulting from Covid-19, including reducing capacity on its Asia, Tasman and Domestic networks, redeploying its fuel efficient 787 Dreamliner fleet to drive operational efficiencies and using tactical pricing to stimulate demand on the impacted sectors. However, the airline now believes that the financial impact is likely to be more significant than previously estimated and with the situation evolving at such a rapid pace, the airline is not in a position to provide an earnings outlook to the market at this time. An update on earnings expectations will be provided when appropriate

 

QANTAS AIRLINES (IR Circulars – 3/9)

Announcing the changes, Qantas Group CEO Alan Joyce, said: “In the past fortnight we’ve seen a sharp drop in bookings on our international network as the global coronavirus spread continues.

“We expect lower demand to continue for the next several months, so rather than taking a piecemeal approach we’re cutting capacity out to mid-September. This improves our ability to reduce costs as well as giving more certainty to the market, customers and our people.

 

BOOKING HOLDINGS (8K – 3/9)

“As we explained when we provided first quarter 2020 guidance during our fourth quarter earnings announcement on February 26, 2020, the circumstances of the COVID-19 outbreak are changing rapidly and our guidance was based on the information we had at the time. As the situation has worsened and the negative impact on travel demand has increased since we provided guidance, in particular more broadly across Europe and in North America, we have decided to withdraw that guidance. Given the rapidly evolving situation, we are unable at this time to reliably quantify the impact of the COVID-19 outbreak on our future financial results. We plan to provide more information during our first quarter earnings call based on the information we have available at that time.”

Mr. Fogel continued, “While the full impact and duration of the COVID-19 outbreak is unknown at this time, we have been through travel disruptions in the past and expect that this disruption will ultimately be temporary. We believe the company has a strong operating model and solid balance sheet, which will enable us to weather this disruption. We remain confident in our long-term prospects and strategy, and we will continue to manage the company in a measured way to build value for the long term. In the meantime, we will continue to monitor the situation and support our customers, partners and employees during this difficult time. Our thoughts remain with the people impacted by this outbreak.”

 

HOST HOTELS (8K – 3/9)

Host Hotels & Resorts, Inc. (NYSE: HST), the nation’s largest lodging real estate investment trust (the “Company”), today announced it is withdrawing its full-year 2020 guidance due to the ongoing financial impact of reduced travel demand as a result of the global coronavirus (COVID-19) outbreak.

 

VAIL RESORTS (8K – 3/9)

Regarding the Company’s outlook, Katz said, “Given the uncertainty surrounding the impact of the coronavirus on the broader U.S. travel market and any specific impact to the performance of our Company, we are not issuing guidance at this time for fiscal 2020 and are withdrawing our previous guidance issued on January 17, 2020. In the week ended March 8, 2020, we saw a marked negative change in performance from the prior week, with destination skier visits modestly below expectations. We expect this trend to continue and potentially worsen in upcoming weeks.”

 

TRIVAGO (20F – 3/6) 

Many events beyond our control can adversely affect the travel industry, with a corresponding negative impact on our business and results of operations. Natural disasters, including hurricanes, tsunamis, earthquakes or volcanic eruptions, as well as other natural phenomena, such as outbreaks of the Zika virus, the Ebola virus, avian flu and, most recently, a novel strain of coronavirus first identified in Wuhan, Hubei Province, as well as other pandemics and epidemics, have disrupted normal travel patterns and levels in the past. We believe that the Wuhan coronavirus outbreak will have a negative impact on our global business volumes in 2020. The travel industry is also sensitive to events that may discourage travel, such as work stoppages or labor unrest, political instability, regional hostilities, increases in fuel prices, imposition of taxes or surcharges by regulatory authorities, travel-related accidents and terrorist attacks or threats. We do not have insurance coverage against loss or business interruption resulting from war and terrorism, and we may be unable to fully recover any losses we sustain due to other factors beyond our control under our existing insurance coverage. The occurrence of any of the foregoing events may have a material adverse effect on our business, results of operations, financial condition and prospects.

 

ITV.GB (Earnings Call – 3/5)

Total advertising is expected to be up 2% in Q1. This is the third quarter of growth, and we are seeing double-digit growth in online and partnerships revenues. Early indications suggest that total ad revenue will be down 10% in April. In March and April, we have seen an impact from travel advertising deferments relating to the coronavirus. All deferments to date are included in our guidance.

 

AERCAP HOLDINGS (20F – 3/5)

Such events are likely to cause our lessees to incur higher costs and to generate lower revenues, which could result in a material adverse effect on their financial condition and liquidity, including their ability to make rental and other lease payments to us or to obtain the types and amounts of insurance we require. This in turn could lead to aircraft groundings or additional lease restructurings and repossessions, increase our cost of re-leasing or selling aircraft, impair our ability to re-lease or otherwise dispose of aircraft on favorable terms or at all, or reduce the proceeds we receive for our aircraft in a disposition.

The effects of epidemic diseases, such as the coronavirus disease (COVID-19) outbreak, and natural disasters, such as extreme weather conditions, floods, earthquakes and volcanic eruptions, may adversely affect the demand for air travel, the financial condition of our lessees and of the aviation industry more broadly, and ultimately our financial condition, results and cash flows.

 

SUNSTONE HOTEL INVESTORS (8K Update – 3/5)

IRVINE, CA – March 5, 2020 – Sunstone Hotel Investors, Inc. (the “Company” or “Sunstone”) (NYSE: SHO), the owner of Long-Term Relevant Real Estate® in the hospitality sector, today announced that due to uncertainty related to the ultimate impact on travel demand resulting from the COVID-19 virus outbreak, the Company is withdrawing its first quarter and full-year 2020 guidance.

On February 18, 2020, as part of the Company’s full-year 2019 earnings report, Sunstone provided first quarter and full-year 2020 guidance for certain operational and earnings metrics. Included in this guidance was approximately $1 million of lost revenue resulting primarily from known group customer cancelations related to COVID-19.  Since the time this guidance was provided, the Company has experienced a material increase in expected lost revenue from group customer cancelations, which, as of today’s date, have increased to approximately $11 million. The majority of the lost revenue is related to business that was scheduled to occur in March 2020. The Company believes that the impact from these trends will most likely result in the Company failing to achieve the previously provided first quarter guidance for net income, comparable portfolio RevPAR growth, Adjusted EBITDAre, Adjusted FFO, and Adjusted FFO per diluted share.  The impact of COVID-19 on travel demand continues to evolve and the Company is currently not able to accurately assess the financial impact on its full-year operations. As such, the full-year guidance previously provided on February 18, 2020 should no longer be relied upon.  

John Arabia, President and Chief Executive Officer, stated, “Since the time of our earnings call, we have witnessed a sizeable increase in both group cancelations and corporate travel policy restrictions related to COVID-19, both of which are expected to reduce our near-term occupancy and hotel revenues.  As a result, we are unlikely to achieve our first quarter 2020 guidance. Furthermore, as we are currently unable to quantify the full-year impact of COVID-19 on hotel operating fundamentals, we believe it is prudent to withdraw our previously provided full-year guidance.  As the situation evolves, we will continue to assess the expected impact of COVID-19 on our operations and earnings, while working to protect the hotel employees and guests.”

 

DESCARTES SYSTEMS (6K – 3/5)

As we continue to increase our international operations we increase our exposure to international business risks that could cause our operating results to suffer.

While our headquarters are in Canada, we currently have direct operations in the U.S., EMEA, Asia Pacific and South American regions. We anticipate that these international operations will continue to require significant management attention and financial resources to localize our services and products for delivery in these markets, to develop compliance expertise relating to international regulatory agencies, and to develop direct and indirect sales and support channels in those markets. We face a number of risks associated with conducting our business internationally that could negatively impact our operating results. These risks include, but are not limited to:

The risk of travel advisories or travel restrictions related to the outbreak of contagious illnesses, such as the coronavirus that is currently impacting China and other geographies, which could impact our ability to operate in certain markets and/or manage our operations in those markets;

 

DELTA – (Prospectus – 3/4)

In 2003, an outbreak of a coronavirus known as severe acute respiratory syndrome (SARS) originating in China became an epidemic and resulted in a slowdown of passenger air traffic due contagion fears. With RPK growth being cut in half, widebody aircraft values took a brief hit due to oversupply in the market as airlines tried to cut capacity. Impact on values was minor and short-lived; however, a new, recently discovered coronavirus, also originating from China, may have a similar impact on RPK growth and aircraft pricing. The first case of the new virus was linked to a seafood market in Wuhan, China, with the first person reported ill in December 2019. By the end of January 2020, several countries confirmed the illness had reached their borders including to the U.S., Australia, Japan, Canada, France, and Germany plus several Southeast Asian countries. With asymptomatic patients being able to spread the virus, the Chinese government has quarantined Wuhan and several surrounding cities, essentially cutting off transportation links to around 35 million people. Several countries are weighing whether to close their borders with China to suppress the spread of the virus despite a significant impact on their economies, and many have limited travel to China. As news of the virus spreads, markets have fluctuated, with the Dow Jones Industrial Average closing down 1.6% on January 27, 2020, and markets in South Korea and Japan dropping nearly 3.0% the next day. However, U.S. markets were back to record highs by early February. How much of an impact this will have on air travel globally remains to be seen, though with the epidemic occurring over the Chinese Lunar New Year, it would not be surprising to see RPK growth in 2020 fall below previous forecasts.

 

LUFTHANSA – (PR – 3/4)

German airline giant Lufthansa said Wednesday it would ground 150 of its more than 750 planes worldwide, days after announcing a slimmed-down timetable over the effects of the novel coronavirus.

“25 long-haul aircraft and 125 short- and medium-haul aircraft” will no longer fly, a spokesman for the group also including carriers Eurowings, Austrian and Swiss told AFP.

Shares in Lufthansa have plunged in recent days as the likely impact of the COVID-19 disease on the aviation sector in particular has become clearer.

 

BROWN-FORMAN (Earnings Call – 3/4)

While we experienced some improvement in the quarter and had anticipated further improvement in the fourth quarter, resulting from the phasing of certain customer purchases, we now estimate that as a result of the coronavirus, our Travel Retail business for the full year will be down similar to year-to-date performance. Our used barrel business declined significantly in the third quarter. The decline in this business reflects both a reduction in demand due in part to the U.S. tariff impact on Single Malt Scotch Whisky; and secondly, softening prices driven by the increased supply of the used barrels in the market. This business and our other non-branded business, which includes contract bottling and bulk whiskey and bulk wine sales, have negatively affected our underlying net sales year-to-date by about 1 percentage point.

 

GENERAL ELECTRIC (IR Presentation – 3/4)

Focus: COVID-19 as of today

Impact – too early to assess full-year 2020

  • Estimated $(0.3)-$(0.5)B FCF* & $(0.2)-$(0.3)B operating profit impact in 1Q
  • Impact embedded in 1Q estimates of ~$(2)B FCF* & ~$0.10 adjusted EPS*

 

RYANAIR – (6K – 3/2)

Ryanair remains one of the strongest airlines in the industry with €4bn in cash on its balance sheet, industry leading unit costs, 90% of the fleet is owned, and is mainly debt free. We expect that this Covid-19 Virus will result in further EU airline failures over the coming weeks.

Ryanair Group CEO, Michael O’Leary said:

“Our focus at this time is on minimising any risk to our people and our passengers. While we are heavily booked over the next two weeks, there has been a notable drop in forward bookings towards the end of Mar, into early Apr. It makes sense to selectively prune our schedule to and from those airports where travel has been most affected by the Covid-19 outbreak.

 

DIRECT LINE INSURANCE  (Annual Report – 3/2)

In addition, the Coronavirus outbreak (specifically the disease COVID-19) has the potential to impact the 2020 result of our Travel business. We have Travel reinsurance protection to mitigate the cost of an event over a 28 day period to £1 million up to a limit of £10 million. The full coverage, if utilised, can be reinstated once on the same terms. Currently, incurred claims are around £1 million. Like all businesses, we are subject to the consequences of disruption to financial markets and global supply chains which, over time, could impact the performance of our investments and the cost and speed of fulfilling customers’ claims

 

FLEETCOR TECHNOLOGIES (10K – 3/2)

When travel is severely curtailed across a geographic region during adverse weather conditions, or as a result of a natural catastrophe or public health crises, the number and amount of transactions we process can be significantly diminished, particularly in our fleet business, and revenue can materially decline. For example, during parts of January 2014, severe winter weather shut down a large portion of the eastern U.S. Natural catastrophes such as hurricanes in east Texas (Hurricane Harvey) and in Florida (Hurricane Irma), each in 2017, wildfires in California in 2017 and 2018 and in Colorado in 2012 and flooding in Arkansas in 2019, had similar effects on a more local basis. In December 2019 and January 2020, an outbreak of COVID-19, a new strain of coronavirus in Wuhan, China has resulted in travel disruption and has effected certain companies’ operations in China, although, at this point, the extent to which the coronavirus may impact our results is uncertain. Prolonged adverse weather events or travel bans due to medical quarantine or in response to natural catastrophes, especially those that impact regions in which we process a large number and amount of payment transactions, could have a material adverse effect on our business, financial condition and results of operations.

 

NEWELL BRANDS (10K – 3/2) 

In addition, our global operations expose us to risks associated with public health crises, such as pandemics and epidemics, which could harm our business and cause our operational results to suffer. For example, in December 2019 and January 2020, an outbreak of a new strain of Coronavirus in Wuhan, China, has resulted in travel disruption and an impact on corporate operations in China. At this point, the exact extent to which the Coronavirus may impact our supply chain or results of operations is uncertain; however, our revenues may be impacted in the first half of 2020.

 

AIR NEW ZEALAND – (PR – 2/27)

While the situation is uncertain, based on current assumptions of lower demand as well as the benefit of the announced capacity reductions and lower jet fuel prices, the airline currently expects a net negative impact to earnings in the range of $35 million to $75 million as a result of Covid-19.

At the midpoint of the estimated range above, which is approximately $55 million, the airline is targeting earnings before other significant items and taxation to be in a range of approximately $300 million to $350 million.

 

NORWEGIAN CRUISE (10K – 2/27)

Public perception about the safety of travel and adverse publicity related to passenger or crew illness, such as incidents of viral illnesses, stomach flu or other contagious diseases may impact demand for cruises and result in cruise cancellations and employee absenteeism. For example, the recent outbreak of the COVID-19 coronavirus has resulted in costs and lost revenue related to customer compensation, itinerary modifications, travel restrictions and advisories, the unavailability of ports and/or destinations, cancellations and redeployments and has impacted consumer sentiment regarding cruise travel. The spread of the COVID-19 coronavirus, particularly in North America, could exacerbate its effect on us. Any future wide-ranging health scares would also likely adversely affect our business, financial condition and results of operations.

 

MGM RESORTS (10K – 2/27)

Leisure and business travel, especially travel by air, are particularly susceptible to global geopolitical events, such as terrorist attacks, other acts of violence or acts of war or hostility or the outbreak of infectious diseases. We are dependent on the willingness of our customers to travel by air. Since most of our customers travel by air to our Las Vegas and Macau properties, any terrorist act or other acts of violence, outbreak of hostilities, escalation of war, or any actual or perceived threat to the security of travel by air could adversely affect our financial condition, results of operations and cash flows. In addition, the outbreak of infectious diseases, such as the recent coronavirus, may severely disrupt domestic and international travel. For instance, the coronavirus outbreak has resulted in several countries, including United States, issuing travel warnings and suspending flights to and from China. In addition, on February 4, 2020, the Hong Kong SAR government temporarily suspended all ferry service from Hong Kong to Macau, until further notice. We are unable to predict the extent to which disruptions to travel as a result of the coronavirus will impact our results of operations but we expect that the current disruption will have an adverse effect on MGM China’s results of operations for the first quarter of 2020 and potentially thereafter. Furthermore, although we have been able to purchase some insurance coverage for certain types of terrorist acts, insurance coverage against loss or business interruption resulting from war and some forms of terrorism continues to be unavailable.

 

DIAGEO (6K – 2/26)

Public health measures across impacted countries in Asia Pacific, principally in China, have resulted in: restrictions on public gatherings, the postponement of events and the closure of many hospitality and retail outlets. Several countries and many businesses have also imposed restrictions on travel.  

It is difficult to predict the duration and extent of any further spread of the COVID-19 outbreak both in and outside of Asia. Based on current information we have made assumptions to estimate the fiscal 2020 impact on the performance of the following businesses:

 

SABRE CORP (8K – 2/26)

As we kick off 2020, a global health crisis related to the Coronavirus (COVID-19) is impacting travel bookings, but more importantly, the lives of many around the world. The situation continues to evolve, and while we hope its impact will be short-term in nature, Coronavirus will have a material impact on our 2020 financial results. We have not incorporated its impact into our 2020 guidance at this point.”

 

BOOKING HOLDINGS (10K – 2/26)

As a result of the recent coronavirus outbreak originating in China, we began in January 2020 to experience, and continue to experience, a significant decline in travel demand and increase in customer cancellations predominantly related to travel to, from or in China and certain other Asian markets, though concerns about the coronavirus are also negatively impacting travel demand (and therefore our business) generally. Some countries have implemented travel bans or restrictions and some airlines have suspended or limited flights to or from China. We are working with our travelers and travel service provider partners to address cancellations, requests for refunds, rebookings and similar matters. In addition, like many other companies, we have instructed or allowed employees in high-risk areas to work from home or not report to work, which, especially if this persists for a prolonged period of time, may have an adverse impact on our employees, ability to service travelers, operations and systems. The ultimate extent of the coronavirus outbreak and its impact on travel in currently affected countries or more broadly is unknown and impossible to predict with certainty. As a result, the full extent to which the coronavirus will impact our business and results of operations is unknown. However, decreased travel demand resulting from the outbreak has had a negative impact, and is likely to have a negative and material impact, on our business, growth and results of operations. In addition, we may incur additional customer service costs in connection with servicing travelers affected by the outbreak, which would also have a negative impact on our results of operations.

 

UNITED AIRLINES (10K – 2/25) 

An outbreak of disease or similar public health threat, or fear of such an event, that affects travel demand, travel behavior, or travel restrictions could have a material adverse impact on the Company’s business, financial condition and operating results. In addition, outbreaks of disease could result in increased government restrictions and regulation, including quarantines of our personnel or an inability to access facilities or our aircraft, which could adversely affect our operations.

In December 2019, a novel strain of coronavirus (“COVID-19”) was reported in Wuhan, China. The World Health Organization has declared COVID-19 to constitute a “Public Health Emergency of International Concern.” On January 30, 2020, the U.S. Department of State issued a Level 4 “do not travel” advisory for China. The U.S. government has also implemented enhanced screenings, quarantine requirements and travel restrictions in connection with the COVID-19 outbreak.  The Company has suspended its flights between the United States and each of Beijing, Chengdu, Shanghai and Hong Kong through April 24, 2020. These routes represented approximately 5% of the Company’s 2020 planned capacity and the Company’s other trans-Pacific routes represented an additional 10% of the Company’s 2020 planned capacity. As of the date of this report, the Company is experiencing an approximately 100% decline in near-term demand to China and an approximately 75% decline in near-term demand on the rest of the Company’s trans-Pacific routes. The extent of the impact of the COVID-19 on the Company’s operational and financial performance will depend on future developments, including the duration and spread of the outbreak and related travel advisories and restrictions and the impact of the COVID-19 on overall demand for air travel, all of which are highly uncertain and cannot be predicted. If traffic on the Company’s trans-Pacific routes were to remain at these levels for an extended period, and/or routes in other parts of the Company’s network begin to see significant declines in demand, our results of operations for full year 2020 may be materially adversely affected.

 

ROYAL CARIBBEAN (10K – 2/25) 

The year 2020 has started off challenging as we address the impact of the recent coronavirus outbreak on our operations. Prior to the outbreak, our sailings in China were trending particularly well both in terms of rate and volume. Our itineraries in China were expected to represent 6% and 4% of our full year and first quarter 2020 capacity, respectively. The travel restrictions and other measures taken by China and other countries to contain the disease have resulted in the cancellation of an increasing number of our cruises in the region. We have also implemented several measures restricting the boarding of certain at-risk guests and crew on our ships. These and other concerns and restrictions relating to the coronavirus outbreak are having an impact on the demand for cruises and causing travel restrictions, guest cancellations, an unavailability of ports and/or destinations, ship redeployments and an inability to source our crew, provisions or supplies from certain places. All of these issues are having and are likely to continue to have a material impact on our bookings, operations and our overall financial performance. However, given the fluidity and uncertainty of this situation, we are unable to predict the full financial impact that this incident will have on our operations and financial condition, including what our yields and earnings for 2020 will be.

 

MASTERCARD – (8K – 2/24)

The fundamentals of our business remain strong, as our switched volume and switched transaction growth remain in-line with our expectations. However, cross-border travel, and to a lesser extent cross-border e-commerce growth, is being impacted by the Coronavirus. As a result, we now expect that if the trends we have seen recently — primarily in our cross-border drivers — continue through the end of the quarter, year-over-year net revenue growth in the first quarter will be approximately 2-3 percentage points lower than discussed on our January 29, 2020 earnings call. Under these circumstances, we would expect year-over-year net revenue growth of 9-10% in the first quarter on a currency-neutral basis, excluding acquisitions.

 

TELEDYNE (10K – 2/24)

Air travel declines have occurred after terrorist attacks and heightened security alerts, as well as after the high-profile outbreaks of disease, including the recent outbreak and spread of the Wuhan, China-originated Coronavirus. Additional declines in air travel resulting from these factors and other factors could adversely affect the financial condition of many of our commercial airline and aircraft manufacturer customers and, in turn, could adversely affect our Aerospace and Defense Electronics segment. In addition, a prolonged virus epidemic or pandemic, or the threat thereof, could result in worker absences, lower productivity, voluntary closure of our offices and manufacturing facilities, disruptions in our supply chain, travel restrictions on our employees, and other disruptions to our businesses. Moreover, health epidemics may force local health and government authorities to mandate the temporary closure of our offices and manufacturing facilities.

 

KKR & CO (10K – 2/18)

Political developments, natural disasters, war or threat of war, terrorist attacks, public health crises and other events outside of our control can, and periodically do, materially and adversely impact our portfolio companies and other investments around the world. Our investment strategies target opportunities globally, across North America, Europe, Asia-Pacific and the Middle East. Political instability and extremism, civil unrest and anti-government protests in any region where we have material business operations or investments can, and periodically does, have an adverse impact on our and our portfolio companies’ business results, reputation or license to operate. In addition, occurrence of war or hostilities involving a country in which we have investments or where our portfolio companies operate could adversely affect the operations and valuations of our portfolio companies and investments in such country. Natural disasters, such as extreme weather events, climate change, earthquakes, tsunamis or floods, can also have an adverse impact on certain of our portfolio companies and investments, especially our real asset investments and portfolio companies that rely on physical factories, plants or stores located in the affected areas. As the effects of climate change increase, we expect the frequency and impact of weather and climate related events and conditions to increase as well. For example, unseasonal or violent weather events can have a material impact to businesses or properties that focus on tourism or recreational travel. Public health crises, pandemics and epidemics, such as those caused by new strains of viruses such as H5N1 (avian flu), severe acute respiratory syndrome (SARS) and, most recently, the novel coronavirus (COVID-19), are also expected to increase as international travel continues to rise, and also directly and indirectly impact us and our portfolio companies in material respects by threatening our and their employees’ well-being and morale, interrupting business activities, supply chains and transactional activities, disrupting travel, and negatively impacting the economies of the affected countries or regions.

 

EXPEDIA (10K – 2/14) 

Because these events or concerns, and the full impact of their effects, are largely unpredictable, they can dramatically and suddenly affect travel behavior by consumers and decrease demand. D ecrease in demand, depending on its scope and duration, together with any future issues affecting travel safety, could significantly and adversely affect our business, working capital and financial performance over the short and long-term. In addition, the disruption of the existing travel plans of a significant number of travelers upon the occurrence of certain events, such as severe weather conditions, actual or threatened terrorist activity, war or travel-related health events, could result in significant additional costs and decrease our revenues leading to constrained liquidity if we, as we have done historically in the case of severe weather conditions and travel-related health events, provide relief to affected travelers by refunding the price or fees associated with airline tickets, hotel reservations and other travel products and services.

With respect to the 2019 Novel Coronavirus outbreak specifically, we currently expect that our first quarter 2020 financial results will be negatively impacted, potentially to a material degree. In addition, as of the time of this Annual Report on Form 10-K, we expect the 2019 Novel Coronavirus will continue to negatively impact our businesses beyond the first quarter of 2020, but the extent and duration of such impacts over the longer term remain largely uncertain and dependent on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the coronavirus, the extent and effectiveness of containment actions taken, including mobility restrictions, and the impact of these and other factors on travel behavior.

 

ESTEE LAUDER (10Q – 2/6)

While our business is performing well overall, we continue to face strong competition globally and economic challenges in certain countries. We are cautious of the continued decline in retail traffic primarily related to certain brick-and-mortar stores in the United States and the United Kingdom. This is due to the impact of shifts in consumer preferences as to where and how they shop, as well as adverse macroeconomic conditions in the United Kingdom. Our business in Hong Kong continues to be challenged, as the ongoing situation there has negatively impacted traffic in downtown shops and the airport and also led to intermittent store closures. We continue to monitor the geopolitical tensions between the United States and China and the uncertainties caused by the evolving trade policy dispute, which could increase our cost of sales and negatively impact our overall net sales, or otherwise have a material adverse effect on our business. We also continue to monitor the potential implications of the ongoing economic and political uncertainties stemming from the United Kingdom’s exit and transition from the European Union (i.e. “Brexit”) and continue developing our risk mitigation strategies to address such uncertainties. These strategies include changes related to regulatory and legislative compliance, assessing alternatives to supply chain routing, revising customer arrangements and analyzing inventory levels. We are monitoring the potential impacts of the recent outbreak of the coronavirus on our global business. After experiencing continued strong momentum into January, we have seen a significant decline in air travel and consumer traffic in key shopping and tourist areas. Although it is difficult to anticipate the full impact of the coronavirus on our business, global travel retail, localities most affected by the virus outbreak and destination markets favored by tourists are expected to experience the greatest negative impact in the coming months followed by a gradual recovery later in the fiscal year. We are also cautious of foreign currency movements, including their impacts on tourism. Additionally, we continue to monitor the effects of the global macroeconomic environment; social and political issues; regulatory matters, including the imposition of tariffs; geopolitical tensions; global health issues and global security issues.

 

Don’t miss critical insights. AlphaSense gives you access to full Earnings call transcripts and allows you to keep track of themes unfolding within your coverage universe through intelligent AI-powered search.

Sign up for a free trial to learn how AlphaSense enhances the workflow of 70% of the world’s hedge funds and over 50% of the S&P 500. Already have an account? Login here.

Remote Work Is A Major Theme as Coronavirus Fears Intensify

Interested in staying up-to-date on COVID-19’s impact across sectors? Visit our Coronavirus Impact Tracker for daily updates pulled from earnings calls, press releases, 8ks, and more.

As the global health crisis continues, companies around the world have been forced to adopt remote work policies in order to mitigate the spread of the virus.

Initially, the tech sector led this charge. On Monday March 2nd, Twitter became the first major tech company to strongly encourage all employees to work from home. Shortly thereafter, Facebook, Google, Microsoft, and Adobe announced that they would cancel, alter, or pull out of various upcoming conferences, encouraging employees and the public to stay home and avoid large gatherings. On March 4th, Amazon sent an email to its Seattle office requesting that all employees work from home until March 31st.

Since, due to government-mandated work from home orders, the rest of the market has joined them.

How much is remote work impacting performance? We compiled an overview of all companies discussing remote work in earnings call transcripts, press releases, or other company documents.

Here’s what we found:

  • The first week of March, proactive discussion in earnings call and event transcripts was mostly limited to companies that offer a product that facilitates remote work. The second week of March, companies across sectors reported a variety of implications of Coronavirus-induced remote work.
  • Video conferencing companies are seeing abnormally high growth: Zoom, for instance, added more users in January and February of 2020 that all of 2019 combined. Many video conferencing companies are also offering free or discounted services.
  • Company commentary and broker research around remote work has outpaced to media coverage and initial speculation, according to AlphaSense data (see chart below).

Don’t miss critical insights: Sign up for a free trial or login here.

Here are the highlights:

[Note: We are updating this post to reflect the most recent commentary. Last updated 4/3.]

Palo Alto Networks (3/31 – M&A Call)

From a technology perspective, we’re fully leveraging our remote secure working capabilities through Prisma Access for our employees to enable them to securely connect to the applications they need both in the cloud and in our data centers and offices. Additionally, we have transitioned our security operations center to a remote model in which all our analysts are working from home. Our partnership with Google allows us to scale our products in a linear fashion and ensure that we had no issues in meeting the high demand we’re seeing for remote secure access.

Let me talk about the business impacts of COVID-19. From a sales perspective, we have seen a few dynamics. One, the working from home phenomenon has prompted many organizations to purchase incremental firewalls to accommodate the new traffic from employees no longer working from their corporate offices. We are well positioned to help customers with GlobalProtect, our attached firewall subscription that allows organizations to secure remote workforces. We are also seeing an increase in coordinations regarding Prisma Access from customers who are contemplating a new paradigm in terms of remote working as organizations around the globe are mandating their workforce where possible to work from home.

 

Progress Software Corp (3/26 – Earnings Call)

Question – Mark William Schappel: Great. And then an additional question here. Could you just give us an idea of how your — how you see a professional services business holding up and how the company just plans to manage business offering professional services?

Answer – Yogesh Gupta: Absolutely. Yes, Mark. So it’s actually interesting. Even before the coronavirus impacted the way people do business, the vast majority of Progress professional services was being delivered remotely. We have rather limited set of people that used to go to on-prem anyway. Of course, since this, 100% of it is being delivered remotely. We are seeing no disruption in the project. And as far as we are seeing, we’re not seeing delays in ongoing projects either. So at least from — I know that some other companies have seen different things in their business, but from our perspective and from our professional services business, we are not seeing a project impact at least today.

 

Valvoline (3/24 – 8K)

Quick Lubes’ store team members already have minimal contact with customers through the Company’s existing drive-through, stay-in-your-car service experience. Valvoline has also taken additional actions to modify in-store procedures to further reduce direct contact between store teams and customers. The Company is monitoring the situation closely and is prepared to make additional changes as necessary.

Valvoline globally is taking broader actions designed to help further prevent the spread of the COVID-19 virus, including limiting domestic and international travel and implementing work-from-home arrangements, among others. On a positive note, in China, after a temporary suspension, construction on the lubricants plant has resumed, work-from-home protocols substantially ended earlier this month and sales trends are improving.

 

Kingsoft Corp (3/24 – Earnings Call)

And for the cloud business, we experienced quite positive impact from the coronavirus situation due to the increased use of online working, online education, the work from home situation. The cloud business performed very well in 2019. The revenue growth was 70% and up, and we are confident that we will maintain similar growth rate in 2020.

We mentioned that we couldn’t give detailed revenue growth guidance for the Beijing Office Software business. But this business also benefited from the current situation. The technology adopted for online working, online education, also speed up the performance of WPS.

 

J.B. Hunt (3/23 – Press Release)

J.B. Hunt has taken several precautions to prevent the spread of COVID-19. Earlier this month the company issued a directive to work from home until at least April 3, 2020, for employees whose on-site presence is not required to perform their work. 

Ford Motor Company (3/20 – Press Release)

Since the beginning of the outbreak, Ford has taken all possible measures to minimize the impact of coronavirus, including asking all employees to work remotely unless they are performing a business-critical job that requires being onsite, limiting visitors to the plants, and increasing the frequency of cleaning at the company’s facilities, among others.

 

Volkswagen (3/19 – Press Release)

All measures taken to date remain applicable until further notice, always with the aim of preventing personal contact wherever possible and thus containing the spread of the coronavirus. These include:

More flexible use of remote working

Particular protection of employees in Covid-19 risk groups.

 

Gartner HR (3/19 – Press Release)

Gartner, Inc. survey of 800 global HR executives on March 17 found that 88% of organizations have encouraged or required employees to work from home, regardless of whether or not they showed coronavirus-related symptoms. Nearly all organizations (97%) have canceled work-related travel, more than an 80% increase since March 3.

A greater percentage of organizations plan to reduce work for external partners rather than employees — one-fifth of organizations plan to stop or limit consultant spend and/or reduce the number of contract workers. Only 10% of employers plan to reduce working hours, and just 6% report asking employees to take unpaid leave.

To manage remote talent during the COVID-19 pandemic, Gartner recommends HR leaders do the following:

  • Provide direction, confidence and resilience. Employees are relying on leaders at all levels of the business to take action and set the tone. Communications from senior business leaders to managers should prioritize associate health and business sustainability. Communicate regularly with employees, maintaining an open dialog. Gartner’s survey found that 56% of organizations have communicated a plan of action to employees in the event the COVID-19 outbreak.
  • Contextualize coronavirus for the organization. Leaders should be a trusted source for accurate and up-to-date information on coronavirus and how it is impacting the organization. Avoid sharing information from social media; leverage trusted resources such as the World Health Organization and the Centers for Disease Control and PreventionContextualize information and data as much as possible so that it specifically relates to the organization.
  • Encourage intentional peer-to-peer interactions. With reduced or no face time in the office, employees should maintain regular professional and personal interactions with their peers. Gartner’s survey found that 40% of organizations have set up additional virtual check-ins for employees with managers and 32% of organizations have introduced new tools for virtual meetings. HR leaders should encourage employees to leverage communication platforms they already use, either at work or in their personal lives, to create new ways to work together.
  • Establish team guidelines. Remote work looks different for each employee depending on their needs and those of their families. With unprecedented school closures, many employees must take on a double role as they support their children and families throughout the workday. Organizations can meet employees’ needs by empowering teams to adapt to their conflicting time demands. For instance, teams can set “core team times” when all team members are available to collaborate.
  • Provide flexibility for employees’ remote work needs. When preparing for employees’ eventual return to the office, empower employees to make choices best suited for their needs and comfort levels. Where possible, allow employees to decide when to return to the office. Enable essential employees whose work requires them to return to the office to choose the hours that work best for them to return to avoid peak commute times

Yum! Brands (3/16 – Press Release)

Third, at our corporate offices and restaurant support centers, we’ve directed employees to postpone all nonessential business travel (and we’ve prohibited travel to highly-affected countries) while we continue to assess developments both abroad and in the U.S. Based on the dynamic nature of COVID-19, our global RSC offices also have plans in place so employees can work remotely as needed.

NASDAQ (3/15 – Press Release)

In consultation with industry stakeholders, and following guidelines from the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC) concerning the elevated risks associated with COVID-19 coronavirus, Nasdaq’s North American staff have been operating across a combination of work-from-home, split teams, and rotating staff schedules since March 9; this remains in effect until further notice. These measures will ensure consistency of Nasdaq’s operations as we continue to serve our client’s unique needs.

 

Slack (3/13 – Q4 2020 Slack Technologies Earnings Call)

Additionally, we are taking into consideration our best guess of the potential impact from COVID-19. We have paused all nonessential travel and have encouraged employees to work from home, as have some of our customers and prospects.

TransUnion (3/12 – Bank of America Merrill Lynch Securities Information Services Conference)

First, I’d just like to say thank you to Bank of America, and thank you to Gary for being flexible and pivoting to this teleconference format so we still have this opportunity to get together. Obviously, there’s a lot going on in the world and lot for us to talk about, and I think effective communication is really important in times like this.

Yes. So we are — we’re thinking a lot and focused on the coronavirus issue initially, taking care of our employee population. We have been implementing various degrees of work from home, social distancing, travel diminishment policies. And I think you’ll see us continue down that path, where in the coming weeks, we will likely be working from home, except in nonessential type of situations. So certainly doing our part there.

Xunlei (3/11 – Earnings Call)

About the situation with coronavirus, we are headquartered in Shenzhen Guangdong province. So we do not have any offices in Wuhan or Hubei province. Our employees today are not personally affected by the coronavirus so far. Our employees started working from home online since February 10 and resumed the normal operation on-site about 2 weeks ago.

In the short term, we have not seen any significant negative impact of the coronavirus on our operations as our users are all over the country. We actually saw some positive impact as part of our business, particularly in cloud computing and the subscription business as people stayed at home more. But in the longer term, we are unable to predict any future impact as the coronavirus situation evolves. Ensuring the health and safety of our employees is always our top priority. We are strictly following the guidance issued by the local government authority and provided our employees with masks and other protective equipment and guidance during this period of time, while paying close attention to the development of the virus and will act accordingly to maintain normal operations of the company.

Emerson Electric Co (3/11 – JP Morgan Industrials Conference)

Like you said, I — we have more things going forward this cycle than we did last cycle from — ahead of the cost structure, we’re hunkered down. We have chances to accelerate things. We get the mentality of the people is that we weren’t looking at growth this year. And so we had a mentality of people, okay, where do we hunt down? And how do we save? And then how do we get our cost structure in better shape as quick as possible? And that’s where we are.

And the only counter thing would be the coronavirus where people are really nervous, and we’re working full out, 100%. We’re not doing remote stuff. We’re not doing like Bayer did in St. Louis, like some guy comes back from Germany, and they shut the whole campus down. We’re not doing that. We’re working and I need my people to work, but I am also taking care of my people that cannot come in because of coronavirus. And so right now, we’ve been, knock on wood and go — keep things going. And that’s the key issue for me. Can we keep our facilities going? And right now, we are.

Principia Biopharma (3/10 – 10K)

If the COVID-19 outbreak does not subside, we may experience significant disruptions that could materially impact our business. We may need to limit operations or implement limitations, including work from home policies, and may experience limitations in employee resources. In addition, the COVID-19 outbreak could result in reduced operations of third-party manufacturers upon whom we rely, disrupt our supply chain, or otherwise limit our ability to obtain sufficient materials to manufacture our drug candidates. Furthermore, our clinical trials may be affected by the COVID-19 outbreak. Site initiation, patient enrollment and trial data collection may be delayed or stalled due to prioritization of hospital resources toward the COVID-19 outbreak, patient or staff unwillingness to visit hospitals and participate in our trials, or quarantines that may impede patient or staff movement and study drug availability at trial sites, interrupt healthcare services or otherwise prevent patient compliance with clinical trial protocols. We may experience delays in receiving approval from local or regional IRBs or regulatory authorities to initiate or modify our planned clinical trials. The global outbreak of COVID-19 continues to rapidly evolve, is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, our third-party drug manufacturing capabilities, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations.

 

Akamai Technologies (3/9 – Deutsche Bank Media, Internet & Telecom Conference)

But I’m pleased to say, within the last 1.5 years, we’ve kicked in some initiatives that would allow us to find some new logos around the globe, and that continues to add in some booking strength in terms of growth. So I would say, in the near term, you’re going to continue to see the security solutions that we offer is kind of the main driver of growth. You have some new products, like page integrity that come out later this year, that should be, hopefully, very, very successful and probably pretty easy to roll into the quota-bearing reps sort of bag.

And then you have some longer-term sort of opportunities around identity cloud or customer identity as well as what the coronavirus is, working from home, our enterprise solutions would be a very logical selection for companies as they continue to reach a remote audience with cloud-based applications. And so we have like a much more dynamic, improved, secure gateway product that rolls out later this year. And so I’m pretty excited about some of the opportunities in the enterprise security space, which my belief is that the addressable markets in that sort of dwarf the security space that we’re in today.

Ciena (3/5 – Earnings Call)

With regards to the second part of the question, Jim, do you want to talk about the work from home and the…

Answer – James E. Moylan: Sure. I think it’s a very interesting question, Tal. And I will say that just like many other companies, we’ve taken a lot of steps to protect our employees with respect to the coronavirus. We are encouraging, in some cases, in some countries, people to work from home. We’ve talked about travel bans into some countries. So we’ve done a lot of things that will accelerate what has already been, in many cases, a movement toward working from home. And we certainly, we at Ciena, are looking at expanding our collaboration tool set. I think other companies are doing the same thing. It would not surprise me if this combination of new technologies around collaboration and this situation that has occurred here is that you will see more people work from home. And over time, yes, that’s going to mean more bandwidth needed in a lot of different places. It’s not a near-term effect. But yes, I think the direction is good for us.

 

Teledoc (3/5 – Earnings Call)

If they go into the emergency department, we have some technologies we use in the emergency department that are particularly relevant in coronavirus. We’ve been doing this for years. If you come into the emergency department, you are seen remotely. There is one provider off-site; can be at home. Most of the time, it’s in a Jefferson facility, and that one provider covers 2 emergency departments. We don’t have a triage nurse in most of those situations. So they come in, they see the doctor. The doctor does an exam via telemedicine, write orders on the patient and writes a note in the chart. Again, in this situation where I don’t want people coughing and sneezing on me or even to walk in the room and shake their hands, this is perfect. It prevents that from happening, okay?

Then they go into the acute care setting. If they’re really sick and it’s a neuro stroke program like for InTouch or any of the other use cases InTouch has, and you see they have tons of them, they can be seen by a remote physician with more expertise, if that’s needed. At our shop in coronavirus territory now, we actually hand the patient an iPad, and they go in the room and there’s paired iPads and nobody else needs to go in the room unless the patient’s sick enough that somebody else needs to go into the room to do something. So we separate people out. We have used the JeffConnect app to do screening for coronavirus on our premises in the emergency department, and we have done it from home. Fortunately, in Pennsylvania, we don’t yet have a positive, but we’ve done this screening in both of those situations.

 

Zoom (3/4 – Earnings Call)

Before tuning the revenue over to Kelly, I’d also like to address the global impact we’re seeing from the coronavirus. While this tragic situation is very fluid, Zoom is focused on using our resources to help alleviate some of the disruption and the communication challenges as an alternative to enforce the meetings for our employees, customers and community.

I’m happy to report that all of our employees in the affected areas are healthy. Given the recent emergence and a growing number of coronavirus cases in the United States, we have directed our high-quality employees to work from home, unless there’s a business critical need for them to be in the office. We are taking this step out of abundance of caution.

Zoom is doing everything we can, especially for global educational institutions, to provide resources and support to our customers and as those navigated the coronavirus outbreak, including we are proactively moderating capacity globally to ensure maximum reliability made usage increases.

In China, we have removed the 40 minutes limit on free meetings, and we are providing informational sessions and on-demand resources. So anyone who learned how to use the Zoom platform with ease.

 

VMWare (3/4 – Morgan Stanley TMT Conference)

Yes, and as we describe it now, we say, we’re uniquely positioned to help customers build, run, manage, connect and protect, right? And they’re in any app, any cloud, any device environment. So obviously, build with the Heptio and the Pivotal acquisitions, and we’ll be shortly launching the Tanzu portfolio. We got this ability to capture this Kubernetes transition and make it part of what they already do with VMware. Right.

Run, this is the huge steps we’ve taken with the cloud guys. Obviously, Amazon, but now the partnerships with Azure, the Oracle announcement, the Google partnership, Alibaba, the continued momentum with IBM. We sort of got them all, right, at this point, as well as the ability to do data center modernization, hybrid cloud. Nobody else able to do that. So our 1 portfolio in a multi-cloud sense is unrivaled. Right, manage all the devices. And while you’re always looking for silver linings, hey, coronavirus. People want to do more work from home, “Hey, I got a product called Workspace ONE.” Right? We’re enabling people to do that, some of our biggest Q3 deal. Our Q4 deals were around Workspace ONE.

 

Fastly (3/4 – 10K)

In light of the uncertain and rapidly evolving situation relating to the spread of the coronavirus (COVID-19), we have taken temporary precautionary measures intended to help minimize the risk of the virus to our employees, our customers, and the communities in which we participate, which could negatively impact our business. As a company with employees, customers, partners and investors across the globe, we believe in upholding our company value of being good people by doing our part to help slow the spread of the virus. To this end, we are temporarily requiring all employees to work remotely, have suspended all non-essential travel worldwide for our employees, are canceling or postponing Fastly-sponsored events, and are discouraging employee attendance at industry events and in-person work-related meetings. While we have a distributed workforce and our employees are accustomed to working remotely or working with other remote employees, our workforce is not fully remote. Our employees travel frequently to establish and maintain relationships with one another and with our customers, partners, and investors, and some of our business processes assume that employees can review and sign documents in person. Although we continue to monitor the situation and may adjust our current policies as more information and guidance become available, temporarily suspending travel and doing business in-person could negatively impact our marketing efforts, challenge our ability to enter into customer contracts in a timely manner, slow down our recruiting efforts, or create operational or other challenges as we adjust to a fully-remote workforce, any of which could harm our business. The extent to which the coronavirus (COVID-19) and our precautionary measures may impact our business will depend on future developments, which are highly uncertain and cannot be predicted at this time.

 

Veritone Inc (3/4 Earnings Call)

Question – Patrick D. Walravens: Okay. Last one for me. And I know there’s a lot of uncertainty, but you mentioned the coronavirus having some impact on the ad business. How do you think it’s likely to play out more? People working from home, less travel, some supply chain disruptions. What are you keeping an eye on in your business as we move through this epidemic?

Answer – Chad Steelberg: Yes. I mean, I think you touched on all the high points. Essentially, in our advertising business, we’ve seen some push out of ad campaigns already by clients who have already suffered some supply chain disruptions due to the outbreak. And we could experience more pushouts from additional customers in the Veritone business.

On the SaaS side, however, we have far less direct exposure to the coronavirus. But we could see some sales cycles extend as customers, particularly in the public safety, gets distracted with, obviously, much higher priorities as the epidemic hits the U.S., and we fully support their efforts. On the work from home component, definitely, we’re seeing companies testing with that. We have a great organization here that operates already in 3 or 4 different offices. And most of our sales and customer engagements is happening over the phone and video conferencing already. So from an ongoing operations standpoint, in terms of our employees and how we engage with our customers, I see very little impact and towards the business.

 

Spotify (3/4 – Morgan Stanley TMT Conference)

Answer – Benjamin Daniel Swinburne: Great. Yes. Got one up in the middle, maybe while the microphone’s headed up. One thing we didn’t talk about, doesn’t seem like a huge factor for Spotify is anything around the virus and macro that impacts the company or how you guys work or anything else?

Answer – Paul Aaron Vogel: Yes. I mean, it’s still early. Right now, we don’t think so. I mean, look, obviously, it affects everybody. It affects employees. As a company, we’re trying to figure out how much people should travel and those types of things. But we obviously don’t manufacture product. We have no supply chain issues. We have no people issues. Everyone’s able to work. There’s no change in the product, I think, of that sort. And honestly, I think a service like ours is probably, and we don’t know this because we haven’t really experienced yet, somewhat countercyclical or at least we would survive well in that type of environment. Because if you’re at home more or if you’re not going out more, you’re probably not going to cut off your streaming services, whether it’s audio or video or things that actually you get enjoyment from, that you don’t need to actually go out and be with people. So we’ll see, but right now, we don’t see an impact on the business.

 

Veeva Systems Inc (3/4 – Morgan Stanley TMT Conference)

For the industry we serve, it’s a busy time and it’s a time of change. There’s — they do a lot of collaboration around the world. Some of them are fine-tuned already to do that in a virtual way, such as Veeva. Some are less so. And with the — some of them are decreasing travel, and so they’re having to get better about doing virtual communications. We’re helping many of our customers by providing Engage Meeting, one of our products for the pharmaceutical companies to engage remotely with health care providers. We’re providing that free of charge until September, and that’s helping some of our customers.

We have certainly some customers that are working on treatments and vaccines for the COVID-19 virus. So they’re certainly very busy. And I felt — I read that this morning, Moderna, one of our customers, actually introduced the first candidate for a vaccine. So they’re very busy.

For us, for Veeva, we’ve operated in a virtual way quite well for many years here. We just embrace the virtual technology. We haven’t seen projects canceled. We’ve seen some delays in some projects, but nothing that would materially affect our financials. So we’re continuing to focus and to be productive and to run virtually in the places where we need to where there’s a serious outbreak

When we started Veeva CRM, there was no concept of doing a remote meeting with a doctor. Now we are ready there. Some of our customers, they hadn’t purchased Engage Meeting, but man, they want it in a hurry right now because of this COVID-19 virus.

 

Five9 (3/4 – Morgan Stanley TMT Conference)

Answer – Meta A. Marshall: I’m going to start this session with kind of the topic du jour of any potential corona impact that you’ve seen or just any changes in behavior that you’ve seen just kind of in the couple of weeks that we’ve been working through this.

Answer – Rowan M. Trollope: Sure. So at a high level, I’ll just point out, the vast majority, 92% of our business, is U.S., domestic business. So certainly, we’re somewhat more insulated than others from international exposure whatever there would be, on that front. Our business is a cloud SaaS business. And I think from a business continuity perspective, there’s definitely a perspective amongst the customers that cloud-based software has the flexibility of letting people work from home. I think you’ve seen that recently with Zoom and some of the UC vendors, UCaaS companies. The same is true of the contact center. So these contact center environments are environments that frankly are like big rooms like this, probably like giant airplanes, in a sense, where you wouldn’t necessarily want to have your agents all consolidated in the environment of — in the event of an outbreak or a pandemic. So some of our — one of the benefits of Five9 is the ability to have your agents actually work from home. You just bring your laptop home, and you can actually take calls and do your messaging and do everything that you can do in the office at home. So that’s a sort of fundamental power of the cloud. We certainly haven’t seen anything on the downside or upside candidly with this — with the more recent news around coronavirus. So it’s kind of business as usual for us.

 

8×8 Inc (3/4 – Morgan Stanley TMT Conference)

So if you think about it, what do we do? We do virtual office, which enables workers to work from home seamlessly and look like they’re in the office. We do virtual contact center that enables contact center agents to work from their home and answer customer problems seamlessly. And so every once in a while you may hear a dog barking in the background, which tells you that the contact center agent is actually safe and at home. Video conferencing, which we just launched 1.5 months ago. Just in between January and February, free meetings increased threefold and new user sign-ups. And then the part that was even more gratifying is virtual office where we made free meetings available integrated with our virtual offering, Virtual Office X Series, we saw adoption double between January and February.

We’ve also seen an impact on our CPaaS business, of all things, with food delivery in Asia Pacific, where we’re seeing increased text messaging and voice calling for food deliveries.

The goal here is, as I said, we’ve made meetings available for free for everybody, whether they’re a customer or not. We’ve done outreach programs to all of our various customers. Several customers have asked us, a very large customer, which is in the financial services industry, has asked for increasing the pace of our deployments because they want to enable every one of their workers to work from home. We have a very large university that has asked us to see if they can deliver classrooms for students seamlessly, whether they’re in the dorm or whether they are global because about 20% of their student population are international students.

So it’s a scary time but business must continue on, and I think we can help as a company to enable this to be as seamless as possible.

 

Guidewire Software (3/4 – Earnings Call)

Finally, I want to proactively address COVID-19 and its potential impacts to Guidewire and the actions we’re taking here to be prepared. We’re monitoring the fast-moving events very closely and have a regular team meeting to update our response. We have some formal restrictions on travel in place in line with government and CDC recommendations. We are also supporting and accommodating employees who do not feel comfortable traveling for work-related activities. Additionally, we have seen evidence our customers and prospects are enacting their own preventative policies and believe that more will follow. Our employees regularly use a variety of tools to work and engage remotely, and we are ramping up our approach to supporting and, in some cases, encouraging remote work.

While widespread restrictions on travel and in-person meetings could affect service delivery and sales activity, we do not currently anticipate a material financial impact this year.

 

Endava PLC (3/4 – Morgan Stanley TMT Conference)

Sure. So I mean, obviously, the big question is, are we seeing any impact in the business from the coronavirus. The — we’re not seeing any impact in terms of revenue flows and clients, discussions with clients about business opportunities. And — so no impact coming through from the top line at all. And obviously, we’ve been putting a lot of work into testing and making sure all our business continuity plans in this place — in this area are working well. And for us, that is mainly around the ability of our staff to work from home.

And so the one area where we have seen some activity is where some members of staff, who traveled, have decided that they want to self-quarantine. So we’ve seen some members of staff, not that many, but some members of staff moving to the self-quarantine, working from home environment. Now that actually has 0 impact on us from a revenue or profitability point of view because they then essentially continue doing the work that they were doing anyway, but they do it in a home context for a couple of weeks.

 

Ping Identity (3/4 – Earnings Call)

Question – Matthew George Hedberg: That’s great. And then maybe as a follow-up to the coronavirus. Obviously, thoughts go out to everybody impacted on that. But I’m curious — and one of the byproducts could be more employees working remotely or from home. I’m curious, outside of this event, how does remote workers or that trend benefits you guys when you think about application access?

Answer – Andre Wong Durand: Well, one of the benefits of identity-based security is that the entire notion of being on the network or, said another way, being in the building or being on the VPN becomes somewhat irrelevant to the security model. So when you hear about Zero Trust in its association with leveraging identity to allow anytime, anywhere access to any resources by people that are essentially anywhere, what you’re really hearing is that identity — a strong identity foundation, strong identity security and single sign-on to all application resources does allow a workforce to work from anywhere. So while I don’t think the drivers are maybe as direct as everyone’s going to go on video conferencing, companies that have good foundations in their identity and access management solutions, especially ones that have adopted strong authentication and single sign-on and are kind of adhering to the road map of Zero Trust, are in a really good position to allow their workforce to work from home.

 

Progressive Corp (3/4 – Earnings Call)

Question – Michael David Zaremski: My first question is on any potential impact from the current situation with the coronavirus. The New York Times has come out and said that they’re seeing just recently ad spend fall fairly materially across the brand with (inaudible) to 25%. And I’m curious if you think Progressive should in the near term — or is part of that? And also, are you seeing any impact maybe from your [call medics] drivers on the work frequencies if people are maybe working from home?

Answer – Susan Patricia Griffith: Mike, that’s a great question. So I’ll start with the ad spend. Right now, we’re going to continue to spend. This is a prime time of the year when people are buying insurance, we’re getting into that season. We’ll continue to spend. That we have some flexibility in. But again, whether you drive a little bit or a lot, you still are required to have auto insurance. And so our intentions will be to spend as long as we feel sufficient. So again, we’ll have to be nimble because all of this, as you know, is ever-changing.

The great question on the UBI. So with the recent deaths in Washington, we asked the UBI team, just to take a look at UBI vehicle miles driven or traveled by week in January and February this year compared to the prior 2 years. And we are not quite seeing a difference. And again, that’s very little data, but that tells us we haven’t seen it yet. Again, now that we’ll look at it weekly, we can start to see that. We’ll look at it across the country where we can. So we’ll be able to understand pretty quickly. If you go back to something like the financial crisis, I was running claims at the time and we saw frequency drop really quickly. And so we’ll have some good insight. We get our frequency data on a daily basis. So we’ll understand very quickly where we’re at.

From an internal perspective, we already have over 25% of our people working from home. We have had many team meetings were having a tabletop pandemic exercise tomorrow, I believe. And then our Chief HR leader, Lori Niederst, had a meeting yesterday with our Chief Medical Officer, talking about the same things that most companies are talking about in terms of nonessential travel and what to do if you’re coming from a country that’s been affected.

So right now, we aren’t seeing any effect. But again, this is such a moving target that we have a lot of data points that we’re going to be looking at literally on a daily basis to understand how it will affect possibly our frequency.

 

Logitech International SA (3/3 – Investor Transcript)

But if I ground myself back in our business and I’ll go back to the reality of what we do for a living, here’s what I think. First, I think if we end up being quarantined in our homes, and we need to spend more time at home and people are encouraged not to accumulate to work together, you’re probably going to want to have your own workspace at home. So you’ll continue to have your workspace at work, but you’ll also have your workspace at home. Here, we workspace at home, you’re going to, want to have something at home that’s good. And that’s great for Delphine’s business. If you’re a home more, it is probably not going to stop this from happening. People are going to continue to want to game, so they’ll keep gaming. And that probably speaks well for Ujesh’s business. And the reality is, if we’re doing more and more remote work, we’re going to do more and more video connecting. If you’re doing more and more video connecting, an amazing, affordable solution is the way to go. So if I look across all 3 of our businesses, and I put myself in that dark place that I don’t think will happen tomorrow or 6 months from now, it could. I actually think, gosh, I’d rather be here than anywhere. So I think we’re a great investment for growth, and we’re a great investment for risk management.

 

XEROX (2/28 – 10K)

Xerox has no sales operations in China or South Korea, but sources a significant amount of product and/or components there.  At this time, the coronavirus outbreak in China and South Korea has not impacted the company’s operations. Xerox is actively assessing possible implications to its supply chain and planned customer delivery on a daily basis to minimize any potential disruption and impact. Our suppliers in the affected regions are slowly resuming their operations. We continue to regularly communicate with suppliers and transportation partners and are currently activating business continuity plans and mitigation strategies as appropriate, including but not limited to premium airfreight, alternate sourcing, asset recovery and reverse logistics covering equipment, supplies and parts. If the coronavirus becomes more prevalent in the western hemisphere and businesses require their office employees to work from home for an extended period of time, sales and use of Xerox products and services could decline.

 

CBRE (2/27 – Earnings Call)

Question – Anthony Paolone: Just to follow-up on the virus impact. So can you just give us a little bit more detail? Like are employees working from home? Are you seeing lease signings just get pushed out or sales closings pushed out? Like what is the day-to-day effect in the places where you’ve seen the most impact?

Answer – Leah C. Stearns: Sure, Anthony. With respect to the day-to-day impact, it really is more of a supply issue. I would say demand continues to be there. We have people who are very active. They’re working remotely. It’s really about being able to get out and perform, for example, diligence on properties if we have sales in the transaction pipeline, things like that. It’s not that we’re seeing that demand go away. It’s just — there’s a bit of pause with respect to people actually being able to do physical activities on the ground. But we continue to see a very strong overall environment in terms of asset allocations continuing to flow into real estate, particularly given their strong position on a relative basis to broader equities and other asset classes. So we still feel very good about the overall real estate market and the demand drivers there.

 

Don’t miss critical insights. AlphaSense gives you access to full Earnings call transcripts and allows you to keep track of themes unfolding within your coverage universe through intelligent AI-powered search.

Sign up for a free trial to learn how AlphaSense enhances the workflow of 70% of the world’s hedge funds and over 50% of the S&P 500. Already have an account? Login here.

Healthcare is Racing to Fight Coronavirus on the Front Lines

Interested in staying up-to-date on COVID-19’s impact across sectors? Visit our Coronavirus Impact Tracker for daily updates pulled from earnings calls, press releases, 8ks, and more.

The entire value chain of healthcare, from drug development to healthcare delivery, is actively responding to the growing impact of the Coronavirus. As the virus spreads region to region, healthcare is increasingly under pressure to deliver and service the populations affected by the virus.

COVID-19 will require focus from the majority of the Healthcare industry for the coming months. Uncover how these developments are impacting the industry with all relevant commentary from companies across the Healthcare spectrum.

 

Takeaways

  • Overall, healthcare companies are unsure of the overall impact of COVID-19 on their business.
  • Most healthcare companies are racing to the front lines testing options for a novel Coronavirus vaccine, virtual screening, and expanded testing options.
  • Healthcare Technology is focused on business continuity to ensure continued-service for all customers (including those working on vaccines), and providing new technologies for virus detection and monitoring
  • Biotech & Pharma is measuring the impact on their supply-chain and some companies are reporting that their China operations are slowly returning to normal levels though concerns linger.  Manufacturers are making alternative plans to source through India and Europe
  • Multiple pharma companies have pledged to not use the pandemic as pricing leverage even where API and raw material shortages may exist
  • Companies across the healthcare sector are retracting previous guidance and providing updated guidance throughout April.

Don’t miss critical insights: Sign up for a free trial or login here.

Here are the highlights. [Note: We are updating this post and our compilation post daily to reflect the most recent commentary. Last updated 4/5]

 

Iqvia Holdings Inc.  (4/3 – 8K)

The company expects a revenue impact from COVID-19 in the TAS segment of approximately $20 million to $30 million in the first quarter compared with the company’s expectations on February 12, 2020. During the quarter, technology deployments continued and demand for analytics and technology remained strong, although business development activity began to slow at the end of the quarter due to COVID-19 related meeting postponements and delayed decision making related to certain projects.

Activity within the Contract Sales and Medical Solutions (CSMS) business has also become more challenging due to a decline in sales rep visits, and physician attention diverted to the COVID-19 crisis. However, for the first quarter of 2020, IQVIA expects the CSMS business to perform in line with the company’s original expectations.

Across the business, the company expects a continued recovery in Asia, but expects difficult conditions in Europe and North America to persist at least through the end of the second quarter. The monthly revenue impact of COVID-19 is therefore expected to be greater in the second quarter, but due to cost containment measures, the proportional Adjusted EBITDA drop-through impact is expected to lessen during the second quarter. 

Becton Dickinson & Co (4/2 – 8K)

Becton, Dickinson and Company, a New Jersey corporation (“BD”), is submitting this report with respect to certain financing activities it has taken in the wake of the COVID-19 pandemic. As is discussed more specifically below, these include securing an aggregate $1.9 billion of unsecured term loan funding and a $381 million increase in the borrowing capacity under our revolving credit facility.  While BD believes it had sufficient liquidity prior to taking these actions to fund its operations and meet its obligations, BD has taken these steps as a precautionary measure to preserve its financial flexibility in light of the uncertainty in the global markets resulting from the COVID-19 pandemic.

Boston Scientific Corp  (4/2 – 8K)

On April 2 , 2020, the Company announced that, in light of the disruption and uncertainty created by the evolving COVID-19 pandemic and its anticipated impact on the Company’s operations , all of our executive officers, including our Chief Executive Officer, Chief Financial Officer, and our other named executive officers, will be taking a temporary reduction in base salary for up to 6 months.
Assuming the second quarter impact of the COVID-19 pandemic will be more significant than the first quarter of 2020, Boston Scientific is taking proactive steps to reduce costs and be in a strong position to support customers and patients when healthcare systems begin to recover, and elective procedures start to return to normal volumes. 

Centene Corp  (4/2 – 8K)

In connection with the Company’s offers to exchange certain series of outstanding notes for new notes that have been registered under the Securities Act of 1933, as amended, the Company announced that as a result of the spread of COVID-19 and the resulting disruption and volatility in the global capital markets, the Company has deferred redemption of the 2022 notes at this time. While the Company currently is in a strong liquidity position and believes it has adequate access to capital, the Company believes it is prudent in this period of time to defer the redemption of the 2022 notes. Until the Company delivers such notice of redemption, the 2022 notes will remain outstanding.

Quest Diagnostics Inc  (3/31 – 8K)

The Company’s operating results in January and February were consistent with the guidance for full year 2020 provided on January 30, 2020. However, in March, the Company experienced, and anticipates it will continue to experience, a material decline in testing volumes due to the COVID-19 pandemic. During the last two weeks of March, volumes declined in excess of 40% inclusive of COVID-19 testing. Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, a significant reduction in physician office visits, the cancelation of elective medical procedures, customers closing or severely curtailing their operations (voluntarily or in response to government orders), and the adoption of work-from-home or shelter-in-place policies, all of which have had, and we believe will continue to have, an impact on the Company’s operating results, cash flows and financial condition. It is possible that the Company will experience an adverse impact on cash collections from customers, clients and payers as a result of the impact of the COVID-19 pandemic.
 
The Company believes COVID-19’s adverse impact on its operating results, cash flows and/or financial condition will be primarily driven by: the severity and duration of the COVID-19 pandemic; the COVID-19 pandemic’s impact on the U.S. healthcare system and the U.S. economy; and the timing, scope and effectiveness of federal, state and local governmental responses to the COVID-19 pandemic. These primary drivers are beyond the Company’s knowledge and control, and as a result, at this time the Company cannot reasonably estimate the adverse impact the COVID-19 pandemic will have on its businesses, operating results, cash flows and/or financial condition, but the adverse impact is likely to be material. The Company is therefore withdrawing its previously announced guidance for full year 2020.
 
The Company expects to release first quarter 2020 financial results on April 22, 2020 and conduct a conference call at which time it will provide updates on the impact of the COVID-19 pandemic.

Stryker Corp  (3/31 – 8K)

As the COVID-19 pandemic expands, unprecedented measures to slow the spread of the virus have been taken by local governments and health care authorities globally, including the deferral of elective medical procedures and social contact restrictions, which have had, and we expect will continue to have, a significant negative impact on Stryker’s operations and financial results.

Amgen Inc  (3/31 – 8K)

As the COVID-19 pandemic continues to evolve, we are committed to doing everything we can to keep our staff and their families safe and to help the communities where we live and work reduce the number of people exposed to the virus. We are also committed to delivering an uninterrupted supply of our medicines for the patients who need them. If you are a patient, medical professional, employee, or member of the community, please see our COVID-19 Information Center page.

IMPACT TO OUR BUSINESS

At this stage of the COVID-19 pandemic we cannot rule out future impact on our business. For example, since the pandemic was declared, we have observed fewer patient/doctor interactions and our representatives are having fewer visits with health care providers which may affect our sales in the future.

SUPPLY OF OUR MEDICINES

Amgen continues to provide an uninterrupted supply of medicines for patients around the world and we do not currently anticipate a shortage of our medicines due to COVID-19

CLINICAL TRIALS AND R&D EFFORTS

An increasing number of clinical trial sites are restricting site visits and imposing restrictions on the initiation of new trials and patient visits to protect both site staff and patients from possible COVID-19 exposure.

Given the safety concerns around COVID-19 and the associated risk to maintaining normal clinical trial operations, we are making decisions study-by-study and country-by-country to minimize risk to the patients and facilities

Veeva Systems Inc  (3/30 – 10K)

The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on our customers and our sales cycles, impact on our customers, employee or industry events, and effect on our vendors and partners, all of which are uncertain and cannot be predicted. For example, in response to the COVID-19 outbreak, we have shifted certain of our customer events to virtual-only experiences, and we may be forced to or may deem it advisable to similarly alter, postpone, or cancel entirely additional customer, employee, or industry events in the future.
Customers may also delay or cancel purchasing decisions or projects in light of uncertainties to their businesses arising from the COVID-19 outbreak. At this point, the extent to which the COVID-19 outbreak may impact our financial condition or results of operations is uncertain. Due to our subscription-based business model, the effect of the COVID-19 outbreak, and any impact to our sales efforts, may not be fully reflected in our results of operations until future periods, if at all.
In addition, the stock market has been unusually volatile during the COVID-19 outbreak and such volatility may continue. To date, during certain periods of the COVID-19 outbreak, our stock price declined significantly, and such declines may continue to happen.

Mylan N.V.  (3/30 – Press Release)

Dutch pharmaceutical company Mylan N.V. (NASDAQ: MYL) and US-based Pfizer Inc. (NYSE: PFE) are anticipating that the closing date of the proposed transaction involving Mylan and Upjohn, a division of Pfizer, will now occur in the second half of 2020, the companies said.

This delay is due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process.

Johnson & Johnson  (3/30 – Press Release)

ohnson & Johnson (NYSE: JNJ) (the Company) today announced the selection of a lead COVID-19 vaccine candidate from constructs it has been working on since January 2020; the significant expansion of the existing partnership between the Janssen Pharmaceutical Companies of Johnson & Johnson and the Biomedical Advanced Research and Development Authority (BARDA); and the rapid scaling of the Company’s manufacturing capacity with the goal of providing global supply of more than one billion doses of a vaccine. 
(Johnson & Johnson) expects to initiate human clinical studies of its lead vaccine candidate at the latest by September 2020 and anticipates the first batches of a COVID-19 vaccine could be available for emergency use authorization in early 2021, a substantially accelerated timeframe in comparison to the typical vaccine development process.

Boston Scientific Corp  (3/30 – 8K)

Boston Scientific Corporation (the “Company”) is withdrawing its guidance for the first quarter and full year 2020 previously issued on February 5, 2020. As the COVID-19 pandemic has expanded worldwide, medical authorities globally (including the U.S. Surgeon General, the American College of Surgeons, and the U.K. National Health Service) have advised the deferral of elective medical procedures. This disruption, as well as others caused by the evolving COVID-19 pandemic and macroeconomic environment, are expected to negatively impact the Company’s financial results. In addition, given the ongoing uncertainty of the scope and duration of the pandemic, the Company is currently unable to estimate those specific impacts.

Abbott Laboratories  (3/27 – Press Release)

Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the fastest available molecular point-of-care test for the detection of novel coronavirus (COVID-19), delivering positive results in as little as five minutes and negative results in 13 minutes...
…”The COVID-19 pandemic will be fought on multiple fronts, and a portable molecular test that offers results in minutes adds to the broad range of diagnostic solutions needed to combat this virus,” said Robert B. Ford, president and chief operating officer, Abbott. 

 

CVS Health Corp  (3/26 – 8K)

Federal, state and local governmental policies and initiatives designed to reduce the transmission of COVID-19 have resulted in, among other things, the cancelation of elective medical procedures in certain jurisdictions, our customers being ordered to close or severely curtail their operations and the adoption of work-from-home policies, all of which have an impact on our businesses. The legislative and regulatory environment governing our businesses is dynamic and changing frequently, including increases to the medical costs we must cover without a corresponding increase in the premiums we receive in our insured Health Care Benefits products. Among other impacts of these initiatives, we expect an adverse impact on our medical membership due to customer reductions in force and an adverse impact on the timing and collectability of payments to us from customers, clients, government payers and members as a result of the impact of COVID-19 on them.

The various initiatives we have implemented to slow and/or reduce the impact of COVID-19, such as colleagues working remotely, and the COVID-19-related support programs we have put in place for our members, customers and colleagues have increased our operating expenses and reduced the efficiency of our operations. In addition, the significant deterioration of the U.S. and global economies is having a significant adverse impact on our net investment income and the value of our investment portfolio.

The COVID-19 pandemic is developing rapidly. We believe COVID-19’s adverse impact on our businesses, operating results, cash flows and/or financial condition primarily will be driven by the severity and duration of the pandemic, the pandemic’s impact on the U.S. and global economies and the timing, scope and effectiveness of federal, state and local governmental responses to the pandemic. Those primary drivers are beyond our knowledge and control, and as a result, at this time we cannot reasonably estimate the adverse impact COVID-19 will have on our businesses, operating results, cash flows and/or financial condition, but the adverse impact could be material.

Thermo Fisher Scientific Inc (3/26 – Press Release)

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that it has received the CE mark in the European Union for its diagnostic test to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19.

“The CE mark certification is an important step in combatting the outbreak of COVID-19 across Europe,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific“We are committed to fighting this disease and we will continue to work with regulatory authorities and customers around the world to expand the availability of diagnostic testing and stem the spread of the coronavirus.”

 

Baxter International (3/25 – Press Release)

CHF Solutions (Nasdaq: CHFS), a medical device company dedicated to changing the lives of patients suffering from fluid overload, announced the use of its Aquadex therapy in the treatment of patients infected with the coronavirus COVID-19.

In the last week, critically ill patients in New York City and the state of Georgia, who have been infected with COVID-19, have been treated for volume overload using the Aquadex system.  CHF Solutions expects increased demand for this ultrafiltration therapy as the rate of affected patients that are infected with COVID-19 is likely to increase.

The World Health Organization (WHO) recently released a protocol for treating patients infected with COVID-19, highlighting the need for effective fluid management treatment strategies when caring for the critical patient population because the risk of volume overload is very high.

Bristol-Myers Squibb Co  (3/25 – 8K)

Bristol Myers Squibb is diligently monitoring manufacturing and supply facilities across the globe. At this time, the Company does not anticipate disruptions to the supply of our medicines for patients due to COVID-19.
All of our internal manufacturing facilities are operating as usual, along with our key contract manufacturers.
We continue to hold an adequate amount of safety stock and are at an appropriate level based on anticipated needs.
At this time, we are not seeing disruptions to our ability to supply medicines to our customers and patients. Logistics considerations have been increasingly complex due COVID-19, however, operational plans have been in place and are successfully mitigating these challenges.

Iqvia Holdings Inc  (3/24 – Press Release)

 Q2 Solutions, a leading clinical trial laboratory services organization resulting from an IQVIA and Quest Diagnostics joint venture, today announced its collaboration with the University of Texas Medical Branch (UTMB) to develop a novel assay for COVID-19 (SARS-CoV-2) tests, an essential tool for rapid development of a Coronavirus vaccine. Once a viable assay is developed, Q2 Solutions labs will produce it for use in clinical trials to determine the effectiveness of a COVID-19 vaccine.

An assay is an analysis done to determine the biological or pharmacological potency of a drug. Compared with the conventional plaque-based neutralizing assay, UTMB’s novel reporter COVID-19-based test may provide several potential advantages, including increased sensitivity and dramatic increase in assay throughput because the assay time is shifted from multiple days to a single day.

 

Cepheid Inc  (3/23 – Press Release)

The US Food & Drug Administration (FDA) has granted Emergency Use Authorisation (EUA) to United States-based Cepheid’s Xpert Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus causing COVID-19, it was reported on Saturday.

The test is intended to operate on any of the company’s more than 23,000 automated GeneXpert Systems worldwide, with a detection time of around 45 minutes.

 

Humana Inc  (3/23 – 424B5)

The spread of COVID-19, or actions taken to mitigate this spread, could have material and adverse effects on our ability to operate effectively, including as a result of the complete or partial closure of facilities or labor shortages. Disruptions in public and private infrastructure, including communications, financial services and supply chains, could materially and adversely disrupt our normal business operations. We have transitioned a significant subset of our employee population to a remote work environment in an effort to mitigate the spread of COVID-19, as have a number of our third-party service providers, which may exacerbate certain risks to our business, including an increased demand for information technology resources, increased risk of phishing and other cybersecurity attacks, and increased risk of unauthorized dissemination of sensitive personal information or proprietary or confidential information about us or our members or other third-parties. The outbreak of COVID-19 has severely impacted global economic activity, including the businesses of some of our commercial customers, and caused significant volatility and negative pressure in the financial markets. In addition to disrupting our operations, these developments may adversely affect the timing of commercial customer premium collections and corresponding claim payments as well as the value of our investment portfolio.

The rapid development and fluidity of this situation precludes any prediction as to the ultimate adverse impact to us of COVID-19. We are continuing to monitor the spread of COVID-19 and related risks.

 

Thermo Fisher Scientific (3/23 – 8K)

We are subject to risks associated with public health crises and epidemics/pandemics, such as the novel strain of coronavirus that recently originated in China.

Our global operations expose us to risks associated with public health crises and epidemics/pandemics, such as the novel strain of coronavirus that recently originated in China (COVID-19) and has spread globally. In recent weeks, the continued spread has led to disruption and volatility in the global capital markets, which increases the cost of, and adversely impacts access to, capital and increases economic uncertainty. It is likely that the pandemic will cause an economic slowdown of potentially extended duration, and it is possible that it could cause a global recession.

COVID-19 is having, and will continue to have, an adverse impact on our operations, supply chains and distribution systems, including as a result of impacts associated with preventive and precautionary measures that we, other businesses and governments are taking. Due to these impacts and measures, we have experienced, and will continue to experience, significant and unpredictable reductions or increases in demand for certain of our products. Many employers in the United States and Europe are requiring their employees to work from home or not go into their offices. If the pandemic continues and conditions worsen, we will experience a decline in sales activities and customer orders, and it remains uncertain what impact these declines will have on future sales and customer orders once conditions begin to improve. In addition to existing travel restrictions, countries may continue to close borders, impose prolonged quarantines, and further restrict travel, which would significantly impact our ability to support our sites and customers in those locations and the ability of our employees to get to their places of work to produce products, or significantly hamper our products from moving through the supply chain. As a result, given the rapid and evolving nature of the virus, COVID-19 will negatively affect our revenue growth, and it is uncertain how materially COVID-19 will affect our global operations generally if these impacts persist or worsen over an extended period of time. Any of these impacts would have an adverse effect on our business, financial condition and results of operations, and at this point, the extent of the impact of COVID-19 remains uncertain.

 

Johnson & Johnson (3/20- Press Release)

Q: The Covid-19 outbreak is impacting supply chains around the world. Has Johnson & Johnson been affected by any supply chain disruption?

A: Covid-19 is a very dynamic situation, but thanks to the hard work and dedication of our supply chain teams around the world, as of today we have sufficient inventory for patient needs and are working diligently to minimize impact.

We are also monitoring closely both our supply levels and product demand in order to ensure adequate and effective distribution of our products and services.

Q: What steps is the company’s supply chain taking during this Covid-19 pandemic?

A: Most critical is having robust business continuity plans in place across our global supply chain network to prepare for unforeseen events and to meet the needs of the patients, customers and consumers who depend on our products.

These steps include maintaining key inventory at major distribution centers away from high-risk areas and working with external suppliers to support our preparedness plans.

Q: How have similar crises in the past helped prepare the Johnson & Johnson supply chain for Covid-19?

A:Unfortunately, this is not the first time we have needed to mobilize quickly in response to a crisis. It’s part of our 134-year heritage to step forward to help where we can.

 

UnitedHealthcare (3/18 – Press Release)

UnitedHealthcare announced today several updates that provide people and families expanded access to the care, support and resources they need to navigate through this unprecedented time. These actions will expand access to testing and medical care, medication, telehealth services and virtual care including rollout of an innovative, personalized digital platform which includes a symptom checker to help members rapidly assess their risk for COVID-19. The company is also expanding its efforts to engage those people with the highest risk of contracting serious illness.

“In response to COVID-19 we are taking actions to support our members by significantly expanding access to our telehealth, virtual care and digital capabilities for patients and their health care practitioners,” said Dirk McMahon, CEO of UnitedHealthcare.

 

Regeneron Pharmaceuticals Inc (3/18 – Press Release)

Biotechnology company Regeneron Pharmaceuticals Inc (NASDAQ:REGN) stated on Tuesday that it has started a clinical programme to evaluate Kevzara (sarilumab) in patients hospitalized with severe COVID-19 infection in partnership with Sanofi.

According to the company, Kevzara is a fully-human monoclonal antibody that inhibits the interleukin-6 (IL-6) pathway by binding and blocking the IL-6 receptor. IL-6 may play a role in driving the overactive inflammatory response in the lungs of patients who are critically ill with COVID-19. It is being investigated for its ability to reduce the overactive inflammatory immune response associated with COVID-19.

The company added that IL-6 is supported by preliminary data from a single-arm study in China using another IL-6 receptor antibody.

This US based trial will begin at medical centres in New York, one of the epicenters of the US COVID-19 outbreak and will assess the safety and efficacy of adding Kevzara to usual supportive care, compared to supportive care plus placebo. The multi-centre, double-blind, Phase 2/3 trial has an adaptive design with two parts and is anticipated to enroll up to 400 patients.

In conjunction, the first part will recruit patients with severe COVID-19 infection across 16 US sites to evaluate the impact of Kevzara on fever and patients’ need for supplemental oxygen.

 

Laboratory Corp of America (3/17 – Press Release)

Today, the U.S. Food and Drug Administration took two additional significant diagnostic actions during the coronavirus outbreak (COVID-19) by issuing Emergency Use Authorizations (EUAs) to: Hologic for its Panther Fusion SARS-COV-2 Assay, and Laboratory Corporation of America (LabCorp) for its COVID-19 RT-PCR test.

‘Staff at FDA have been working nonstop to expedite the review and authorization of diagnostics during this public health emergency,’ said FDA Commissioner Stephen M. Hahn, M.D. ‘Our device center has been in continual contact with the medical device community, in particular diagnostic developers, since January-providing technical assistance to test developers to help facilitate the availability and distribution of tests so that health care professionals can accurately detect the COVID-19 virus.

 

Vifor Pharma (3/12 – Full-Year Earnings Call)

Question – Emily Field: Yes. And then I know you did mention coronavirus in your prepared remarks. But just — it’s just — and I know you don’t run the dialysis clinics. But just if you would — could just give us any guidance on whether there’s a proper safety procedures in place for all the employees and patients there? Obviously, these are (inaudible) necessary procedures. So one would expect that those are not going to be deferred regardless of how the situation plays out. But just any color there would be helpful.

Answer – Colin Bond: Well, I’ll talk just on the operations, liquidity, FX impact, and then Stefan will talk about the employees. So in terms of the FX impact, first of all, that’s the one that is possible to quantify with the weakening of the dollar and the euro against the Swiss franc. If, and that’s a big if, if the Swiss franc was to stay as strong as it is today against — against the dollar and the euro, that would have an impact of approximately 2% on our top line.

But the like-for-like currency is within our guidance. And then at the EBITDA level, because we do a really nice job of rolling hedging, the EBITDA impact negative would be up to CHF 15 million. But again, that’s if the Swiss franc stayed as strong as it is today for the rest of the year.

In terms of our liquidity, you can clearly see that we are cash positive, net of debt, we have undrawn credit facilities.

In addition to that, none of our debt is repayable until 2022 when the bond is repayable.

So in the short term, we have all the liquidity and financing we need. And we’re going to be very cash positive from the operations in 2020. So we — in terms of the operational — operations, we review this on a daily basis.

We have at least a year of inventory for all of our key products for Ferinject nearly 2 years of inventory. And in all markets, we have approximately 2 months of inventory as a minimum available. And we’re in daily contact with all our carriers and distributors. So we’re doing a really nice job of monitoring the situation, and we feel well prepared to respond to anything that happens. On the employee side, I’ll pass over to Stefan.

Answer – Stefan Schulze: Yes, Emily, it’s Stefan again. I thought you were asking about the procedures with regards to dialysis clinics. If I understand the question correctly, in that sense, I would refer to FMC really. Of course, dialysis providers are used to deal with the problem of patients having infections and they have respective procedures in place.

To the extent, it was referring to our own employees, then we are probably mirroring what many other companies do. We have a management crisis team in place, and we provide our employees the opportunity more and more to work from home across the European affiliates and beyond. So we take all the same measures, as you would expect from a company which tries to slip up to the corporate responsibility.



UnitedHealth Group (3/12 – Barclays Global Health Conference)

Question – Steven James Valiquette: Okay. Great. Yes, that’s helpful. And then from a health care payer perspective, a few other managed care companies at our conference would seem to suggest that investors could potentially just think of coronavirus as an extension of a flu season, which you just kind of touched on a little bit, and that if it did proliferate into next year or next year’s season, these other managed care companies could just reprice for that across some or most of their product lines. So I guess I’m curious whether you share that view conceptually or would you characterize it differently?

Answer – Dirk C. McMahon: Yes. This is Dirk McMahon again. Thanks, Steve. What I would say is, first of all, the main thing as far as coronavirus is, as Doc described, you don’t have a good feel on the penetration rate or the spread rates. So without knowing that, it’s a little bit difficult to handicap. What I can tell you is during a normal flu season, we’ll — and that would be normally from the fourth quarter of 1 year to the first quarter of the next, that 6-month time frame, typically, we would have about $450 million in a normal flu spend over that 6-month period of time. And that’s — we would, of course, price for that, and we plan on that every year. But again, our ability to sort of handicap what’s happening with the coronavirus versus a normal flu season, at this stage, we don’t have enough data to be able to make that determination.



Johnson & Johnson (3/11 – Barclays Health Conference)

Answer – Ciro Roemer: Well, Kristen, thank you for having us. It’s a pleasure for us to be here and represent Johnson & Johnson.

I would say, first of all, Johnson & Johnson being the global health care leader it is, is closely monitoring the coronavirus situation. And we’re trying to take steps to prevent, first of all, help the spread of the virus as well as exploring the potential for a vaccine. I think you know that we have a division in our pharm organization that is very much involved with vaccines in regards to Ebola but also now with the COVID virus.

We understand that the impact of the coronavirus, certainly it’s a devastating health issue. We remind ourselves of our credo, and that’s what’s guiding us at the moment. Just for context, we have provided over 1 million surgical masks across the world. We’re very actively involved with our consumer department, providing enough medicines. I think we donated 11,000 cases of MOTRIN; 50,000 bottles of BAND-AID; alcohol. We’re donating generators and other medical devices to hospitals. And certainly, we have activated our global team of scientists to work on a vaccine and other solutions.

As you can imagine, we’re closely monitoring the coronavirus situation of — an area of impact and interest certainly for you all is manufacturing. Our manufacturing centers are producing medical and pharmaceutical products as we speak. Also in China, to a large extent, we’re back online and producing products. Of course, we’re in close alignment with the Chinese government to ensure that we can continue to provide and supply critical products to our customers.

The impact that we are seeing is more on elective procedures. As you can imagine, in China, Japan and South Korea, the impact has been meaningful. Those procedures are starting to come back online. But I would say they’re not back to historic levels. We’re starting to see a similar trend in certain parts of Europe. And in the U.S., I would say we’re in the early innings of this whole event evolving. We’re — it’s a fluid situation, I would say. We’re closely monitoring it. I think what I can share is that many institutions have told their surgeons and their medical personnel not to travel. I don’t know if you’re aware, but the AAOS made the decision yesterday to cancel their meeting in Orlando. That’s the most important orthopedics congress that happens every year, around 17,000 health care providers join that congress. It’s canceled. It was going to be held at the end of the month. So that’s not going to continue. We expect that large meetings, certainly in March and April, will have a tendency to be canceled.



AmerisourceBergen (3/10 – Barclays Health Conference)

Question – Steven James Valiquette: So let me — just give me 2 seconds here to shift gears. Obviously, coronavirus, major topic around this conference. So we’ll certainly kick off with a few questions around that. And yes, so the shutdown in China, and there’s also been some restrictions from India and a few drugs has created some concerns for investors that drug shortages could occur just due to API shortages. So let’s just start maybe curious to see what you’re seeing and hearing in relation to this? And also, does ABC typically stockpile inventory of certain drugs in these types of situations? I guess we’ll just start there.

Answer – Steven H. Collis: Steve, thank you. And obviously, the coronavirus has had an effect because we would much rather be doing this in person with you and seeing all of our investors and other parties that have an interest in ABC and not having this annoying train in the background, would also be an advantage. But as you would expect, as a responsible company, we’ve been actively monitoring COVID-19 since the outbreak in Wuhan, literally from December when we first got reports of it. Obviously, that’s an important area for chemical and API manufacturing, and we are in constant communication with our manufacture partners. And we have those sort of bilateral relationships and the concern for the mutual customer, the provider customers and ultimately, the patients we serve to plan and analyze to ensure sustainability of supply. So we are monitoring this very fluid situation and trying to be as proactive as we can to make the necessary preparations and investments to prepare for a disruption if one would occur. So as an active participant — ABC is an active participant in the pharmaceutical supply chain. We’re constantly monitoring the situation, and we will continue to work closely to ensure a stable supply chain.

Answer – Steven H. Collis: Yes. I mean, as you correctly say, we can’t say too much. I would say that this crisis, the coronavirus crisis, actually highlights a lot of what we’ve been saying, how important it is for us to be very strong financial companies and to have strong cash flow ability to invest in our business and to continue to grow our business and our relationship with our customers and our relationships with manufacturers. As I said on the earnings call, we are ready and prepared for the upcoming trials, but we also believe that the global settlement framework that we’ve outlined makes a lot of sense for states, governments, the attorney generals, the patients that will ultimately benefit. And we are committed to resolving this because we just frankly think that it’s not productive to continue with litigation. So we remain committed to transparency. And of course, any definitive developments that occur, we will update our shareholders in an appropriate manner.



Humana (3/10 – Barclays Health Conference)

Question – Steven James Valiquette: Okay. All right. And somewhat tied into that, don’t know if you’re able to comment on this or not, but just given your comment on the last quarterly results about 1Q 2020 earnings representing about 24% of full year earnings and recognizing that you’ve already factored in flu seasonality and then so far coronavirus not really changing much, should we assume there’s no incremental impact as far as 1Q ’20? And that guidance you gave around 24% of full year earnings, that still holds the way, the way you see things right now?

Answer – Brian Andrew Kane: Yes, I would say that holds, and we reaffirmed guidance last night or 2 nights ago, whatever, just to that effect. So yes.

Question – Steven James Valiquette: Okay. Great. Okay. Before I dive into a few other parts of the business, I did have one other question I forgot to ask around coronavirus, and that’s really just the concept of having any sort of reinsurance coverage for pandemics, et cetera. Just curious if that’s something that — has that been triggered any time in recent history that you can think of?

And if we also had to compare coronavirus to any of the other virus type situations, whether it’s SARS, MERS, Ebola, you name it, is there any of those that you would say the pulse is parallel to what’s happening this year? So I’m curious to get your thoughts around both those subjects on coronavirus.

Answer – Brian Andrew Kane: I think — yes, I think on the second one, it’s really hard to compare. We just don’t know enough yet, I mean, what the incidence rate is, how prevalent it is, what the mortality rate is, because a lot of it’s unreported still. So I think we got to withhold judgment on that comparing it to other viruses that we’ve seen.

I think with respect to reinsurance, again, I think it’s too early to tell. I think, honestly, it will depend on how severe it is. Other than that, other industries are probably higher on the pecking order than we would be, but I don’t know. We haven’t had those conversations. I think it will depend on how severe the challenge is.

Certainly, people who are unsured, I think, will get — are most likely to get the coverage on this topic. And then industries that are perhaps more systemic in nature that could really impact the economy like airlines, et cetera, might get something. But it’s hard to say on whether the insurance — the health insurance industry would get you reinsurance for an extreme outbreak. I don’t know the answer to that. We’d obviously be supportive of that, but it’s hard to say whether that would come forward.



Eli Lilly Co (3/10
– Barclays Global Health Conference)

Answer – Jeffrey Emmick: This is Jeff. I’ll comment briefly on that. Obviously, we have a pretty significant work stream across the company that’s evaluating the effect of COVID-19 on all of our clinical development programs. To date, most of the impact has been, when it comes to clinical development, has been in China, but that may continue to evolve.

Right now, I can speak at least to tirzepatide. We haven’t had a significant impact on our tirzepatide development program to date. Our China registration program is actually a separate trial being done in China and several other countries across Asia. But we continue to monitor this very closely. Obviously, there’s always the risk of patients actually in the trials having — or coming down with coronavirus. We do have a lot of high-risk patients so we’re monitoring it very closely. But I think we’ve got the right resources around this.

There are opportunities for us to — we’re allowed to get study drug to patients even if they can’t come into the office, for example, and I will be working closely with regulators as well on addressing any gaps in data or patient visits, et cetera. But we feel pretty confident that we’ve got a solid plan around continuity when it comes to clinical trial operations.

 

Quest Diagnostics (3/10 – Barclays Global Health Conference) 

Question – Jack Meehan: Just wanted to start, Mark, with the here and now obviously, the topic de jure has been the coronavirus. I was curious if you could weigh-in just how you expect this to impact the business and demand for testing services and have you seen any increased testing rates so far related to the new test?

Answer – Mark J. Guinan: Right. Thanks for the question, Jack, and pleasure to be on the phone here. What we’ve shared publicly is that we started yesterday with specimens collected yesterday in California, at our Esoteric Lab in San Juan Capistrano, we’ll be ramping up capacity. There’s a validation process across multiple pieces of equipment and then across multiple sites. It’s going to take us several weeks to maximize our capacity through that validation process across the 2 Esoteric sites and then some — we do have some of that equipment, we’re using in some of our regional labs, and Steve shared yesterday in an interview that within several weeks, we expect to be able to do several tens of thousands of tests a week.

Now we’re all speculating. So I have no idea what demand will be. But based on the discussion that took place in D.C. last week with the Vice President — or with Secretary Azar, the sense is that the demand could far outweigh capacity even with us and our — the international lab and multiple regionals and hospitals all ramping up as quickly as possible that it is a race to increase capacity. So we’re not in any way, sizing this, and saying, we think we’re going to get x, and therefore, we’re only going to create so much capacity. We’re going to create as much capacity as we possibly can as quickly as we can. And then, obviously, monitor the incidence rate and see if we need to slow that down, but we’re not at all being cautious.

The next phase, Jack, would be likely, there are several IVD manufacturers who have suggested they have some kits that would be available as well. We’re probably a couple of weeks away from those. If that ends up being accepted and validated, then the next step of capacity would be acquiring some of those kits in addition to the laboratory-developed tests that we’ve already put up and got approval for it through emergency use.

So that’s kind of where we’re at. We’ve shared a couple of instances already where we can’t size this. We’re not going to predict how much testing we’re going to ultimately do. It’s unpredictable. And that we do think there is potential for an offset on utilization because society seems to be changing behavior around certain things. We’re not having this conference in personThat’s a prime example.

And so one could imagine that some people might choose to engage less with the health care in structure for concerns around catching something in the office and the waiting room from the doctor, et cetera. We don’t know. And we’ve already had a couple of investor 101s this morning. I’ve been asked certainly, we don’t share mid-quarter updates. However, if there was anything material that we’ve seen a change in our business, we’d feel obligated to share something. And again, we don’t know. So one thing you might think about is our average patient counter, which is our acquisition is the mid-$40 range. Certainly, the coronavirus reimbursement should at least cover that, if not be a little higher. And so you’d say a one-for-one swap would be about even, but we don’t know how many people is going to be one-for-one and office visits replaced for a corona visit. And then the other question is mix. If people who don’t engage are skewed toward healthy annual wellness check. Certainly, we do a lot of tests in those — the whole battery of chemistries and lipids and blood count and so on, how our seniors are going to react. Seniors consume more of our business. So are they going to be more or less likely to go the doctor, one camp can say, “Hey, for the smallest sniffle, they may rush in because, obviously, I want to get — seriously, I only want to get in-treatment quickly.” And the other thing is they’re the mostly at risk. So therefore, maybe they’re going to mills cautious. We don’t know. So all we can share is some of our thinking, but we can’t quantify any at this point. We just want to acknowledge that. Like other industries, we think that there could be some potential for negative impact to our business if people change their behaviors. However, unlike many other industries, we also will do some testing specifically related to corona.


Teleflex (3/10 – Barclays Global Health Conference)

Question – Kristen Marie Stewart: Obviously — yes. Obviously, the big topic all around here has been coronavirus, the reason why we are virtual today. You’ve said that basically, the amount that you included within your guidance thus far has been a $5 million to $10 million impact. I was wondering if you could kind of talk with us just about any updated forecast you may or may not have? Or just kind of thinking, as you’ve seen the virus spread through different geographies, just how you’re thinking about that today?

Answer – Liam J. Kelly: Yes, thank you. So you’re correct. Yes, we have $5 million to $10 million in revenue in Q1 and an impact of $0.05 to $0.10 associated with the coronavirus. That is based on what we saw when we gave our guidance for the year, and it’s included in our guidance. And it was really the impact that we saw in China. The lower end of that range would have been if China get back to normal in early March. The upper end of that range is contemplated that China gets back to normal in April. Now what we are seeing on the ground, we have 1 small manufacturing plant in China, that has been up and running now for about 10 days and running pretty well. Our office got back to a pretty normal working conditions over a week ago. So yesterday week, our people went back to work in the office. And 2 weeks ago, the individuals that had left Shanghai — so 2.5 weeks ago, in a population of 20 million people, there were only 10 million people living in Shanghai. Two weekends ago, all of those individuals returned. So now there’s 19 million people. Obviously, Hubei is still in lockdown. So the travel was restricted there. But our people tell us that things are slowly starting to get back to normal in Shanghai, which is probably a good indicator for at least the Eastern seaboard, where most of our products are sold and our expectation is that as we go through the month of March that Shanghai, Beijing and large cities like that will get back to some semblance of normality.

 

Cardinal Health (3/10 – Barclays Global Health Conference)

Question – Steven James Valiquette: Okay. Great. And also thanks for your flexibility around this whole coronavirus situation. And speaking to that and also to dive right into that, certainly, it’s top of mind for a lot of investors, so a few questions around that as it relates to the pharmaceutical supply channel. First of all, the shutdown in China has created some concerns that drug shortages could occur just due to API and bulk material constraints. Just curious if you guys were able to discuss what you’re seeing right now in relation to that. And also, I mean, in these situations, when Cardinal and drug distributors perhaps try to stockpile some inventory of key drugs, that you’re anticipating some shortages. So let’s just start around that dynamic first.

Answer – David C. Evans: Well, Steve, thanks for having me on the phone, and thanks to everyone joining us. Yes. The coronavirus definitely had its impact across many different ways. One thing I do want to make sure I start with, just because I think it’s really important for everybody to know, is besides focusing specifically on our M and P segments related to the impacts of it, we also, as a company, have been working on this now for over a month.

As it relates to our own business continuity, with each one of our distribution centers, manufacturing centers and our headquarters to make sure that we have backup systems in place, testing, working at home, backup players to be able to make it into our distribution centers because we have a higher standard of requirement to make sure that our customers get drugs or medical supply. So I just want to make sure to let everybody know that we’re not only looking at our products that we sell but our own people, safety of them and making sure we can get products specifically to our customers.

As far as on the P segment and the tie-in to the coronavirus, we do — we had anticipated this a while back. So when we first saw it in China, our Red Oak team immediately began looking through our database to see where we either had finished those, which are very little coming from China, but more importantly, where there’s any raw materials coming from, in particular, the Wuhan province, where was ground zero for this.

There are some raw materials at a nearby province. So knowing that, we did stock up on some extra inventory on key products that had raw materials coming from that area very early on to make sure that we understood that we — what was going on, that we could have some extra. We’ve done this as it’s moved around the world. We constantly use our database to understand if we’re going to have any finished good or raw material problems with any of the pharmaceutical items.

So we looked in Italy, when it began in Italy, et cetera, and we continued to adjust our inventory where we can get extra product to stock up to make sure that we’re staying ahead of it.

The good news is, through our conversations, and I’ve had a few myself directly, most of the manufacturers are carrying a few months’ worth of inventory on handSo I feel like, at least for the next few months, we should be fine to be able to get the majority of items that we need. Now if this were to extend past early summer, then I think everyone’s going to be looking at some potential supply disruptions not only because of the API materials, but — one of the other piece that’s harder to track because there’s so many of them is key starting materials or KSMs, so the items that go into the manufacturing of the API. Some of those are — have some potential disruptions, and so some of the suppliers, again, are keeping their eyes on those, but tell us so far that they hold several months of APIs and finished dose stock and KSMs and we should — that we should be okay for a few months.

Question – Steven James Valiquette: Okay. Great. Now at the same time, where there’s some risk of API shortages, there’s also some price increases happening on API. And I know from tracking that side of the industry, prior times in my career, I can almost guarantee it’d probably be in pass-through by a lot of the finished dose drug manufacturers as well, whether it’s brand or generic, but probably more on the generic side.

So I guess, I’m curious how is that being factored into the company’s view on the generic market and spot prices within the market? And if there is generic inflation, I’m curious if you’re seeing that, and that would obviously help to offset — I mean, that’d be a positive for a drug wholesaler, would help to offset some of the risk of volume shortages. Just curious how you’re viewing on the pricing side.

Answer – Michael C. Kaufmann: Yes. It’s a good question. I would say, so far, we’ve not seen any material price increases that I would say are related to the coronavirus yet. There are manufacturers that are starting to see some price increases on API. And as you know, we’ve talked about this in the past. Our goal for Red Oak is to never take any price increases. So we’re always going to fight aggressively to make sure that we’re getting after the low cost. Now there are times when you sometimes do take them if it’s the right thing for ourselves and the supplier. And when we do, we are typically able to pass those price increases through to our customers, and the goal there being to maintain our sale margin per unit.


Laboratory
Corporation of America Holdings (3/10 – Barclays Global Health Conference)

Question – Jack Meehan: 
Great way to start. I wanted to focus on kind of the here and now, the topic de jure is, obviously, the coronavirus. I was wondering if you could give us an update on how you expect the outbreak to impact the testing rates in your Diagnostics segment. And then just remind us of the operational exposure within Covance.

Answer – Adam H. Schechter: Sure. So first, I’ll start off again by saying, I couldn’t be more proud of the LabCorp team, particularly our scientists and our operations teams that have been able to get a test up and running in the marketplace for the novel coronavirus. And we started to take orders and receive samples, Thursday, 6:00 p.m. of last week, and that continued through the weekend and through yesterday. And we believe that we will continue to do everything we can to build up our capacity as we move forward.

In terms of impact, as I mentioned on the fourth quarter call, we believe that the range that we’ve given for guidance will cover what we currently believe the impact would be from the coronavirusSo there will be some pushes and pulls. We give annual guidance, we don’t give quarterly guidance. But I do believe that there will be some things within the quarter that may occur, particularly when you think about our central lab in China, for example, where we had quite a backlog as China took an extended holiday through the New Year’s, and therefore, that laboratory had a backlog. We’re trying to work through that backlog. People are back to work in the laboratory. But whether that happens in the first quarter or second quarter is yet to be determined.

In addition to that, in some of Asia, but also in certain parts of Europe, we’ve seen clinical trial enrollment slowed down for a period of time. And we still have to wait to see the impact of that as we continue to see the coronavirus in other countries in the world, but we do believe that there may be some impact thereIf you look at the diagnostic testing that we do in the United States, we haven’t seen any significant impact of the number of tests or type of tests as we sit here today. But of course, we’ll be watching that very closely. And when you start to think about people going in for wellness exams, for example, we’re going to adopt this for routine testing. That might slow down a bit even as we see coronavirus testing go up a bit in the diagnostic area in the United States.


Centene Corp (3/10 – Barclays Global Health
Conference

Question – Steven James Valiquette: All right. Great. So since coronavirus is certainly top of mind for probably most investors right now, let’s start with a couple of questions related to that.

Last week on your conference call, you guys sort of articulated, there has not really been any big uptake in utilization at the time as a result of coronavirus, and it was essentially business as usual, I think, was the — like the general phrasing.

But the world is kind of evolving pretty rapidly here day by day. And I think as people in many parts of the U.S. now are focusing on, let’s call it, personal conservatism. I’m curious if you’re seeing any signs that maybe there’s less utilization of the U.S. health care system overall? Maybe we’ll just start high level there.

Answer – Edmund E. Kroll: Well, it’s still early, Steve, I know you know that. And we’re still in a process of — we’re ready, we’re reaching out to the various constituencies. I think as we said last week, we feel like we’re well positioned for a situation like this, given the local approach that Centene has always had to managing populations in the markets we participate in. So I would say, again, prefacing it by saying, it’s still early. We haven’t seen a change from the comments we made last week on the March 4 call, where we did the 2020 guidance. And we — I’ll just throw a couple of the other data points out there that we highlighted last week on this topic.

Greater than 80% of the cases that have been out there so far on the coronavirus are mild. And as far as populations go, the older ones seem to be the more vulnerable at Centene, which includes WellCare. We’ve got 94% of our combined population — patient — membership population, 94% younger than 70 years of age and 45% is less than 20, given our big participation, #1 market share in Medicaid, especially the TANF and the CHIP populations.

Varian Medical Systems (3/9 – Conference Call)

Thank you, Anshul, and thank you all for joining us. Today, we announced that the COVID-19 outbreak will negatively impact our operating results.

Across the company’s Asia Pacific geographies, health care resources are being prioritized for the treatment and management of the outbreak. Consequently, we are experiencing delays in hardware and software installations and acceptance as well as in delivery of interventional oncology procedures. While no orders have been canceled, we expect revenues to be negatively impacted. And as of today, estimate second quarter of fiscal 2020 revenues to be in the range of $800 million to $825 million. While uncertainty remains around the duration, severity and geographic scope of the COVID-19 outbreak, we preliminarily estimate 7% to 9% revenue growth for fiscal year 2020.

 

Regeneron Pharmaceuticals (3/6 – J.P. Morgan Biotech Conference Call)

Question – Cory William Kasimov: All right. Thanks, Matt. So we didn’t intend to ask many questions beyond IO with regard to the pipeline on this call, but just given the circumstances, everything that’s happening in the world, I did want to ask you on COVID-19. And maybe if you could just remind us what Regeneron is doing on this front? And when we could potentially hear more about your efforts?

Answer – Justin Holko: Sure. Thanks, Cory. We — as you can imagine, we do have a lot that we are doing in this space. Just to rewind a little bit, we do have a proven track record as it pertains to responding to these outbreaks of infectious disease. Back in 2012, we responded to the call with MERS. We most recently spoke about the fact that we have what looks to be a potentially curative cocktail against Ebola that was found to be superior to other therapies and that readout in last August. And so you can imagine that the team here is very much focused on this as it pertains to the new — the COVID-19, SARS-CoV-2 outbreak.

 

Cooper (3/5 – Q1 2020 Earnings Call)

 Having said that, Asia Pac is already rebounding, and we expect growth in Q2, even in the face of the coronavirus…  Our business in China is relatively small, only roughly 2.5% of our revenues, and we have no manufacturing or packaging located in the country. So that’s obviously helped.

We have been able to maintain or supply of product in China, which is sold through third-party distributors. So the impact has largely been around the parts of our business that sell into hospitals. That being fertility and our specialty lens business.

We’re also seeing a modest impact in other countries where there’s heightened virus activity, but our businesses are proving to be relatively resistant. At this point, we’re estimating the total revenue impact in Q2 will be roughly $15 million, comprised of $11 million in CooperVision and $4 million in CooperSurgical. I believe we’ll likely claw some of this back as we move through the year, but we’re not including that in guidance. Having said that, we’re holding our full year revenue guidance unchanged, driven by the improved MyDay production and new contracts we’ve won in our fertility business, which we expect to generate higher sales in Q3 and Q4.

Underlying all this is the assumption, our global operations largely returning normal in May, the beginning of our fiscal third quarter. Brian will provide additional numbers, but our expectations for a strong year remain intact.

 

Merck (3/5 – KGaA Full Year 2019 Earnings Call)

We are looking into more or less applicable historical models of other crisis. We have determined that these crisis, be it precision, be it the disease threats have an industry-specific impact, which we must take into account that we’re now sharing with you a scenario, which we have developed in mid-February on this Slide 26.

Under this scenario, we assume that the COVID-19 outbreak peaks in Q1, eases in Q2 and that the situation is sort of back to normal in the second half of the year. In total, this scenario translates into a drag on our full year sales of around 1%, mainly coming from China and mainly occurring in Q1. And this is already reflected in our qualitative outlook for 2020. However, should the effect be significantly more pronounced or should the crisis result in a global recession, please note that this guidance would need to be adjusted, and we can probably go into more detail during the discussion?

 

Align Technology (3/4 – M&A Conference Call)

Question – Kevin Caliendo: I just wanted to go back to the reiteration of the 1Q guidance because I think it’s a relief to a lot of investors that you’re able to do that. And as you mentioned in the context from when you gave guidance, you’re really the first company to talk about the impact of COVID-19. It would imply if things got worse in Japan, things got worse in Korea, these are key markets for you. Things certainly went from 0 to bad in Italy, another market you’ve called out as being an important growth driver. Are we to assume that either China wasn’t as bad as maybe what you originally thought? Or is it just there’s strength in other markets that have been able to offset what we would anticipate being sort of less than what you might have guided for in some of those other countries?

Answer – Joseph M. Hogan: Hey, Kevin, it’s Joe. Look, we wanted to give you that guidance because we knew that would be top of your mind right now because we were first in, and then we had to take our best estimate in the sense of where we are. And we’re really confident in what we told you. As it stands today and what we see, we hold with our first quarter guidance. I don’t want to do any more granularity right now about where it’s coming from and how it’s going on or how we call China or whatever because it’s just an incredibly fluid situation. So please just take our forecast for what it is and the confidence we have behind it. And we’ll certainly update you as soon as the quarter closes.

 

Veeva (3/4 – Morgan Stanley TMT Conference)

Answer – Stan Zlotsky: Got it. And maybe just stepping back a little bit. We’re asking all our companies at the conference this year in light of everything that’s happening out there in the world and coronavirus really in the headlines, how does it affect Veeva? And not even Veeva specifically, maybe even just the industry that you serve more broadly.

Answer – Peter P. Gassner: For the industry we serve, it’s a busy time and it’s a time of change. There’s — they do a lot of collaboration around the world. Some of them are fine-tuned already to do that in a virtual way, such as Veeva. Some are less so. And with the — some of them are decreasing travel, and so they’re having to get better about doing virtual communications. We’re helping many of our customers by providing Engage Meeting, one of our products for the pharmaceutical companies to engage remotely with health care providers. We’re providing that free of charge until September, and that’s helping some of our customers.

We have certainly some customers that are working on treatments and vaccines for the COVID-19 virus. So they’re certainly very busy. And I felt — I read that this morning, Moderna, one of our customers, actually introduced the first candidate for a vaccine. So they’re very busy.

For us, for Veeva, we’ve operated in a virtual way quite well for many years here. We just embrace the virtual technology. We haven’t seen projects canceled. We’ve seen some delays in some projects, but nothing that would materially affect our financials. So we’re continuing to focus and to be productive and to run virtually in the places where we need to where there’s a serious outbreak.

 

Abbvie (3/4 – Cowen Healthcare Conference)

Question – Stephen Michael Scala: Okay. We’ve been polling the audience here at the conference about the COVID-19 situation. One of the questions we’re asking the audience is whether or not they expect the U.S. to go into a recession or even a depression, and the majority of audience participants have said no recession is expected. But refresh our memory on how the aesthetics business works or has performed in less vibrant economic times.

Answer – Michael E. Severino: Yes. I’ll go ahead and take that. So I think the best model that you can look at or the best analog that you can look at is the Great Recession that occurred, obviously, a little more than 10 years ago now. Now what we saw was a temporary slowdown around the time of that recession, which was obviously quite a significant event, but a very rapid return of that warehouse demand, if you will, to levels that match the trajectory that you would have expected had the preceding growth continued. So we see that it’s a pretty resilient business.

 

Centene (3/3 – Guidance and M&A Conference Call)

Before I turn it to Jeff, I want to say a few words about the novel coronavirus, given that it is a focus of many health officials today in the U.S. as well as globally. Needless to say, we are monitoring the situation closely. The situation is fluid. However, we have not seen any impact on our business thus far. It is too early to make a determination given how quickly this could evolve. We do fully expect it to be manageable. Our focus has been on business continuity programs to ensure we’re able to deliver the high-quality care our recipients have come to expect.

Question – Rivka Regina Goldwasser: I understood that the corona — on the coronavirus, it’s still very early. But as we think about the potential implication, I know that Cuomo said — announced plans to waive all payment for all medical expenses related to testing and emergency department care. So if you can just help us kind of like think through potential implication going forward. Should we see — is this something that states would reimburse you or adjust rates for after the fact? Or how should we be thinking about potential financial impact? And if there’s anything historically like H1N1 outbreak that we can use to draw some parallels.

Answer – Michael Frederic Neidorff: I’ll start, and I have some of our medical people on the line, so they can add to it as necessary from a technical standpoint. We’re viewing this virus at this point in time, we have had a flu season every year and some are milder than others. This one right now has been pretty normal, and it has the potential for being a little more severe. And there’s a lot of anecdotal evidence, not our specific evidence. You have anecdotal evidence where doctors, when they get a call from the patients are saying, “Well, probably — look, it’s like a bad cold. So come in, we’ll give you a prescription as needed.” Because they don’t want to expose a lot more people to it. So we’ve not seen a big uptick as a result of this.

Now there are some requirements by states and others to pay for testing, and that’s normal course of business for us. However in this case, my concern is there aren’t a lot of tests available, it’s undersupplied.

So I mean — so I guess as we look at it, it’s business as usual at this point. We have, in our planning, a flu season sometimes, as I said, it’s greater or lessened. If there were some pandemic or some very severe thing, we do have the opportunity to always go back to states and say, “We think it’s appropriate to consider a rate adjustment because of the severity of something.” So right now, it’s business as usual.

Question – Sarah Elizabeth James: Okay. Can you help us think about the risk of the coronavirus in your Centurion book specifically? So is there a potential for higher spread in that type of environment?

And I’m not sure what the age or acuity in that population is. But if there are any issues, do you guys have reinsurance? Or is that the type of contract where you can go back to the states and renegotiate if possible?

Answer – Michael Frederic Neidorff: I think any of these contracts, we feel very comfortable going back. I mean, when the hep C vaccine came out, and things which were exceptional, we went back to the states. And hep C’s hitting a higher incidence of it in that environment, and a lot of them. So we went back and successfully discussed it. And sometimes, we carve out some of that.

It’s hard to say at this point in time. [This flu’s] — we’ve not seen various incidents where it’s greater in that population, in the population at large. And so it’s the type of thing — I would expect it to be normalized, [it hasn’t been confined]. But a lot of us are confined to our offices and other locations where flu spreads. So it’s very similar, I think, as we think about it.

 

Veeva (3/3 – Q4 2020 Earnings Call)

Question – Hoi-Fung Wong: The first thing I want to touch on, I’m sure everyone is following it in the headlines, but obviously the impact of coronavirus and any headwinds you might be seeing in China. I guess, first, just again, what are you guys maybe directly seeing or projecting? And then second, as it relates to your customer base, how should we think about the impact to their business? Obviously, there’s probably maybe some tailwinds as well there and how that might flow through for you guys.

Answer – Peter P. Gassner: All right. This is Peter. I’ll take that one. First, our hearts go out to the people, the families that are seriously affected by this. And we hope they have a speedy recovery.

As it goes to our customers, they’re really working hard to try to develop things that will help the situation, vaccines or cures, actually for this. And we’re helping our customers where we can, but we know they’re working around the clock.

In terms of our business, we haven’t seen project slowdowns yet. We haven’t seen any projects canceled. We’ve seen a little bit of slowdown as customers adjust to working remotely in some regions, nothing that would be material to our financials.

In terms of Veeva, in the countries that are heavily impacted where we have offices, we’ve instituted a work-from-home policy. Now for Veeva, that’s very normal. We handle video conferencing very well. We grew up as a very virtual company so I believe we’re well positioned to handle this.

One of the things that we’re doing, I mentioned on our script, is helping the industry by providing free Veeva CRM Engage Meeting licenses to our customers up until September. That way, they can continue their interactions with the doctors that they need to and they can do that remotely.

So in summary, our customers are working hard to provide the medicines here. There’s no material impact to our business at this time.

 

Teleflex (3/3 – Raymond James Conference)

So as we see our $5 million to $10 million, it will be at the lower end if things get back to pretty much business as normal in China right about now, in early March. The impact will be $10 million — $5 million and $0.05, $10 million and $0.10 on the EPS if the uncertainty continues in China and procedures don’t get back to normal in — until the end of March, early April. I guess where we’re a little bit insulated is the portfolio that we sell in China and also there is, ironically, a little bit of upside also baked into that $5 million to $10 million, where we would envision that some of our CVC coated catheters would get used as some of these patients would get admitted into the intensive care unit because of the condition. And I think that once people return to work, which from our intel, at least, is happening right about now, one would imagine that the procedures would then start flowing through the hospitals. Again, I’m — at least by the end of the month, we’d get back to business as usual. Now the virus has gone beyond the shores of China, as we all know, and is now having some impact in South Korea and Italy. And I think that it is tragic, and I’m not trying to take away from the tragic nature of it, and it is quite infectious, but I would also remind the audience that the general flu in America, just in America, has had 16,800 fatalities already this year in the general flu, and the coronavirus has also tragically had 3,000 fatalities. I think also coming outside of the Chinese health care system moving into a more developed health care systems, like you have in Western Europe and in the Americas, we should be better prepared to contain the virus as long as we’re diligent.

 

Intuitive Surgical (3/3 – Raymond James Conference)

But you look at China specifically, on the procedure side of our business, roughly 3% of our worldwide procedures are performed in China. And yes, they’ve been growing very well as of late as new systems have been installed. There’s no doubt that the coronavirus has been affecting procedure volumes in China and likely had some impact on other countries around the region as well. We’ve seen incidences of outbreaks in Korea as well as Japan and lately, more lately in Italy and even here in Washington state. So it’s really we’re unable to predict what the ultimate impact will be, but clearly there has been some. And we’ll keep you informed as things go.

Yes. I mean we can see differences in trends, and we track them on a regular basis. We’re not going to report here to this group exactly what we see at this point in time because, again, it is very dynamic, and you can look for an update on — after our Q1 earnings.

 

Alnylam Pharmaceuticals (3/3 – Cowen Conference)

I mean, we’ve done — obviously, as all companies are doing right now, done a systematic review of our supply chain in light of the COVID-19 epidemic, and we are in a very good position. We don’t see any implication for our commercial or clinical products. Most of our — we do no drug substance manufacturing or drug product manufacturing in China. And we do that in either the U.S. or in Europe as a company. And we have no — we have sufficient inventory of all of our commercial products as well as clinical development programs as well. So there’s no supply chain implications. Now turning to specific markets and where there might be issues, thus we can talk about Japan. Japan is a big market for us. It probably will exit 2020 as our second largest market. So far, we haven’t seen any implication of the COVID-19 epidemic in Japan.

Question – Ritu Subhalaksmi Baral: On demand?

Answer – John M. Maraganore: On demand. We obviously look at that closely, and we’ll monitor that very closely. But Ritu so far, so good on that side of it.

 

Moderna (3/2 – Cowen Conference)

And of course, we announced a few weeks ago that we shipped to the NIH or coronavirus vaccine for the NIH in the first Phase I.

The last one I’m going to go quickly on it because it has been massively covered is the corona vaccine. So this vaccine’s quite interesting. We have been working with the NIH on the Middle East respiratory syndrome in preclinical models. And so we were quite familiar, the NIH and ourselves, around coronaviruses. We had great preclinical data, including neutralization using the Spike S protein. And so as soon as the sequence was available from China, working with the NIH, we were able to pick a sequence, and the team is moving quite remarkable. In 42 days, we went from the day we pick the sequence to the day we ship the vials to NIH, and that included 2 weeks of sterility testing on the back end. So just to give you a sense of the speed that you can accomplish with a platform like Moderna given the investments we have made in GMP over the years. So the product is with the NIH now. The IND has been filed. And so the NIH will communicate when they start dosing, which will be pretty soon, we believe.

 

Stryker (3/2 – Cowen Conference)

Yes. So first of all, thank you, and thank you for everybody for coming here today. It’s obviously still a very fluid situation, and it’s going to remain so. I don’t think there’s anything magical about the end of the quarter that will suddenly make this disappear.

We have about 2% of our revenue comes from China. We have 3 manufacturing facilities there. They are all opening up and running, but they’re not at full capacity. And clearly, a lot of — essentially, all elective surgeries in China have stopped. And so there will be a revenue impact, certainly, in Q1. We would imagine there’ll be still an impact in Q2 as well as an earnings impact. And I think we have to wait and see how it plays out in some of the other countries like Japan, for example, as well as in the U.S., but we will call that out in terms of this is what we believe the coronavirus revenue and earnings impact is. You can see an adjusted, adjusted number, similar to what we’ve done in the past, whether we’ve had these extraordinary events, whether it’s natural disasters or something like this. So we’ll be able to call it out and give people a sense of the impact.

 

Illumina (3/3 – Cowen Healthcare Conference)

Question – Doug Schenkel: All right. Great. Thanks, Francis. Maybe to kick off with a topic that’s at the forefront of all of our minds right now, and we’ve been asking everybody. We’ve done these discussions with over the past 2 days to comment on COVID-19 and what your — really what your business exposure is from a revenue risk standpoint, at the supply chain positioning perspective, how you’re positioned when it comes to supply chain and then also what opportunities that you found to be helpful and I would think, in your case, moving along with diagnostics and monitoring of the outbreak?

Answer – Francis A. deSouza: Sure. As you can imagine, COVID-19 is [doubling] for us, and there are a number of a number of aspects that we are monitoring closely. First and foremost, we want to make sure that our employees are safe, and so we’ve put into place programs to make sure that they stay safe. For example, in China, our employees are working from home. We are limiting travel, certainly, to some regions in the world. But in general, we’re limiting travel to sort of business essential travel.

The other thing we’re doing is monitoring our supply chain and our ability to continuously serve our customers. The reality is we don’t really do manufacturing in China. And as we’ve gone through our suppliers, we have a small number of suppliers out of China. At this point, they are continuing to able to supply to us. In addition, we’re monitoring our ability to deliver our products to customers in China. And at this point, we’re still able to do that. We are dispensing for certain types of products to be distributed within China, and we fall within that category.

The other change that’s taking place is the 5% tariff that had been imposed on our hardware going into China has been removed. And so that’s played out over the last few weeks.

From a business perspective, we expect that the majority of the impact from a revenue perspective in Q1 to be in China, and we’re monitoring that closely. And as you know, it represents about 10% of our business.

And there are a number of things playing out. One thing that’s playing out is that the authorities in the Chinese CDC are using our sequencers as part of managing the outbreak. And so some of you may have seen the photo in the Chinese Daily of the iSeqs in — but it’s iSeqs, it’s MiSeqs, it’s MiniSeqs that are being used as part of managing the outbreak. And so on the one hand, we expect some impact from increased use of sequencing in that application, which historically has not been a big application for us. We expect that there may be some prebuying by customers taking place. On the other hand, it could be that there is an impact where people don’t go into hospitals to get routine testing. And so we’re monitoring to see how those puts and takes play out, and we’ll update you as we have more information.

Question – Doug Schenkel: Recognizing this is no longer just a China challenge, is it just too early to even have a handle on how this might impact business in places like Italy and South Korea and some of the other places where the outbreak has been a little bit more pronounced over the last week or so?

Answer – Francis A. deSouza: Yes, it’s too early at this stage. The dynamics we expect will be similar. There will be increased use for infectious disease monitoring. In fact, I think once we get through the COVID-19, I think you will see this potentially as a catalyzing event to say we truly do need a global surveillance network that will watch for naturally occurring viruses like we’re seeing right now, but also for things like antimicrobial resistance or potentially even bioterror.

And so I think there is an awakening in the — certainly in the infectious disease community around the need for a global surveillance network long term. So I think as we come out of that, there will be more of a conversation around that.

In terms of impact in those countries, it is too early, and I think you’ll see the same dynamics, increased infectious disease, a question about whether the hospital capacity is there for routine testing.

 

Hologic (3/3 – Cowen Healthcare Conference)

Question – Doug Schenkel: So just to set this up, again, we’ve started most of our discussions at the conference with a question on COVID-19. For you guys, China represents only about 3% of sales. But I am curious, what were you expecting for revenue growth in China?

Answer – Michael J. Watts: Yes. Our international business, as you know, Doug, has been growing kind of at a high-single digit, low-double-digit rate. And China has been in that ballpark, depending upon the quarter. So pretty consistent with the rest of international. I mean, clearly, that will be affected by what’s happening over there now, but we haven’t yet quantified that. And at 3% of revenue, hopefully, it’s pretty manageable.

Question – Doug Schenkel: Okay. Is there any China supply chain, either direct or indirect, that we need to be thinking of?

Answer – Michael J. Watts: Yes. I would say, minimal. I think we’re — certainly, no direct impact we did in recent days and cover a little bit of indirect impact on some of our smaller products, mainly our bone density products and ultrasound products. But it should be okay in the near term. If things continue to stay challenging there for longer term, it would be something to keep an eye on in the second half, but pretty minimal.

Question – Doug Schenkel: Yes. It’s been interesting over the course of this week and checking in with folks over the last couple of weeks that, that indirect supply chain is a little harder for a company…

Answer – Michael J. Watts: It does. It takes a little bit longer to uncover those things. But again, in our case, we think it’s pretty small.

Question – Doug Schenkel: Okay. So beyond China, because unfortunately this is clearly moving globally, what’s the opportunity and pathway for Hologic to actually provide a solution, a diagnostic for COVID-19?

Answer – Michael J. Watts: Yes. I think we — we’re in a pretty good position to help with the public health threat as we did with Zika a few years ago.

Question – Doug Schenkel: Yes. You’ve done this before.

Answer – Michael J. Watts: I mean we’ve done this before, as you say. I think there’s 2 primary paths for us, Doug. One is, we are developing a test for the U.S. market under the EUA procedure, so Emergency Use Authorization, if you’re not familiar. Moving as fast as we can on that in consultation with the FDA and hopefully to — hopefully expect to make that filing within the next few weeks.

Secondly, one of the things that may not be immediately apparent is on Panther Fusion. Remember, Panther Fusion has an open-channel capability. So labs will be able to develop their own tests on Panther Fusion in an automated, high-throughput fashion if they so choose. So probably 2 ways that we can help.

Question – Doug Schenkel: Can you help provide guidance for folks to develop an RUO-based, PCR-based tests to run on COVID-19?

Answer – Michael J. Watts: Yes. I believe there have been protocols that have been published.

Question – Doug Schenkel: Okay.

Answer – Michael J. Watts: So that will be up to the labs obviously to take a look at those protocols, adopt as they see fit, but that can be done under the CLIA regulations.

Question – Doug Schenkel: Okay. And then so that’s a pretty unfortunate but exciting way that you can help and hopefully drive some volume. On the flip side, yes, I haven’t thought about this as much with you guys as some of the other diagnostic companies we cover. But in previous years, yes, there are companies where they will actually see a decrease in volume forecast because people just aren’t going to hospitals or even their PCPs as much if they don’t have to. Is that something we should be thinking about right now?

Answer – Michael J. Watts: Yes. I think that’s certainly a possibility. We have seen that in the past with some really difficult flu seasons, for example. And given that some of our business is basic screening and well-woman checks, I mean that’s certainly a possibility. And we would not expect obviously a significant upside from our own test development efforts on this at all. It all depends on the severity of disease, how long it lasts, how much testing is done. But there certainly is that potential for visits to be hit on the negative.

 

Zoetis (3/3 – Cowen Healthcare Conference)

Question – Well, that’s thankful for all of those with pets. So — and then just in terms of a demand perspective, can you comment what you have seen since the beginning of this year, both in China or anywhere else, impacting demand both on companion animal and livestock?

Answer – Kristin C. Peck: Sure. I mean from a revenue or from a demand perspective, there are 2 main things that we’re watching at least at Zoetis. One is with quarantining and people being nervous to get out that much. We are seeing a reduction in overall vet visits. What remains to be seen is that’s a temporary thing. And then once the quarantines are lifted and people feel comfortable traveling, they’re making up those vets visits. But even if they are, they might not necessarily be making up those doses of antiparasitics and things like that, that they would have used. So we do see — one thing we’re watching is just a reduction in vet visits and therefore, reduction in number of doses of some products such as parasiticides. The other thing that we’re watching very carefully that we are starting to see, is also a reduction in overall consumption of protein. So as you limit tourism, and you limit travel and you limit people going out to eat, there’s a reduction in overall protein consumption. Some of that moves to the grocery sector and people buy it, but it tends to change when it does. So most of us, when we go out, we tend to buy the larger steak. In when we’re home, we eat the chicken or the burger. So the nature of what you’re buying sort of changes. And I know that I don’t make steaks the same size at home that I tend to find in restaurants, so the overall volume changes. So we are watching that as to how that progresses as it spreads to sort of Europe and the U.S. But for us in China we saw, in 2019, a significant outbreak called African Swine Fever. We were expecting a significant uptick in exports from the U.S. and Brazil and Europe into that market, great demand. I will say the frozen supplies have gotten very low in China. Some of that supply that we, the U.S. and Brazil and other people, ship get stuck at the ports with coronavirus. And then when it did, it was getting frozen since the overall consumption level in China has not scaled the same level. But remains to be seen — I mean at this point, this is all within our guidance range, but remains to be seen is if this lasts much longer and these consumption patterns of much less eating out at restaurants, much less tourism and travel, that could be a longer term but it’s a little too early for us to see. But from a demand perspective, that’s really where we see the risk.

Question – Kathleen Marie Miner: Are you seeing the decreased pet visits in this country also or other part of Europe…

Answer – Kristin C. Peck: No. I mean that would just be starting that — we have — we saw it in China, obviously. I mean a lot of them, they weren’t allowed out. I mean vets weren’t even allowed to open. So by definition, that happened. We haven’t seen that yet in the U.S. or Europe. But that’s certainly — having watched what happened in China, what we’re watching for right now as we understand what the potential impact will be. But again, it really depends on how long that is. Because a lot of those will be made up. So sometimes that’s more doses that you’re missing.

 

Agilent (3/3 – Citi Conference)

I mean, your guidance assumes a 1.5 to 3-week impact from coronavirus in China based on the fact that you got a factory up and running. The second factory is 70%, 75% up and running. It feels like things are not worse than what you — at least in China specifically.

Answer – Robert W. McMahon: Yes, that’s correct. Yes. I mean, things are tracking to kind of we expected. Now, I think we said this on the call that, at our earnings call, we expected February to be the brunt of it. And we’ve seen that. And — but we’re exiting February kind of where we expected it to be, not only from a factory perspective, but one of the other areas that we look at is service calls. And the service call rate at the end of this month was tracking pretty in line with where it was the end of February last year, which is actually very positive. Now how we’re actually doing the service is very different. So the investments that we’ve been making in WeChat over the last 2, 3, 4 years is really paying dividends because we’re actually doing service calls via WeChat as opposed to having people on site in certain factories and so forth.

 

Regeneron Pharmaceuticals (3/2 – Cowen Conference)

So where are we right now? With the new coronavirus outbreak, we have already immunized mice to develop fully human antibodies to the infection. We are now at the point where we are identifying lead candidates for treatment and prophylaxis treatment. It’s our intent to have the lead antibodies manufactured and ready for clinical trial use later this summer. While we’re not able to share more details with you at this time, know that this is a priority for Regeneron to address this important human health need.

 

Gilead Sciences (3/2 – Cowen Conference)

So remdesivir as a molecule, we’ve had at Gilead for a while. It was discovered and developed as an antiviral with a relatively broad antiviral activity in-vitro. It’s shown efficacy in-vitro against Ebola, which is a different class of virus, but also against SARS and MERS, which are both coronaviruses in-vitro. The homology of the polymerase that remdesivir inhibits is very high between SARS, MERS and this new coronavirus. So I think that’s probably one of the biggest drivers of why we are interested and others are interested in it.

More recently, we’ve gotten data from the Chinese CDC, where they’ve evaluated in-vitro efficacy and have demonstrated in-vitro efficacy of remdesivir against this particular isolate. We are awaiting data from our CDC here in the States to confirm that. There’s a slight difference between the 2 and that the Chinese CDC use vero cells or monkey cells and the U.S. CDC will use human cells. So we think that will be a little closer to what actual efficacy, at least a potency against the virus will be.

That’s in-vitro data. I think, really, it’s really important to emphasize there’s an investigational drug and we are in clinical trials right now, and those fall into several categories. We do have compassionate use work going on. You’ve seen the New England Journal article on that one patient. There have been other patients who’ve been treated with compassionate use. Those are all anecdotal.

There are 2 trials going on in China. They’re sponsored by and run by the investigator in China. We supply drug to them. There’s one in severe patients, one in more moderately ill patients and those studies are active and ongoing. And hopefully, we’ll see data from those in April, depending on enrollment.

And then the NIAID, we’ve been working with them to get another trial up and running. That study is now up and running in Nebraska and we’re looking to expand sites there. The NIAID will be doing that but we’re trying to support as best we can. And then, finally, we’ll be running sort of a simple trial that we’ve also been discussing with the FDA around making that trial available more broadly.

 

Johnson & Johnson (3/2 – Cowen Conference)

With respect to the vaccine, I think you’re — what Dr. Fauci had referenced in terms of 12 to 18 months is probably a very reasonable time line. If you just think about what has to happen with respect to, first, having some animal studies, making sure it’s then safe in humans and then the efficacy part, that seems to be as quickly as, I think, anything can be done.

With respect to our candidates for a vaccine, we are screening possible vectors. Where we have a differentiated capability, we believe, is around our scalability. So the ability to produce hundreds of thousands of vaccines is something that’s not uniquely possessed within the industry. And if you think about what we did on both the Ebola and HIV front in terms of some clinical development trials that we are now conducting, those are in the hundreds of thousands.

So if you remember an acquisition we did many years ago known as Crucell. They had a PER. C6 technology there that allows us to have this kind of manufacturing capacity. So whether it’s a vaccine that we potentially discover or some other vaccine that may be a candidate to contain the virus, I would imagine, we’re some part of the discussion. In fact, I believe, Alex and Paul are with the administration this afternoon with other health care CEOs and management to help figure out what is the best solution and best path forward.

In terms of business impact because I’m sure that’s on everybody’s mind as well, right now, I would say I don’t anticipate — and I’ll caveat my comments to be first quarter contained, right? Until we find out how long the duration of this is, the pervasiveness of the virus is, it would be hard to say we would certainly provide the best information we have available on our April call to recap the Q1 results.

I would say, though, from a supply perspective, I’m not overly concerned. I think if you look at where our supply chain exists, we’re pretty well covered. On the demand side, I could see some modest impact in Consumer, around Skin Care in terms of just people buying less. There’s less activity in that, but perhaps that’s offset by self-care. So think of MOTRIN or even LISTERINE potentially.

On the Pharmaceutical side, people still will take those drugs. You may see some lower demand from closed or limited hours for infusion centers or even pharmacies. But by and large, I think we’re pretty well covered there.

Medical Device, as other peers in our industry have indicated there, we are seeing a much reduced level of elective surgeries. And so we’ll probably track to the market there. Overall, though, I think if I look at the overall health of Johnson & Johnson’s business, I see this as a temporary blip that will largely be recovered.

 

Dentsply Sirona (3/2 – Q4 2019 Earnings Call)  

During this difficult period, our priority has been the safety and welfare of our associates. At the current time, we have not experienced a significant disruption to our global supply chain due to coronavirus. However, in many parts of China, dental clinics and hospitals remain closed for business. And in other parts of the world, we are beginning to see an impact.

Given the unique situation, today, we’re letting you know that China, Japan, Korea and Taiwan, represented approximately 10% of 2019 sales. While we hope the impact of the virus is controlled as soon as possible, it is difficult to estimate at this time when commercial activity, and more specifically, the dental market will return to normal levels.

We estimate that in the first quarter of 2020, we have an exposure of approximately $60 million to $70 million in sales stemming from coronavirus. Assuming activities get back to normal in April, we estimate a non-GAAP EPS impact of $0.10 to $0.12.

We acknowledge it is more difficult to forecast accurately in the current environment, and this explains the wider than usual EPS guidance range we are providing today.

With that said, these are the key elements of our guidance for fiscal ’20. We expect 3% to 4% internal revenue growth. However, accounting for the potential impact of coronavirus in the first quarter, we believe growth will likely be towards the bottom end of the range. We expect roughly a $30 million currency headwind for the year.

 

Exact Sciences (3/2 – Cowen Conference)

This year, on our fourth quarter call, we talked about the flu also having an impact on the business. Coronavirus, I think it’s still very early, so it’s something we’re watching closely. To the extent that it does have an impact on the business, again, I would think it would be temporary like the flu.

 

Edwards Life Sciences Corp (3/2 – Cowen Healthcare Conference)

Question – Joshua Thomas Jennings: Well, generally, your front-burner issue clearly is COVID-19. And just wanted to maybe review, I mean, China has been the hardest hit, just Edwards’ exposure to China to start with. And then maybe we can just ask a couple of more follow-up questions. I know it’s a fluid situation in all regions. But maybe we could just start with China and Edwards exposure and going on from there.

Answer – Scott B. Ullem: Sure. So I mean our biggest concern, of course, is the patients that we’re supporting and our employees in the region. And so we’re watching that carefully. In terms of production, we don’t have any real production directly in China. But you’re right, it’s a fluid situation. So we’re watching this unfold.

Question – Joshua Thomas Jennings: And just in terms of there has been some spread into other regions, we’re hearing about some cases in Europe and more and more diagnosis, some in the United States, very early, but any sense of impact outside of China and maybe not just to Edwards but just from a procedural standpoint, electroprocedures, per se? And maybe we can talk about the electiveness of TAVR in the (inaudible)?

Answer – Scott B. Ullem: Yes. So I think we’re probably best positioned to talk about TAVR specifically rather than other sectors within health care. But it’s something we’re watching carefully for the diseases that we treat, such as severe aortic stenosis. This is not an elective procedure. It’s a procedure that is time sensitive, and patients need to care as soon as they can get it. And so we’re working with our hospital partners, with our physician partners to do everything we can to support cases and watching carefully as this disease starts to make its way into other geographies.

 

Biogen (3/2 – Cowen Conference Healthcare)

Question – Philip M. Nadeau: One thing that we’ve all been focusing over the last week is COVID-19 and the potential disruptions to supply chains. Can you remind us of your exposure to Asia? And maybe just generally what the redundancies in your supply chain, should there be further disruptions in Asia or worldwide?

Answer – Michel Vounatsos: So we established — we have established a subsidiary in China last year. The exposure so far is really negligible, I will say, unfortunately. But we timed this increase for the company because I’m a strong supporter of China in terms of market and epidemiology, and it’s a great place to be. But versus the current crisis, supply chain is good. So far, so good.

 

Steris plc (3/2 – Raymond James Institutional Investors Conference)

Question – Lawrence Soren Keusch: No, we have about 10 minutes, so we can do some Q&A in the room. Mike, let me start off because, obviously, this will come up throughout the day, which is the situation with coronavirus, obviously, clearly remains dynamic. But maybe you can remind investors about the exposure for STERIS from both a revenue and supply chain perspective, I guess, focusing in on the Asia Pacific area. So that sort of question. And then have another one after that.

Answer – Michael J. Tokich: Yes, certainly. So for STERIS, our revenue base in — well, China, particularly, even in Asia Pacific is not really material. It’s not large for us. So we do not think that as of right now we would have any material impact from the coronavirus. Obviously, that’s on a top line standpoint. Supply chain is the only concern we would have. But for us, we have all the inventory we need to finish this fiscal year, so it would actually be into next fiscal year, depending on how long this issue lasts, we would more comment on that in May time frame. But for this fiscal year, I think, again, we would not — we do not expect to see a material impact through the rest of this month to finish our fiscal year.

Question – Lawrence Soren Keusch: Okay. And then I guess, just following up on that. So is it fair to say that China is around 5% of revenue or is it less?

Answer – Michael J. Tokich: Yes, it’s less, it’s probably low single digits, China itself. So what we do in China, we have a, I’ll call it cherry picking strategy. We use dealers or distributors. We do not have feet on the ground for our own sales force. And we are targeting the Tier 1 or private hospitals in China, who want to look more like the U.S. So very nascent for us from a top line standpoint.

Question – Lawrence Soren Keusch: Okay. And just to finish up on this topic. If the virus sees an increasing spread into Europe and the U.S. and elective surgical procedures are curtailed. I would assume that the hospital sterilization business could see some impact. Maybe AST has a little bit more insulated and less companies start to reduce manufacturing. Is that fair?

Question – Michael J. Tokich: Yes, I would say, I would agree with you. So I mean, if you look at the largest part of our business, it’s all about surgical procedures. So any time there is a slowdown in surgical procedures. Obviously, we would potentially be at risk on that point. I would say that the AST business probably is a little more insulated, as with life sciences. Obviously, if there’s vaccines or something of that nature for the virus and that could actually help us on the back end.

 

Novartis (2/28 – Annual Shareholders Meeting)

Question – Unidentified Shareholder: [Interpreted] Good morning, ladies and gentlemen. I’m [Volte Krov] from Bern. Chairman, I’d like to begin by thanking you because some things have improved since the years of Vasella. Mr. Vasella, back then, we just used to get a coffee and a croissant. We’ve been getting much better catering in recent years, so thank you very much.

I would like to know, though, whether you’re going to be signing up to the call for tender from the Swiss national research fund to develop a vaccine or treatment for coronavirus. That would be a very nice thing for the company to do.

Now I want to say something about the dividend. I think we’re only getting a 4% increase. It’s absolutely miserable. You could certainly have paid a higher dividend that this CHF 0.10 that we’re getting on top of last year is, frankly, laughable.

I also want to talk about the share price. Nestlé and Novartis used to have very close share prices. Nestlé has gone up to over CHF 100 now, whereas Novartis is jogging along behind. Why can’t you do better? You should start doing better, I believe, not just talking about doing better.

I want to hear what happened in the end with the case in Greece as well, please? Because there was a hefty scandal there, but it’s all gone rather quiet in recent times. So I’d like to know how that one turned out, please.

Answer – Joerg Reinhardt: [Interpreted] Yes. Thank you, Mr. [Krov]. Yes. Well, a little increase in the dividend. That’s better than we’ve had in some years. So we’ll see what we can do next year.

As to vaccines for coronavirus and others, our vaccines business was sold off to GSK a couple of years ago. So our vaccine experts, well, they moved to GSK at the same time, and I’m sure they’re very busy trying to develop a vaccination for coronavirus as we speak. So that would be for them. When you have exited a business of that type, it’s not very easy to just jump back into it. And I’m sure that all companies around the world who work in the field of vaccines are very busy trying to come up with a vaccine for coronavirus. They will be heavily involved. If you’re not a company working in the field of vaccines, then it’s not something you can just dream up overnight. We decided that vaccines were not a business for us, and I’m afraid, that, that remains the case regardless of coronavirus.

 

Mylan N.V. (2/27 – Q4 2019 Earnings Call)

I want to take a moment to address the very serious matter of the coronavirus. We’ve been in close contact with our colleagues around the world regarding recent developments and are following government and health organization recommendation. The health and safety of our teams and their families is our priority, and we’re supporting those on the ground where possible.

Our business exposure in China, specifically, is limited. However, given the global nature of our supply chain, operations and businesses, our results could potentially be impacted. The guidance we disclose today does not include any anticipated impact from coronavirus, however, we will continue monitoring the situation very closely from a business perspective.

 

Insulet Corp (2/27 – Leerink Global Healthcare Conference)

Question – Danielle Joy Antalffy: Yes, okay. That’s great. One other question, while we’re on this, what questions we’ve been getting since the earnings call, on COVID-19 and the impact there. And you guys did talk about this, but I think what folks are trying to get a handle around is, is there any risk to the guidance? Or do you feel like this is very much under control and reflected in the guidance from a supply perspective, you obviously don’t sell into China?

Answer – Wayde D. McMillan: Yes. So no impact to the guidance at this point. What we said on our earnings call on Tuesday was that we had sufficient inventory going into the quarter. We are lucky enough to be one of the people in China that has our employees ramping up at the plant. We are manufacturing at the plant. We’re shipping, and we also have our U.S. manufacturing with our first-line ramping up here in the U.S. So that’s providing us some redundancy already. It’s still early in that Line 1 and the yield coming off that line, but it is starting to contribute. So between our China manufacturing ramping up, our U.S. manufacturing starting to produce and the inventory we had, we feel confident at this time. As Shacey said on the call, our #1 concern is our employees there and our people traveling. And so we’re monitoring that very closely. We’re also monitoring our ramp-up over time. It is a day-to-day thing. Our team is very focused and working with our third-party manufacturer, literally daily. We have a very strong team here, experienced team working it. So that gives us the confidence that we’ll be able to continue to ramp in our third-party facility. We’ll continue to ramp in the U.S. and gives us the confidence that we’ll be able to manage through this. Having said that, I don’t think anybody really knows where this thing is going to go over time. And so we just have to continue to manage it literally day-to-day.

 

Don’t miss critical insights. AlphaSense gives you access to full Earnings call transcripts and allows you to keep track of themes unfolding within your coverage universe through intelligent AI-powered search.

Sign up for a free trial to learn how AlphaSense enhances the workflow of 70% of the world’s hedge funds and over 50% of the S&P 500. Already have an account? Login here.

Coronavirus Cheatsheet: Week of March 2nd

Interested in staying up-to-date on COVID-19’s impact across sectors? Visit our Coronavirus Impact Tracker for daily updates pulled from earnings calls, press releases, 8ks, and more.

 

Takeaways:

  • Management teams reporting Q1 Earnings are split between guiding to a wider-than-normal range or providing guidance excluding the impact of Coronavirus.
  • Some companies are already updating Q1 guidance via Press Release to account for the pandemic’s impact.
  • Most companies are adding Coronavirus as a Risk Factor in their 10-Ks
  • All management teams are being asked to comment on the impact of Coronavirus

 

Don’t miss critical insights: Sign up for a free trial or login here.

 

Week of 3/2: Updates

[Updated 3/6] We’re hearing sharp negative impacts to operations in China, with Travel and Retail hit the hardest. Starbucks called out China comparable store sales down 78% in February, albeit improving since troughing in the second week. Supply chain commentary seems to be improving with AMD commenting that they’re “actually back to near-normal supply capacity in our supply chain.” See below for full details.

Walmart Inc (3/5 – UBS Global Consumer Retail Conference)

In China, our stores, for the most part, have stayed open, which — the communities there need that, but it’s been challenging in China, and we talked about that a couple of weeks ago. The U.S. are starting to see more news, which I think everybody anticipated, and we’re just going to be really careful about it.

From a supply chain standpoint, we haven’t seen major impacts. So not much different than I would have said a couple of weeks ago. I do think in ways, the work that our merchants did around tariffs over the last 12 to 18 months helped us think about some things differently that are probably paying off some now and how you think about supply chain differently. It does feel like — I’m reading the same things you are, but it does feel like China is starting to kind of come back to work, which will help from a factory standpoint. And we’ll just have to keep monitoring it day-to-day, week-to-week. We’re seeing, as you would expect, stock-up with customers on certain items, but not tremendous changes in customer behavior. Again just week-to-week, we’ll have to see how it transforms and we’ll have to keep people safe and continue to run the business efficiently as we can.

 

Twitter (3/5 – Morgan Stanley TMT Conference)

Well, it’s really too early to tell the impact on our business. But there are 2 things that we’re doing to make sure that we’re ensuring better information around what’s going on and also the health and safety of people around the world and also our folks. So first and foremost, people are talking about the coronavirus a lot on Twitter. And this is challenged by potentially misleading information. So it goes back to that #1 priority in health. But people are struggling to find where the latest updates are and where the best information is.

 

Lowe’s Companies Inc (3/5 – UBS Global Consumer and Retail Conference)

Well, look, what I would say is, I mean, this is a unique market environment, with the coronavirus. I mean like all other businesses and retailers, I mean, we’re staying really close to our supply base around the world, our manufacturing base, because we are predominantly a business that really penetrates heavy in spring from a sales perspective.

As we look at Q1, we see no short-term interruptions in the business. As a matter of fact, our business trends are strong. As we look farther into the year, into Q2 and beyond, it becomes more uncertain because you’re at the mercy of the new cycle. You’re at the mercy of what happens next.

Well, as recently as last night, I’m looking at factory production around the world and what their capacity is relative to where they’re accustomed to being. And so that’s the level of visibility we’re placing on this, tracking every PO, by manufacturer, by geographic location. And all I can say is we see no short-term negative benefits to our business. Our supply chain, relative to what we need for our spring business is either in the store, in the DC or on the water. And so we’re in a really good position there.

We’re going into this season, with our best in-stock position in over 5 years. So we’re really ready for spring. But beyond that, it’s hard to have clarity because we just don’t know what’s going to happen, but we’re staying close to it, and we’re going to be as flexible and as agile as we can.

 

Akamai Technologies Inc (3/5 – Morgan Stanley TMT Conference)

So obviously, if events get canceled, then it could have an impact. Now no event is overly material. And if you saw the Olympics go from Q3 to Q4, I’ve been hearing some talk about maybe it moves to October or something like that. It’s just a shift out of Q3 to Q4. And with the Olympics, the way to think about that in terms of our revenue, we get revenue from the rights holders, you get revenue from the live television and there’s a drag-along effect with some of the other verticals in the market. So it would have an impact, but it wouldn’t be overly material. And certainly, a shift from one quarter to another, you just adjust your models, and it doesn’t have a major impact on 2020… So in terms of the supply chain, there could be some timing issues. If there — we do have some component parts that come out of China. Most of our manufacturing is not done there in terms of our servers. We do a really good job of planning out in advance. So to the extent that this is a temporary shift, you may see some CapEx lower Q1, maybe it picks up a bit Q2, Q3. But we’re not anticipating anything that would have a major impact on the business at this point. But obviously, if this goes on for many, many months, it could have a little bit of an impact.

Question – Keith Weiss: And you’re not seeing any demand-side impacts, either positive…

Answer – Edward J. McGowan: No, so….

Question – Keith Weiss: I guess there is a potential for it to be positive.

Answer – Edward J. McGowan: Yes. So there is an interesting bull case here, you hate to talk about benefiting from something like this. But to the extent that you see businesses shut down and people working from home, schools being closed and people doing — being kept up in their house. There is the potential for more internet usage. There’s the potential for additional streaming usage, additional commerce traffic because people wouldn’t want to go outside, they want to shop, similar to what you saw in Q4, right? That’s probably the best way to think about it. We’re not seeing it today because right now, that isn’t a big phenomenon around the world in places that would have a big impact. But if you see things spread here to the U.S., Western Europe, India, you could see a benefit. In China, today we do not do the delivery of — in China from Chinese customers or Chinese users in China. We only deliver out of China and then customers going into. So it would not have a big impact on us.

 

Visa Inc (3/5 – Evercore ISI Payments & FinTech Innovators Forum)

Yes. Right, as you said, David, I mean, we gave you the best picture we could of what we were seeing through the end of February. And as you saw, I mean, the primary impact was on the cross-border business. And the cross-border business part was also travel-related, primarily at this point. And these things happen. We’ve gone back and looked at SARS. There’s a recovery track.

Clearly, coronavirus is playing out differently than SARS. SARS was fairly Asia Pacific. Through the end of February, our impacts are also largely Asia Pacific, but it’s become apparent since then that the virus has spread outside of Asia, so this will become more of a global phenomenon.

We also know that the recovery track takes some time. SARS took 5 or 6 months for things to get back to normal in the cross-border business in the markets that were impacted at that time. That was now 20 years ago. China was not significant as a part of our business, nor was it significant as it is today in the global economy. So there’s no question, the impact will be different this time, and they’re hard to predict.

So in terms of resiliency, as you know, we are fortunate to have a business that has a great cash profile. So in that sense, the business continues to generate good margins and good cash flows. We clearly have a great and strong balance sheet. So from all that standpoint, I mean, we can withstand a fairly substantial shock, so to speak. And it’s really going to be more a matter of what is the impact, at least over a period of time that this all continues, what the impact on our revenues is going to be.

We gave you our best sense of the quarter. It is, as we said, a fluid situation. The trend was deteriorating week after week, and we indicated that we haven’t bottomed out yet, and we don’t know exactly when that might happen.

 

Autozone Inc (3/5 – UBS Global Consumer and Retail Conference)

Yes, we’re seeing some slowness coming from Asia, but the product — there is product flowing. Obviously, it isn’t flowing at the level that it needs to be. And it’s our understanding the factories are coming online and are progressing online, and the government is going through a certification process with each of the factories. And they’re ramping up, specifically the factories that are supplying us are ramping up. So we think that it will be, as we said on the call or Bill said on the call, it’s — the next few weeks will be critical as we kind of watch them continue to ramp up. To your point, you’re right. Our inventory turns relatively slow. We have X amount of weeks of supply in the system. We also have the ability to buy from ourselves, if we are able to rebalance out some of that inventory. So for now, we seem to be okay. And for what we can see in front of us, we don’t see a significant disruption. If things change, then we’ll have to address that when it happens. But at the moment, it feels as though we have inventory available. There’s inventory coming and will be coming based on our understanding. And so we don’t see this as being, at the moment, disruption of any great magnitude. I’m sure that there will be a little bit of a flow for the — our distribution folks as it will be for any company, who is getting very low volume right now and will get ramped up pretty significantly.

 

Zebra Technologies Corp (3/5 – Morgan Stanley TMT Conference)

 Obviously, the coronavirus makes a very fluid situation. Lots of news coming out every day and lots of reactions… For us, it has been predominantly a supply chain impact. In our call 3 weeks back, we did highlight some softness in China from tariffs and from the coronavirus, demand issues. But since our supply chain is largely China based, that was the bigger issue. We have dedicated teams that are working very closely with all our Tier 1, Tier 2, Tier 3 suppliers to make sure that we are in contact several times a day to make sure we have up-to-date information that we can help if there’s issues and stuff. The supply chain is definitely coming back to life in China. They’re definitely ramping up. Depending on the supply — the contract manufacturer or the region they’re in, they’re slightly different ramps. If they source more people from Wuhan, they might be a little slower to getting back into gear, but todays its definitely either people are almost at capacity or getting at towards capacity. So from what we’ve seen so far, it seems to be kind of developing in a reasonable fashion.

 

Take-Two Interactive Software Inc (3/5 – Morgan Stanley TMT Conference)

In terms of business continuity, we’re not concerned. In terms of our consumer, we’re not concerned. And we have the ability to work remotely if it comes down to that. And I don’t believe it will. So I mean I do think there’s going to be a whole lot more cases of coronavirus than we’ve seen so far because it’s more transmissible than a regular flu. I think it’s terribly unfortunate that and I’m in the media business, I can’t really be super critical, but I think it’s really unfortunate that the press is not seemingly aware that we have currently, right now, in America 25 million cases of the flu. And in any given flu season in America, somewhere between 30,000 and 60,000 people typically pass away from the flu. That seems to be lost in the shuffle. And this is a flu virus. And I think it’ll be a whole lot of it. I think there’ll be — it seems to have a slightly higher fatality rate. I actually think when we understand what the denominator is and that can be much higher, I could be wrong, I’m not a doctor, but assure I do talk to a lot of doctors. I think it’s going to be very unpleasant. I think the market may take a real hit, actually. I think things will slow down.

So with all — with that said, it also will pass [this] flu virus and we’ll develop herd immunity and vaccines will be developed, and we have been through this before. So I think given that we’ve been through flu pandemics many times before, pretty good idea of how it’s going to pencil out. But I think people were mindful of what the flu does every year around the world, particularly in developing countries, they might be a little less concerned. We’ve had really significant flood problems. As recently as 2009 and 2010, where, I think, 800,000 people died in ’09 and ’10 from the flu. So all that said, as it happens, our business is not particularly exposed to it.

 

Autodesk Inc (3/5 – Morgan Stanley TMT Conference)

But coming back from that, one of the things I got to do is spend time with a lot of the key principals, not just our own sales team, but at our largest resellers. And really a cross-section of all geos, at the same time, not just the U.S. but also from Europe, from the Middle East and from APAC. And the consensus among everyone is that we’re not seeing any impact. We continue to not see an impact at this point. And obviously, it’s a fluid situation, and it’s one that we’re monitoring very closely. I know everyone, at this point, is kind of monitoring it very closely. So we’re not seeing any impact.

It’s something that we’ll continue to keep a sharp eye on as it goes forward. But there’s 2 other things that I’d say. One is, from a resiliency standpoint, we’ve got a totally different business model than we had the last time there was a concern like this right back in 2008, 2009. Significantly more resilient business model that I think will help us, should there begin to be some significant headwinds.

I think the other is, and talking this through, again, with the heads of our largest resellers, is there’s — if you’re in the airline business, or in the restaurant business, if that table went unfilled for an item, it’s never coming back. If that plane flew with 50% occupancy rate instead of the 80%, you needed to get to breakeven. That demand is not coming back.

So there’s demand that is going to be lost for good in certain segments. And there’s the potential for an impact to delay in our industry. And I think that the general sense is, if there is any impact, what we would see is more delay than lost demand.

 

Hewlett Packard Enterprise Co (3/5 – Morgan Stanley TMT Conference)

As I think about the implication of what we see today in the coronavirus. We have not seen yet an impact to the demand outside China. And in China, we have a unique model, which basically, 5 years ago, we decided to do a joint venture with a local Chinese partner, where we sold 51% of our assets to the Chinese partner. And therefore, it’s an entity called H3C. We actually have rights in the governance, but we collect the dividends of what they do. But we don’t sell directly, China. As you can imagine, there will be some short-term impact in China on the demand, but we don’t see, as of now, an impact on demand in the rest of the world.

On the supply chain side, obviously, we see an impact. And that’s where I said in the call, “Because of the uncertainty and because of the time the supply chain will time — will take to recover, we felt prudent, a, to not guide for Q2 because whatever number I give The Street, it will be wrong; and b, is to adjust the free cash flow for the timing of the recovery.” Because as you can imagine, the revenue will take a little bit of time to recover. And then you have the need to augment the inventory as you rebuild some of the buffers, because ultimately, you’ve got to get that motion in place.

And I will say I spend a lot of time with my suppliers. In fact, I have spoken to 50 of the top suppliers; and yesterday, to the top 2 suppliers. And I will characterize this as a recovery in progress. Most of the, what I call, the PCAs, PCBs, which are manufactured in China, we expect on the capacity side, recover between the next 2 to 4 weeks. Some of them will be online, but they are — all of them are online, but there will be a full labor capacity in the next 2 weeks to 4 weeks.

The question is the entire supply chain behind them, it takes a little bit of time because you think about the components that these people need to build these motherboards and circuit boards and other components, will take a little bit of time. But from a capacity perspective, between 2, 4 weeks, we expect them to be at full capacity.

And then there is all the other stuff we have to worry about, logistics. I was telling Katy before we came here, that — remember that 50% of the logistics is done through commercial airline and 50% through freight airlines. And when you have no commercial airlines going to China, and therefore, the bellies of these planes are not full or that people are not traveling, it is a challenge that we have been working through.

So I think I will say demand side, not a significant impact. We don’t see it yet. Supply chain, definitely, and will take 4 to 8 weeks to recover. And ultimately, we expect that to improve as we go along. And then also on the commodity side, we expect that to improve as well over time.

 

Equifax Inc (3/5 – Evercore ISI Payments & FinTech Innovators Forum)

How long it lasts, you could talk — we haven’t brought up yet the coronavirus, what’s the impact of that. But we haven’t seen any impact from it. Obviously, we’re changing our travel patterns like everyone else is, and being careful and doing the elbows and everything else that the rest of the world is doing. But there’s no question this is a tailwind for us. We haven’t seen much impact from that in the last few — in the last week. But because there’s usually a lag on when that goes into the marketplace. But there’s no question that’s going to be helpful to us as we go into 2020.

Answer – David Mark Togut: But you’re calling out maybe other effects from coronavirus?

Answer – Mark W. Begor: No, no, no. We don’t see any impacts. I just said, let’s not forget that there could be, but we don’t see any of that impact in any of our guidance. And we haven’t given new guidance. We gave guidance a couple of weeks ago for the first quarter and for the year. You’re pointing out that, that interest rate drop should be a tailwind to that guidance, and it’s hard to disagree with that.

Exxon Mobil Corp (3/5 – Investor Day)

You all know, today, oversupply is driven by industry investments and some of these growth markets have exceeded demand, and we’ve got a very challenging short-term margin environment, which is now being compounded by the growing economic impact to the coronavirus that we’re seeing around the world. And that is creating a lot of uncertainty, particularly in the near term, and I would say, particularly here in Wall Street. However, the longer-term horizon is clear. And today, our focus is on that horizon and the future. And I’m providing all of you an update on the progress we’ve made on our long-term plans to structurally grow our earnings and cash flow while improving returns.

 

Okta Inc (3/5 – Earnings Call)

While we continue to closely monitor the business environment, to date, we have not experienced any impact to our demand related to the coronavirus, and this is reflected in our guidance.

 

Costco Wholesale Corp (3/5 – Earnings Call)

Our February results benefited by last week’s big uptick in sales, the fourth week of last month, mostly, we believe, related to concerns around the coronavirus. This positively impacted the month’s total and comparable sales numbers by approximately 3 percentage points…

Lastly, our comp traffic or frequency for February was up 9.2% worldwide and 8.9% in the U.S. Now given the impact in week 4 where we really saw the big uptick, as I know many did out there, it was related to the concerns over coronavirus, the first 3 weeks — within that 9.2% worldwide for 4 weeks, the first 3 weeks stood at 7.6%. And again, within the 8.9% U.S. frequency number for the 4 weeks, within that for the 3 weeks, it was 6.9%. So still a good showing prior to that. For February, the average transaction was up 2.7%.

Now turning to the coronavirus and all the issues and impact surrounding it. Like everyone, we are keeping a close eye on the developments around the coronavirus, including the impact on operations, the health and safety of our members and employees and, of course, our supply chain. As already discussed, we saw strength in our February traffic and comp sales related to the news and concerns about the virus, particularly in the last week of the month, and that’s continuing in the first few days of this week.

Our warehouses have overall remained open with only a few total days of closures at a couple of locations in Korea. As well, our Shanghai location, there’s been some limitations required on the number of people in the facility at any given time.

Members are turning to us for a variety of items associated with preparing for and dealing with the virus such as shelf-stable dry grocery items, cleaning supplies, Clorox and bleach, water, paper goods, hand sanitizers, sanitizing wipes, disinfectants, health and beauty aids and even items like water filtration and food storage items. And we’re doing our best to stay in stock on these and other items. We’re getting deliveries daily, but still not enough given the increased levels of demand on certain key items. It’s been a little crazy this past week in terms of outside shopping frequency and sales levels and not only in the United States.

In terms of placing quantity limits on what a member can purchase. We are doing that in some instances. It tends to be at all locations but may differ regionally based on supply levels. I do want to give 3 big shout-outs. Our buying staffs, both here regionally and abroad, working, in some cases, around the clock to procure supplies for both existing suppliers and from other sources where possible. Second, a shout-out to our warehouse employees. These last 9 or so days has been beyond busy. Even with the traffic jams, in the parking lots and the long lines to check out, they’ve been absolutely awesome. And anecdotally, we’re hearing that daily from members. We hear a few other things occasionally, too. And lastly, our suppliers, both domestically and abroad, we feel our strong long-term relationships have helped to this crisis. We’ve been there for them, and they are certainly there for us now.

Overall, in terms of what the coronavirus-related demand items, in terms of that, it’s looking better, but not perfect, and we’ll see what each day brings…

In terms of supply chain, closures of many manufacturing facilities extended well beyond the typical 1 week Chinese New Year holiday, which was the last week in January. In many cases, factories over there were closed for 1 to 2 additional weeks. That’s now improving each week. Initially, 2 to 3 weeks of factory — so initially, there are 2 to 3 weeks of factory closures, not 1. Then about 3 weeks ago, and just pulling some of the buyers that — a deal with the factories, they felt there was a rough number of 20% to 25% production levels, moving up to 40% and now as high as 60% to 80%. But again, it’s improving, and this still has a little ways to go.

In terms of transportation issues, whether it’s Chinese New Year and then a couple of additional closure weeks. There were not only product issues but also trucking and port issues. These are also abating with port capacity in China improving each day as well. And I say port capacity, it’s also the shipping lines that come to the various ports.

Domestically, truck capacity is plentiful. However, exporting items, including KS items as well as other U.S.-manufactured items to our locations in Asia and Australia. It’s been a little bit of a challenge because of some container shortages here. But overall okay, just taking a little more work.

We’re finding other ways to handle any potential out of stocks by shifting SKUs to alternative items and categories, particularly in the areas of domestic goods, food and sundries and fresh.

And as you might expect, our travel business is impacted due to reduced demand as well as higher-than-normal cancellations of previously booked trips, particularly as it relates to cruises and international travel. I don’t know if there’s any surprise with that.

At this point, it’s hard to quantify what the financial impact will be for our future results — to our future results. Again, the first 1.5 weeks of this fiscal quarter has been — the last 1.5 weeks has been quite good with the sales, but we’ll see what tomorrow brings. We’ll continue to pass that information along, and of course, we do report monthly sales results.

 

Cooper Companies Inc (3/5 – Earnings Call)

 Having said that, Asia Pac is already rebounding, and we expect growth in Q2, even in the face of the coronavirus…  Our business in China is relatively small, only roughly 2.5% of our revenues, and we have no manufacturing or packaging located in the country. So that’s obviously helped.

We have been able to maintain or supply of product in China, which is sold through third-party distributors. So the impact has largely been around the parts of our business that sell into hospitals. That being fertility and our specialty lens business.

We’re also seeing a modest impact in other countries where there’s heightened virus activity, but our businesses are proving to be relatively resistant. At this point, we’re estimating the total revenue impact in Q2 will be roughly $15 million, comprised of $11 million in CooperVision and $4 million in CooperSurgical. I believe we’ll likely claw some of this back as we move through the year, but we’re not including that in guidance. Having said that, we’re holding our full year revenue guidance unchanged, driven by the improved MyDay production and new contracts we’ve won in our fertility business, which we expect to generate higher sales in Q3 and Q4.

Underlying all this is the assumption, our global operations largely returning normal in May, the beginning of our fiscal third quarter. Brian will provide additional numbers, but our expectations for a strong year remain intact.

 

Advanced Micro Devices Inc (3/5 – Financial Analyst Day)

From a business standpoint, it is a very dynamic situation. So let me give you some color to kind of give you, a view of what’s going on.

From an overall supply chain standpoint, our supply chain is primarily focused in China, Malaysia as well as Taiwan. And I would say, it’s a very robust supply chain. So we have taken a number of actions to ensure that we have continuity in that supply chain. And based on what we see today, we’re actually back to near-normal supply capacity in our supply chain.

So that is something that we continue to be very focused on. We’re also monitoring our customers, since a lot of our customers have supply chains that are very dependent on China and some of those operations. And we did see some disruptions, certainly through Chinese New Year and in month of February. There’s a lot of progress being made. I would say, all of us in the ecosystem are trying to return those operations to as normal as possible. And we expect that to continue over the next couple of weeks, I’m sorry, over the next coming weeks.

Now let me turn to the demand standpoint. I think from a demand standpoint, again, this is a very fluid situation. So there are lots of puts and takes. What we have seen is, outside of China, the overall demand has actually been about what we expected for the first quarter.

In China, we have seen some reduction in consumer demand, particularly in the off-line channel networks and those, I think, will continue for some time. We have also seen some other puts and takes, where the demand for infrastructure has increased beyond what we had expected originally. And so with all of that, we had guided the first quarter at our first quarter earnings call at $1.8 billion, plus or minus $50 million. We are not updating that as of now. Our best visibility is that the impact in the first quarter will be modest, but we’ll keep watching that and perhaps we’ll be in the lower half of the range, but still within the range of our original guidance. You also saw from Devinder that for the rest of 2020, we are standing — our first quarter — our 2020 guidance remains unchanged, and we see a very exciting growth path over the 2020 year.

[Updated 3/5] Based on what we’re seeing from companies with operations in China, many companies will see a negative impact to earnings as the virus spreads globally. Travel and supply chains have been hit the hardest. But we’ve been surprised to hear green shoots out of China: Supply chains starting to come back online, PayPal speaking to a “stabilization or maybe a little bit of acceleration coming out of China now,” and several companies expecting a strong 2H from pent up demand. See below for full details.

PayPal (3/5 – Evercore ISI Payments & FinTech Innovators Forum)

Sure, sure. So I’ll start with the fact that our core business has been performing very well. And I think that offset some of the impact when you look at what we shared in terms of the impact of COVID and how that relates to our first quarter guidance, still coming in within the range that we provided. But specific to Coronavirus, obviously, the topic of the day here. But things like this are, at best, difficult to forecast. And we’ve got a vast cross-border business that extends pretty prominently into Asia and China as well. And so the impact that we’ve seen has been really concentrated up to the point of our guidance in that region: China, Hong Kong, Southeast Asia. And specifically, what we were seeing is more on the Chinese seller side. So demand has held up pretty well, best we can tell. But certainly, I think there’s been an impact more on fulfillment with Chinese sellers…

Yes. Well, so e-commerce trends are, I don’t think necessarily are going to be substantively changed based upon an exogenous event like coronavirus. In fact, some hypothesize that if people are staying at home, you might even see e-commerce trends increase. And so the demand side has still been there. It’s the supply side, it’s what the — the sellers and the ability to fulfill those orders that have had more of an impact on our numbers. But we’ve got a durable business. We’ve got a multifaceted portfolio of products. And we’re in all the regions, major regions of the world. And so I think it’s certainly reasonable to assume that if there is a prolonged and material impact from coronavirus, there’s going to be some impact on growth. But we’ve got a very profitable business model that is showing strong incremental margins. And I don’t think that, that’s in question based upon what is hopefully maybe a more transitory event.

 

Western Digital Corp (3/5 – Morgan Stanley TMT Conference)

And obviously, it’s still a very dynamic situation. It has been for quite a while. And I’ll start first with the supply side. So far, we’ve been really pleased in terms of how our team has executed. We probably got a little bit lucky in some ways because we had planned to operate through Chinese New Year anyway. So we kept the employees, 80%, 90% of employees on our site, and we were able to continue to execute during Chinese New Year. And even when it was extended, we did have some discussions with the government. But based on the precautions that we had taken naturally for our employees of wearing masks, checking temperatures on the way in and disinfecting on a daily basis very rigorously, the government was comfortable with us continuing to operate.

So we have a factory in Shanghai and a factory in Shenzhen that we were able to operate through that whole period of time. So that’s gone extremely well. We’ve done a lot of work in terms of the downstream supply chain, and it’s also done very well. We had a couple of suppliers that were in the Wuhan area. One of them is back up and running. One, we’re expecting to be back up and running on March 10. And from this quarter’s standpoint, we’re obviously burning into some of our buffer inventory, but we think we’ll be fine in terms of the shipments for this quarter. And that we expect to have our buffer inventories back to normal levels by the end of April.

So I’d say from a supply standpoint, so far, we’re pretty pleased with how things have gone. Overall, as a company, we’re obviously restricting travel and being very cautious in a number of countries around the world that we operate in. And the hard part to understand is the demand side. And so far, demand has been fine. Now the reality is we tend to ship a lot of our revenue in the last month of the quarter. So it’s obviously a little early to predict how things will land. But thus far, everything has been going okay. I think it’s well documented, some of the downsides our customers are seeing in terms of handsets and mobile, which is a less significant segment for us than it once was, and then also on the PC side.

But on the data center side, we’re actually seeing normal business and maybe even a little bit of upside there. So net-net, so far, it looks like it’s okay. But as I said, it’s a very dynamic situation, and it could easily change in the next few weeks.

 

Burlington Stores Inc (3/5 – Earnings Call)

The situation is evolving very rapidly and there are a lot of unknowns. Our guidance for the first quarter does not, and cannot, incorporate a full set of risks that we, along with other retailers may be exposed to in the coming weeks. That said, we are taking steps to prepare as best we can for a range of possible outcomes.

 

Honeywell International – (3/5 – Leadership Webcast Series: Aerospace)

Yes, it’s certainly a dynamic environment right now. And so what we try to do is look at it objectively. I don’t think anybody can really forecast what this is going to do and what it’s going to mean for us in the aerospace history. It’s a — it’s an emotional topic, and it’s one that’s driven by consumer sentiment.

And so it’s not like it affects our entire business. And we’re, of course, pushing very hard to offset the effects that we are expecting to see with overdriving retrofits, mods, upgrades, engineering services, connected decouple revenue opportunities and things of that nature. So we’ll see. It’s hard to tell right now. And I think the market is still trying to get a read on exactly what it’s going to mean for us but — and how long it laps, but it doesn’t really affect the long-term fundamentals of the company.

 

Kroger Co (3/4 – Earnings Call)

From a financial standpoint, it is too early to tell the effect on our business. It is not included in our guidance. And while it is obviously very early for this public health event in the United States, we’re not seeing anything so far that would cause us to change our guidance.

We generally believe that we have limited supply chain exposure in China as the majority of the products we source is domestic. We certainly feel for those in America and around the world who have been affected. The health and well-being of our associates, our customers and our communities is Kroger’s top priority. Always being there for our communities is part of our heritage and especially in times of uncertainty. We believe everyone deserves to have access to affordable fresh food.

 

Arista Networks – (3/4 – Morgan Stanley TMT Conference)

Answer – Jayshree V. Ullal: Well, I think at our last earnings call, and we haven’t updated anything since, it was much more early stages. I think it was Feb 13, Ita? And so if you look at it now, since we’ve had about another 2, 3 weeks, what we can confidently say is, our contract manufacturers are not in China. So we’re very comfortable that we can build product. However, a lot of our inventory and components are built in China, and we’re seeing the return back of workers, not quite to 100%, but people are coming back, but we’re definitely seeing a shortage in inventory and component supply that we’re building into our lead times. Our lead times have extended by 2 to 4 weeks. So we think it’s tight, but we think it’s okay. And it’s something we’re monitoring. If it continues to improve and the workers come back and we get the components, Arista is very comfortable and committed to building more inventory on components that often have 16- to 20-week lead times, right? So we do that routinely.

So if the situation doesn’t degrade, and, in fact, improves, then I think we’ll start to improve. If it continues for a long tail, then we’re monitoring the situation. We’ll have to see.

 

Dell Technologies Inc (3/4 – Morgan Stanley TMT Conference)

Yes. Look, let’s acknowledge that there’s a lot of uncertainty out there right now. And we’ve been pretty focused on ensuring that our team members and our supplier base and our customers are — that we’re taking care of them in the appropriate way. Our guidance last week — we give annual guidance. I don’t give quarterly guidance, so we don’t give quarterly guidance. We didn’t factor coronavirus into an annual guide. I don’t think I know enough to say — is there an annual impact. We just started our new fiscal year. So — and so it didn’t make sense to me to try to be overly precise on that at this point when there’s so many unknowns out there…

Principally, you look about — you think in 2 areas. One is our domestic China business, which is a pretty large business unit for us. Obviously, the China economy over the last month has been fairly severely impacted and business activity has been down. And so we do expect a softer domestic China business this quarter. The size and extent of that, we’re still working our way through.

And then the question becomes — it’s a question we think about a lot, which is — and then — let me go to the other part, and I’ll come back to that, which is around supply chain. So our supply chain, we’re in pretty good shape right now in the supply chain. We’ve — we had, had the — I think more — maybe more luck than not. We had our notebook factories running over Chinese New Year. We were paying overtime to our workers to work because of the building supply and inventory. And so we’re in pretty good shape on notebooks. Our server and storage capabilities are generally unaffected by this. We’ve had to adjust a few lead times in certain of our clients, those new products.

And so with what we know today — and there’s still certain factories that need to reopen in China. But we feel generally okay about our supply chain as long as they reopen in the time frame that the government says they’re going to be allowed to reopen. If that changes, then we’ll have to ship — we are spending a few extra dollars on logistics costs as you move parts and product around the supply chain, but that’s just — and some of the logistics dynamics are a bit more complicated these days.

But the real thing that we begin to think about then is, okay, how long does this last? And when you think about demand or customer demand, is that demand perishable or is it deferred? And it gets down into — you have to think your way through the customer sets. If you look at our PC businesses, which is roughly sort of low to mid-70s sort of business oriented and the rest of it consumer, if it’s consumer demand and there’s a consumer out there that needs a notebook today or tomorrow, and if you don’t have it, does that demand move to some other provider or other manufacturer? It may be. Yes. There’s probably more likely that, that type of demand would be perishable. If it’s a business relationship where you have a contractual relationship and you’re working with them on deliveries, that demand probably is more deferred, if you will. And so I think we’re just going to have to work our way through this and see how this plays out over the next number of weeks and try to get better insight as we go through the quarter.

But there’s a bit — there’s some unknowns out there clearly. And it’s our job to navigate through that. I don’t — and for me to start to say it’s this impact, I think, at this point is probably trying to be a bit too precise.

 

Uber (3/4 – Morgan Stanley TMT Conference)

As it relates to the effect of corona on our business, frankly, historically, there has been very little effect. The geographies where you have seen significant effects societally from corona account for about 1% of our bookings on a global basis. So that’s certainly something that is there, but it’s not material for the company overall.

The airport side of the business — I think the first shock that you’ve heard of is travel. The airport side of the business is about 15% of gross bookings. It’s a little bit higher margin than the rest of the business, but I wouldn’t say significantly so. And as expected, our airports business has slowed down a little bit relative to the balance of the business overall. But again, nothing that is alarming in any way, shape or form and nothing that we can’t adjust to.

Keep in mind, I was in the travel sector, so I understand how shocks affect the travel sector. This is different for us, right? We are a technology company. One part of our business, our Rides business, certainly, to the extent that people stop leaving the house, will take a hit. One part of our business, Eats will probably be, actually, benefited.

We’ve got a very diverse geographic footprint. We have an incredible balance sheet. 2/3 of our costs are variable. So we have a lot of levers to pull to adjust to areas of strength of the business that we can lean into or areas where we see some weakness as a result of corona where we can kind of lean back from.

Every pattern that we’ve seen is that corona will — if it hits, it hits, but then there will be a bounce back. So this point, we’re quite confident of our Q4 profitability target.

 

Progressive (3/4 – Earnings Call)

Question – Michael David Zaremski: My first question is on any potential impact from the current situation with the coronavirus. The New York Times has come out and said that they’re seeing just recently ad spend fall fairly materially across the brand with (inaudible) to 25%. And I’m curious if you think Progressive should in the near term — or is part of that? And also, are you seeing any impact maybe from your [call medics] drivers on the work frequencies if people are maybe working from home?

Answer – Susan Patricia Griffith: Mike, that’s a great question. So I’ll start with the ad spend. Right now, we’re going to continue to spend. This is a prime time of the year when people are buying insurance, we’re getting into that season. We’ll continue to spend. That we have some flexibility in. But again, whether you drive a little bit or a lot, you still are required to have auto insurance. And so our intentions will be to spend as long as we feel sufficient. So again, we’ll have to be nimble because all of this, as you know, is ever-changing.

The great question on the UBI. So with the recent deaths in Washington, we asked the UBI team, just to take a look at UBI vehicle miles driven or traveled by week in January and February this year compared to the prior 2 years. And we are not quite seeing a difference. And again, that’s very little data, but that tells us we haven’t seen it yet. Again, now that we’ll look at it weekly, we can start to see that. We’ll look at it across the country where we can. So we’ll be able to understand pretty quickly. If you go back to something like the financial crisis, I was running claims at the time and we saw frequency drop really quickly. And so we’ll have some good insight. We get our frequency data on a daily basis. So we’ll understand very quickly where we’re at.

From a vendor perspective, we always think of the concerns around auto parts that are possibly made in China. So we had our property process team talk to all of our OE vendors, the percentage of OE that we use on our vehicles, the percentage they get from China, et cetera. For the most part, with the exception of one OE, we feel like there’s low risk at this time. And even with that partner, they have an inventory. Again, it’s always those like first and second order effects. So it could be that more cars are told, because you can’t get parts and then there’s used car parts. So it’s — we’re going to keep watching that.

So right now, we aren’t seeing any effect. But again, this is such a moving target that we have a lot of data points that we’re going to be looking at literally on a daily basis to understand how it will affect possibly our frequency.

 

ViacomCBS Inc (3/4 – Morgan Stanley TMT Conference)

Yes. Sure. So look, to state the obvious, a lot of volatility in the equity markets, and particularly this week, triggered by COVID-19, we’ve certainly felt a fair bit of pain in the ViacomCBS equity as have many others. What I’d say is, conceptually, the — our industry, the broader media industry on a relative basis is probably less exposed to this than some other industries. And more specifically, ViacomCBS is probably less exposed relative to certain of our competitors.

But practically speaking, what I can tell you is, as we looked at our business, we’ve seen no material effect to date. The only thing that has occurred is we’ve moved the Sonic release date in a couple of Asian markets as we’ve held the film. And so we remain excited about our path ahead. We’re on track with our guidance, and of course, we’ll continue to monitor the situation. And should anything change dramatically, we’ll assess. But for now, we’re not seeing any material impact.

 

Abbvie Inc (3/4 – Cowen HealthCare Conference)

Well, so it’s still early in terms of our ability to understand direct impact on sales, reporting the numbers and, obviously, not closed yet. But you’d expect the sort of disruption that happened in the health care system in China to lead to that sort of temporary warehousing effect that I described. But as things return to normal, as the situation returns to normal, as China already seems to be on that path, you’d expect that demand to come back. So it would follow the same sort of pattern that I described as a much larger analog of the recession of the last decade.

 

Discover Financial Services (3/4 – KBW Cards, Payments & FinTech Symposium)

As far as how this virus is going to play out and what that’s going to do, it’s anyone’s guess. But we will continue to leverage the data externally to leverage the data on the millions of customers internally and to do kind of stay the course, do the right thing and make sure that we’re responsible in our decision-making and our actions. But right now, there is nothing that we’re seeing that is causing us any alarm. But again, we’re going to continue to monitor in a very smart way, leveraging the data on a regular basis.

 

Mastercard (3/4 – KBW Cards, Payments & FinTech Symposium)

So we were monitoring, running up to Monday last week, and we continue to do that. I’m not going to repeat what we said in the announcement. So there is an impact on the first quarter. The question that we had at the time in which we put in the release, that there’s too many question marks around this. So severity, duration, they are not a good set of answers.

I think the one thing to say, so we sit here and we think about the impacts on our business. Actually, the more noteworthy impact that I feel is that we have large teams in China and people are worried. We have people traveling. So there’s a lot of effort the leadership team put into making people feel cared for and understood, and we can do what we — we do what we can do, providing masks and all those things. So that’s equally important, but we feel reasonably prepared to see what comes. And then whenever there’s something else to say, Warren will do that. We keep monitoring.

 

VMware (3/4 – Morgan Stanley TMT Conference)

And while you’re always looking for silver linings, hey, coronavirus, people want to do more work from home, hey, I got a product called WorkspaceONE, right? We’re enabling people to do that. Some of our biggest Q3 deal — or Q4 deals were around Workspace ONE.

 

Veeva Systems Inc (3/4 – Morgan Stanley TMT Conference)

For the industry we serve, it’s a busy time and it’s a time of change. There’s — they do a lot of collaboration around the world. Some of them are fine-tuned already to do that in a virtual way, such as Veeva. Some are less so. And with the — some of them are decreasing travel, and so they’re having to get better about doing virtual communications. We’re helping many of our customers by providing Engage Meeting, one of our products for the pharmaceutical companies to engage remotely with health care providers. We’re providing that free of charge until September, and that’s helping some of our customers.

We have certainly some customers that are working on treatments and vaccines for the COVID-19 virus. So they’re certainly very busy. And I felt — I read that this morning, Moderna, one of our customers, actually introduced the first candidate for a vaccine. So they’re very busy.

For us, for Veeva, we’ve operated in a virtual way quite well for many years here. We just embrace the virtual technology. We haven’t seen projects canceled. We’ve seen some delays in some projects, but nothing that would materially affect our financials. So we’re continuing to focus and to be productive and to run virtually in the places where we need to where there’s a serious outbreak…

So for example, just to make a super simple example, when we started out with Veeva CRM, this was before actually the iPad was introduced. Then the iPad was introduced, we upgraded and our customers could move right onto iPad right away. When we started Veeva CRM, there was no concept of doing a remote meeting with a doctor. Now we are ready there. Some of our customers, they hadn’t purchased Engage Meeting, but man, they want it in a hurry right now because of this COVID-19 virus.

 

Splunk Inc (3/4 – Earnings Call)

I think after a year of evaluation, what we heard over and over at this year’s RSA was very little discussion about Microsoft or anybody else on the security front. Almost no discussion about Open Source. I think the maturity — where, obviously, this was last week. So we’ve already got some of the effects of coronavirus and people being concerned about the volatility of the economy and that would — what last week told me is people are kind of circling the wagons and making sure that they have vendors they can trust, that the value is super clear on what they’re actually working with and if this goes with any patterns we’ve seen in past economic disturbances. The companies are very, very customer centric. And have a track record of value and delivery wind up doing pretty well.

 

Align Technology Inc (3/4 – Conference Call)

In terms of a Q1 ’20 outlook, at this time, there’s no change to our Q1 ’20 outlook. As you may recall, when we gave guidance in Q1, news for the novel coronavirus outbreak in China had just begun, and we stated that we had factored it into our guidance for the first quarter. The virus is now called COVID-19, and the situation in China and other affected countries remains very fluid. News reports reflect increases in reported cases in other countries, including South Korea, Japan, some parts of Southeast Asia and Italy and United States. We continue to monitor all impacted markets very carefully or in close contact with all our relevant agencies globally. The safety and well-being of our employees remains our top priority. And thankfully, none of our employees or their immediate family members have been infected with COVID-19.

 

Salesforce.com (3/4 – Morgan Stanley TMT Conference)

Right now, it’s hard for me to say what the long-term impact will be. I think I would just say, the broader secular trend of these digital technologies essentially driving changes in people’s business models and their customer experience, that’s going to exist before and after this really sort of tragic and unprecedented in our economy. And so you know, Mark Hawkins and Marc Benioff both talked about these, that were durable now. I’d just emphasize it which is, our business model is designed to be durable. The company has been through a number of events like recessions. So I think we’re going in just trying to focus on the health and well-being of all of our stakeholders. We’re confident in the durability of our model. And I believe that the broad trends driving investment in technologies like ours are enduring independent of any short-term event.

 

Roku Inc (3/4 – Morgan Stanley TMT Conference)

Yes, in terms of coronavirus, what we mentioned is, today, we’ve only seen minor impacts, largely around supply chain in manufacturing. We had moved our Player manufacturing into Vietnam in the fall as a result of the potential tariff situation. But like the rest of the industry, a lot of the component supply chain runs in part through China. And so to the extent there’s continued disruption or significant disruption of the supply chain, so that can impact our ability to replenish our inventory.

 

Snap Inc (3/4 – Morgan Stanley TMT Conference)

 Yes. Well, fortunately, for our business, the impact to date has been minimal. I think that’s largely due to the fact that our community is concentrated both geographically and demographically in places that are less impacted, at least from a health perspective from the virus. So you know that Asia, for example, has seen sort of an outsized impact. Our community is mostly outside of Asia. And if we look at the health impacts to young people, our service, large, 13- to 34-year-old population, they don’t exhibit the same sort of symptoms that may be more advanced age folks do.

So I think from a health perspective, the health of our community and our business, so far the impact has been minimal. The thing we’re really paying attention to, as the situation evolves, is how our advertising partners will be impacted, and we really want help support them to grow their business during this volatile period. So we’re going to continue to try to drive a lot of value for them, and I think we are optimistic that this will be a short-term impact.

 

Zoom (3/4 – Earnings Call)

Zoom is doing everything we can, especially for global educational institutions, to provide resources and support to our customers and those navigating the coronavirus outbreak, including: we are proactively monitoring capacity globally to ensure maximum reliability made usage increases; in China, we have removed the 40-minute limit on free meetings; and we are providing informational sessions and on-demand resources so anyone can learn how to use the Zoom platform with ease.

With the reliability of our high-quality video platform, we have seen a large increase in the number of free users, meeting minutes and new video use cases. For instance, in China, health care workers under stressful conditions in affected areas are able to connect live on video with therapists…

Due to the coronavirus, we have already seen significant usage of our platform. And accordingly, we will expand our capacity to meet the increased demands of both paid and free users. For FY ’21, we believe our gross margins will be at the lower end of our long-term target of 80% to 82%…

I think, first of all, I don’t think that’s temporary. The reason why is — I mean in terms of experience about using the videoconference like Zoom, you get a company in Silicon Valley, like [Invasion], Zephyr or GitLab, which are great companies, they do not have a single physical office to really understand how to enable remote workers to work together. However, if you look at companies in other part of the world or maybe on other side, California, quite often, we need to help them, we deal in the future of communication, we need to enable video, and we need to explain that. But given this coronavirus, I think overnight, almost every business really understands they needed a tool like this. This will dramatically change the landscape. I truly believe in the future, every business would turn to video for the remote workers for the collaboration.

In terms of our results, Nikolay, for Q4, we did not see any impact directly related to coronavirus. As a reminder, we have definitely seen an uptick in usage, but a lot of that is on the free side. So it’s very early to tell whether or not that’s going to convert long term into paying customers. As we mentioned, we are seeing impact and continued to build capacity to ensure that we can support this increased usage. So we are seeing an impact on our gross margins, which is why we’re guiding you towards the lower end of our range for next year…

Walmart (3/4 – Raymond James Conference)

Certainly, I’m looking at reading the same things as you are and with Coronavirus and certainly, we’re concerned about associates and and customers and making sure we’re doing the right thing there. When you look at kind of the underlying economy, it still feels good to us. And we said that a couple of weeks ago at our analyst meeting, inflation is low, interest rates are very low, wages are good. Fuel prices are low. So all of that portends to being — having a pretty good economy, particularly here in the U.S. And so I think, overall, the consumer feels pretty good.

 

American Express (3/4 – KBW Conference)

And we have gone through January and February, maintaining that same momentum. Now when you look around the globe, we are a global company, you will see that in the markets in Asia, most impacted by the coronavirus, so we’re talking Mainland China, Hong Kong, Taiwan, Singapore and Japan. You do see for those countries, material reductions in travel, both inside the countries and in and out of the country. And that has caused a moderation in spending trends in those countries that for those countries is material. But for our overall company, that is not a material part of our business. And so if you were to look at our filings, you would see that what we broadly call our Asia Pacific region is 9%, 10% of our revenue in PTI. But that actually encompasses a lot more than just the companies I just talked about. Australia, for example, as part of our Asia Pacific reason. And actually, Australia has been particularly strong. And for reasons, I’m not sure I can fully explain, even stronger in the most recent weeks than it was in February.

So sitting here today, in terms of the impact on us, we really see nothing that would cause us to have a materially different view of our plans for the year than we started. However, the obvious question that we’re watching every hour, every day, and that all of you and all of our competitors, like when you just had on the stage are watching is, are the impacts, the kinds of impacts that we have seen in those 5 Asian countries I just articulated. Are you going to see that impact spread into Europe and into the U.S.? And if it does spread, how long does it last? And as we sit here today, we don’t have material factual evidence of that spread. We have lots of anecdotes, right? And certainly, we have, if you look at just the last couple of days, a little bit of softness in some of the T&E bookings. But again, let’s put that in perspective, for our company, about 8% of our overall billings volume globally come from airlines. And I am an old airline CFO. I would remind you an airline stopped flying to China. They actually generally redeploy the plane somewhere else and consumers often do the same thing. And if they’re not going to go to Europe. Often, they go somewhere else in the U.S. So airlines are only 8% of our billings. T&E in total is down to 25% of our business. And I think, Sanjay, that’s some — at least in the U.S., I think that’s something people sometimes forget. I suspect you’ll get to a question about, gee, do we have any learnings from SARS? Well, SARS was 17 years ago. Even the general lesson that SARS, I think, teaches us is these things end and there’s a strong rebound afterwards. We were also a different company back in the SARS however T&E was a bigger portion of our company. And in the interim, we’ve had 17 years of much higher growth rates outside of T&E, particularly in our commercial business.

 

Visa (3/4 – KBW Conference)

So obviously, this is a very fluid situation. And we put out numbers on, I guess, Monday night saying we would — we expect our revenue to be 2.5 to 3.5 basis points — percentage points below the outlook that we provided for our fiscal second quarter, which ends at the end of this month.

The reality is that most of that impact is travel in and out of Asia and intra-Asia, which is not altogether surprising given that, that was the initial epicenter of the buyers. We are seeing it in the impact in both card-present as well as card-not-present, although the reality is that much of the card-not-present impact is actually travel, people using online travel agencies and the like. Although intra-Asia, we are seeing some, although smaller impact on just e-commerce in general beyond travel.

In the places where we process the majority of the transactions and therefore, have insight daily into volumes, we’re largely seeing domestic volumes hold up with the exception of Hong Kong and Singapore, where there definitely is an impact on domestic volumes. And just as a reminder, we don’t have a domestic business in China, so that’s why I’m not commenting on China. There’s no transactions domestically for us to see or analyze.

It has only been a couple of weeks that the virus has moved in a fairly pronounced way outside of Asia and it’s plain and simple. There’s just too few data points to draw any conclusions about its impact. That said, we factored some deterioration outside of Asia into the estimate that we put together on the 2.5 to 3.5 percentage point decline in revenue.

 

Dollar Tree (3/4 – Earnings Call)

Let me give you a bit of an update on the coronavirus as it affects our supply chain as we see it today. Our global sourcing group and merchants along with our logistics team are meeting daily and updating our progress on visibility to individual purchase orders. Generally, we are seeing production pickup, and factory attendance is increasing each week. Our global sourcing team in China and third parties that provide quality assurance inspections are nearly at normal levels. All ports and third-party freight consolidators are open and operating at near-normal levels, and we are getting all needed space on vessels for our freight. At this point, all of our Easter merchandise and lawn and garden seasonal product is in our domestic supply chain, either in distribution centers or flowing to stores. At this point, we see a very small percentage of product canceled and some products moving on to later delivery, usually by a few weeks. And our teams are working to mitigate with sources elsewhere, including domestic sources, to mitigate any effect there. More to come.

Our initial outlook for fiscal 2020 includes the following assumptions: our outlook does not include any potential impact related to the supply chain or other aspects of the company’s business for the COVID-19 coronavirus. 

We certainly are seeing a spike on anything that’s related to hand sanitizers and cleaning surfaces. But I would say we’re also in first [of] month right now in tax refund time. So right now there is money in the market for all those reasons, plus a heightened efforts for everyone to wash their hands and use hand sanitizer. So we’re seeing that in the stores as well.

 

Centene (3/4 – Conference Call)

Needless to say, we are monitoring the situation closely. The situation is fluid. However, we have not seen any impact on our business thus far. It is too early to make a determination given how quickly this could evolve. We do fully expect it to be manageable.

 

Moody’s (3/4 – Raymond James Conference)

So — well, so there’s lots of people who are thinking about this. And I would say maybe the one that’s most traditional that everyone would expect is the rating analysts need to incorporate expectations related to coronavirus or COVID-19, whatever you want to call it, in each of their sectors and with respect to each of their companies. So the ratings process incorporates this just in terms of the way we actually assign ratings to institutions and to entities. And then you’ve got, I’ll call it, big picture experts who might be health care experts or they might be more familiar with the way the World Health Organization or the CDC organization might work. We might incorporate them into the ratings process as well. We’ve got scenario analysis that we do in our group that does economic forecasting. So in Westchester and in London and a couple of other places, we have maybe 100-some-odd econometricians. And they produce forecasts at the MSA level and at the bigger picture macro level in order to address questions like this. So we’re updating those forecasts right now and incorporating scenarios that are COVID related — COVID-19 related.

 

Xilinx (3/4 – Morgan Stanley Tech Conference)

With respect to impacts to the company on the supply side, we don’t have — most of our supply chain is not in China. So we don’t see any impact of availability of products. With respect to the demand side, we haven’t seen capacity normalizing post-Lunar New Year, to the extent we would have expected by now. And so while the impact currently has been modest, I think the expectations are if this obviously is protracted, global consequences, there could be more meaningful impacts to the business in subsequent quarters.

 

Home Depot (3/4 – Raymond James Conference)

So on our global supply chain, I would say, for Q1, we’re in pretty good shape. So product for Q1 is largely in our stores. So Q1 and 2, for us, is a big strength. Spring and outdoor project business, we’re largely set. So all our merchandising space has largely transitioned to spring product. We’ll be finished with that in our northernmost markets in the next week or 2. But — so all that product that comes in, think grills and patio sets and the outdoor power equipment I was talking about previously, for Q1, that product is largely in-store, in our supply chains or on the water.

Q2, I would say, it’s a very fluid situation. So as you say, we have very strong relationships with our supplier partners. For our direct imports, where we’re working directly with factories in Asia, we are in constant contact with them and monitoring their capacity and how they’re getting back up to speed and what their shipping horizons, timing is going into Q2. It’s fluid. We’re literally looking at this PO to PO. The good news is the ports are open and functioning. We haven’t had delays in ports. It’s really a matter of workers getting back to factories from the Chinese New Year. Most of those workers or many of those workers are in residence at the factories. And for those 2 weeks of Chinese New Year’s, they travel home to wherever their provinces may be out of the major cities. So it’s been a transportation issue in restrictions of travel intra-country to get those workers back to the factories.

So again, we’re in contact, varying degrees, as you can imagine, of building back to capacity. The next set of suppliers are suppliers that, while we don’t procure directly from China, we know the country of origin is China and Asia. And we’re in constant contact with them, starting to build orders into Q2. Again, it’s PO to PO. You’re obviously not going to order too deep into Q2. You just — the supply chain won’t handle that sort of cube. So we just have to keep working it. Nothing alarming at this point. We said there was nothing in our guidance for 2020 that included coronavirus. We were 3.5% to 4% at our analyst meeting in December and after our first quarter — after our Q4 earnings call. And there’s no change to that at this point. But certainly, it’s a fluid situation.

 

Brown-Forman (3/4 – Earnings Call)

Specifically, our base in China has been growing underlying net sales at a double-digit rate since fiscal 2018, led in large part by our growing e-premise business where we have been focusing our investment in this market. Our performance through January had essentially not been affected by the coronavirus. So understandably, we do expect a marked slowdown in our fourth quarter in this market in other parts of Asia and have already experienced this in February. Despite this near-term headwind, we remain optimistic about the long-term growth potential for our portfolio throughout Asia.

So again, if you looked at what we did, we took our overall forecast down, as you saw, we reduced our underlying forecast with 2 factors. First, it was the tempering of the growth and contribution from some of our international markets, again reflecting some short-term disruptions as well these macro and economic and geopolitical challenges. So when we look at our base business, but we would estimate now that our base business is doing is probably growing in the 3.5% to 4.5% range. It is, therefore, a couple of points less than what our expectations were just 3 months ago. But the second factor that we built into our forecast, and this is what you’re asking specifically about Vivian, that led to a reduction in our top line outlook, and again not surprising, is this unpredictability and uncertainty surrounding the coronavirus and what it may have on our business globally. So we’ve estimated at this point, there’s about a point drag including those markets that are currently affected. So to your point, directly from the Asian markets, including China and other parts of Asia, Travel Retail and we haven’t Italy in there. So collectively, that’s about 8% of our business. And as I said earlier, yes, we’ve already seen areas — many of these areas already affected in results. But that being said, we also have, in that 1%, some additional downside impact. And we don’t know, none of us knows that’s going to be enough, too much we’re learning daily as this situation and So we’re really only looking at our fourth quarter. We haven’t had to estimating downstream, secondary effects on anything beyond the demand we see in an expectation for perhaps it some other markets. We don’t know about the economy and the consumer confidence and sentiment and how they may linger into our first quarter and summer months. 

 

Lyft (3/4 – Keybanc Conference)

I think users and people around the United States are reevaluating their daily routines in light of all the media attention. And I will say anecdotally, talking to a number of friends and colleagues. People are using more Lyft. I think when you turn on the TV or watch any sort of media channel right now, and all you hear about is coronavirus. If you have to get from point A to point B, you begin to second think any sort of situation where you’re going to be crammed into a bus or crammed into a train or subway. And when you’re pack against people and you hear distant coughing, I think there’s nothing worse in terms of the human psyche right now because there’s just so much fear. And so what I can tell you to date, we have not seen a demand impact. Quarter-to-date, we feel great about the quarter. We are reaffirming Q1, both in terms of revenue and adjusted EBITDA.

And I think one important data point, which will probably be a big surprise for a lot of investors. Last week, it was markets in free fall, fear, paranoia about coronavirus in the United States. Last week was our single biggest week in our history in terms of both revenue and rides. And so again, I don’t want that to get lost. It was literally our all-time best, with — even weeks with New Years. It was last week. So it’s impossible to predict. There are so many different scenarios where we can go from here, but I do think there’s some mitigating factors from Lyft, especially what’s priced into our stock at this point. Again, we feel good about the quarter, and we’re just going to keep putting up numbers.

Sirius XM (3/4 – Morgan Stanley Conference)

And all the news has been about the coronavirus. So what does it mean for us? Well, we’ve done a bunch of things operationally because you really don’t know where it’s going. So we’ve got sort of tiger teams in place to make sure there’s adequate at home work capabilities across all the different product lines that we’ve got — guys who figure out staffing in the event people can’t get to offices? How do you cover all the bases to keep all the wheels running and turning we did — we asked our employees not to travel internationally. That’s not a huge thing for us. We do have a bunch of call center operations in the Philippines. So it’s not a major thing. We’ve checked supply chains with the OEMs. And honestly, things look — looks pretty good. The supply chain for automotive is fairly long as I think most people know. And so if it goes on for a couple of months, I think there’s probably not a whole heck of a lot of impact on us. If it goes on for much longer than that where people can’t get in. We can’t get printed circuit board supply, right? That could be an issue. But it’s got to run for a few months before we think we start to see anything. So other than that, it’s just keep cracking away the business everyday.

 

Hewlett Packard Enterprise (3/3 – Earnings Call)

Additionally, the outbreak of the coronavirus at the end of January impacted component manufacturing, resulting in higher quarter end backlog. 

Also, we do feel it is prudent to revise our fiscal year ’20 free cash flow outlook from $1.9 billion to $2.1 billion to $1.6 billion to $1.8 billion, given that we expect some impact on cash conversion cycles driven by the ongoing recovery from supply constraints and impact of the coronavirus.

Unfortunately, this is also causing supply and demand disruptions and affecting our revenue profile. The outbreak at the end of January started to impact component manufacturing and resulted in constrained supply and higher quarter-end backlog worldwide, and we have been in constant contact with our suppliers and are establishing specific mitigation and recovery plans. So this is affecting our revenue profile for the full year. This is why we’re not guiding in the short term. And relative to what we said at SAM, where we were experiencing — we’re thinking we would be returning to growth in fiscal year ’20, I don’t think that it is likely at this stage that we’ll grow in fiscal year ’20, as a whole for the fiscal year. But we do anticipate recovery of those supply chain constraints over time and face easier comps during the course of the year.

Answer – Antonio Fabio Neri: I would like to add a couple of comments. One is on the coronavirus. Obviously, this is very fluid at this point in time. There is uncertainty. We have a daily process with each of our suppliers that we managed very, very tightly. And some of those suppliers are dependent on other suppliers because, as you can imagine, the supply chain is a little bit longer with Tier 2, Tier 3 suppliers that provide what I call low-level components to build what I call the printed circuit boards or the PCIs or the PCBAs, and that’s a challenge we see today. And we see recovery, but obviously, it’s going to take time. And that’s why Tarek said we cannot provide right now a definite guidance. I think it will be not appropriate. And that’s why we felt prudent not to provide Q2, but because the recovery is going to happen through the year that we felt comfortable reaffirming the 2020 guidance.

 

Ross Stores (3/3 – Earnings Call)

As noted in our press release, our guidance does not reflect the potential unknown impact from the evolving coronavirus outbreak. While we’re closely monitoring the situation, there remains a high level of uncertainty over supply chain disruptions in China. In addition, it is unclear how a further possible spread of the coronavirus could negatively impact U.S. consumer demand.

 

Digital Realty Trust (3/3 – Citi Conference)

On the customer side, I would say, to date, we’ve seen limited impact. We’ve been doing business very recently with customers into APAC and out of APAC. We are obviously big believers in a virtual world. It’s driving through our data centers every day, and business is getting done in a virtual format in many fronts. That being said, we have no idea where this current scenario goes, and there’s always a potential impact to business. My glass half-full on that is the breadth of our customer base, 2,000 today, going to close to 4,000 with our combination or depth of relationship, both personally and contractually. With some of these top buyers, allows for easy repeat buying and allows us to keep continuing to support their business in the event that they don’t have the physical ability to go to a new location as they’ve seen most of our sites. They know our capability. We’re on board as a vendor with them. From a supply chain standpoint, we are — obviously have the potential risk of impact given numerous components within our 4 walls. Could be manufactured or imported for some of the countries impacted. From our advanced discussions that well predate today where we are on this coronavirus. We feel that we look — appear to be insulated, whether it pertains to batteries, UPS, switchgear, for at least 12 months’ worth of time. So, so far so good. But again, as I mentioned in the opening statements, we don’t know where this is going. We take it very seriously. And lastly, and I probably should put this front. From a people front at Digital, we are relatively small in the people front. Today, only 1,500 employees, but we are very international. So we’ve taken steps to shut down all travel into and out of APAC. That happened several days ago, and we’ll obviously evaluate this step-by-step as things need to be evaluated for other international parts of the world.

 

Teleflex (3/3 – Raymond James Conference)

So as we see our $5 million to $10 million, it will be at the lower end if things get back to pretty much business as normal in China right about now, in early March. The impact will be $10 million — $5 million and $0.05, $10 million and $0.10 on the EPS if the uncertainty continues in China and procedures don’t get back to normal in — until the end of March, early April. I guess where we’re a little bit insulated is the portfolio that we sell in China and also there is, ironically, a little bit of upside also baked into that $5 million to $10 million, where we would envision that some of our CVC coated catheters would get used as some of these patients would get admitted into the intensive care unit because of the condition. And I think that once people return to work, which from our intel, at least, is happening right about now, one would imagine that the procedures would then start flowing through the hospitals. Again, I’m — at least by the end of the month, we’d get back to business as usual. Now the virus has gone beyond the shores of China, as we all know, and is now having some impact in South Korea and Italy. And I think that it is tragic, and I’m not trying to take away from the tragic nature of it, and it is quite infectious, but I would also remind the audience that the general flu in America, just in America, has had 16,800 fatalities already this year in the general flu, and the coronavirus has also tragically had 3,000 fatalities. I think also coming outside of the Chinese health care system moving into a more developed health care systems, like you have in Western Europe and in the Americas, we should be better prepared to contain the virus as long as we’re diligent.

 

Fortinet (3/3 – Morgan Stanley Conference)

First, from the sell side. We just finished the 2 months. The quarter — the previous quarter and 10 quarters the same. So we’re on track for first 2 months. So we don’t see any initial problem there. And — but do the [spare amount unit] come almost 50% of the business. So that’s where there it is still risk. We’re not changing our guidance. So far. And also from the supply chain from other manufacturer side, that we have over 90% manufacturers outside China and it come down like a single-digit of our manufacturing. And also a lot of low-end because we more manufacture with it directly. A lot of low-end already manufactured because we also care the overall cost, including shipping cost is a lot of low-end a shipping capacity, already manufactured a few months ago. And so we — so far, we don’t change any of the guidelines. And so everything on track, but I do believe there’s a blurred dynamic, and there’s still the risk, so.

We don’t see much impact. At least it’s not quite mature. We do see certain industry like whether it’s the cruise line or is it certain airline, maybe a little bit slow down. But we are still broad and cover different vertical, and also still broad and cover a few [profits] diversified, so we don’t see that as much as — effect the results or impact it.

 

Cummins (3/3 – Evercore ISI Conference)

So I think as you’re aware, when we gave our guidance back at the beginning of February, we didn’t include any impact of the coronavirus at the time. Things were still moving pretty rapidly, a pretty fluid situation.

What we’ve seen right now, we have about 10 facilities in the Hubei province in China, many more dotted throughout the rest of the country. In general, our facilities open 1 to 4 weeks after the Lunar New Year. So a delay on opening there. And our total China exposure on consolidated sales is about $40 million to $50 million a week. In addition to that, our JV income is about $200 million a year in China. So definitely had some negative impacts on domestic China consumption given the delays in start-up of our facilities. Almost all of the facilities now are up and running to some degree. Some of them 100%, some less than that. And I’d say the ones that are running a little less than that, it’s really driven at this point by OEM partners whose facilities aren’t up and running 100%.

So we’ll know a little bit more about what the full year impact is, the demand, I think, by the time we get to Q1 earnings. Just need to see to what extent potentially the government does some stimulus and whether the demand that we did lose in the first quarter comes back in the second half of the year.

So from a finished Cummins product perspective, we do not export a significant amount of material outside of China. We generally produce and sell in country. The area that we’re paying very close attention to is more some of our Tier 2 and Tier 3 suppliers that have some of their facilities out in China that export some of those to our global facilities.

So at this point, we’ve had no disruption, 20 of our facilities related to that. But certainly a very concerted effort by our supply chain organization tracking individual part numbers and understanding where the risks could be in the supply chain related to some of the delays of those Tier 2 or 3 suppliers that have been ramping up production.

 

Charter Communications (3/3 – Morgan Stanley Conference)

I mean it’s a little early on the advertising side on coronavirus. So I’m going to refrain from commenting there. The advertising business is healthy for us. It’s really attractive.

 

Intuitive Surgical (3/3 – Raymond James Conference)

But you look at China specifically, on the procedure side of our business, roughly 3% of our worldwide procedures are performed in China. And yes, they’ve been growing very well as of late as new systems have been installed. There’s no doubt that the coronavirus has been affecting procedure volumes in China and likely had some impact on other countries around the region as well. We’ve seen incidences of outbreaks in Korea as well as Japan and lately, more lately in Italy and even here in Washington state. So it’s really we’re unable to predict what the ultimate impact will be, but clearly there has been some. And we’ll keep you informed as things go.

Yes. I mean we can see differences in trends, and we track them on a regular basis. We’re not going to report here to this group exactly what we see at this point in time because, again, it is very dynamic, and you can look for an update on — after our Q1 earnings.

 

Citrix Systems (3/3 – Raymond James Conference)

The coronavirus, okay. So I think like most other companies, we have travel restrictions now in place in certain countries. And so it’s too early to say what it would mean in terms of our own business in the near term, frankly. We, like most — like many software companies tend to have a pretty back-end loaded quarter. So it’s — so I don’t — so we don’t know yet.

But I think that, perhaps, more importantly, over the longer course of time, it is — there’s no doubt that the concept of business continuity is an increasingly important topic. And there’s clearly an opportunity for Citrix to be part of a corporation solution to ensuring that regardless of the environment, whether there’s a pandemic or whether there are natural disasters, that Citrix is undoubtedly a way companies can help to ensure that their business continues on and that people can remain productive regardless of the circumstances.

 

AT&T (3/3 – Morgan Stanley Conference)

There’s clearly impacts that are starting to emerge, and it’s a fluid dynamic. Kind of what we see this week may be different next week. I think we’re all prepared for that.

I do expect that there are going to be some impacts that flow through handsets, especially for those vendors that are more oriented towards China. And we’re already starting to see that happen. I don’t expect that those shortages are going to be anything that probably impact first quarter dynamics in any significant way for voice postpaid kind of constructs around things. We’re seeing some things in prepaid entities, like if — I shouldn’t say prepaid, but watches, tablets, maybe some shortages popping up there that are particular SKUs that may have some nominal impacts, but it’s not significant.

Look, I think the vendors right now are fairly optimistic that this is contained and it’s going to be isolated to several weeks of delay for particular SKU items, not that there’s going to be complete stockouts. I think this morning, Foxconn indicated that they felt like they were starting to get some of their production in China turned back up and that they would get themselves back to somewhat normal constructs around the end of March. Obviously, once they get back to normal at the end of March, it takes a period of time for that to work its way through the entire supply chain and replenish. But if that in fact happens, then we expect it’s going to be relatively contained and manageable, and all the tactics we’ve used to stockpile and allocate those types of things should be able to get us through with some reasonable confidence.

 

United Parcel Service (3/3 – Raymond James Conference)

The coronavirus was not in our 2020 guidance. And as our CEO, David, said during his February 24 interview on Bloomberg, we do anticipate an impact on our results. But given the uncertainties, I just think it’s too early for us to quantify the impact at this point with another month left in the quarter. We’re closely monitoring U.S. industrial production. And so despite some of those challenges, on a more positive note, I would say the enhanced flexibility of our network is going to allow us to minimize emerging headwinds where possible, and I think we have a track record of that.

So I’ve been meeting with investors all morning, and that’s generally been the first question that came up. So first, we have a lot of employees and customers on the ground over in China. So anyone who is impacted, we’re obviously focused first and foremost on making sure they have the right health care and needs from a protection standpoint. The business obviously slowed. I referenced in my comments, we maintained our Lunar New Year operations, coming out of Lunar New Year and sort of extended that by a couple of weeks, recognizing the downturn in the market. The — our planes are flying in and out of China right now. This week, we’re starting to see a rebound in activity in China and Hong Kong, specifically, Tyler. But this thing is moving quickly. I think we’re trying to position ourselves to take advantage of some pent-up demand, and we’ll take it week-by-week as far as extended impact. But we are seeing a rebound this week.

Answer – Tyler Brown: Okay, that’s great. And I don’t want to keep it too near-term focused, but what happens in the Air Freight market when something like this happens? All the wide-body domestic flights going to Asia are just not there. There was a lot of capacity that’s basically been taken out. It seems like the parcel carriers are still flying. Is that market getting extremely tight? And is that an opportunity, quite frankly?

Answer – Brian Newman: Yes. It’s — the big question is timing. They’re with the belly space and a lot of the commercial aircraft coming off-line. And I think expected deliveries that would be coming over from China in the next week or 2, it’s — there’s going to be a need probably to shift some from sea to air. And so I mentioned our planes are flying. So the real question for me is not if, it’s when and how. And so is it a gradual or accelerated recovery, and that’s one of the reasons we’re taking a look here in the month of March to see how that comes back online.

 

Alnylam Pharmaceuticals (3/3 – Cowen Conference)

I mean, we’ve done — obviously, as all companies are doing right now, done a systematic review of our supply chain in light of the COVID-19 epidemic, and we are in a very good position. We don’t see any implication for our commercial or clinical products. Most of our — we do no drug substance manufacturing or drug product manufacturing in China. And we do that in either the U.S. or in Europe as a company. And we have no — we have sufficient inventory of all of our commercial products as well as clinical development programs as well. So there’s no supply chain implications. Now turning to specific markets and where there might be issues, thus we can talk about Japan. Japan is a big market for us. It probably will exit 2020 as our second largest market. So far, we haven’t seen any implication of the COVID-19 epidemic in Japan.

Question – Ritu Subhalaksmi Baral: On demand?

Answer – John M. Maraganore: On demand. We obviously look at that closely, and we’ll monitor that very closely. But Ritu so far, so good on that side of it.

 

Moderna (3/3 – Cowen Conference)

And of course, we announced a few weeks ago that we shipped to the NIH or coronavirus vaccine for the NIH in the first Phase I.

The last one I’m going to go quickly on it because it has been massively covered is the corona vaccine. So this vaccine’s quite interesting. We have been working with the NIH on the Middle East respiratory syndrome in preclinical models. And so we were quite familiar, the NIH and ourselves, around coronaviruses. We had great preclinical data, including neutralization using the Spike S protein. And so as soon as the sequence was available from China, working with the NIH, we were able to pick a sequence, and the team is moving quite remarkable. In 42 days, we went from the day we pick the sequence to the day we ship the vials to NIH, and that included 2 weeks of sterility testing on the back end. So just to give you a sense of the speed that you can accomplish with a platform like Moderna given the investments we have made in GMP over the years. So the product is with the NIH now. The IND has been filed. And so the NIH will communicate when they start dosing, which will be pretty soon, we believe.

 

Verizon (3/3 – Morgan Stanley Conference)

But when we look at the economic and financial impact on us, right now, not significant, not material, not to say there’s been no impact, but not material at this point. I think you see the — that’s linked to the fact that our business model is obviously based off of being more of a monthly service revenue model than the — most of it linked to the upfront transaction. So we haven’t seen a material impact yet.

As you see on the handset side, I think there is a risk on the equipment revenue side that we’ll see an impact there. Not so much in the first quarter. Obviously, there was handsets in the pipeline as the impact started to come through. But if we see continued disruption, you’ve heard some of the handset companies talk publicly about. If that carries on for a significant time period, I think we’ll see a more material impact on our equipment revenue line. That doesn’t really impact the earnings profile as significantly for us, given that it’s not where most of the earnings come from. The earnings come from the service revenue. But certainly, there may be some — in the future months some impact on the equipment. So we’ll have to wait and see.

The other thing, as I think about the income statement side, that we haven’t got enough data on yet to see if there’s any change in consumer behavior. And as I say, we haven’t got the data yet to know, but we’ll stay close to that. And then you mentioned on the network side and not seeing anything material impacting our supply chain at this point. But I think, obviously, the major thing is, this is obviously a fluid situation, and we’ll have to wait and see how it continues to evolve. And as it evolves, if it’s going to impact either the income statement as we think about revenue or consumer behavior or the way that our supply chain on our network side will operate, we’ll update everyone as appropriate. But as of right now, not a material impact, but we’ll wait and see how it plays out.

And obviously, we’ll have to see how if the supply chain around that gets disrupted with the coronavirus. But we still have line of sight to 20-plus 5G devices coming into our ecosystem during the course of 2020. You’ve seen some of those announced already. You’ve got the Samsung models launching later this week. So absolutely still feel good about seeding the ecosystem with a lot more 5G devices this year than what we saw last year.

 

Stryker (3/3 – Cowen Conference)

Yes. So first of all, thank you, and thank you for everybody for coming here today. It’s obviously still a very fluid situation, and it’s going to remain so. I don’t think there’s anything magical about the end of the quarter that will suddenly make this disappear.

We have about 2% of our revenue comes from China. We have 3 manufacturing facilities there. They are all opening up and running, but they’re not at full capacity. And clearly, a lot of — essentially, all elective surgeries in China have stopped. And so there will be a revenue impact, certainly, in Q1. We would imagine there’ll be still an impact in Q2 as well as an earnings impact. And I think we have to wait and see how it plays out in some of the other countries like Japan, for example, as well as in the U.S., but we will call that out in terms of this is what we believe the coronavirus revenue and earnings impact is. You can see an adjusted, adjusted number, similar to what we’ve done in the past, whether we’ve had these extraordinary events, whether it’s natural disasters or something like this. So we’ll be able to call it out and give people a sense of the impact.

 

Target (3/3 – Earnings Call)

But first, I want to address the question of whether we’ve accounted for any known or anticipated impact related to the coronavirus. And the answer is that as of today, we haven’t seen a large impact on our business or outlook. Of course, we are monitoring our import programs down to the purchase order, and we’ve already made some slight adjustments to our plans to ensure we are well positioned throughout the year. But because of our size and the flexibility that comes from our multi-category portfolio, we haven’t seen anything so far that would cause our financial expectations for 2020 to deviate from our longer-term algorithm.

And certainly, from a merchandising standpoint, we know that we’re going to see some periodic delays. We’re out in front of that, making changes in our assortment and our promotional and presentation plans. But all that’s reflected right now in our view of guidance for certainly the first quarter and the balance of the year. We’ve also been working very closely with some of our domestic vendors, our DSD partners, as we see some growing demand in categories like household essentials and food and beverage to make sure we are supporting that with the right level of inventory.

But over the last few days as obviously everyone’s been reporting, we’ve certainly seen a U.S. consumer that’s starting to stock up on household essentials, disinfectants, food and beverage items. All those staple items that the CDC has recommended, they add to their pantry. And certainly, we’ve seen aggressive shopping across the country in our stores. So we’re obviously working closely with our domestic vendors, with our DSD partners to make sure that we’re elevating inventory in preparation for what we think is going to be a continued demand for stock-up items.

So certainly, we’re seeing that across our network. We expect that to continue over the next few weeks, and we’ll watch it carefully over time.

 

Autozone (3/3 – Earnings Call)

At this point, I’d like to talk about any disruption we may be seeing from the ongoing coronavirus epidemic. While we have not incurred disruption thus far, we must and are being diligent. We have created a contingency plan for each merchandise category sourced from China. Our teams have done a wonderful job planning for potential scenarios. At this point, we have nothing substantial to report. But the longer this outbreak lasts, the more it will impact ourselves in both our and the overall retail industry. It is currently a very fluid situation as many of the factories have just begun to reopen after an extended Chinese Lunar New Year holiday. Some are coming back online quickly while others quite slowly, and certain of them haven’t come back online yet. The next few weeks will be critical.

As you would expect, over the last month or so, we have been very focused on the supply chain aspects of coronavirus and, in the last week or 2, more and more focused on what’s happening here in the United States and, ultimately, Mexico and Brazil. We see no indications at this point in time of any demand destruction as a result to coronavirus. But just like we said with the supply chain, it’s an incredibly, incredibly fluid situation. I think the next couple of weeks to a month, are going to be critical to see what actually happens. We don’t have good insights into that.

 

WP Carey (3/3 – Citi Conference)

I mean it’s early to see how that flows through our tenant base right now. We have not seen any level of distress or any concerns about tenants’ ability to pay rent. Clearly, it looks like it’s going to impact consumer confidence. It’s almost impacting supply chains, especially those that go through China and other affected areas. I think what’s important to note is that within the broader real estate sector, I think net lease is viewed more as a safe haven asset given the duration of the leases and the focus on credit underwriting. I think within the net lease peer set, I would expect us to outperform in a down economy or a downside scenario. Again, we have close to 11 years as a weighted average lease term. More importantly, our focus on underwriting and on managing our portfolio is acquiring operationally critical real estate, and in many cases on master leases, which adds another degree of downside protection. We’ve seen that through past cycles. In fact, if anything, I think, given our business model, our flexible balance sheet, any kind of dislocation could create a buying opportunity for us to the extent our cost of capital maintains the current strength that it has now.

 

Agilent (3/3 – Citi Conference)

I mean, your guidance assumes a 1.5 to 3-week impact from coronavirus in China based on the fact that you got a factory up and running. The second factory is 70%, 75% up and running. It feels like things are not worse than what you — at least in China specifically.

Answer – Robert W. McMahon: Yes, that’s correct. Yes. I mean, things are tracking to kind of we expected. Now, I think we said this on the call that, at our earnings call, we expected February to be the brunt of it. And we’ve seen that. And — but we’re exiting February kind of where we expected it to be, not only from a factory perspective, but one of the other areas that we look at is service calls. And the service call rate at the end of this month was tracking pretty in line with where it was the end of February last year, which is actually very positive. Now how we’re actually doing the service is very different. So the investments that we’ve been making in WeChat over the last 2, 3, 4 years is really paying dividends because we’re actually doing service calls via WeChat as opposed to having people on site in certain factories and so forth.

 

Chevron (3/3 – Analyst Meeting)

First, let me address the short-term impacts of the coronavirus. No doubt, demand for our products is down. Our focus is on protecting our people and maintaining safe operations. This time, our operations and supply chains are functioning normally. We’re taking all appropriate precautions to keep it this way, but it’s a fast-changing situation.

 

United Rentals (3/3 – Evercore ISI Conference)

The coronavirus question is interesting one, very interesting times here. We’re fortunate enough to not have had that much exposure to it. We’ll see what the coming weeks and days even bring, but we’re not expecting a huge impact right now. I don’t think our crystal ball is any clear than anybody else’s on this. Personally, we’re more focused on making sure our employees and then, therefore, our customers are operating in a mindful manner of what’s going on around them. Supply chain seems to be what’s been disrupted in most industries right now. We have not had this disruption. And I wasn’t here for all of Terex’s commentary, but our suppliers have not pushed out any lead times for us, the things that would be meaningful for our business. We haven’t had any of those impacts. That’s one of the areas where we think coronavirus is showing up early.

So we don’t necessarily see a huge impact right now, and we don’t expect a huge impact on our end markets. But you know we’re going to stay tuned. The good news is we don’t need to know. We have enough flexibility within our annual CapEx cadence and within the way that we can run our business that we don’t have to the basis point predictability of the end market. We’re just going to adjust accordingly. But right now, the end market sees that 2.7% growth that we have at the midpoint of our guidance holds for us.

 

Qorvo (3/3 – Raymond James Conference)

Now to our updated view on the business, including the near-term financial outlook and the effects of the coronavirus on it. This morning, we’ve provided updated guidance for our March quarter to approximately $770 million revenue, down from $820 million to the midpoint of our January 29 earnings call guidance or a decrease of roughly $50 million from our previous midpoint.

If you recall, we were one of the earliest companies to comment on the potential impact of the virus on our results. Reflecting some impact in March, providing an expanded range given the uncertainty and providing a view on how we thought it may impact our June quarter. Unfortunately, COVID-19 effects worsened since we provided guidance, and our current view is reflected in today’s updated outlook.

As far as the commercial effects of the virus, we’re seeing both supply and demand effects. On the supply side, some parts of the supply chain are experiencing reduced labor, which is limiting throughput. There have also been some isolated component shortages. At present, neither of these factors appears to be getting worse and from recent customer comments and our interactions across the supply chain, it may be getting better. On the demand side, with the disruption around the Lunar New Year and some ongoing concerns, we are seeing some demand effects beyond what we anticipated. We are seeing demand stability and in some cases it improved, but the effects are likely to persist through the June quarter, a comment we made on our January earnings call.

We do see these effects as largely delays to be captured later. As far as our own operations, we have experienced no COVID-19 cases and are operating well. We took precautions early to safeguard our employees, and since we have been running strong. Most of our employees work through the Lunar New Year. With great credit to our team, our operations have been held up as a benchmark by local authorities for other factories in the area. We’ve provided an update with our best view at the moment. But as you know, there’s a lot of uncertainty with this situation. We are staying abreast of the situation, doing our best to support customers, suppliers and local authorities, while keeping the welfare of our employees and their families, the top priority.

 

Thermo Fisher Scientific (3/3 – Conference Call)

Financially, the net of how we see the world right now is because activity in China is still very slow, it will be a slowly ramping back up. We expect that the first half of the year will have less revenue than our original guidance back in January. And that we see opportunities for the second half to have positives, it’s very hard to quantify them right now because we know governments are going to stimulate the economies around the world. They’re already talking about it and doing that. We’ll see how it plays out.

So yes, I’d say that basically that we’re — we’ve put in a reasonable assumption for a net headwind from coronavirus for the year in 2020. Clearly, if they’re well positioned with some products that can assist health authorities address the virus then that will be a tailwind. But what to think about the macro — potential — macro impacts, I put them in a reasonable assumption into the 2020 numbers as the baseline.

 

SBAC (3/3 – Citi Conference)

Well, knock on wood, we haven’t seen any direct or even one-off indirect impacts yet. I think, I mean, it’ll pop in probably hard-to-imagine ways. Certainly, well, people stay at home. It probably actually benefits the communications sector, not that that’s anybody’s wish.

We don’t supply chain anything really from these affected areas. We are in Latin America, and we recently expanded into South Africa. I’m struggling to think, Mike, because I don’t see it yet. I mean, we’ve put in similar warnings to the government agencies about not travel bans, so to speak, but warnings and watching where people go to, go from. I mean, we canceled out a Mobile World Congress and wouldn’t be sending people to the Far East and things like that, but I don’t really see a direct or even an indirect impact at this point.

 

Duke Realty (3/3 – Citi Conference)

Now let’s talk a little bit about the coronavirus and the full impact. I don’t think any of us know clearly what the impact is. At this point, it would appear that there will be short-term disruptions in the supply chain of raw materials and finished goods. And I’ll reiterate short term. We spent a lot of time in the last 10 days talking to our clients. And they are anticipating short-term disruptions, 30 to 90 days. Depending on who they are and what their products are will ultimately determine what that impact is, but every one of our clients have said this has not changed their long-term real estate strategy. They are going to continue to move ahead with leases and build-to-suits acquisitions in 2020 and 2021. And just to reiterate: We signed leases last week with major clients across the country. So while it’s making clearly a lot of headlines and it has a lot of us nervous, most of our clients say it’s business as usual working forward.

 

Union Pacific (3/3 – Raymond James Conference)

The year is obviously off to a challenging start with volumes down 10% year-over-year. Now we came into the year expecting tough comparisons in International Intermodal as a result of the 2018 pre-shipping ahead of the 2019 tariffs. But we didn’t have a good line of sight or really had even heard much about the coronavirus impact. We are really just now starting to see the impact of the virus on our first quarter volumes as the Lunar New Year was extended and factory production in China is slow to ramp up. How that ultimately plays out, however, is a little still to be determined as we can’t predict the full extent or timing of the production lull. What I can state confidently, however, is that U.S. consumers are continuing to buy TVs, build houses, drive cars, et cetera. So when the impact of the virus is behind us and production ramps back up, we’ll stand ready to move the goods. 

 

Microchip (3/3 – Conference Call)

Well, let’s see if we can talk through it. Longer term, or even nearer term, there should not really be any demand destruction if work were to — the whole world were to go normal for the June quarter, then there should not be a demand destruction. So the only issue for the June quarter is, will all the factories be back to work? Will coronaviruses should be resolved? We don’t really know that. At this point in time, the cases in China are starting to decline. But the cases outside of China are rising rapidly in Italy and Germany and Korea and Japan and lots of other places. So where would that net effect be? We don’t really know. But coronavirus itself, if you get out a couple of quarters, if coronavirus issue goes away, it should not be destructing demand. And some of the demand we’re losing right now, there should be some makeup for it because there’ll be a pent-up need for product from all the customers who wanted to buy it.

 So Gil, I think as Ganesh mentioned in an answer to another question about the end market, coronavirus has not differentiated or distinguished between factories that’s an automotive factory or building consumer products, building communication gear and this has largely been — the demand has largely been the issue of factories were shut down longer than the normal 1-week Chinese New Year. Some were shut down for 2 weeks. Some were shut down for 3 weeks. And when they came back, they didn’t come back to full production. So this is not an end market kind of issue. All end markets have been affected because the factories have been affected in China.

 

Live Nation (3/2 – Morgan Stanley Conference)

We talked a bit and gave some of those numbers on the earnings call. But our business in Asia, if you look over the next 3 months, is a couple of hundred thousand fans. If you look at our business in Italy, it’s roughly the same scale. We said between — at the time, which were the 2 main hotspots between Italy and Asia over the next 3 months, makes up less than 0.5% of 1% of our fans expected for the year. From an overall timing standpoint, globally, we see about 70% of our fans are June onward. So depending on which version of what you read today, it gives us some comfort that we’ve got a little time for things to play out. I think, probably the most important piece for us, though, is to remember that we’re just — we’re in 100 offices in 40 countries, very diversified, geographically. So what we know because the CNN headlines are telling us constantly, there’s a hotspot in Kirkland, Washington today. There’s this that you assume over the next few months, they’re going to be hotspots. And when those hotspots occur, there will be some impact in terms of quarantines, whatever happens in those markets at that time.

I think the 2 things that just give us some level of comfort, as we look macro: first, we don’t see this as an existential change in fan behavior; we don’t see any drop in fan demand. Bonnaroo sold out today faster than it ever has. Pandora and [McGrath] sold out last week in Australia faster than it ever has. So the fan demand remains. We know that the artist wants to do the shows. This is how the artists earn their living. So we’re talking in the vast majority of cases about an artist saying, all right, if you have a — if we can’t do the show next Saturday night in Seattle, well, when do we come back in 3 months — when do we come back, we’re rescheduling that show, is the primary focus. And it’s just gaining some market by market. And when you do 40,000 shows across those 4 countries, I think, it’s our belief that on a macro basis, we’re unlikely to see something that, there is a real disruption at any one time.

 

Trimble (3/2 – Morgan Stanley Conference)

What we — what I’d anchor you is on December — February 12 on our earnings call, we talked about the impact within a Q1 context and within a Q1 context, we quantified about 3 weeks of delay minus a couple weeks of buffer equal to about 1-week impact on the supply chain plus a degradation in the sales within the China market that was baked into our Q1 — I think, our Q1 guide. And I think we are reasonably ahead of the curve of companies of talking about that Q1 impact. What we’ve seen in the days and, I guess, couple weeks that have unfolded since then is that it’s clearly — has clearly spread, and so we would expect to have some negative ramifications out of that. The quantification of such is way premature for us to be talking about. And so at this point, I would anticipate the update on our next earnings call. To put a little maybe context behind it, though, Trimble’s revenue today is about 1/3 ARR.

 

Stanley, Black and Decker (3/2 – Raymond James Conference)

Throughout the first quarter, we really have not seen much revenue being generated in the local Chinese business, as you might expect. And that probably will be the case through the remainder of the first quarter. But probably the bigger question you have in your mind is our supply chain. Our supply chain in China serves 40% of our capacity across the company.

As it relates to the virus and where we are on China as far as our manufacturing capabilities as of today. We shut down these 10 plants for the 2 weeks of the holiday season around Chinese New Year. The week after that, these plants began to open up and the production capabilities and utilization have got to about 50%, 60% on average across those plants sometime last week. We’re continuing to make progress on that. And those numbers continue to improve as we sit here today. And we’re continuing to focus on getting more employees back to work, that’s one of the challenges we have right now, where all the employees have not returned to the plants. We have a process that we need to go through with every employee before they get into the plant around checking for fever and other symptoms that are visible and then, obviously, wearing masks within the plant to try to protect our employees as much as possible in that environment. We do believe it will take another 2 or 3 weeks probably to get to 100% utilization in these plants. And that obviously is assuming that the virus doesn’t worsen in China, that it stabilizes and begins to — to begin to go — retract or go backwards.

If that happens to get worse, then obviously, those numbers could change. But right now, that’s what our plans are, and we believe that’s achievable based on where we are today. This will cause some pressure for us in March and April from a revenue perspective. So we see that revenue in the last 2 weeks of March will probably be pressured based on these capacity challenges we’re having and also in the month of April. We do believe it’s more of a timing-related matter at this stage. But obviously, that’s very dependent on where the virus goes and how significant it is. If things stabilize, and we don’t see a dramatic worsening, we think that’s probably where we are. We have a timing issue we have to work through for the first half of the year and the full year as well. 

 

Fidelity National Information Services (3/2 – Raymond James Conference)

So we had our fourth quarter earnings call about 2 weeks ago and included some expectation for coronavirus impacting the guidance we provided at that time, which I just took you through on the screen. I think the way to think about the coronavirus impact is certainly the way we’re thinking about it is the part of the business where we would expect to see the most impact from corona would be in our merchant business, which is about 30% of consolidated revenue, and in specific, within our e-commerce segment within merchant, which is about 25% of merchant.

So in terms of revenue that could be most impacted by corona on a total basis, you’re looking at less than 10% of total revenues. We’ll certainly see some impact in terms of cross-border, airlines, travel-related e-comm transactions. But at the point in time, we believe that to be immaterial, which is consistent with our expectations when we provided the guidance a few weeks ago.

 

Exact Sciences (3/2 – Cowen Conference)

This year, on our fourth quarter call, we talked about the flu also having an impact on the business. Coronavirus, I think it’s still very early, so it’s something we’re watching closely. To the extent that it does have an impact on the business, again, I would think it would be temporary like the flu.

 

Regeneron Pharmaceuticals (3/2 – Cowen Conference)

So where are we right now? With the new coronavirus outbreak, we have already immunized mice to develop fully human antibodies to the infection. We are now at the point where we are identifying lead candidates for treatment and prophylaxis treatment. It’s our intent to have the lead antibodies manufactured and ready for clinical trial use later this summer. While we’re not able to share more details with you at this time, know that this is a priority for Regeneron to address this important human health need.

 

Twilio (3/2 – Morgan Stanley Conference)

Then as far as the business goes, I think that, obviously, we don’t know exactly if there will be an impact on the business. We can imagine scenarios that — where there’s an impact because of travel or hospitality industries are impacted, while we have those customers. And if there’s less usage of their products, then that could mean less usage of our product. We can also imagine some upside, wherein, for example, in the on-demand delivery of food, for example, people are staying in, instead of going out, that can be more usage of certain use cases like that. And obviously, we’re in the electronic communications business.

So if there are scenarios where people are using more electronic communications to communicate as opposed to in-person — in-person meetings, that could be an upside.

 

Weyerhaeuser (3/2 – Raymond James Conference)

So we had dialed back our China exports already even before the coronavirus. Certainly, I think the activity in China has slowed. I don’t think that’s a secret. And so I think that will be choppy for a little while. But again, the rationale behind having a diverse mix of customers is that we have opportunities to flex that volume. And so we had already started doing that in flexing some of that China volume back to the domestic market for higher-margin opportunities.

In Japan, to date, we really haven’t seen any impact from the coronavirus. We continue to have solid order files from our Japanese customers. Obviously, it’s a dynamic situation. So we’ll continue to watch that, but to date, we haven’t seen any real impact there.

 

Gilead Sciences (3/2 – Cowen Conference)

So remdesivir as a molecule, we’ve had at Gilead for a while. It was discovered and developed as an antiviral with a relatively broad antiviral activity in-vitro. It’s shown efficacy in-vitro against Ebola, which is a different class of virus, but also against SARS and MERS, which are both coronaviruses in-vitro. The homology of the polymerase that remdesivir inhibits is very high between SARS, MERS and this new coronavirus. So I think that’s probably one of the biggest drivers of why we are interested and others are interested in it.

More recently, we’ve gotten data from the Chinese CDC, where they’ve evaluated in-vitro efficacy and have demonstrated in-vitro efficacy of remdesivir against this particular isolate. We are awaiting data from our CDC here in the States to confirm that. There’s a slight difference between the 2 and that the Chinese CDC use vero cells or monkey cells and the U.S. CDC will use human cells. So we think that will be a little closer to what actual efficacy, at least a potency against the virus will be.

That’s in-vitro data. I think, really, it’s really important to emphasize there’s an investigational drug and we are in clinical trials right now, and those fall into several categories. We do have compassionate use work going on. You’ve seen the New England Journal article on that one patient. There have been other patients who’ve been treated with compassionate use. Those are all anecdotal.

There are 2 trials going on in China. They’re sponsored by and run by the investigator in China. We supply drug to them. There’s one in severe patients, one in more moderately ill patients and those studies are active and ongoing. And hopefully, we’ll see data from those in April, depending on enrollment.

And then the NIAID, we’ve been working with them to get another trial up and running. That study is now up and running in Nebraska and we’re looking to expand sites there. The NIAID will be doing that but we’re trying to support as best we can. And then, finally, we’ll be running sort of a simple trial that we’ve also been discussing with the FDA around making that trial available more broadly.

 

Microsoft (3/2 – Morgan Stanley Conference)

On the second half of your question, which is specifically on COVID-19, I think you really think about the adjustments we’ve made have been pretty narrow to the supply chain, as we have said for our guidance this quarter. Our focus primarily day-to-day is on the health and safety of employees, partners, customers and the communities in which we operate. And so that, for us, really is the first priority and then watching the pace of the supply chain recovery. We’ll continue to do what others are doing and continue to keep an eye on it.

 

American Tower (3/2 – Citi Conference)

These sites run autonomously, actually, and the leases are paid electronically through means of not having to either collect cash in a storefront or checks or anything like that. So the short-term impact of the coronavirus on our business should be de minimis. The long-term impact should be, I would imagine, neutral to positive depending on how this goes because mobile connectivity could get more important if people want to gather less or congregate less in offices or conferences or whatever it may be.

 

S&P Global (3/2 – Raymond James Conference)

Going to your question about coronavirus. First of all, we saw in the Ratings business, that you’ve talked about in particular, the first 8 weeks of the year, the ratings volume was up 7%. It was very robust. It was across the board most geographies, most asset classes. And last week, it really halted to a stop. This was based on the uncertainty in the markets about coronavirus, what impact it’s going to have on different industries, what kind of credit impact it might have. In addition, there were uncertainties about rates. Rates were plunging. Spreads were increasing. And when you get a market like that, the investment-grade issuers, they stop going to market. There were no investment-grade issuance last week at all. And then there were a few loans and a few noninvestment grade bonds. So you saw a very little amount of issuance.

 

Johnson & Johnson (3/2 – Cowen Conference)

With respect to the vaccine, I think you’re — what Dr. Fauci had referenced in terms of 12 to 18 months is probably a very reasonable time line. If you just think about what has to happen with respect to, first, having some animal studies, making sure it’s then safe in humans and then the efficacy part, that seems to be as quickly as, I think, anything can be done.

With respect to our candidates for a vaccine, we are screening possible vectors. Where we have a differentiated capability, we believe, is around our scalability. So the ability to produce hundreds of thousands of vaccines is something that’s not uniquely possessed within the industry. And if you think about what we did on both the Ebola and HIV front in terms of some clinical development trials that we are now conducting, those are in the hundreds of thousands.

So if you remember an acquisition we did many years ago known as Crucell. They had a PER. C6 technology there that allows us to have this kind of manufacturing capacity. So whether it’s a vaccine that we potentially discover or some other vaccine that may be a candidate to contain the virus, I would imagine, we’re some part of the discussion. In fact, I believe, Alex and Paul are with the administration this afternoon with other health care CEOs and management to help figure out what is the best solution and best path forward.

In terms of business impact because I’m sure that’s on everybody’s mind as well, right now, I would say I don’t anticipate — and I’ll caveat my comments to be first quarter contained, right? Until we find out how long the duration of this is, the pervasiveness of the virus is, it would be hard to say we would certainly provide the best information we have available on our April call to recap the Q1 results.

I would say, though, from a supply perspective, I’m not overly concerned. I think if you look at where our supply chain exists, we’re pretty well covered. On the demand side, I could see some modest impact in Consumer, around Skin Care in terms of just people buying less. There’s less activity in that, but perhaps that’s offset by self-care. So think of MOTRIN or even LISTERINE potentially.

On the Pharmaceutical side, people still will take those drugs. You may see some lower demand from closed or limited hours for infusion centers or even pharmacies. But by and large, I think we’re pretty well covered there.

Medical Device, as other peers in our industry have indicated there, we are seeing a much reduced level of elective surgeries. And so we’ll probably track to the market there. Overall, though, I think if I look at the overall health of Johnson & Johnson’s business, I see this as a temporary blip that will largely be recovered.

 

Analog Devices (3/2 – Raymond James Conference)

So coronavirus, we are an off-quarter company, so we did have our earnings call just a couple of weeks ago, and we took the opportunity to reflect in the guidance for the coming quarter how we were thinking about the coronavirus. At the time, we knew there was quite a bit of unpredictability. So what we tried to do to be helpful to investors is not only give you our view on what the impact in the current quarter is, but also the assumption set that we put in to arrive at that.

And that assumption set is basically a few things: One, for our China business, we assumed that our industrial, our automotive and our consumer business would basically bottom out near 0 for the month of February and then begin to return after that. And we looked at the 5G deployment activity and said some of that 5G deployment would be shifting just as the availability of employees to work in the technology companies necessary to build the products was going to have some level of delay. Though there would be some existing inventory, they will be able to come back a little bit faster. So we did assume that there was a slippage in that. We sized that at $70 million of impact to us for the quarter, and that’s reflected in our guide of $1,350 million for the quarter. At this point, we are not changing our guidance. I think it’s — the world is evolving at such a rapid pace. It would be difficult for us to constantly be giving you an updated point of view.

I would say that as you hear more and more semiconductor companies report their impact, you’ll find that sort of on a relative basis, that seems to be in line with what everyone else appears to be saying, although we were a little bit early. But I think from what we’ve heard so far since that time, we feel good with where we are.

 

Zimmer Biomet (3/2 – Raymond James Conference)

Sure, yes, happy to do it. As you said, the situation is incredibly fluid. Every morning, you wake up, open up the Wall Street Journal, there’s a new article on the coronavirus and how it continues to evolve. Look, the way I look at it is our most acute challenge is within China. That should be obvious. Just to kind of put it into frame and give some perspective, China is about a little less than 5% of our overall global revenue. It’s growing in the low double digits. So it’s a very meaningful market for us from not only a scale perspective or from a growth perspective as well. And what we’ve seen relative to Coronavirus is actually a pretty significant reduction in elective procedures. In fact, about 85% to 90% reduction in elective procedures through February. So it’s been a pretty significant headwind for us. We’ve not seen any significant or material improvement or recovery in February. So we expect that at a minimum to continue through March, right? 

 

Fleetcor (3/2 – Raymond James Conference)

We don’t have any business in Asia. So we’re not really impacted, certainly, directly by shutdowns in those countries or we’re not that impacted by being — we’re not a manufacturing concern, so we don’t have inventory coming in that we’re dependent upon. But we are transportation, related to some of our businesses are transportation-related, and we have seen some softness, particularly in the over-the-road sector as the manufacturing category has slowed down a bit in the United States. But although we may see a little bit of softness there, we certainly expect to see that come back at a later date when this is resolved. So we don’t see a meaningful impact from coronas to us.

 

Dentsply Sirona (3/2 Earnings Call)

At the current time, we have not experienced a significant disruption to our global supply chain due to coronavirus. However, in many parts of China, dental clinics and hospitals remain closed for business. And in other parts of the world, we are beginning to see an impact.

Given the unique situation, today, we’re letting you know that China, Japan, Korea and Taiwan, represented approximately 10% of 2019 sales. While we hope the impact of the virus is controlled as soon as possible, it is difficult to estimate at this time when commercial activity, and more specifically, the dental market will return to normal levels.

We estimate that in the first quarter of 2020, we have an exposure of approximately $60 million to $70 million in sales stemming from coronavirus. Assuming activities get back to normal in April, we estimate a non-GAAP EPS impact of $0.10 to $0.12.

We acknowledge it is more difficult to forecast accurately in the current environment, and this explains the wider than usual EPS guidance range we are providing today.

With that said, these are the key elements of our guidance for fiscal ’20. We expect 3% to 4% internal revenue growth. However, accounting for the potential impact of coronavirus in the first quarter, we believe growth will likely be towards the bottom end of the range. 

 

Camden Property Trust (3/2 – Citi Conference)

We have not seen any changes in patterns or people coming into our properties or web traffic or what have you. We have looked at and tried to sort of think through forward what happens in a corona environment — in corona, sort of virus maybe induced recession or a slowdown in the economy.

And there are probably 2 periods in time that were interesting in the sense that — so if you think about a normal kind of recession, recessions are sort of different than sort of event-induced recessions.

Let’s take 9/11 as an example, and also the financial crisis as an example. One of the things, I think, was instructed by those 2 recessions and the — was that, people sort of sheltered in place, if you will. It’s kind of an interesting concept, given corona. And the turnover rates dropped dramatically. Even though demand went down, we had fewer people moving out to buy homes and fewer people moving out generally. Now demand did go down and people had to consolidate. So people who couldn’t afford their apartment because they lost their jobs or what have you, move back with their parents or they consolidated within the community, a 1 — two 1 bedrooms became 1 2-bedroom, and we had vacancy in our in 1 bedroom. So it’s likely to — the corona-induced slowdown is likely to create more, sort of shelter in place as long as people have jobs. They aren’t going to move around as much, and that should keep turnover down. The question will be, how much demand is destroyed? And what happens to jobs, overall, if there is a kind of corona-impacted recession.

 

Week of 2/24

Updated Guidance via Press Release

Paypal (2/27) 

“PayPal’s business trends remain strong; however, international cross-border e-commerce activity has been negatively impacted by COVID-19. We currently estimate the negative impact from COVID-19 to be an approximate one percentage point reduction, on both a spot and foreign currency-neutral basis, to PayPal’s year-over-year revenue growth for the first quarter, as compared to the revenue guidance provided on January 29, 2020. 

Stronger performance quarter-to-date across our diversified business is partially offsetting this one percentage point negative impact. We now expect to report first quarter 2020 revenue towards the lower end of our previously guided range of $4.78 – $4.84 billion. We are reaffirming our first quarter 2020 GAAP and non-GAAP EPS guidance.

At this time, the duration of COVID-19’s impact is difficult to estimate. We are continuing to closely monitor this evolving situation. We will provide further updates on our first quarter earnings call in April.”

 

Mastercard (2/24) 

“We have been closely monitoring the impact of COVID-19 and our thoughts are with the individuals and families whose lives have been affected by the spread of the disease. Our top priority is to ensure the health and safety of our employees and support those in need.

The fundamentals of our business remain strong, as our switched volume and switched transaction growth remain in-line with our expectations. However, cross-border travel, and to a lesser extent cross-border e-commerce growth, is being impacted by the Coronavirus. As a result, we now expect that if the trends we have seen recently — primarily in our cross-border drivers — continue through the end of the quarter, year-over-year net revenue growth in the first quarter will be approximately 2-3 percentage points lower than discussed on our January 29, 2020 earnings call. Under these circumstances, we would expect year-over-year net revenue growth of 9-10% in the first quarter on a currency-neutral basis, excluding acquisitions.1

There are many unknowns as to the duration and severity of the situation and we are closely monitoring it. If the impact is limited to the first quarter only, we expect that our 2020 annual year-over-year net revenue growth rate would be at the low end of the low-teens range, on a currency-neutral basis, excluding acquisitions. We anticipate giving further updates on our first-quarter earnings call.”

 

Commented on Coronavirus with Earnings Release:

Best Buy (2/27 8K) 

Best Buy CFO Matt Bilunas commented, “As we enter FY21, we are closely monitoring the developments related to the coronavirus outbreak. This is a very fluid situation, which makes it difficult to determine exact financial impacts from disruptions in supply chain. Based on what we know today, we have assumed the majority of the impacts occur in the first half of the year. Therefore, we view this as a relatively short-term disruption that does not impact our long-term strategy and initiatives. Our guidance ranges for both Q1 and the full year reflect our best estimates of the impacts at this time.”

 

CBRE (2/27 8K) 

“We continue to see a backdrop that supports our business performance. Based on what we know today, the global economy is expected to grow this year on par with 2019, though we are closely watching the potential impact of ongoing risks, particularly the coronavirus. With this in mind, we expect that continued favorable macro conditions and our ability to take market share across business lines should drive our 11th consecutive year of solid double-digit adjusted earnings per share growth in 2020.”

Earnings and Conference Call Remarks

Carlyle Group (2/28 – CS Conference)

There’s definitely going to be a short-term financial hit. You can’t have half of the world’s second largest economy be dormant and not have an impact to global economy. You can’t have 55% of global manufacturing output go through China in some shape or form without there being a short-term hit. And I think people underestimate the disruption to the supply chain. We’ve got estimates of close to 60,000 containers that are in the wrong places, wrong ports, wrong railway stations because everything is disrupted. To get that all moving and going in sequence in the right way, it’s going to take a long time.

 

Ansys (2/27 Earnings Call Transcript) 
“The recent outbreak of the coronavirus is bringing new challenges to China and to other countries in the region. The outbreak could potentially delay some deals originally planned in the first half of 2020 to the second half of the year. This has an insignificant impact on our annual outlook and is factored into our Q1 guidance…The combined effect of the China sanction and coronavirus, which I described earlier, delays first half revenue and further strengthens projected revenue growth in the second half of 2020.”

Paypal (2/27 Earnings Call Transcript) 

“We’re seeing some impact from corona. But I would basically say the core business is good. And look, I think one of the things we’re also beginning to see is some stabilization and a little bit of recovery, on the China side, they attacked this first. They’re now beginning to see some of the factories returning. Still a little bit of skeleton crews, but we’re seeing stabilization and maybe a little bit of acceleration coming out of China now.”

 

Teleflex (2/27 Conference Transcript) 

“Answer – Liam J. Kelly: Yes. So again, we’re really happy with the 8.1% that we delivered last year. Our long-range plan was to get to 6% to 7%. I think that, as we guided for the year, we wanted to be relatively conservative and realistic right out of the gate. There are a couple of one-off impacts that we see, in particular, in the first quarter, the quarter we’re in right now, such as the coronavirus sterilization issue. If you add both of those together, they have an impact of about 30 basis points in our full year growth, and that’s a bit of a headwind. But the other side of that is — and we have one less billing day in the first quarter as well, which will cost us around $9 million.

The upside to that is, and what I expect should happen during the year is, you get those 2 items behind us, hopefully, coronavirus will act like a normal flu, once you get into April and the weather warms up and incidents start to go down, that’s what we would expect, sterilization issue will be behind us at the end of the quarter. We have the final cycle being validated as I sit here. And the billing day will actually come back in the fourth quarter. And this is a unique year because it’s a leap year obviously. We actually have an additional billing day in the fourth quarter as well. So — and as you go through the year, you will begin to see the UroLift ramp, you’ll see the other core parts of our business start to ramp as we go through the year, and obviously MANTA, which is one of our nice growth opportunities, will also continue to ramp during the year.”

 

Universal Health Services (2/27 Earnings Call Transcript) 

“As far as the coronavirus, like everybody else, I think any commentary that I would give at this point would be purely speculative. It’s impossible to know what the impact will be, specifically in the first quarter, but we’re certainly prepared. Our hospitals are prepared as best as they can be. If the coronavirus becomes more widespread, but I think virtually impossible to predict a financial impact.”

 

BKNG (2/26 Earnings Call Transcript) 

“Now turning to more recent events. The coronavirus has had an impact across our business since it made news headlines on January 21. The early impacts were in Greater China, but we also saw these impacts across Asia and to a lesser extent, in other regions outside of Asia as well. To help with context, the APAC region represents a little over 20% of our room nights with no single country accounting for more than a mid-single-digit share of total room nights. In APAC, we’ve seen an increase in cancellations, reduction in new bookings and pressure on ADRs.

As you all know, it’s not possible to predict where and to what degree outbreaks of the coronavirus will disrupt travel patterns. While the incidence of infections has slowed in China, in the last week alone, new outbreaks have occurred in South Korea, Iran and Italy. We’ve been able to measure the impacts on our business so far in Asia and we’ve seen a recent impact on room night bookings in Europe following the outbreak in Italy. As a result, we’re providing only a near-term outlook with a wider guidance range to account for the possibility there will be a growing travel disruption in Europe.

Based on where we are in the quarter and considering the continued impact of the coronavirus, we’re forecasting Q1 booked room nights to be down 5% to 10% versus the prior year. Clearly, we’re dealing with a very fluid situation and it’s extremely difficult to predict where Q1 will come out, but this is our best estimate based upon the data we have available now. We forecast total gross bookings to decline 8% to 13% on a constant currency basis and about 200 basis points more in U.S. dollars. Our Q1 forecast assumes that constant currency ADRs of the company will be down about 4%…

Question – Kevin Campbell Kopelman: Great. Could you give us more color on the latest trends in Europe travel bookings that you’ve seen over the last few days following the outbreak of the coronavirus in Italy?

Answer – David I. Goulden: Yes, Kevin, this is David. Let me take that. Maybe just kind of maybe frame it in the way that the quarter shapes up and our projections do take into account what we’ve seen in the last few days. So let me kind of give you a lay of the land, first of all, by region, not surprising. We already mentioned that China is the worst impacted. Asia, excluding China, has also been impacted for some time. The rest of the world, which obviously includes Europe and Europe’s a big piece of that for us, was growing through February, but we also expect it to be impacted to the negative in March as well. And to give you a bit more color in terms of just how it played across the quarter, on a consolidated basis, we, of course, saw room night growth in January, even though we saw some tapering off at the end with the virus hitting the news on the 21st. Expect February to be approximately flat from a growth rate point of view. And therefore, to get to our guidance for the quarter, expect to see declines in March.

Question – Kevin Campbell Kopelman: Got it. And that March expectation is based on just the worsening kind of trend over the last few days?

Answer – David I. Goulden: Yes. I mean, we really, obviously, as I mentioned, we’re dealing with a very fluid situation, very difficult to predict what’s going on because we’re responding to something that we have no control over. We’re giving you kind of our best view on it. So when we built what we expect to happen in March and created the guidance range, we’re looking very specifically at what has happened over the last few days after the outbreak in Italy and the response we’ve seen in Europe in response to that, which is not surprising has been negative. So yes, we are expecting and we’re seeing, even though we’re going to get room night growth through rest of world in February, towards the end of February that is already in decline. And we expect it to continue to decline into March.”

 

Ameren (2/26 Earnings Call Transcript) 

“Of course, we continue to work closely with the developers for both projects to monitor the time of the manufacturing and shipment of certain facility components coming from China, due to the potential for issues associated with the coronavirus. At this time, both projects remain on schedule to be in service by the end of 2020, and we expect to see meaningful contributions to earnings in 2021 from these investments.”

 

Baxter International (2/26 Conference Transcript) 

“It might have been in general — a general (inaudible), I don’t know. But — so the ultimate impact of coronavirus, it’s not clear how widespread this is going to be.

So let me share a few things in terms of these puts and takes. The takes are, look, we’re very reliant on China suppliers for a variety of our products. Also, people are not going to hospitals in China for any elective procedures. So things like our anesthesia gases business in China will suffer as a result of this. That’s a downside. So those are things that could be very — that could be disruptive to us, the former more disruptive than the latter. So the supply chain impact could be more, depending on how sustained this is.

Now on the upside, to the extent that people do go to hospitals as a result of this, our acute business will benefit. One of the things I love about our acute business is that it literally saves patients lives because their kidneys are failing, and we are there at the moment of need to address a critically important need. And so we’re seeing strong performance in that business, and that will continue.

IVs as well. So IV bags is another business that will benefit from this. So those are — there are puts and takes. It will depend on how this goes. Of course, depending on the global nature of this virus and how severe it is — does it start to impact our manufacturing operations? It’s an open question. So this is a great uncertainty for us, and it’s something that we will have to — we’re going to — we’re watching on a daily basis as you can imagine.”

ILMN (2/26 Earnings Call Transcript) 

“Yes. I mean, we’re evaluating this closely as I’m sure a lot of people with any China exposure is. And China exposure isn’t just the revenues that you have in China, but also the supply chain exposure that you might have. So we’re definitely evaluating this closely. Listen, the main thing here is that we’ve been actively working on is making sure our employees are safe, making sure our customers are also — they have what they need. They’re safe, but they’re also — they have — any instruments or consumables that they need, that they can also test for coronavirus because some of our reagents and instruments are used for it. And we are actually seeing, in fact, some customers ramping up some work on coronavirus. But at the end of the day, this will likely have an impact.

It’s having an impact in China in terms of people having access to be able to get to their place of work, to be able to go outside. This could have, especially if protracted, if this gets prolonged, this could have an impact on clinical testing in terms of people being able to do reproductive health or oncology testing. I mean the type of testing that gets done on our instruments in the clinic is usually pretty critical testing. It’s not just routine or, really, things that you could avoid doing. But having said this, when there’s access challenges to the clinic or to the hospital, it could have an impact. At this stage, it’s early to tell. We’ll obviously be giving more information.

In terms of supply chain, Puneet, I mean that’s the other thing that we’re focused on. We have very limited exposure when it comes to China. We don’t manufacture in China. In terms of distributing in China, getting product into China, we haven’t had any exposure there or we haven’t had any impact there. So we’re very focused on getting product into China, as I mentioned. We’ve got distribution in China. We haven’t had any impact. We have limited — very limited exposure in terms of third-party suppliers that actually supply from China or that supply components out of China. And we have redundancies in the supply chain to address that. We have also safety stock, inventory on hand for a number of months to help us offset that. So on the supply chain, obviously, we’re also evaluating closely, but we don’t feel we have — we have limited exposure from China.”

Southern Copper (2/26 Earnings Call Transcript) 

“Now looking into the coronavirus. Well, we already mentioned that we believe that — well, we hope that it will be contained, that the damage that it may create at the Chinese as well as the world economy will be limited. So far, on the commercial side of our operations, we have not — we haven’t had any impact related to the project. Our shipments, even the ones for China are moving forward as scheduled. And we are, in that regard, tranquil. Regarding the supply chain impact, we haven’t had any so far. As you know, our operations both are in Mexico and Peru, and we have not experienced any trouble in any of these countries and nothing related to or parts from China. In some cases, our suppliers are bringing in the parts that we require and some other materials from different sources. Obviously, that may take a little bit longer, but nothing specifically has affected us. Our inventories are sufficient to cover our operations at this point, and we have nothing to report regarding delays or anything like that, neither on the commercial side, as I say, nor at the supply chain for the corporation.”

 

Square (2/26 Earnings Call Transcript) 

“Amrita Ahuja: Sure. In short, we didn’t see any material impact in our Q4 results, as you can see, nor do we expect a material impact in Q1 for our results. When you look across the Seller and Cash ecosystems today, we continue to see healthy trends in performance. We have sellers in a variety of industries on our platform, and we’re actually under-indexed to tourism. Although, of course, we’ll continue to monitor any impact to the overall consumer spend numbers that we see.”

 

TJX (2/26 Earnings Call Transcript) 

Before I turn the call over to Scott, we know you may have a lot of questions related to coronavirus. What I have to say is that at this time, we have not seen an impact to our business and it is too early for us to speculate about the future. Again, our priority is the health and well-being of our associates and we have made certain adjustments in terms of travel in our global buying offices. We are monitoring the situation closely and thinking of everyone worldwide who has been affected… Thanks, Ernie. As Ernie mentioned, we are monitoring the coronavirus outbreak closely. But at this time, we have not included any potential financial impact in our fiscal ’21 guidance.

 

Abbvie (2/25 Conference Transcript) 

“Question – Geoffrey Craig Porges: Okay. One last question for Rob. Just can you talk a little bit about what your demand and your supply exposure is to China, assuming this coronavirus then continues?

Answer – Robert A. Michael: Yes. So on the demand side, we don’t have a very large business in China as AbbVie so — HUMIRA is fairly small in China. So we don’t have a significant exposure there.

In terms of — on the supply chain side, we have enough redundancy globally. That’s been part of our supply chain strategy all along, to ensure that we don’t have any supply disruptions related to China.”

 

Arista Networks (2/25 Conference Transcript) 

“Yes. I mean, I don’t know that we have anything new to add at this point. It’s only been, to your point, less than a couple of weeks since we did the call. We don’t have any direct manufacturing footprints in China. But obviously, we do have some supply chain impacts that — there’s a lot of those components and subcomponents that are manufactured in China. So it’s a question of working through piece by piece, right? There’s a lot of detailed work that’s ongoing now. Planning for various outcomes and understanding where we’re at in terms of near-term supply. But there’s, obviously, supply in the supply chain already, which will help. And then it’s a question of just blocking and tackling around every single component and understanding where they are.

I mean it’s changing, obviously. Some factors are coming up. They’re coming up at different schedules. So it really is just a — it’s a supply chain — detailed supply chain exercise to go figure out exactly where we are, and then look at alternatives, and plan out for some period of time. And that’s all in play now. But we don’t really have anything new to add from what we said on the call, which is we don’t have a direct manufacturing footprint there. We do have some existing supply chain availability, and then we’ll go figure out where we are from there.”

 

Cheniere Energy (2/25 Earnings Call Transcript) 

“The strong supply growth, warm weather and slowing economic growth that we saw in the fourth quarter of 2019 have continued into early 2020 and have recently been compounded by the impact of the novel coronavirus outbreak. Since the start of 2020, we have seen JKM spot prices decrease by approximately 50%, with prices for March falling below the previous record low of $3.65 recorded in May of 2009. While it’s currently too early to gauge the potential impact of the coronavirus on the near-term market balance, decreased short-term LNG demand in China is putting additional pressure on a market still working to absorb the wave of incremental supply into the market over the past 2 years. I’ll speak more about our 2020 outlook in a few moments… 

That being said, we await clarity on the impact of coronavirus on Chinese economic and foreign trade priorities. While the impact of the outbreak on China’s economic growth is uncertain, we see potential for Chinese gas demand to decrease in the near term, followed by a rebound with the resumption of normal industrial activity and as a result of stimulus measures already being implemented by the Chinese government. Longer term, we believe that the U.S. and China are natural partners on energy trade and are hopeful that the tariffs can be removed permanently to facilitate new long-term agreements.”

CRM (2/25 Earnings Call Transcript) 

With respect to the coronavirus, I’m sure Marc will have some comments on that, but it’s not affecting us right now. Certainly, we’re concerned. We’re watching to see what happens here. And we’re empathetic to those who it is affecting. But overall, I think we are — the company is in a terrific spot, and I think we’re all proud of the results here.

Answer – Marc R. Benioff: Well, number one, I think all of our hearts go out to all of the families around the world who have been impacted by the coronavirus and certainly, the world governments and their impact to contain what is possibly going to be a serious pandemic. So we have been listening and paying attention closely to what’s been happening around the world. Certainly, we’ve had a number of customers come to us just in our normal course of business and talk to us about how their businesses have been impacted. Those have been mostly limited to airlines and hospitality companies, companies who have their operations primarily in China or who have significant supply chains based in China.

I think that when we’ve looked at architecting Salesforce over the last 21 years and as we’ve looked at navigating the economic crises that we’ve been through before, we’ve been through 2 serious recessions. Now as we look at navigating a biological crisis — when we started Salesforce, Parker and I really built a business model that was designed to transcend these situations so that we would have durable growth over time regardless of the crises. I think that really played out in a surprising way with a level of strength in 2009, ’10 and ’11 financial crisis that if you look at our revenue curves, it looks like it never happened because whether our bookings are up or down 1 quarter or the next, the strength of our revenue model and the resulting cash flow and commitment we’ve had to incremental operating margin over 21 years has really paid out to have a level of durable capability for the company that I think has been unprecedented in the technology industry and given our investors, the returns that have been so strong for them and something that we’re very committed to continuing to do more than I think Mark will know, 93%, 92%. What is it?”

Insulet (2/25 Earnings Call Transcript) 

“Finally, turning to our manufacturing innovation and global operational excellence. First, I would like to acknowledge that as we all deal with the global challenges of the coronavirus and its impact on families, employees and the operations of many global organizations, it highlights the importance of our investment in manufacturing and supply chain redundancy… 

Question – Robert Justin Marcus: Okay. And I’m sorry if you touched on this in the prepared remarks, I’m jumping across a couple of different calls tonight. But can you touch on your supply chain in China and any impact from coronavirus? How manufacturing in China is? How much safety stock do you have? And if you foresee any potential supply disruptions here?

Answer – Shacey Petrovic: Yes, Robbie, it’s a great question. And I want to first just commend our team because they are managing through this incredibly capably, and we do not anticipate any product supply issues due to the coronavirus at this time. Our — as we mentioned earlier, our automated facility in the U.S. is starting to provide manufacturing redundancy and risk mitigation and additional capacity as line 1 ramps, and then we bring line 2 on. And we’ve got our best people, frankly, on this here and on the ground in Shenzhen. We have a comprehensive plan in place to make sure that we’ve got risk mitigation. So plenty of inventory on hand. And then, Acton continues to produce more and more every day. And then our facility in Shenzen is also up and producing again.”

HP (2/24 Earnings Call Transcript) 

Before I turn the call to Steve, I want to briefly address the coronavirus situation. First and foremost, the well-being of our employees, partners, customers and their families is our #1 priority. We are following the processes and protocols outlined by public health authorities. We are also providing resources to assist with the public health response.

From a business perspective, as you all know, the situation is fluid. We are actively working to return to full production as quickly as possible. We are working with our logistics providers to ensure we get the necessary capacity to meet customer demand. Overall, we are viewing the situation as temporary in nature and we are aggressively navigating the challenges…  With regards to the financial impact from the coronavirus, we are factoring in our best assumptions at this time, recognizing that the situation remains highly dynamic…

Answer – Steven J. Fieler: Yes. And what we saw in Q1 was our demand remained solid certainly on the commercial side, and so I think that’s an important factor. Ironically, I think the coronavirus may ultimately push out some of the Win 10 refresh time lines, given some of the constraints we’re going to see in Q2, so that could support a better second half than we originally anticipated.

Answer – Enrique J. Lores: Additionally, to some of the shortages we have seen on processors during the last quarter, so this really is smoothing out the transition to the new system.

Answer – Rajagopal Raghunathan Kamesh: And on the coronavirus impacts, does your guidance include any impacts to demand outside of China?

Answer – Steven J. Fieler: No, the guide really reflects the economic conditions as we saw today. And the demand impact was really China-based as well as the supply chain and logistics impact from the China production and manufacturing.

Answer – Enrique J. Lores: And as we said before, the biggest impact is driven by the supply chain impact. That, of course, will have an impact in sales all over the world.”

HPQ (2/24 Earnings Call Transcript) 

Candidly, if we just reflect on the current situation with coronavirus and the working capital required to run our Personal Systems business, it’s really important that you have that flexibility in your operating cash as we do today…  Yes. So we increased our full year outlook by $0.10. I think what we’ve demonstrated is we do have multiple levers to drive profit at the company, and our outlook does assess the various risks and opportunities that we see. Maybe just a few high-level points. The first is we have factored into our guidance, what you see in Q2, the impact of coronavirus. We see it as a temporary issue at this point. Again, it’s dynamic. But that is both in Q2 and does reflect our overall full year guide.

In the second half, Personal Systems is going to have a tougher compare, whereas Print should show a better compare and year-over-year improvement. But also second half, and I think what’s important is we do expect to see more of the structural cost reductions and savings, and we have increasing confidence in that. You factor all those elements together, which is why we increased the full year by $0.10, and we’ve got confidence in delivering that, albeit the coronavirus remains dynamic.

 

Keysight Technologies (2/24 Earnings Call Transcript) 

This guidance incorporates our current assessment of the coronavirus impact. Given the dynamics of the situation, we expect any impact from coronavirus to simply be a pushout in demand and do not anticipate any impact on our full year results at this time… 

Answer – Ronald S. Nersesian: Yes, John, this is Ron. I’m going to give you a little bit of a long answer on this because I figured there’s a lot of interest in the effects of the coronavirus. First of all, it’s a very unfortunate situation affecting not only China, but we’re seeing it, obviously, in South Korea, Italy and other countries, including customers around the world. The situation is changing. So here’s an up-to-the-minute update as far as what we know at this point. The first thing I’d like to say is that we have a lot of sales in China, but we do not do much manufacturing at all. Over 99% of our products are not manufactured in China. We do receive about 10% of our parts or a little bit less than 10% of our parts from China, but all of this is built into what our guide is.

So let’s talk about our employees. We have 991 people in China and another about 233 non-Keysight workers that help us in sales, support and research & development. Of those, 1,224 workers, luckily, none have reported coronavirus cases at all. The other thing that’s worthwhile to note is, if you look at Hubei province and Wuhan, they’re not a big employment center for us. We have folks in Beijing, Shanghai, Chengdu, in Sichuan province and Shenzhen primarily as well as some salespeople that are scattered throughout the rest of China. 1/3 of those people are back at work already as we’ve opened up offices in Beijing, Shanghai, Chengdu and Shenzhen. And the rest, the other 770 folks are working remotely through video conferences, remote support — with remote control of instruments and giving daily reports to sales management. So we get a daily report on the health status of everyone, the sales funnel and how everybody is doing in order to make sure we’re taking care of our customers as well as our employees.

We’re working through that same process in other parts of the field or in other regions. But clearly, the impact in other regions is smaller and not as big of a center for us. So let’s talk about the business implications as we know it. Last quarter, we guided $1.055 billion in revenue, and we delivered $1.141 billion in orders or we delivered $86 million in orders above what we said, assuming a book-to-bill of 1. Of that $86 million in orders, we shipped $40 million of it, so we actually delivered revenue of $1.095 billion, not $1.055 billion. But the additional $46 million we have in backlog that could help smooth out any timing delays that we would see from the coronavirus. We have guided $1.158 billion, plus or minus $20 million, and we’ve built in approximately $20 million worth of impact into our guide. The key point, though, that you should remember is that we have a good backlog situation. We have very differentiated products. And we’re very confident at this point that we’ll be able to make up any delays that we see in the second half of the year, therefore, not affecting Keysight’s performance in fiscal year ’20. I hope that helps, John.”

 

Palo Alto Networks (2/24 Earnings Call Transcript) 

Please note that our guidance does not reflect any potential disruptions in our global supply chain that could result from the coronavirus, which we are carefully monitoring.”

 

Zoetis (2/24 Conference Transcript) 

“Answer – Unidentified Analyst: Got you. And then just another question, something that’s come up a lot that’s topical is coronavirus and your exposure to China. Obviously, you talked about your overall revenue exposure at length given all the ASF impact. So first one to ask, is there any direct exposure that you would think of or that you’ve seen either in the companion animal or the livestock business? But then also what about indirect exposure in terms of API, sourcing, supply chain?

Answer – Glenn C. David: Yes, yes. So sure, as you size the market for China, for us, it’s about a $200 million market. What we’ve seen and what we’ve heard to date in terms of the impact of coronavirus that could have an impact on that direct revenue, as you mentioned, will be 2 things: a, from a companion animal perspective, our customers bring in their pets into the vet for visits, and we expect that traffic to be slower now, obviously, based on the impact of the coronavirus. The other factor and what we’re hearing a lot is the food and beverage industry has been negatively impacted based on the coronavirus obviously due to less travel into the markets and also people just going out less for dinner and things of that nature. So that, from a short-term perspective, will limit the amount of protein consumption. So those are 2 areas that we expect will impact our direct business. We don’t expect it at a material level to date. But again, based on the amount of time that the virus stays out there, that can have an impact over time, but it’s a little too early to tell the magnitude of that.

From an other area perspective in terms of our supply chain, APIs, things of that nature, we typically carry, for the most of our products, over 6 months of inventory of API. So we don’t expect a disruption to our overall supply chain based on what we know today.”

 

Added Coronavirus Detail to 10K

Ansys (2/27 10K – Added Detail) 

In addition, our business could be adversely affected by the effects of a widespread outbreak of contagious disease, including the recent outbreak of respiratory illness caused by a novel coronavirus first identified in Wuhan, Hubei Province, China. Any outbreak of contagious diseases, and other adverse public health developments, may cause us or our customers to temporarily suspend operations in the affected city or country. In addition, a significant outbreak of contagious diseases in the human population could result in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic downturn that could affect demand for our products, our ability to collect against existing trade receivables and our operating results.”

 

Avery Dennison (2/26 10K – Added Detail) 

“Although the outbreak originated in China, cases have been confirmed in other countries as well. The extent to which the novel coronavirus will impact our results is dependent on future developments, which are uncertain and unpredictable.  Any widespread health crisis could adversely affect the economies and financial markets in impacted countries, potentially leading to an economic downturn that could adversely affect demand for our products and negatively impact our business. We expect that the coronavirus will adversely impact our first quarter and full year 2020 results; while we will take measures to try to mitigate this impact, there can be no assurance that these actions will be able to partially or fully offset the impact.

 

Valero Energy (2/26 10K – Added Detail) 

Global concern about the coronavirus outbreak could result in lower demand for and consumption of transportation fuels, which would have a negative impact on our results of operations.”

 

McDonald’s (2/26 10K – Added Detail) 

“Severe weather conditions, natural disasters, hostilities and social unrest, any shifting climate patterns, terrorist activities, health epidemics or pandemics (or expectations about them) can adversely affect consumer spending and confidence levels and supply availability and costs, as well as the local operations in impacted markets, all of which can affect our results and prospects. For example, the recent outbreak of the coronavirus in China has disrupted local operations, and neither the duration nor scope of the disruption can be predicted. Therefore, while we expect this matter to negatively impact our results, the related financial impact cannot be reasonably estimated at this time. Our receipt of proceeds under any insurance we maintain with respect to some of these risks may be delayed or the proceeds may be insufficient to cover our losses fully.”

 

Updated Guidance via Press Release

EOG Resources (2/28 Earnings Call Transcript) 

“Question – Arun Jayaram: Yes, Bill, I was wondering if you could comment on how EOG is thinking about some of the demand impacts from the Coronavirus and the state of the oil market today? And what would be the company’s game plan if we did move into an environment where we have sustained oil price that caught in the low 40s for some bit of time?

Answer – William R. Thomas: Yes, Arun, certainly, this is a huge world event, and it’s developing. And we like everybody else is watching really daily the developments around the world, and we certainly hope and pray it’s a short-term event. But if it turned to a longer-term event, as Billy said, we’re in a fantastic position. Number 1, we got a great balance sheet, and we are committed to that, and that’s certainly been a strength of EOG for years and years and years. And so that puts us in a great position. And then we’re very flexible. We have an operational ability to adjust activity. And I think I’ll let Billy comment a little bit more about that, maybe some of the specifics.

Answer – Lloyd W. Helms: Yes, Arun. So the way I would add to that is we have the capability to adjust our rig activity and frac fleets down to really be in line with our sustainable CapEx or smart maintenance capital numbers. So we’ve set out a plan that really allows us to capture the highest performing rigs and frac crews in the market, but we have a tremendous amount of flexibility to adjust downward if we need to and so — and the same would apply to our allocation of capital to our infrastructure spend and other things. We have the same capability to adjust that downward if needed. So we’ll just be patient here and watch to see how the market unfolds and adjust accordingly.”

 

AES Corp (2/28 Earnings Call Transcript) 

“Before I turn the call over to Gustavo, let me address the issue of COVID-19 or the coronavirus. As a long-term contracted generator, overwhelmingly in U.S. dollars and the U.S. utility business, we see limited impact from most likely scenarios from the coronavirus epidemic. Furthermore, as I have previously laid out, AES has a strong pipeline of contracted, mostly renewable projects, that ensure our growth over the coming years. Although we may suffer some delivery delays, both our solar and energy storage businesses have largely secured their supplies of lithium-ion batteries and photovoltaic sales for this year. We will continue to closely monitor the situation and take proactive measures to ensure the resiliency of our business.”

Vistra Energy (2/28 Earnings Call Transcript) 

I think one of the things they’d like to see is whether we can withstand the business cycles, including things like what’s going on with the coronavirus right now, which I think in 2020 we’re going to have a very good year despite what could be symptoms of a recession off of that — off the coronavirus. So I think we’re a very strong company. I think we’ll show that in 2020, but I think it’s very important for us to do that.”

Dell (2/27 Earnings Call Transcript) 

Obviously, we’re trying to be thoughtful around the dynamics in the environment right now, although our guidance doesn’t specifically include coronavirus… Yes, the coronavirus is a — has created some level of uncertainty, if you will, and we signaled in the guidance conversation that I had in my prepared remarks that we did expect our sequentials — or normal sequentials from Q4 to Q1 to be softer as a result of the coronavirus impact. We are not looking at that at this point with what we know that, that isn’t — that it affects the full year. The question that we’ve been thinking our way through is, as we look at the impact of the coronavirus is, there’s 2 principal impacts right now. One is in our domestic China business, which has been, obviously, with the Chinese economy softening, and given the — what they’re going through to try to contain the virus. We do expect an impact in Q1 in the China business itself. And then the question becomes to this extent that there’s supply chain or lead time dynamics, how do you think about demand as a perishable, or does it defer? I think our thinking right now is that, to the extent that it’s the only demand that we see that is perishable at this point is that consumer demand, where they want to buy a product now, and if you don’t have the right product or the lead times don’t work, perhaps they move elsewhere.

Now, we’ll obviously continue to refine that as we move forward and learn more about impacts. But I do think for the full year, we feel good about our cash forecast at this point in time. We’ve got a very efficient working capital model. I think if you look at the amount of debt coming due, I think it’s very, very manageable this year. And our whole goal was to get ahead and try and drive some of the future maturity stacks down.”

Trade Desk (2/27 Earnings Call Transcript) 

“Of course, we’re also watching the virus around the world, the coronavirus, and trying to measure the impact that, that will have on everything globally. And while we don’t think it will have a significant impact, in the current environment, it’s prudent to be measured. So we’re more comfortable moving expectations up as we go, but our optimism is as strong as it could be.”

 

Autodesk (2/27 Earnings Call Transcript) 

“First off, the whole coronavirus situation is a human situation. It’s kind of a human tragedy. And the best thing that can happen here for all of us is that it just gets resolved and contained relatively quickly and there’s a vaccine next year for the next flu season. But from a business perspective, how it impacts you is it depends on your business, and we’ve looked pretty deeply at our business. And here’s kind of a lay of the land I’ll give you. If you are a software vendor that’s exposed to big deals from especially large industrials that have kind of global supply chain disruption, you’re going to feel some effects from this, all right? That’s not us. In addition, if you’re in the travel industry, obviously, you’re going to feel some effects from this.

But here’s what’s different about Autodesk, and here’s why I want to help you understand how we look at the business and why we took into account some China effects in Q1, but we don’t see longer-term effects at this point, okay? Now I will say, if this becomes a pandemic, all bets are off and we’ll have a different discussion. But right now, our business is what we call almost micro-verticalized. We cut across lots of different verticals. And it’s not just industrial verticals, it’s company-sized verticals. We go from the biggest to the smallest. Our business, especially in the first half of the year, is not heavily dependent on large deals and large companies, particularly large industrials. So we don’t see that kind of sensitivity in our business.

But in addition, and I think this is super important for you to understand, it’s one of the great things about being an indirect company, our business happens hyper-locally. And what I mean by that is the VARs, especially in APAC, that transact with the customers are actually new to customers, all right? You’re not dealing with a situation where people travel or there’s a diaspora of salespeople heading in various directions to get the business done. Customers need our software. They need our softwares now. And the VARs are there. So this combination of this micro-verticalization is spread across various companies of various sizes. And it’s hyper-locality of our business is why when SARS hit last round, we didn’t see much impact on our business.

So right now, what we’ve done, we looked at China. Obviously, we just said, all right, more China. China was already having issues as well. So we’ve prudently looked at Q1 with regards to China, looked at the short-term impacts. But we don’t see right now any other impacts in our business. Of course, like I said earlier, if the pandemic hits, we’ll have a different discussion. But right now, I just want you to pay attention to that notion of highly verticalized, micro verticals, different customer segments and hyper-local, which is a great advantage of where we’re at… it’s not a — we haven’t taken into account a significant headwind from coronavirus. We expect our recurring revenue to actually show slight growth sequentially gain.”

 

Monster Beverage (2/27 Earnings Call Transcript) 

“And then if I could just talk about the coronavirus for one second, I’ve been asked and I haven’t really answered it because I was waiting to answer it on the call. And we don’t normally give numbers, sales in various countries. But what I can tell you is that our sales in China in 2019 were less than 1% of our consolidated net sales for the company. So that puts a little bit in perspective because it was a little bit of nervousness, but it’s less than 1%.”

 

Live Nation (2/27 Earnings Call Transcript) 

The coronavirus has had a lot of press lately, so I wanted to give some context for us. First, as it relates to China and Asia shows generally, show cancellations have been minimal given our activity levels in China, with 17 shows totaling approximately 75,000 fans. Looking over the next 3 months, our Asia activity is limited, with 70 shows and 200,000 fans in the region.

Second, as it relates to Italy, we have 30 shows booked over the next 3 months with approximately 125,000 fans. Collectively, this accounts for less than 0.5% of our 100 million-plus fans we expect to attend our shows this year. More broadly, while we expect that there will be further areas of breakout over the next few months, one of our strengths is that we are highly diversified geographically. Thus far, we have seen no pullback in fan demand or ticket buying outside of the specifically affected areas. And overall, our attendance is weighted toward the latter part of this year with over 70% of our attendance expected from June through the end of the year.”

 

VMWare (2/27 Earnings Call Transcript) 

“I’d also point out with — even in today’s coronavirus, right, customers are anxious, saying, “How can I have more resilience for a work-at-home environment?” And again, that even accelerates today’s offering of EUC.

But what we talked about at the RSA conference is entirely consistent with our Intrinsic Security strategy where it isn’t about end-user computing, it’s about secure end-user computing. And we’re going to redefine the category and really bring management and security into a singular, integrated set of solutions for customers. And this idea of, right, the security industry today is highly bespoke, highly fragmented, way too many products, complexity for customers to manage and validating and putting these pieces together, this has to come to an end. And that’s really the strategy that we’ve laid out is to bring security intrinsically into the core platforms, redefine these categories, minimize the space that customers need to test, validate, operationalize by making it part of the environments that they’re already running.”

 

Factset Research Systems (2/27 Earnings Call Transcript) 

“No, it’s definitely a very serious topic. First and foremost, for us, our employees are safe, which is key. And we’re also very used to working remotely. So that’s been a question mark. And from that perspective, I’d say it’s business as usual, though there’s no as usual right now, right?

In terms of ASV, if I think about Hong Kong and China, it’s less than 1% of our total ASV. So that’s what’s going on in that, right? But from the perspective of exposure directly to that, there isn’t a lot. I think we’ll see how this progresses and the impact it could potentially have. But I think right now, for lack of a better word, it’s contained because our exposure to that — those countries aren’t as large at this point.”

W.R. Berkley (2/27 – Credit Suisse Financial Services Forum) 

“Why don’t I give a broad based in (inaudible) specifically (inaudible) network. Broad-based, in general, there’s nothing about the coronavirus that would cause particular claims or considerations. Business interruption generally is not covered by these things, workers’ compensation generally would not be covered by these things. I think that the likely issues are — have responsibilities because (inaudible) take decisions in order to prevent adverse consequences, none of which would be covered by insurance. So you close a plant for a week or a month, not an insured loss. So those are the kinds of things that are likely to happen. A hotel in Canary Islands got quarantined by the Spanish government. It’s not an insured event. I’m not sure what the people who were inside the hotel think. And most of them wouldn’t have insurance that would cover. So to the most part, the coronavirus is a noninsurance event, not in a 100%, you never know specifics within (inaudible).”

 

Don’t miss critical insights. AlphaSense gives you access to full Earnings call transcripts and allows you to keep track of themes unfolding within your coverage universe through intelligent AI-powered search.

Sign up for a free trial to learn how AlphaSense enhances the workflow of 70% of the world’s hedge funds and over 50% of the S&P 500. Already have an account? Login here.